3-substituted propionic acids as αV integrin inhibitors

ABSTRACT

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α v -containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

CROSS REFERENCE TO RELATED APPLICATION

This application is a national phase application under 35 U.S.C. § 371of International Patent Application No. PCT/US2017/060376, filed Nov. 7,2017, which claims priority to U.S. Provisional Application Ser. No.62/418,848 filed Nov. 8, 2016, which are expressly incorporated fullyherein by reference.

FIELD OF THE INVENTION

The present invention relates to substituted 3-azolopropionic acids asαV integrin antagonists, pharmaceutical compositions comprising suchcompounds and to their use in therapy, especially in the treatment orprophylaxis of diseases, disorders, and conditions for which an αVintegrin antagonist is indicated in a human.

BACKGROUND OF THE INVENTION

Integrins belong to a large family of α/β heterodimeric transmembraneproteins that are involved in cell adhesion to a wide variety ofextracellular matrix proteins, cell-cell interactions, cell migration,proliferation, survival, and in maintenance of tissue integrity (Barczyket al. Cell and Tissue Research 2010, 339, 269; Srichai, M. B.; Zent, R.in Cell-Extracellular Matrix Intereactions in Cancer, 2010). In mammals,there are 24 α/β integrin heterodimers known from various combinationsof 18 alpha and 8 beta subunits. Transforming Growth Factor-β (TGF-β)has a central role in driving a number of pathological processesunderlying fibrosis, cell growth, and autoimmune diseases. Alpha V (αV)Integrins, that include αVβ1, αVβ3, αVβ5, αVβ6, and αVβ8, are involvedin a critical pathway that leads to the conversion of latent TGF-β toits active form (Henderson, N. C.; Sheppard, D. Biochim, Biophys. Acta2013, 1832, 891). Thus, antagonism of such αV integrin-mediatedactivation of latent TGF-β provides a viable therapeutic approach tointervene in TGF-β-driven pathological states (Sheppard, D. Eur. Resp.Rev. 2008, 17, 157; Goodman, S. L.; Picard, M. Trends Pharmacol.Sciences 2012, 33(7), 405; Hinz, B. Nature Medicine 2013, 19(12), 1567;Pozzi, A.; Zent, R. J. Am. Soc. Nephrol. 2013, 24(7), 1034). All five αVintegrins belong to a small subset (8 out of 24) of integrins thatrecognize the Arginine-Glycine-Aspartic acid (RGD) motif present intheir native ligands such as fibronectin, vitronectin, andLatency-Associated Peptide (LAP).

The expression of αV integrin subtypes varies significantly. Forexample, βVβ6 is expressed on epithelial cells at very low levels inhealthy tissue but is significantly upregulated during inflammation andwound healing. αVβ3 and αVβ5 are expressed on osteoclasts, endothelial,smooth muscle, and solid tumor cells, as well as on pericytes andpodocytes, while αVβ1 is expressed on activated fibroblasts andmesangial cells.

Fibrotic conditions that represent major unmet medical needs areIdiopathic Pulmonary Fibrosis (IPF), liver and kidney fibrosis,Non-Alcoholic Fatty Liver Disease (NAFLD), Non-AlcoholicSteato-Hepatitis (NASH), as well as systemic sclerosis. Two drugs,pirfenidone an nintedanib, that act by non-integrin-mediated mechanisms,have recently been approved for treatment of IPF. The present inventionrelates to compounds that inhibit or antagonize the action of one ormore of the αV integrins in the treatment of pathological conditions,such as fibrosis and cancer, mediated by these integrins.

A number of selective or nonselective small molecule, peptidic, andantibody-based antagonists of αV integrins have been reported in theliterature (Kapp, T. G. et al. Expert Opin. Ther. Patents 2013, 23(10),1273; O'Day, S. et al. Brit. J. Cancer 2011, 105(3), 346; Pickarski, M.et al. Oncol. Rep. 2015, 33, 2737; Wirth, M. et al. Eur. Urol. 2014,897; Henderson, N. C. et al. Nature Medicine 2012, 19(12), 1617; Horan,G. S. et al. Am. J. Resp. Crit. Care Med. 2008, 177, 56; Puthawala, K.et al. Am. J. Resp. Crit. Care Med. 2008, 177, 82; Reed, N. I. et al.Sci. Transl. Med 2015, 7(288), 288ra79; Anderson, N. A. et al. WO2014/154725 A1, WO 2016/046225 A1, WO 2016/046226 A1, WO 2016/046230 A1,WO 2016/046241 A1).

SUMMARY OF THE INVENTION

In one aspect, the present invention provides compounds of Formula (I),(IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIIa), (IIIb), (IVa) and(IVb) as well as the subgenera and species thereof, includingstereoisomers, tautomers, pharmaceutically acceptable salts, andsolvates thereof, which are useful as αV integrin antagonists.

In another aspect, the present invention also provides processes andintermediates for making the compounds of the present invention.

In another aspect, the present invention also provides pharmaceuticalcompositions comprising a pharmaceutically acceptable carrier and atleast one of the compounds of the present invention or stereoisomers,tautomers, pharmaceutically acceptable salts, or solvates thereof.

In another aspect, the compounds of the invention may be used intherapy, either alone or in combination with one or more additionaltherapeutic agents.

The compounds of the invention may be used in the treatment of adisease, disorder, or condition associated with dysregulation ofα_(v)-containing integrins in a patient in need of such treatment byadministering a therapeutically effective amount of the compound, or astereoisomer, a tautomer, or a pharmaceutically acceptable salt orsolvate thereof, to the patient. The disease, disorder, or condition maybe related to pathological fibrosis. The compounds of the invention canbe used alone, in combination with one or more compounds of the presentinvention, or in combination with one or more, e.g., one to two, othertherapeutic agents.

The compounds of the invention may be used for the manufacture of amedicament for the treatment of a disease, disorder, or conditionassociated with dysregulation of α_(v)-containing integrins in apatient.

Other features and advantages of the invention will be apparent from thefollowing detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The present application provides compounds, including all stereoisomers,solvates, prodrugs and pharmaceutically acceptable salt and solvateforms thereof, according to Formula I. The present application alsoprovides pharmaceutical compositions containing at least one compoundaccording to Formula I, or a stereoisomer, a tautomer, or apharmaceutically acceptable salt or a solvate thereof, and optionally atleast one additional therapeutic agent. Additionally, the presentapplication provides methods for treating a patient suffering from an αVIntegrin-modulated disease or disorder such as for example, IdiopathicPulmonary Fibrosis (IPF), liver and kidney fibrosis, Non-Alcoholic FattyLiver Disease (NAFLD), Non-Alcoholic Steato-Hepatitis (NASH), cardiacfibrosis, and systemic sclerosis, by administering to a patient in needof such treatment a therapeutically effective amount of a compound ofthe present invention, or a stereoisomer, a tautomer, or apharmaceutically acceptable salt or a solvate thereof, and optionally incombination with at least one additional therapeutic agent.

I. Compounds of the Invention

In one embodiment, the present invention provides, inter alia, acompound of Formula (I):

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt ora solvate thereof, wherein:

A, E, and G are independently N, O, S, NR^(6a), CHR^(6b) or CR^(6b);

M and L are independently N or C; with the proviso that M and L are notboth N;

as indicated by the dotted circle, the ring formed by A, E, G, M, and Lcan be fully saturated, partially saturated, or unsaturated; and thering formed by A, E, G, M, and L can be either aromatic or non-aromatic;

R¹ is an Arginine mimetic moiety selected from the group consisting of

one of the asterisks in each of the arginine mimetics moiety is anattachment point to X, and the other two asterisks are hydrogen;

R^(f)═H, Me, Et, COOEt;

R^(g)═CH₃, CH₂CH₃, CH₂CCl₃, phenyl, 4-fluorophenyl, 4-methoxyphenyl,benzyl,

R^(e) is OH, C₁₋₄ alkyl, halo, haloalkyl, C₁₋₄ cycloalkyl, amino, amido,carbamate, or sulfonamide;

r is an integer of 0, 1, 2, or 3;

X is a C₁₋₆ alkylene substituted with 0, 1, or 2 R^(7b);

Z is a covalent bond, O, S, NH, —O—(C₁₋₃ alkylene)-, —S—(C₁₋₃alkylene)-, or —NH—(C₁₋₃ alkylene)-, wherein the C₁₋₃ alkylene is eachindependently substituted with 0, 1, or 2 R^(7a);

R² is hydrogen or C₁₋₆ alkyl; or alternatively, R² and R³, together withthe atoms to which they are attached, form a carbocyclyl or aheterocyclyl, wherein the carbocyclyl and heterocyclyl are eachindependently substituted with 0, 1, 2, or 3 R¹²;

R³ is hydrogen, C₁₋₆ alkyl, 3- to 10-membered carbocyclyl,carbocyclylalkyl, 6- to 10-membered aryl, arylalkyl, 3- to 14-memberedheterocyclyl, heterocyclylalkyl, 5- to 14-membered heteroaryl,heteroarylalkyl, wherein the alkyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl, by themselves or as part of another group, are eachindependently substituted with 0, 1, 2, or 3 R⁵;

R⁴ is hydrogen, C₁₋₁₀ alkyl, 3- to 10-membered carbocyclyl,carbocyclylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 6-to 10-membered aryl, arylalkyl, 5- to 14-membered heteroaryl,heteroarylalkyl, NR^(a)R^(b), OR^(a), S(O)_(n)R¹⁰, C(O)NR^(a)R^(b),NHC(O)OR^(a), NHC(O)NR^(a)R^(b), NHC(O)R¹⁰, OC(O)NR^(a)R^(b), OC(O)R¹⁰,NHS(O)_(n)NR^(a)R^(b), or NHS(O)_(n)R¹⁰; wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁹;

n is an integer of 1 or 2;

R⁵ is H, R^(5a), or a structural moiety selected from

L¹ and L² are each independently C₁₋₄ alkylene;

R^(5a) and R^(5b) are each independently C₁₋₆ alkyl, phenyl, or 5- to7-membered heterocyclyl; wherein the alkyl, phenyl, and heterocyclyl areeach independently substituted with 0 to 3 R^(5d);

R^(5c) is C₁₋₆ alkyl or 5- to 7-membered carbocyclyl; wherein the alkyland carbocyclyl are each independently substituted with 0 to 3 R^(5d);

R^(5d), at each occurrence, is independently halo, OH, alkoxy, oxo, oralkyl; or alternatively, two adjacent R^(5d), together with the atoms towhich they are attached, form a carbocyclyl moiety;

R^(6a) is each independently hydrogen, C₁₋₆ alkyl, haloalkyl, alkoxy,amino, haloalkoxy, hydroxyalkyl, aminoalkyl, or C₃₋₅ cycloalkyl, whereinthe cycloalkyl is substituted with 0, 1, 2, or 3 halo, cyano, nitro,amino, or OH;

R^(6b) is each independently hydrogen, halo, cyano, nitro, amino, OH,C₁₋₆ alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl, orC₃₋₅ cycloalkyl, wherein the cycloalkyl is substituted with 0, 1, 2, or3 halo, cyano, nitro, amino, or OH;

R^(7a) and R^(7b) are each independently halo, cyano, hydroxyl, amino,C₁₋₆ alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy,amido, carbamate, or sulfonamide;

R⁸ is each independently halo, cyano, oxo, nitro, OH, NR^(a)R^(b), C₁₋₆alkyl, alkoxy, alkylamino, haloalkyl, haloalkoxy, haloaminoalkyl,hydroxyalkyl, aminoalkyl, alkylsulfonyl, sulfonamide, 3 to 6 memberedcarbocyclyl, 3 to 6 membered heterocyclyl, 6- to 10-membered aryl, or 5-to 10-membered heteroaryl; or alternatively, two R⁸ at adjacentpositions, together with the atoms to which they are attached, form acarbocyclyl or heterocyclyl; wherein the aryl and heteroaryl, bythemselves or as part of another group, are each independentlysubstituted with one or more groups independently selected from halo,cyano, hydroxyl, amino, C₁₋₆ alkyl, haloalkyl, hydroxyalkyl, aminoalkyl,alkoxy, haloalkoxy, amido, carbamate, and sulfonamide; and thecarbocyclyl and heterocyclyl, by themselves or as part of another group,are each independently substituted with one or more groups independentlyselected from halo, cyano, hydroxyl, amino, oxo, C₁₋₆ alkyl, haloalkyl,hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, andsulfonamide;

R⁹ at each occurrence is independently halo, cyano, nitro, OH,NR^(a)R^(b), C₁₋₆ alkyl, alkoxy, alkylamino, haloalkyl, haloalkoxy,haloaminoalkyl, hydroxyalkyl, aminoalkyl, alkylsulfonyl, sulfonamide, 3to 6 membered carbocyclyl, 3 to 6 membered heterocyclyl, 6- to10-membered aryl, or 5- to 10-membered heteroaryl; or alternatively, twoR⁹ at adjacent positions, together with the atoms to which they areattached, form a carbocyclyl or heterocyclyl; wherein the aryl andheteroaryl, by themselves or as part of another group, are eachindependently substituted with one or more groups independently selectedfrom halo, cyano, hydroxyl, amino, C₁₋₆ alkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, and sulfonamide; andthe carbocyclyl and heterocyclyl, by themselves or as part of anothergroup, are each independently substituted with one or more groupsindependently selected from halo, cyano, hydroxyl, amino, oxo, C₁₋₆alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido,carbamate, and sulfonamide

R¹⁰ is C₁₋₆ alkyl, 3- to 10-membered carbocyclyl, 3- to 10-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl;wherein the alkyl, carbocyclyl, heterocyclyl are each independentlysubstituted with 0, 1, 2, or 3 R¹¹;

R¹¹ is halo, cyano, nitro, OH, amino, C₁₋₆ alkyl, alkoxy, 3- to10-membered carbocyclyl, 3- to 10-membered heterocyclyl, 6- to10-membered aryl, or 5- to 10-membered heteroaryl; wherein the aryl,alkyl, cycloalkyl, heteroaryl, and cycloheteroalkyl are eachindependently substituted with 0, 1, 2, or 3 R¹³;

R^(a) and R^(b), at each occurrence, are independently hydrogen, C₁₋₁₀alkyl, 3- to 10-membered carbocyclyl, or 3- to 10-membered heterocyclyl;wherein the alkyl, carbocyclyl, heterocyclyl are each independentlysubstituted with 0, 1, 2, or 3 R¹⁴; and

R¹², R¹³ and R¹⁴, at each occurrence, are independently halo, cyano,nitro, OH, amino, C₁₋₆ alkyl, alkoxy, aminoalkyl, haloalkyl, haloalkoxy,haloaminoalkyl, 3 to 6 membered carbocyclyl, or 3 to 6 memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl;wherein the aryl and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with one or more groupsindependently selected from halo, cyano, hydroxyl, amino, C₁₋₆ alkyl,haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido,carbamate, and sulfonamide; and the carbocyclyl and heterocyclyl, bythemselves or as part of another group, are each independentlysubstituted with one or more groups independently selected from halo,cyano, hydroxyl, amino, oxo, C₁₋₆ alkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, and sulfonamide.

In one embodiment of Formula (I), Z is a covalent bond.

In one embodiment of Formula (I), A, L, E, G, and L form a ring moietyselected from pyrazole, pyrrole, thiazole, furan, thiophene, imidazole,oxazole, isoxazole, isothiazole, triazole, oxadiazole, thiadiazole,pyrrolidine, tetrahydrofuran, imidazolidine, pyrazolidine, oxazolidine,isoxazolidine, thiazolidine, isothiazolidine, and dioxolane; wherein thering moiety is substituted with 0, 1, or 2 R^(6a) or R^(6b).

In one embodiment of Formula (I), A, L, E, G, and L form a ring moietyselected from the following structural formula:

wherein R^(6a) is the same as defined in claim 1, (e.g., R^(6a) ishydrogen); R^(6c) is halo, cyano, nitro, amino, OH, C₁₋₆ alkyl,haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl, or C₃₋₅cycloalkyl, wherein the cycloalkyl is substituted with 0, 1, 2, or 3halo, cyano, nitro, amino, or OH; and t is an integer of 0, 1, or 2.

In one embodiment of Formula (I), R³ is selected from the groupconsisting of hydrogen,

In one embodiment of Formula (I), R⁴ is selected from hydrogen and thefollowing structural moiety

In one embodiment of Formula (I), R³ and R⁴ are not both hydrogen.

In one embodiment of Formula (I), R⁵ is H or R^(5a); and R^(5a) ismethyl, ethyl, isopropyl, n-butyl, isopentyl, or a structural moietyselected from

In one embodiment of Formula (I), the compound is represented bystructural Formula (IIa), (IIb), (IIc), or (IId):

wherein X, R¹, R², R³, and R⁴ are the same as defined in Formula (I);and

R⁵ is H, methyl, ethyl, isopropyl, n-butyl, isopentyl, or a structuralmoiety selected from

In one embodiment of Formula (IIa), (IIb), (IIc), or (IId), R¹ isselected from a structural formula selected from the group consisting of

In one embodiment of Formula (IIa), (IIb), (IIc), or (IId), X is C₂₋₅alkylene.

In one embodiment of Formula (IIa), (IIb), (IIc), or (IId), R² ishydrogen.

In one embodiment of Formula (IIa), (IIb), (IIc), or (IId), R³ is C₁₋₆alkyl, 3- to 6-membered carbocyclyl, carbocyclylalkyl, 6- to 10-memberedaryl, arylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 5-to 10-membered heteroaryl, heteroarylalkyl, wherein the alkyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl, by themselves or aspart of another group, are each independently substituted with 0, 1, 2,or 3 R⁸; and R⁴ is hydrogen.

In one embodiment of Formula (IIa), (IIb), (IIc), or (IId), R³ ishydrogen; and R⁴ is C₁₋₁₀ alkyl, 3- to 10-membered carbocyclyl,carbocyclylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 6-to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl,heteroarylalkyl, NR^(a)R^(b), OR^(a), S(O)_(n)R¹⁰, C(O)NR^(a)R^(b),NHC(O)OR^(a), NHC(O)NR^(a)R^(b), NHC(O)R¹⁰, OC(O)NR^(a)R^(b), OC(O)R¹⁰,NHS(O)_(n)NR^(a)R^(b), or NHS(O)_(n)R¹⁰; wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁹.

In one embodiment of Formula (IIa), (IIb), (IIc), or (IId), R⁵ ishydrogen.

In one embodiment of Formula (I), the compound is represented bystructural Formula (IIe) or (IIf):

wherein

X is C₃ or C₄ alkylene;

R³ is 3- to 6-membered carbocyclyl, 6- to 12-membered aryl, 3- to12-membered heterocyclyl, 5- to 12-membered heteroaryl, wherein thecarbocyclyl, heterocyclyl, aryl, and heteroaryl, are each independentlysubstituted with 0, 1, 2, or 3 R⁸;

R⁸ is each independently halo, cyano, OH, amino, C₁₋₆ alkyl, alkoxy,aminoalkyl, haloalkyl, haloalkoxy, haloaminoalkyl, 5- or 6-memberedheterocyclyl, or 5- or 6-membered heteroaryl; wherein the heterocyclyland heteroaryl are each independently substituted with 0, 1, or 2 halo,cyano, OH, amino, C₁₋₆ alkyl, alkoxy, aminoalkyl, haloalkyl, haloalkoxy,haloaminoalkyl; and

R¹ is selected from a structural formula selected from the groupconsisting of

In one embodiment of Formula (IIe) or (IIf), the compound is representedby the following structural formulae:

In one embodiment of Formula (IIe) or (IIf), X is —CH₂CH₂CH₂— or—CH₂CH₂CH₂CH₂—;

In one embodiment of Formula (IIe) or (IIf), R³ is phenyl, 5- to6-membered monocyclic heterocyclyl, 10- to 12-membered bicyclicheterocyclyl, 5- or 6-membered monocyclic heteroaryl, or 10- to12-membered bicyclic heteroaryl; wherein the heterocyclyl, phenyl, andheteroaryl, are each independently substituted with 0, 1, 2, or 3 R⁸. Inanother embodiment, R³ is phenyl, pyridinyl, pyrimidinyl,dihydrobenzofuranyl, dihydrodioxinopyridinyl, or quinolinyl, each ofwhich is optionally substituted with 0, 1, 2, or 3 R⁸.

In one embodiment of Formula (IIe) or (IIf), R¹ is

In one embodiment of Formula (I), the compound is represented bystructural Formula (IIIa) or (IIIb):

wherein X, R¹, R², R³, and R⁴ are the same as defined in Formula (I)above; and

R⁵ is H, methyl, ethyl, isopropyl, n-butyl, isopentyl, or a structuralmoiety selected from

In one embodiment of Formula (IIIa), the compound is represented bystructural Formula (IIIa-1) or (IIIa-2):

wherein X, R¹, R², R³, R⁴, and R⁵ are the same as defined in Formula(IIIa) above.

In one embodiment of Formula (IIIb), the compound is represented bystructural Formula (IIIb-1) or (IIIb-2):

wherein X, R¹, R², R³, R⁴, and R⁵ are the same as defined in Formula(IIIb) above.

In one embodiment of Formula (IIIa) or (IIIb), R¹ is selected from astructural formula selected from the group consisting of

In one embodiment of Formula (IIIa) or (IIIb), X is C₂₋₅ alkylene.

In one embodiment of Formula (IIIa) or (IIIb), R² is hydrogen.

In one embodiment of Formula (IIIa) or (IIIb), R³ is C₁₋₆ alkyl, 3- to6-membered carbocyclyl, carbocyclylalkyl, 6- to 10-membered aryl,arylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 5- to10-membered heteroaryl, heteroarylalkyl, wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁸; and R⁴is hydrogen.

In one embodiment of Formula (IIIa) or (IIIb), R³ is hydrogen; and R⁴ isC₁₋₁₀ alkyl, 3- to 10-membered carbocyclyl, carbocyclylalkyl, 3- to10-membered heterocyclyl, heterocyclylalkyl, 6- to 10-membered aryl,arylalkyl, 5- to 10-membered heteroaryl, heteroarylalkyl, NR^(a)R^(b),OR^(a), S(O)_(n)R¹⁰, C(O)NR^(a)R^(b), NHC(O)OR^(a), NHC(O)NR^(a)R^(b),NHC(O)R¹⁰, OC(O)NR^(a)R^(b), OC(O)R¹⁰, NHS(O)_(n)NR^(a)R^(b), orNHS(O)_(n)R¹⁰; wherein the alkyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl, by themselves or as part of another group, are eachindependently substituted with 0, 1, 2, or 3 R⁹.

In one embodiment of Formula (IIIa) or (IIIb), R⁵ is hydrogen.

In one embodiment of Formula (I), the compound is represented bystructural Formula (IVa) or (IVb):

wherein X, R¹, R², R³, and R⁴ are the same as defined in Formula (I)above; and

R⁵ is H, methyl, ethyl, isopropyl, n-butyl, isopentyl, or a structuralmoiety selected from

In one embodiment of Formula (IVa) or (IVb), R¹ is selected from astructural formula selected from the group consisting of

In one embodiment of Formula (IVa) or (IVb), X is C₂₋₅ alkylene.

In one embodiment of Formula (IVa) or (IVb), R² is hydrogen.

In one embodiment of Formula (IVa) or (IVb), R³ is C₁₋₆ alkyl, 3- to6-membered carbocyclyl, carbocyclylalkyl, 6- to 10-membered aryl,arylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 5- to10-membered heteroaryl, heteroarylalkyl, wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁸; and R⁴is hydrogen.

In one embodiment of Formula (IVa) or (IVb), R³ is hydrogen; and R⁴ isC₁₋₁₀ alkyl, 3- to 10-membered carbocyclyl, carbocyclylalkyl, 3- to10-membered heterocyclyl, heterocyclylalkyl, 6- to 10-membered aryl,arylalkyl, 5- to 10-membered heteroaryl, heteroarylalkyl, NR^(a)R^(b),OR^(a), S(O)_(n)R¹⁰, C(O)NR^(a)R^(b), NHC(O)OR^(a), NHC(O)NR^(a)R^(b),NHC(O)R¹⁰, OC(O)NR^(a)R^(b), OC(O)R¹⁰, NHS(O)_(n)NR^(a)R^(b), orNHS(O)_(n)R¹⁰; wherein the alkyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl, by themselves or as part of another group, are eachindependently substituted with 0, 1, 2, or 3 R⁹.

In one embodiment of Formula (IVa) or (IVb), R⁵ is hydrogen.

In one embodiment of Formula (I), the compound is represented bystructural Formula (Va) or (Vb):

wherein X, R¹, R², R³, and R⁴ are the same as defined in Formula (I)above; and

R⁵ is H, methyl, ethyl, isopropyl, n-butyl, isopentyl, or a structuralmoiety selected from

In one embodiment of Formula (Va) or (Vb), R¹ is selected from astructural formula selected from the group consisting of

In one embodiment of Formula (Va) or (Vb), X is C₂₋₅ alkylene.

In one embodiment of Formula (Va) or (Vb), R² is hydrogen.

In one embodiment of Formula (Va) or (Vb), R³ is C₁₋₆ alkyl, 3- to6-membered carbocyclyl, carbocyclylalkyl, 6- to 10-membered aryl,arylalkyl, 3- to 10-membered heterocyclyl, heterocyclylalkyl, 5- to10-membered heteroaryl, heteroarylalkyl, wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁸; and R⁴is hydrogen.

In one embodiment of Formula (Va) or (Vb), R³ is hydrogen; and R⁴ isC₁₋₁₀ alkyl, 3- to 10-membered carbocyclyl, carbocyclylalkyl, 3- to10-membered heterocyclyl, heterocyclylalkyl, 6- to 10-membered aryl,arylalkyl, 5- to 10-membered heteroaryl, heteroarylalkyl, NR^(a)R^(b),OR^(a), S(O)_(n)R¹⁰, C(O)NR^(a)R^(b), NHC(O)OR^(a), NHC(O)NR^(a)R^(b),NHC(O)RO, OC(O)NR^(a)R^(b), OC(O)R¹⁰, NHS(O)_(n)NR^(a)R^(b), orNHS(O)_(n)R¹⁰; wherein the alkyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl, by themselves or as part of another group, are eachindependently substituted with 0, 1, 2, or 3 R⁹.

In one embodiment of Formula (Va) or (Vb), R⁵ is hydrogen.

In one embodiment, the present invention provides, inter alia, compoundsselected from any one of the Examples as described in the specification,or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt orsolvate thereof.

II. Pharmaceutical Compositions, Therapeutic Utilities, and Combinations

In another embodiment, the present invention provides a compositioncomprising at least one of the compounds of the present invention, or astereoisomer, a tautomer, or a pharmaceutically acceptable salt or asolvate thereof.

In another embodiment, the present invention provides a pharmaceuticalcomposition comprising a pharmaceutically acceptable carrier and atleast one of the compounds of the present invention or a stereoisomer, atautomer, or a pharmaceutically acceptable salt or a solvate thereof.

In another embodiment, the present invention provides a pharmaceuticalcomposition, comprising a pharmaceutically acceptable carrier and atherapeutically effective amount of at least one of the compounds of thepresent invention or a stereoisomer, a tautomer, or a pharmaceuticallyacceptable salt or a solvate thereof.

In another embodiment, the present invention provides a process formaking a compound of the present invention.

In another embodiment, the present invention provides an intermediatefor making a compound of the present invention.

In another embodiment, the present invention provides a pharmaceuticalcomposition as defined above further comprising one or more additionaltherapeutic agents.

In another embodiment, the present invention provides a method for thetreatment of a disease, disorder, or condition associated withdysregulation of α_(V) integrins in a patient in need of such treatmentcomprising administering a therapeutically effective amount of acompound of the present invention, or a stereoisomer, a tautomer, or apharmaceutically acceptable salt or solvate thereof, to the patient.

In another embodiment, the present invention provides a method for thetreatment of the disease, disorder, or condition comprisingadministering to a patient in need of such treatment a therapeuticallyeffective amount of at least one of the compounds of the presentinvention, alone, or, optionally, in combination with another compoundof the present invention and/or at least one other type of therapeuticagent.

In another embodiment, the present invention provides a method foreliciting an integrin receptor antagonizing effect in a patientcomprising administering a therapeutically effective amount of acompound of the present invention, or a stereoisomer, a tautomer, or apharmaceutically acceptable salt or solvate thereof, to the patient. Inone embodiment, the integrin receptor antagonizing effect is anantagonizing effect to any of α_(V)β6, α_(V)β1, α_(V)β3, α_(V)β5, andα_(V)β8; or a combination of one or more of α_(V)β6, α_(V)β1, α_(V)β3,α_(V)β5, and α_(V)β8. For example, the integrin receptor antagonizingeffect can be an α_(V)β6, α_(V)β1, α_(V)β3, α_(V)β5, and α_(V)β8antagonizing effect.

In some embodiments, the disease, disorder, or condition is associatedwith fibrosis, including pulmonary, liver, renal, cardiac, dermal,ocular, and pancreatic fibrosis.

In other embodiments, the disease, disorder, or condition is associatedwith cell-proliferative disorders, such as cancer. In some embodiments,the cancer includes solid tumor growth or neoplasia. In otherembodiments, the cancer includes tumor metastasis. In some embodiments,the cancer is of the bladder, blood, bone, brain, breast, centralnervous system, cervix, colon, endometrium, esophagus, gall bladder,genitalia, genitourinary tract, head, kidney, larynx, liver, lung,muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate,skin, spleen, small intestine, large intestine, stomach, testicle, orthyroid. In other embodiments, the cancer is a carcinoma, sarcoma,lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, orseminoma.

Examples of diseases, disorders, or conditions associated with theactivity of α_(V) integrins that can be prevented, modulated, or treatedaccording to the present invention include, but are not limited to,transplant injection, fibrotic disorders (e. g., idiopathic pulmonaryfibrosis (IPF), interstitial lung disease, liver fibrosis, kidneyfibrosis, skin fibrosis, systemic sclerosis), inflammatory disorders(e.g., acute hepatitis, chronic hepatitis, non-alcoholic steatohepatitis(NASH), psoriasis, irritable bowel syndrome (IBS), inflammatory boweldisease (IBD)), osteoporosis, as well as cell-proliferative disorders(e.g., cancer, myeloma, fibroma, hepatocarcinoma, leukemia, Kaposi'ssarcoma, solid tumors).

The fibrotic disorders, inflammatory disorders, as well ascell-proliferative disorders that are suitable to be prevented ortreated by the compounds of the present invention include, but are notlimited to, idiopathic pulmonary fibrosis (IPF), interstitial lungdisease, non-specific interstitial pneumonia (NSIP), usual interstitialpneumonia (UIP), radiation-induced fibrosis, familial pulmonaryfibrosis, airway fibrosis, chronic obstructive pulmonary disease (COPD),diabetic nephropathy, focal segmental glomerulosclerosis, IgAnephropathy, nephropathy induced by drugs or transplantation, autoimmunenephropathy, lupus nephritis, liver fibrosis, kidney fibrosis, chronickidney disease (CKD), diabetic kidney disease (DKD), skin fibrosis,keloids, systemic sclerosis, scleroderma, virally-induced fibrosis,non-alcoholic fatty liver disease (NAFLD), alcoholic or non-alcoholicsteatohepatitis (NASH), acute hepatitis, chronic hepatitis, livercirrhosis, primary sclerosing cholangitis, drug-induced hepatitis,biliary cirrhosis, portal hypertension, regenerative failure, liverhypofunction, hepatic blood flow disorder, nephropathy, pneumonia,psoriasis, irritable bowel syndrome (IBS), inflammatory bowel disease(IBD), abnormal pancreatic secretion, benign prostatic hyperplasia,neuropathic bladder disease, spinal cord tumor, hernia of intervertebraldisk, spinal canal stenosis, heart failure, cardiac fibrosis, vascularfibrosis, perivascular fibrosis, foot-and-mouth disease, cancer,myeloma, fibroma, hepatocarcinoma, leukemia, chronic lymphocyticleukemia, Kaposi's sarcoma, solid tumors, cerebral infarction, cerebralhemorrhage, neuropathic pain, peripheral neuropathy, age-related maculardegeneration (AMD), glaucoma, ocular fibrosis, corneal scarring,diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricialpemphigoid glaucoma filtration surgery scarring, Crohn's disease orsystemic lupus erythematosus; keloid formation resulting from abnormalwound healing; fibrosis occurring after organ transplantation,myelofibrosis, and fibroids. In one embodiment, the present inventionprovides a method for the treatment of a fibrotic disorder, aninflammatory disorder, or a cell-proliferative disorder, comprisingadministering to a patient in need of such treatment a therapeuticallyeffective amount of at least one of the compounds of the presentinvention, alone, or, optionally, in combination with another compoundof the present invention and/or at least one other type of therapeuticagent.

In another embodiment, the present invention provides a compound of thepresent invention for use in therapy.

In another embodiment, the present invention provides a compound of thepresent invention for use in therapy for the treatment of a fibroticdisorder, an inflammatory disorder, or a cell-proliferative disorderthereof.

In another embodiment, the present invention also provides the use of acompound of the present invention for the manufacture of a medicamentfor the treatment of a fibrotic disorder, an inflammatory disorder, or acell-proliferative disorder thereof.

In another embodiment, the present invention provides a method for thetreatment of a fibrotic disorder, an inflammatory disorder, or acell-proliferative disorder, comprising administering to a patient inneed thereof a therapeutically effective amount of a first and secondtherapeutic agent, wherein the first therapeutic agent is a compound ofthe present invention.

In another embodiment, the present invention provides a combinedpreparation of a compound of the present invention and additionaltherapeutic agent(s) for simultaneous, separate or sequential use intherapy.

In another embodiment, the present invention provides a combinedpreparation of a compound of the present invention and additionaltherapeutic agent(s) for simultaneous, separate or sequential use in thetreatment of a fibrotic disorder, an inflammatory disorder, or acell-proliferative disorder.

The compounds of the present invention may be employed in combinationwith additional therapeutic agent(s), such as one or more anti-fibroticand/or anti-inflammatory therapeutic agents.

In one embodiment, additional therapeutic agent(s) used in combinedpharmaceutical compositions or combined methods or combined uses, areselected from one or more, preferably one to three, of the followingtherapeutic agents: inhibitors of TGFβ synthesis (for example,pirfenidone), inhibitors of vascular endothelial growth factor (VEGF),platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF)receptor kinases (for example, nintedanib), humanized anti-α_(V)β6monoclonal antibody (for example, 3G9), human recombinant pentraxin-2,recombinant human Serum Amyloid P, recombinant human antibody againstTGFβ-1, -2, and -3, endothelin receptor antagonists (for example,macitentan), interferon gamma, c-Jun amino-terminal kinase (JNK)inhibitor (for example,4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol,3-pentylbenzeneacetic acid (PBI-4050), tetra-substituted porphyrinderivative containing manganese (III), monoclonal antibody targetingeotaxin-2, interleukin-13 (IL-13) antibody (for example, lebrikizumab,tralokinumab), bispecific antibody targeting interleukin 4 (IL-4) andinterleukin 13 (IL-13), NK1 tachykinin receptor agonist (for example,Sar⁹, Met(O₂)¹¹-Substance P), Cintredekin Besudotox, human recombinantDNA-derived, IgG1 kappa monoclonal antibody to connective growth factor,and fully human IgG1 kappa antibody, selective for CC-chemokine ligand 2(for example, carlumab, CCX140), antioxidants (for example,N-acetylcysteine), phosphodiesterase 5 (PDE5) inhibitors (for example,sildenafil), agents for treatment of obstructive airway diseases such asmuscarinic antagonists (for example, tiotropium, ipatropium bromide),adrenergic (2 agonists (for example, salbutamol, salmeterol),corticosteroids (for example, triamcinolone, dexamethasone,fluticasone), immunosuppressive agents (for example, tacrolimus,rapamycin, pimecrolimus), and therapeutic agents useful for thetreatment of fibrotic conditions, such as Idiopathic Pulmonary Fibrosis(IPF), liver and kidney fibrosis, Non-Alcoholic Fatty Liver Disease(NALFD), Non-Alcoholic Steato-Hepatitis (NASH), cardiac fibrosis, andsystemic sclerosis. The therapeutic agents useful for the treatment ofsuch fibrotic conditions include, but are not limited to, FXR agonists(for example OCA, GS-9674, and LJN452), LOXL2 inhibitors (for examplesimtuzumab), LPA1 antagonists (for example SAR 100842), PPAR modulators(for example, elafibrinor, pioglitazone, and saroglitazar, IVA337),SSAO/VAP-1 inhibitors (for example, PXS-4728A and SZE5302), ASK-1inhibitors (for example GS-4997), ACC inhibitors (for example, CP-640186and NDI-010976), FGF21 agonist (for example, LY2405319), caspaseinhibitors (for example, emricasan), NOX4 inhibitors (for example,GKT137831), MGAT2 inhibitor, and bile acid/fatty acid conjugates (forexample aramchol). The αv inhibitors of various embodiments of thepresent invention may also be used in combination with one or moretherapeutic agents such as CCR2/5 inhibitors (for example,cenicriviroc), Galectin-3 inhibitors (for example, TD-139, GR-MD-02),leukotriene receptor antagonists (for example, tipelukast, montelukast),SGLT2 inhibitors (for example, dapagliflozin, remogliflozin), GLP-1agonists (for example, liraglutide and semaglutide), FAK inhibitors (forexample, GSK-2256098), CB1 inverse agonists (for example, JD-5037), CB2agonists (for example, APD-371 and JBT-101), autotaxin inhibitors (forexample, GLPG1690), prolyl t-RNA synthetase inhibitors (for example,halofugenone), FPR2 agonists (for example, ZK-994), and THR agonists(for example, MGL:3196). In another embodiment, additional therapeuticagent(s) used in combined pharmaceutical compositions or combinedmethods or combined uses, are selected from one or more, preferably oneto three, of immunoncology agents, such as Alemtuzumab, Atezolizumab,Ipilimumab, Nivolumab, Ofatumumab, Pembrolizumab, and Rituximab.

The compounds of this invention can be administered for any of the usesdescribed herein by any suitable means, for example, orally, such astablets, capsules (each of which includes sustained release or timedrelease formulations), pills, powders, granules, elixirs, tinctures,suspensions, syrups, and emulsions; sublingually; bucally; parenterally,such as by subcutaneous, intravenous, intramuscular, or intrasternalinjection, or infusion techniques (e.g., as sterile injectable aqueousor non-aqueous solutions or suspensions); nasally, includingadministration to the nasal membranes, such as by inhalation spray;topically, such as in the form of a cream or ointment; or rectally suchas in the form of suppositories. They can be administered alone, butgenerally will be administered with a pharmaceutical carrier selected onthe basis of the chosen route of administration and standardpharmaceutical practice.

The term “pharmaceutical composition” means a composition comprising acompound of the invention in combination with at least one additionalpharmaceutically acceptable carrier. A “pharmaceutically acceptablecarrier” refers to media generally accepted in the art for the deliveryof biologically active agents to animals, in particular, mammals,including, i.e., adjuvant, excipient or vehicle, such as diluents,preserving agents, fillers, flow regulating agents, disintegratingagents, wetting agents, emulsifying agents, suspending agents,sweetening agents, flavoring agents, perfuming agents, anti-bacterialagents, anti-fungal agents, lubricating agents and dispensing agents,depending on the nature of the mode of administration and dosage forms.Pharmaceutically acceptable carriers are formulated according to anumber of factors well within the purview of those of ordinary skill inthe art. These include, without limitation: the type and nature of theactive agent being formulated; the subject to which the agent-containingcomposition is to be administered; the intended route of administrationof the composition; and the therapeutic indication being targeted.Pharmaceutically acceptable carriers include both aqueous andnon-aqueous liquid media, as well as a variety of solid and semi-soliddosage forms. Such carriers can include a number of differentingredients and additives in addition to the active agent, suchadditional ingredients being included in the formulation for a varietyof reasons, e.g., stabilization of the active agent, binders, etc., wellknown to those of ordinary skill in the art. Descriptions of suitablepharmaceutically acceptable carriers, and factors involved in theirselection, are found in a variety of readily available sources such as,for example, Remington's Pharmaceutical Sciences, 18th Edition (1990).

The terms “treating” or “treatment” as used herein refer to an approachfor obtaining beneficial or desired results, including clinical results,by using a compound or a composition of the present invention. Forpurposes of this invention, beneficial or desired clinical resultsinclude, but are not limited to, one or more of the following:decreasing the severity and/or frequency one or more symptoms resultingfrom the disease, disorder, or condition; diminishing the extent of orcausing regression of the disease, disorder, or condition; stabilizingthe disease, disorder, or condition (e.g., preventing or delaying theworsening of the disease, disorder, or condition); delay or slowing theprogression of the disease, disorder, or condition; ameliorating thedisease, disorder, or condition state; decreasing the dose of one ormore other medications required to treat the disease, disorder, orcondition; and/or increasing the quality of life.

The dosage regimen for the compounds of the present invention will, ofcourse, vary depending upon known factors, such as the pharmacodynamiccharacteristics of the particular agent and its mode and route ofadministration; the species, age, sex, health, medical condition, andweight of the recipient; the nature and extent of the symptoms; the kindof concurrent treatment; the frequency of treatment; the route ofadministration, the renal and hepatic function of the patient, and theeffect desired.

By way of general guidance, the daily oral dosage of each activeingredient, when used for the indicated effects, will range betweenabout 0.01 to about 5000 mg per day, preferably between about 0.1 toabout 1000 mg per day, and most preferably between about 0.1 to about250 mg per day. Intravenously, the most preferred doses will range fromabout 0.01 to about 10 mg/kg/minute during a constant rate infusion.Compounds of this invention may be administered in a single daily dose,or the total daily dosage may be administered in divided doses of two,three, or four times daily.

The compounds are typically administered in admixture with suitablepharmaceutical diluents, excipients, or carriers (collectively referredto herein as pharmaceutical carriers) suitably selected with respect tothe intended form of administration, e.g., oral tablets, capsules,elixirs, and syrups, and consistent with conventional pharmaceuticalpractices.

Dosage forms (pharmaceutical compositions) suitable for administrationmay contain from about 1 milligram to about 2000 milligrams of activeingredient per dosage unit. In these pharmaceutical compositions theactive ingredient will ordinarily be present in an amount of about0.1-95% by weight based on the total weight of the composition.

A typical capsule for oral administration contains at least one of thecompounds of the present invention (250 mg), lactose (75 mg), andmagnesium stearate (15 mg). The mixture is passed through a 60 meshsieve and packed into a No. 1 gelatin capsule.

A typical injectable preparation is produced by aseptically placing atleast one of the compounds of the present invention (250 mg) into avial, aseptically freeze-drying and sealing. For use, the contents ofthe vial are mixed with 2 mL of physiological saline, to produce aninjectable preparation.

The present invention includes within its scope pharmaceuticalcompositions comprising, as an active ingredient, a therapeuticallyeffective amount of at least one of the compounds of the presentinvention, alone or in combination with a pharmaceutical carrier.Optionally, compounds of the present invention can be used alone, incombination with other compounds of the invention, or in combinationwith one or more, preferably one to three, other therapeutic agent(s),e.g., FXR agonists or other pharmaceutically active material.

The above other therapeutic agents, when employed in combination withthe compounds of the present invention may be used, for example, inthose amounts indicated in the Physicians' Desk Reference, as in thepatents set out above, or as otherwise determined by one of ordinaryskill in the art.

Particularly when provided as a single dosage unit, the potential existsfor a chemical interaction between the combined active ingredients. Forthis reason, when the compound of the present invention and a secondtherapeutic agent are combined in a single dosage unit they areformulated such that although the active ingredients are combined in asingle dosage unit, the physical contact between the active ingredientsis minimized (that is, reduced). For example, one active ingredient maybe enteric coated. By enteric coating one of the active ingredients, itis possible not only to minimize the contact between the combined activeingredients, but also, it is possible to control the release of one ofthese components in the gastrointestinal tract such that one of thesecomponents is not released in the stomach but rather is released in theintestines. One of the active ingredients may also be coated with amaterial that affects a sustained-release throughout thegastrointestinal tract and also serves to minimize physical contactbetween the combined active ingredients. Furthermore, thesustained-released component can be additionally enteric coated suchthat the release of this component occurs only in the intestine. Stillanother approach would involve the formulation of a combination productin which the one component is coated with a sustained and/or entericrelease polymer, and the other component is also coated with a polymersuch as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) orother appropriate materials as known in the art, in order to furtherseparate the active components. The polymer coating serves to form anadditional barrier to interaction with the other component.

These as well as other ways of minimizing contact between the componentsof combination products of the present invention, whether administeredin a single dosage form or administered in separate forms but at thesame time by the same manner, will be readily apparent to those skilledin the art, once armed with the present disclosure.

The compounds of the present invention can be administered alone or incombination with one or more, preferably one to three, additionaltherapeutic agents. By “administered in combination” or “combinationtherapy” it is meant that the compound of the present invention and oneor more, preferably one to three, additional therapeutic agents areadministered concurrently to the mammal being treated. When administeredin combination, each component may be administered at the same time orsequentially in any order at different points in time. Thus, eachcomponent may be administered separately but sufficiently closely intime so as to provide the desired therapeutic effect.

The compounds of the present invention are also useful as standard orreference compounds, for example as a quality standard or control, intests or assays involving the αv integrins. Such compounds may beprovided in a commercial kit, for example, for use in pharmaceuticalresearch involving αv integrins activity. For example, a compound of thepresent invention could be used as a reference in an assay to compareits known activity to a compound with an unknown activity. This wouldensure the experimenter that the assay was being performed properly andprovide a basis for comparison, especially if the test compound was aderivative of the reference compound. When developing new assays orprotocols, compounds according to the present invention could be used totest their effectiveness.

The present invention also encompasses an article of manufacture. Asused herein, article of manufacture is intended to include, but not belimited to, kits and packages. The article of manufacture of the presentinvention, comprises: (a) a first container; (b) a pharmaceuticalcomposition located within the first container, wherein the composition,comprises: a first therapeutic agent, comprising a compound of thepresent invention or a pharmaceutically acceptable salt form thereof;and, (c) a package insert stating that the pharmaceutical compositioncan be used for the treatment of dyslipidemias and the sequelae thereof.In another embodiment, the package insert states that the pharmaceuticalcomposition can be used in combination (as defined previously) with asecond therapeutic agent for the treatment of fibrosis and the sequelaethereof. The article of manufacture can further comprise: (d) a secondcontainer, wherein components (a) and (b) are located within the secondcontainer and component (c) is located within or outside of the secondcontainer. Located within the first and second containers means that therespective container holds the item within its boundaries.

The first container is a receptacle used to hold a pharmaceuticalcomposition. This container can be for manufacturing, storing, shipping,and/or individual/bulk selling. First container is intended to cover abottle, jar, vial, flask, syringe, tube (e.g., for a cream preparation),or any other container used to manufacture, hold, store, or distribute apharmaceutical product.

The second container is one used to hold the first container and,optionally, the package insert. Examples of the second containerinclude, but are not limited to, boxes (e.g., cardboard or plastic),crates, cartons, bags (e.g., paper or plastic bags), pouches, and sacks.The package insert can be physically attached to the outside of thefirst container via tape, glue, staple, or another method of attachment,or it can rest inside the second container without any physical means ofattachment to the first container. Alternatively, the package insert islocated on the outside of the second container. When located on theoutside of the second container, it is preferable that the packageinsert is physically attached via tape, glue, staple, or another methodof attachment. Alternatively, it can be adjacent to or touching theoutside of the second container without being physically attached.

The package insert is a label, tag, marker, etc. that recitesinformation relating to the pharmaceutical composition located withinthe first container. The information recited will usually be determinedby the regulatory agency governing the area in which the article ofmanufacture is to be sold (e.g., the United States Food and DrugAdministration). Preferably, the package insert specifically recites theindications for which the pharmaceutical composition has been approved.The package insert may be made of any material on which a person canread information contained therein or thereon. Preferably, the packageinsert is a printable material (e.g., paper, plastic, cardboard, foil,adhesive-backed paper or plastic, etc.) on which the desired informationhas been formed (e.g., printed or applied).

III. Definitions

Throughout the specification and the appended claims, a given chemicalformula or name shall encompass all stereo and optical isomers andracemates thereof where such isomers exist. Unless otherwise indicated,all chiral (enantiomeric and diastereomeric) and racemic forms arewithin the scope of the invention. Many geometric isomers of C═C doublebonds, C═N double bonds, ring systems, and the like can also be presentin the compounds, and all such stable isomers are contemplated in thepresent invention. Cis- and trans- (or E- and Z-) geometric isomers ofthe compounds of the present invention are described and may be isolatedas a mixture of isomers or as separated isomeric forms. The presentcompounds can be isolated in optically active or racemic forms.Optically active forms may be prepared by resolution of racemic forms orby synthesis from optically active starting materials. All processesused to prepare compounds of the present invention and intermediatesmade therein are considered to be part of the present invention. Whenenantiomeric or diastereomeric products are prepared, they may beseparated by conventional methods, for example, by chromatography orfractional crystallization. Depending on the process conditions the endproducts of the present invention are obtained either in free (neutral)or salt form. Both the free form and the salts of these end products arewithin the scope of the invention. If so desired, one form of a compoundmay be converted into another form. A free base or acid may be convertedinto a salt; a salt may be converted into the free compound or anothersalt; a mixture of isomeric compounds of the present invention may beseparated into the individual isomers. Compounds of the presentinvention, free form and salts thereof, may exist in multiple tautomericforms, in which hydrogen atoms are transposed to other parts of themolecules and the chemical bonds between the atoms of the molecules areconsequently rearranged. It should be understood that all tautomericforms, insofar as they may exist, are included within the invention. Asused herein, “a compound of the invention” or “compounds of theinvention” means one or more compounds encompassed by any one of Formula(I), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIIa), (IIIb), (IVa) and(IVb), or a stereoisomer, a tautomer, or a pharmaceutically acceptablesalt or solvate thereof.

As used herein, the term “alkyl” or “alkylene” is intended to includeboth branched and straight-chain saturated aliphatic hydrocarbon groupshaving the specified number of carbon atoms. For example, “C₁ to C₁₀alkyl” or “C₁₋₁₀ alkyl” (or alkylene), is intended to include C₁, C₂,C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkyl groups. Additionally, forexample, “C₁ to C₆ alkyl” or “C₁₋₆ alkyl” denotes alkyl having 1 to 6carbon atoms. Alkyl group can be unsubstituted or substituted with atleast one hydrogen being replaced by another chemical group. Examplealkyl groups include, but are not limited to, methyl (Me), ethyl (Et),propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl,t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl). When “C₀alkyl” or “C₀ alkylene” is used, it is intended to denote a direct bond.

Unless otherwise indicated, the term “lower alkyl” as employed hereinalone or as part of another group includes both straight and branchedchain hydrocarbons containing 1 to 8 carbons, and the terms “alkyl” and“alk” as employed herein alone or as part of another group includes bothstraight and branched chain hydrocarbons containing 1 to 20 carbons,preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in thenormal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl,isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl,2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the variousbranched chain isomers thereof, and the like as well as such groupsincluding 1 to 4 substituents such as halo, for example F, Br, Cl or Ior CF₃, alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl,arylalkyloxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,cycloalkylalkyl, cycloalkylalkyloxy, hydroxy, hydroxyalkyl, acyl,alkanoyl, heteroaryl, heteroaryloxy, cycloheteroalkyl, arylheteroaryl,arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl,aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano,thiol, haloalkyl, trihaloalkyl and/or alkylthio.

“Heteroalkyl” refers to an alkyl group where one or more carbon atomshave been replaced with a heteroatom, such as, O, N, or S. For example,if the carbon atom of the alkyl group which is attached to the parentmolecule is replaced with a heteroatom (e.g., O, N, or S) the resultingheteroalkyl groups are, respectively, an alkoxy group (e.g., —OCH₃,etc.), an amine (e.g., —NHCH₃, —N(CH₃)₂, etc.), or a thioalkyl group(e.g., —SCH₃). If a non-terminal carbon atom of the alkyl group which isnot attached to the parent molecule is replaced with a heteroatom (e.g.,O, N, or S) and the resulting heteroalkyl groups are, respectively, analkyl ether (e.g., —CH₂CH₂—O—CH₃, etc.), an alkyl amine (e.g.,—CH₂NHCH₃, —CH₂N(CH₃)₂, etc.), or a thioalkyl ether (e.g., —CH₂—S—CH₃).If a terminal carbon atom of the alkyl group is replaced with aheteroatom (e.g., O, N, or S), the resulting heteroalkyl groups are,respectively, a hydroxyalkyl group (e.g., —CH₂CH₂—OH), an aminoalkylgroup (e.g., —CH₂NH₂), or an alkyl thiol group (e.g., —CH₂CH₂—SH). Aheteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10carbon atoms, or 1 to 6 carbon atoms. A C₁-C₆ heteroalkyl group means aheteroalkyl group having 1 to 6 carbon atoms.

“Alkenyl” or “alkenylene” is intended to include hydrocarbon chains ofeither straight or branched configuration having the specified number ofcarbon atoms and one or more, preferably one to two, carbon-carbondouble bonds that may occur in any stable point along the chain. Forexample, “C₂ to C₆ alkenyl” or “C₂₋₆ alkenyl” (or alkenylene), isintended to include C₂, C₃, C₄, C₅, and C₆ alkenyl groups. Examples ofalkenyl include, but are not limited to, ethenyl, 1-propenyl,2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3, pentenyl, 4-pentenyl,2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, and4-methyl-3-pentenyl.

“Alkynyl” or “alkynylene” is intended to include hydrocarbon chains ofeither straight or branched configuration having one or more, preferablyone to three, carbon-carbon triple bonds that may occur in any stablepoint along the chain. For example, “C₂ to C₆ alkynyl” or “C₂₋₆ alkynyl”(or alkynylene), is intended to include C₂, C₃, C₄, C₅, and C₆ alkynylgroups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

As used herein, “arylalkyl” (a.k.a. aralkyl), “heteroarylalkyl”“carbocyclylalkyl” or “heterocyclylalkyl” refers to an acyclic alkylradical in which one of the hydrogen atoms bonded to a carbon atom,typically a terminal or sp³ carbon atom, is replaced with an aryl,heteroaryl, carbocyclyl, or heterocyclyl radical, respectively. Typicalarylalkyl groups include, but are not limited to, benzyl,2-phenylethan-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, naphthobenzyl,2-naphthophenylethan-1-yl and the like. The arylalkyl, heteroarylalkyl,carbocyclylalkyl, or heterocyclylalkyl group can comprise 4 to 20 carbonatoms and 0 to 5 heteroatoms, e.g., the alkyl moiety may contain 1 to 6carbon atoms.

The term “benzyl”, as used herein, refers to a methyl group on which oneof the hydrogen atoms is replaced by a phenyl group, wherein said phenylgroup may optionally be substituted with 1 to 5 groups, preferably 1 to3 groups, OH, OCH₃, Cl, F, Br, I, CN, NO₂, NH₂, N(CH₃)H, N(CH₃)₂, CF₃,OCF₃, C(═O)CH₃, SCH₃, S(═O)CH₃, S(═O)₂CH₃, CH₃, CH₂CH₃, CO₂H, andCO₂CH₃. “Benzyl” can also be represented by formula “Bn”.

The term “lower alkoxy”, “alkoxy” or “alkyloxy”, “aryloxy” or “aralkoxy”refers to any of the above alkyl, aralkyl or aryl groups linked to anoxygen atom. “C₁ to C₆ alkoxy” or “C₁₋₆ alkoxy” (or alkyloxy), isintended to include C₁, C₂, C₃, C₄, C₅, and C₆ alkoxy groups. Examplealkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy(e.g., n-propoxy and isopropoxy), and t-butoxy. Similarly, “loweralkylthio”, “alkylthio”, “thioalkoxy”, “arylthio”, or “aralkylthio”represents an alkyl, aryl, or aralkyl group as defined above with theindicated number of carbon atoms attached through a sulphur bridge; forexample methyl-S— and ethyl-S—.

The term “alkanoyl” or “alkylcarbonyl” as used herein alone or as partof another group refers to alkyl linked to a carbonyl group. Forexample, alkylcarbonyl may be represented by alkyl-C(O)—. “C₁ to C₆alkylcarbonyl” (or alkylcarbonyl), is intended to include C₁, C₂, C₃,C₄, C₅, and C₆ alkyl-C(O)— groups.

The term “alkylsulfonyl” or “sulfonamide” as used herein alone or aspart of another group refers to alkyl or amino linked to a sulfonylgroup. For example, alkylsulfonyl may be represented by —S(O)₂R′, whilesulfonamide may be represented by —S(O)₂NR^(c)R^(d). R′ is C₁ to C₆alkyl; and R^(c) and R^(d) are the same as defined below for “amino”.

The term “amino” is defined as —NR^(c)R^(d), wherein R^(c) and R^(d) areindependently hydrogen or C₁₋₆ alkyl; or alternatively, R^(c) and R^(d),taken together with the atoms to which they are attached, form a 3- to8-membered carbocyclic or heterocyclic ring which is optionallysubstituted with one or more group selected from halo, cyano, hydroxyl,amino, oxo, C₁₋₆ alkyl, alkoxy, and alkylamino. Examples of alkylaminogroup include, without limitation, —NH₂, methylamino, ethylamino,propylamino, isopropylamino and the like.

The term “alkylamino” refers to an alkyl group on which one of thehydrogen atoms is replaced by an amino group. For example, alkylaminomay be represented by N(R^(c)R^(d))-alkylene-. “C₁ to C₆” or “C₁₋₆”alkylamino” (or alkylamino), is intended to include C₁, C₂, C₃, C₄, C₅,and C₆ alkylamino groups.

The term “halogen” or “halo” as used herein alone or as part of anothergroup refers to chlorine, bromine, fluorine, and iodine, with chlorineor fluorine being preferred.

“Haloalkyl” is intended to include both branched and straight-chainsaturated aliphatic hydrocarbon groups having the specified number ofcarbon atoms, substituted with one or more halogens. “C₁ to C₆haloalkyl” or “C₁₋₆ haloalkyl” (or haloalkyl), is intended to includeC₁, C₂, C₃, C₄, C₅, and C₆ haloalkyl groups. Examples of haloalkylinclude, but are not limited to, fluoromethyl, difluoromethyl,trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl,2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl. Examplesof haloalkyl also include “fluoroalkyl” that is intended to include bothbranched and straight-chain saturated aliphatic hydrocarbon groupshaving the specified number of carbon atoms, substituted with 1 or morefluorine atoms. The term “polyhaloalkyl” as used herein refers to an“alkyl” group as defined above which includes from 2 to 9, preferablyfrom 2 to 5, halo substituents, such as F or Cl, preferably F, such aspolyfluoroalkyl, for example, CF₃CH₂, CF₃ or CF₃CF₂CH₂.

“Haloalkoxy” or “haloalkyloxy” represents a haloalkyl group as definedabove with the indicated number of carbon atoms attached through anoxygen bridge. For example, “C₁ to C₆ haloalkoxy” or “C₁₋₆ haloalkoxy”,is intended to include C₁, C₂, C₃, C₄, C₅, and C₆ haloalkoxy groups.Examples of haloalkoxy include, but are not limited to,trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluorothoxy.Similarly, “haloalkylthio” or “thiohaloalkoxy” represents a haloalkylgroup as defined above with the indicated number of carbon atomsattached through a sulphur bridge; for example trifluoromethyl-S—, andpentafluoroethyl-S—. The term “polyhaloalkyloxy” as used herein refersto an “alkoxy” or “alkyloxy” group as defined above which includes from2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl,preferably F, such as polyfluoroalkoxy, for example, CF₃CH₂O, CF₃O orCF₃CF₂CH₂O.

“Hydroxylalkyl” is intended to include both branched and straight-chainsaturated aliphatic hydrocarbon groups having the specified number ofcarbon atoms, substituted with 1 or more hydroxyl (OH). “C₁ to C₆hydroxylalkyl” (or hydroxylalkyl), is intended to include C₁, C₂, C₃,C₄, C₅, and C₆ hydroxylalkyl groups.

The term “cycloalkyl” refers to cyclized alkyl groups, including mono-,bi- or poly-cyclic ring systems. “C₃ to C₇ cycloalkyl” or “C₃₋₇cycloalkyl” is intended to include C₃, C₄, C₅, C₆, and C₇ cycloalkylgroups. Example cycloalkyl groups include, but are not limited to,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl.Branched cycloalkyl groups such as 1-methylcyclopropyl and2-methylcyclopropyl are included in the definition of “cycloalkyl”.

The term “cycloheteroalkyl” refers to cyclized heteroalkyl groups,including mono-, bi- or poly-cyclic ring systems. “C₃ to C₇cycloheteroalkyl” or “C₃₋₇ cycloheteroalkyl” is intended to include C₃,C₄, C₅, C₆, and C₇ cycloheteroalkyl groups. Example cycloheteroalkylgroups include, but are not limited to, oxetanyl, tetrahydrofuranyl,tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl,and piperazinyl. Branched cycloheteroalkyl groups, such aspiperidinylmethyl, piperazinylmethyl, morpholinylmethyl,pyridinylmethyl, pyridizylmethyl, pyrimidylmethyl, and pyrazinylmethyl,are included in the definition of “cycloheteroalkyl”.

As used herein, the term “azacyclyl” refers to a cycloheteroalkylcontaining one or more nitrogen atoms in the ring. Example azacyclylgroups include, but are not limited to, pyrrolidinyl, piperidinyl,morpholinyl, and piperazinyl.

As used herein, “carbocycle”, “carbocyclyl”, or “carbocyclic” isintended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclicor 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, or 13-membered polycyclic(including bicyclic or tricyclic) hydrocarbon ring, any of which may besaturated or partially unsaturated. That is, the term “carbocycle”,“carbocyclyl”, or “carbocyclic” includes, without limitation, cycloalkyland cycloalkenyl. Examples of such carbocycles include, but are notlimited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl,cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl,adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl,[3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane(decalin), [2.2.2]bicyclooctane, fluorenyl, indanyl, adamantyl, andtetrahydronaphthyl (tetralin). As shown above, bridged rings are alsoincluded in the definition of carbocycle (e.g., [2.2.2]bicyclooctane).Preferred carbocycles, unless otherwise specified, are cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, indanyl, and tetrahydronaphthyl. Abridged ring occurs when one or more, preferably one to three, carbonatoms link two non-adjacent carbon atoms. Preferred bridges are one ortwo carbon atoms. It is noted that a bridge always converts a monocyclicring into a tricyclic ring. When a ring is bridged, the substituentsrecited for the ring may also be present on the bridge.

Furthermore, the term “carbocyclyl”, including “cycloalkyl” and“cycloalkenyl”, as employed herein alone or as part of another groupincludes saturated or partially unsaturated (containing 1 or 2 doublebonds) cyclic hydrocarbon groups containing 1 to 3 rings, includingmonocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of3 to 20 carbons forming the rings, preferably 3 to 10 carbons, formingthe ring and which may be fused to 1 or 2 aromatic rings as describedfor aryl, which include cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl,cyclohexenyl,

any of which groups may be optionally substituted with 1 to 4substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy,arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl,arylcarbonylamino, nitro, cyano, thiol and/or alkylthio and/or any ofthe alkyl substituents.

As used herein, the term “bicyclic carbocycle” or “bicyclic carbocyclicgroup” is intended to mean a stable 9- or 10-membered carbocyclic ringsystem that contains two fused rings and consists of carbon atoms. Ofthe two fused rings, one ring is a benzo ring fused to a second ring;and the second ring is a 5- or 6-membered carbon ring which is saturatedor partially unsaturated. The bicyclic carbocyclic group may be attachedto its pendant group at any carbon atom which results in a stablestructure. The bicyclic carbocyclic group described herein may besubstituted on any carbon if the resulting compound is stable. Examplesof a bicyclic carbocyclic group are, but not limited to,1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.

As used herein, the term “aryl”, as employed herein alone or as part ofanother group, refers to monocyclic or polycyclic (including bicyclicand tricyclic) aromatic hydrocarbons, including, for example, phenyl,naphthyl, anthracenyl, and phenanthranyl. Aryl moieties are well knownand described, for example, in Lewis, R. J., ed., Hawley's CondensedChemical Dictionary, 13th Edition, John Wiley & Sons, Inc., New York(1997). In one embodiment, the term “aryl” denotes monocyclic andbicyclic aromatic groups containing 6 to 10 carbons in the ring portion(such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl). Forexample, “C₆ or C₁₀ aryl” or “C₆₋₁₀ aryl” refers to phenyl and naphthyl.Unless otherwise specified, “aryl”, “C₆ or C₁₀ aryl”, “C₆₋₁₀ aryl”, or“aromatic residue” may be unsubstituted or substituted with 1 to 5groups, preferably 1 to 3 groups, selected from —OH, —OCH₃, —Cl, —F,—Br, —I, —CN, —NO₂, —NH₂, —N(CH₃)H, —N(CH₃)₂, —CF₃, —OCF₃, —C(O)CH₃,—SCH₃, —S(O)CH₃, —S(O)₂CH₃, —CH₃, —CH₂CH₃, —CO₂H, and —CO₂CH₃.

As used herein, the term “heterocycle”, “heterocyclyl”, or “heterocyclicgroup” is intended to mean a stable 3-, 4-, 5-, 6-, or 7-memberedmonocyclic or 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-memberedpolycyclic (including bicyclic and tricyclic) heterocyclic ring that issaturated, or partially unsaturated, and that contains carbon atoms and1, 2, 3 or 4 heteroatoms independently selected from the groupconsisting of N, O and S; and including any polycyclic group in whichany of the above-defined heterocyclic rings is fused to a carbocyclic oran aryl (e.g., benzene) ring. That is, the term “heterocycle”,“heterocyclyl”, or “heterocyclic group” includes non-aromatic ringsystems, such as heterocycloalkyl and heterocycloalkenyl. The nitrogenand sulfur heteroatoms may optionally be oxidized (i.e., N→O andS(O)_(p)— wherein p is 0, 1 or 2). The nitrogen atom may be substitutedor unsubstituted (i.e., N or NR wherein R is H or another substituent,if defined). The heterocyclic ring may be attached to its pendant groupat any heteroatom or carbon atom that results in a stable structure. Theheterocyclic rings described herein may be substituted on carbon or on anitrogen atom if the resulting compound is stable. A nitrogen in theheterocycle may optionally be quaternized. It is preferred that when thetotal number of S and O atoms in the heterocycle exceeds 1, then theseheteroatoms are not adjacent to one another. It is preferred that thetotal number of S and O atoms in the heterocycle is not more than 1.

Examples of heterocyclyl include, without limitation, azetidinyl,piperazinyl, piperidinyl, piperidonyl, piperonyl, pyranyl, morpholinyl,tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,morpholinyl, dihydrofuro[2,3-b]tetrahydrofuran.

As used herein, the term “bicyclic heterocycle” or “bicyclicheterocyclic group” is intended to mean a stable 9- or 10-memberedheterocyclic ring system which contains two fused rings and consists ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, O and S. Of the two fused rings, one ring isa 5- or 6-membered monocyclic aromatic ring comprising a 5-memberedheteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, eachfused to a second ring. The second ring is a 5- or 6-membered monocyclicring which is saturated, partially unsaturated, or unsaturated, andcomprises a 5-membered heterocycle, a 6-membered heterocycle or acarbocycle (provided the first ring is not benzo when the second ring isa carbocycle).

The bicyclic heterocyclic group may be attached to its pendant group atany heteroatom or carbon atom which results in a stable structure. Thebicyclic heterocyclic group described herein may be substituted oncarbon or on a nitrogen atom if the resulting compound is stable. It ispreferred that when the total number of S and O atoms in the heterocycleexceeds 1, then these heteroatoms are not adjacent to one another. It ispreferred that the total number of S and O atoms in the heterocycle isnot more than 1. Examples of a bicyclic heterocyclic group are, but notlimited to, 1,2,3,4-tetrahydroquinolinyl,1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydro-quinolinyl,2,3-dihydro-benzofuranyl, chromanyl, 1,2,3,4-tetrahydro-quinoxalinyl,and 1,2,3,4-tetrahydro-quinazolinyl.

Bridged rings are also included in the definition of heterocycle. Abridged ring occurs when one or more, preferably one to three, atoms(i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms.Examples of bridged rings include, but are not limited to, one carbonatom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and acarbon-nitrogen group. It is noted that a bridge always converts amonocyclic ring into a tricyclic ring. When a ring is bridged, thesubstituents recited for the ring may also be present on the bridge.

As used herein, the term “heteroaryl” is intended to mean stablemonocyclic and polycyclic (including bicyclic and tricyclic) aromatichydrocarbons that include at least one heteroatom ring member such assulfur, oxygen, or nitrogen. Heteroaryl groups include, withoutlimitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl,pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl,pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl,isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl,benzodioxolanyl, and benzodioxane. Heteroaryl groups are substituted orunsubstituted. The nitrogen atom is substituted or unsubstituted (i.e.,N or NR wherein R is H or another substituent, if defined). The nitrogenand sulfur heteroatoms may optionally be oxidized (i.e., N→O andS(O)_(p), wherein p is 0, 1 or 2).

Examples of heteroaryl include, but are not limited to, acridinyl,azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl,benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl,benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl,benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl,chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl,1H-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl,indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl,isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl,isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl,methylenedioxyphenyl, naphthyridinyl, octahydroisoquinolinyl,oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl,oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl,phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathianyl,phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl,pyrazolidinyl, pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl,pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl,pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2H-pyrrolyl,pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl,quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl,1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl, thienothiazolyl,thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl,1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, andxanthenyl.

Examples of 5- to 10-membered heteroaryl include, but are not limitedto, pyridinyl, furanyl, thienyl, pyrazolyl, imidazolyl, imidazolidinyl,indolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl,thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl,benzimidazolyl, 1H-indazolyl, benzofuranyl, benzothiofuranyl,benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl,benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl,isoquinolinyl, octahydroisoquinolinyl, isoxazolopyridinyl, quinazolinyl,quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl,imidazolopyridinyl, and pyrazolopyridinyl. Examples of 5- to 6-memberedheterocycles include, but are not limited to, pyridinyl, furanyl,thienyl, pyrrolyl, pyrazolyl, pyrazinyl, imidazolyl, imidazolidinyl,indolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl,thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.

Unless otherwise indicated, “carbocyclyl” or “heterocyclyl” includes oneto three additional rings fused to the carbocyclic ring or theheterocyclic ring (such as aryl, cycloalkyl, heteroaryl orcycloheteroalkyl rings, for example,

and may be optionally substituted through available carbon atoms with 1,2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl,haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl,trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl,cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy,aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl,aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl,heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro,cyano, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl,alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl,arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy,arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,arylsulfinylalkyl, arylsulfonylamino and arylsulfonaminocarbonyl and/orany of the alkyl substituents set out herein.

In accordance with a convention used in the art, a bond pointing to abold line, such as

as used in structural formulas herein, depicts the bond that is thepoint of attachment of the moiety or substituent to the core or backbonestructure.

In accordance with a convention used in the art, a wavy bond in astructural formula, such as

is used to depict a stereogenic center of the carbon atom to which X′,Y′, and Z′ are attached and is intended to represent both enantiomers ina single FIGURE. That is, a structural formula with such as wavy bonddenotes each of the enantiomers individually, such as

as well as a racemic mixture thereof.

It is understood herein that if a carbocyclic or heterocyclic moiety maybe bonded or otherwise attached to a designated substrate throughdiffering ring atoms without denoting a specific point of attachment,then all possible points are intended, whether through a carbon atom or,for example, a trivalent nitrogen atom. For example, the term “pyridyl”means 2-, 3- or 4-pyridyl, the term “thienyl” means 2- or 3-thienyl, andso forth.

When a dotted ring is used within a ring structure, this indicates thatthe ring structure may be saturated, partially saturated or unsaturated.

When a bond to a substituent is shown to cross a bond connecting twoatoms in a ring, then such substituent may be bonded to any atom on thering. When a substituent is listed without indicating the atom in whichsuch substituent is bonded to the rest of the compound of a givenformula, then such substituent may be bonded via any atom in suchsubstituent. Combinations of substituents and/or variables arepermissible only if such combinations result in stable compounds.

One skilled in the art will recognize that substituents and othermoieties of the compounds of the present invention should be selected inorder to provide a compound which is sufficiently stable to provide apharmaceutically useful compound which can be formulated into anacceptably stable pharmaceutical composition. Compounds of the presentinvention which have such stability are contemplated as falling withinthe scope of the present invention.

The term “counter ion” is used to represent a negatively charged speciessuch as chloride, bromide, hydroxide, acetate, and sulfate. The term“metal ion” refers to alkali metal ions such as sodium, potassium orlithium and alkaline earth metal ions such as magnesium and calcium, aswell as zinc and aluminum.

As referred to herein, the term “substituted” means that at least onehydrogen atom is replaced with a non-hydrogen group, provided thatnormal valencies are maintained and that the substitution results in astable compound. When a substituent is keto (i.e., ═O), then 2 hydrogenson the atom are replaced. Keto substituents are not present on aromaticmoieties. When a ring system (e.g., carbocyclic or heterocyclic) is saidto be substituted with a carbonyl group or a double bond, it is intendedthat the carbonyl group or double bond be part (i.e., within) of thering. Ring double bonds, as used herein, are double bonds that areformed between two adjacent ring atoms (e.g., C═C, C═N, or N═N).

In cases wherein there are nitrogen atoms (e.g., amines) on compounds ofthe present invention, these may be converted to N-oxides by treatmentwith an oxidizing agent (e.g., mCPBA and/or hydrogen peroxides) toafford other compounds of this invention. Thus, shown and claimednitrogen atoms are considered to cover both the shown nitrogen and itsN-oxide (N→O) derivative.

When any variable occurs more than one time in any constituent orformula for a compound, its definition at each occurrence is independentof its definition at every other occurrence. Thus, for example, if agroup is shown to be substituted with 0, 1, 2, or 3 R groups, then saidgroup be unsubstituted when it is substituted with 0 R group, or besubstituted with up to three R groups, and at each occurrence R isselected independently from the definition of R.

Also, combinations of substituents and/or variables are permissible onlyif such combinations result in stable compounds.

As used herein, the term “tautomer” refers to each of two or moreisomers of a compound that exist together in equilibrium, and arereadily interchanged by migration of an atom or group within themolecule For example, one skilled in the art would readily understandthat a 1,2,3-triazole exists in two tautomeric forms as defined above:

Thus, this disclosure is intended to cover all possible tautomers evenwhen a structure depicts only one of them.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms that are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, and/or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The compounds of the present invention can be present as salts, whichare also within the scope of this invention. Pharmaceutically acceptablesalts are preferred. As used herein, “pharmaceutically acceptable salts”refer to derivatives of the disclosed compounds wherein the parentcompound is modified by making acid or base salts thereof. Thepharmaceutically acceptable salts of the present invention can besynthesized from the parent compound that contains a basic or acidicmoiety by conventional chemical methods. Generally, such salts can beprepared by reacting the free acid or base forms of these compounds witha stoichiometric amount of the appropriate base or acid in water or inan organic solvent, or in a mixture of the two; generally, nonaqueousmedia like ether, ethyl acetate, ethanol, isopropanol, or acetonitrileare preferred. Lists of suitable salts are found in Remington'sPharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton,Pa. (1990), the disclosure of which is hereby incorporated by reference.

If the compounds of the present invention have, for example, at leastone basic center, they can form acid addition salts. These are formed,for example, with strong inorganic acids, such as mineral acids, forexample sulfuric acid, phosphoric acid or a hydrohalic acid, withorganic carboxylic acids, such as alkanecarboxylic acids of 1 to 4carbon atoms, for example acetic acid, which are unsubstituted orsubstituted, for example, by halogen as chloroacetic acid, such assaturated or unsaturated dicarboxylic acids, for example oxalic,malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, suchas hydroxycarboxylic acids, for example ascorbic, glycolic, lactic,malic, tartaric or citric acid, such as amino acids, (for exampleaspartic or glutamic acid or lysine or arginine), or benzoic acid, orwith organic sulfonic acids, such as (C₁-C₄) alkyl or arylsulfonic acidswhich are unsubstituted or substituted, for example by halogen, forexample methyl- or p-toluene-sulfonic acid. Corresponding acid additionsalts can also be formed having, if desired, an additionally presentbasic center. The compounds of the present invention having at least oneacid group (for example COOH) can also form salts with bases. Suitablesalts with bases are, for example, metal salts, such as alkali metal oralkaline earth metal salts, for example sodium, potassium or magnesiumsalts, or salts with ammonia or an organic amine, such as morpholine,thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-loweralkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl,triethyl, tributyl or dimethyl-propylamine, or a mono, di or trihydroxylower alkylamine, for example mono, di or triethanolamine. Correspondinginternal salts may furthermore be formed. Salts which are unsuitable forpharmaceutical uses but which can be employed, for example, for theisolation or purification of free compounds of Formula I or theirpharmaceutically acceptable salts, are also included.

Preferred salts of the compounds of Formula I which contain a basicgroup include monohydrochloride, hydrogensulfate, methanesulfonate,phosphate, nitrate or acetate.

Preferred salts of the compounds of Formula I which contain an acidgroup include sodium, potassium and magnesium salts and pharmaceuticallyacceptable organic amines.

In addition, the compounds of the present invention may have prodrugforms. Any compound that will be converted in vivo to provide thebioactive agent is a prodrug within the scope and spirit of theinvention. The term “prodrug” as used herein encompasses both theprodrugs based on the carboxylic acid residue, i.e., “prodrug esters”,and the prodrugs based on the arginine mimetics moiety, i.e., “prodrugsof arginine mimetics”. Such prodrugs are preferably administered orallysince hydrolysis in many instances occurs principally under theinfluence of the digestive enzymes. Parenteral administration may beused where the ester per se is active, or in those instances wherehydrolysis occurs in the blood.

The compounds of the present invention contain a carboxy group which canform physiologically hydrolyzable esters that serve as prodrugs, i.e.,“prodrug esters”, by being hydrolyzed in the body to yield the compoundsof the present invention per se. Examples of physiologicallyhydrolyzable esters of compounds of the present invention include C₁ toC₆ alkyl, C₁ to C₆ alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl,methoxymethyl, C₁₋₆ alkanoyloxy-C₁₋₆ alkyl (e.g., acetoxymethyl,pivaloyloxymethyl or propionyloxymethyl), C₁ to C₆ alkoxycarbonyloxy-C₁to C₆ alkyl (e.g., methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl,glycyloxymethyl, phenylglycyloxymethyl,(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl), and other well knownphysiologically hydrolyzable esters used, for example, in the penicillinand cephalosporin arts. Such esters may be prepared by conventionaltechniques known in the art. The “prodrug esters” can be formed byreacting the carboxylic acid moiety of the compounds of the presentinvention with either alkyl or aryl alcohol, halide, or sulfonateemploying procedures known to those skilled in the art. Examples of suchprodrug esters include:

The compounds of the present invention contain an arginine mimeticsmoiety which can form physiologically hydrolyzable esters that serve asprodrugs, i.e., “prodrugs of arginine mimetics”, by being hydrolyzed inthe body to yield the compounds of the present invention per se.Representative examples of prodrugs of arginine mimetics include:

wherein, one of the asterisks in each of the arginine mimetics moiety isan attachment point to the parent molecule and the other two asterisksare hydrogen; R^(f)═H, Me, Et, COOEt; R^(g)═CH₃, CH₂CH₃, CH₂CCl₃,phenyl, 4-fluorophenyl, 4-methoxyphenyl, benzyl,

R^(e) is OH, C₁₋₄ alkyl, halo, haloalkyl, or C₁₋₄ cycloalkyl; and r isan integer of 0, 1, 2, or 3.

Furthermore, various forms of prodrugs are well known in the art. Forexamples of such prodrug derivatives, see:

Bundgaard, H., ed., Design of Prodrugs, Elsevier (1985), and Widder, K.et al., eds., Methods in Enzymology, 112:309-396, Academic Press (1985);

Bundgaard, H., Chapter 5, “Design and Application of Prodrugs”,Krosgaard-Larsen, P. et al., eds., A Textbook of Drug Design andDevelopment, pp. 113-191, Harwood Academic Publishers (1991);

Bundgaard, H., Adv. Drug Deliv. Rev., 8:1-38 (1992);

Bundgaard, H. et al., J. Pharm. Sci., 77:285 (1988); and

Kakeya, N. et al., Chem. Pharm. Bull., 32:692 (1984).

Preparation of prodrugs is well known in the art and described in, forexample, King, F. D., ed., Medicinal Chemistry: Principles and Practice,The Royal Society of Chemistry, Cambridge, UK (1994); Testa, B. et al.,Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry andEnzymology, VCHA and Wiley-VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., The Practice of Medicinal Chemistry, Academic Press, San Diego,Calif. (1999).

The present invention is intended to include all isotopes of atomsoccurring in the present compounds. Isotopes include those atoms havingthe same atomic number but different mass numbers. By way of generalexample and without limitation, isotopes of hydrogen include deuteriumand tritium. Isotopes of carbon include ¹³C and ¹⁴C.Isotopically-labeled compounds of the invention can generally beprepared by conventional techniques known to those skilled in the art orby processes analogous to those described herein, using an appropriateisotopically-labeled reagent in place of the non-labeled reagentotherwise employed. Such compounds have a variety of potential uses,e.g., as standards and reagents in determining the ability of apotential pharmaceutical compound to bind to target proteins orreceptors, or for imaging compounds of this invention bound tobiological receptors in vivo or in vitro.

“Stable compound” and “stable structure” are meant to indicate acompound that is sufficiently robust to survive isolation to a usefuldegree of purity from a reaction mixture, and formulation into anefficacious therapeutic agent. It is preferred that compounds of thepresent invention do not contain a N-halo, S(O)₂H, or S(O)H group.

The term “solvate” means a physical association of a compound of thisinvention with one or more solvent molecules, whether organic orinorganic. This physical association includes hydrogen bonding. Incertain instances the solvate will be capable of isolation, for examplewhen one or more, preferably one to three, solvent molecules areincorporated in the crystal lattice of the crystalline solid. Thesolvent molecules in the solvate may be present in a regular arrangementand/or a non-ordered arrangement. The solvate may comprise either astoichiometric or nonstoichiometric amount of the solvent molecules.“Solvate” encompasses both solution-phase and isolable solvates.Exemplary solvates include, but are not limited to, hydrates,ethanolates, methanolates, and isopropanolates. Methods of solvation aregenerally known in the art.

Abbreviations as used herein, are defined as follows: “1×” for once,“2×” for twice, “3×” for thrice, “° C.” for degrees Celsius, “eq” forequivalent or equivalents, “g” for gram or grams, “mg” for milligram ormilligrams, “L” for liter or liters, “mL” for milliliter or milliliters,“μL” for microliter or microliters, “N” for normal, “M” for molar,“mmol” for millimole or millimoles, “min” for minute or minutes, “h” forhour or hours, “rt” for room temperature, “RBF” for round bottom flask,“atm” for atmosphere, “psi” for pounds per square inch, “conc.” forconcentrated, “RCM” for ring-closing metathesis, “sat” or “sat'd” forsaturated, “SFC” for supercritical fluid chromatography, “MW” formolecular weight, “mp” for melting point, “ee” for enantiomeric excess,“MS” or “Mass Spec” for mass spectrometry, “ESI” for electrosprayionization mass spectroscopy, “HR” for high resolution, “HRMS” for highresolution mass spectrometry, “LCMS” for liquid chromatography massspectrometry, “HPLC” for high pressure liquid chromatography, “RP HPLC”for reverse phase HPLC, “TLC” or “tlc” for thin layer chromatography,“NMR” for nuclear magnetic resonance spectroscopy, “nOe” for nuclearOverhauser effect spectroscopy, “¹H” for proton, “δ” for delta, “s” forsinglet, “d” for doublet, “t” for triplet, “q” for quartet, “m” formultiplet, “br” for broad, “Hz” for hertz, and “α”, “β”, “R”, “S”, “E”,and “Z” are stereochemical designations familiar to one skilled in theart.

-   Me methyl-   Et ethyl-   Pr propyl-   i-Pr isopropyl-   Bu butyl-   i-Bu isobutyl-   t-Bu tert-butyl-   Ph phenyl-   Bn benzyl-   Boc or BOC tert-butyloxycarbonyl-   Boc₂O di-tert-butyl dicarbonate-   ACN acetonitrile-   AcOH or HOAc acetic acid-   AlCl₃ aluminum chloride-   AIBN Azobisisobutyronitrile-   BBr₃ boron tribromide-   BCl₃ boron trichloride-   BEMP    2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine-   BOP reagent benzotriazol-1-yloxytris(dimethylamino)phosphonium    hexafluorophosphate-   Burgess reagent 1-methoxy-N-triethylammoniosulfonyl-methanimidate-   CBz carbobenzyloxy-   DCM or CH₂Cl₂ dichloromethane-   CH₃CN or ACN acetonitrile-   CDCl₃ deutero-chloroform-   CHCl₃ chloroform-   mCPBA or m-CPBA meta-chloroperbenzoic acid-   Cs₂CO₃ cesium carbonate-   Cu(OAc)₂ copper (II) acetate-   Cy₂NMe N-cyclohexyl-N-methylcyclohexanamine-   DBU 1,8-diazabicyclo[5.4.0]undec-7-ene-   DCE 1,2 dichloroethane-   DEA diethylamine-   DMP or Dess-Martin    1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-beniziodoxol-3-(1H)-one    Periodinane-   DIC or DIPCDI diisopropylcarbodiimide-   DIEA, DIPEA or diisopropylethylamine-   Hunig's base-   DMAP 4-dimethylaminopyridine-   DME 1,2-dimethoxyethane-   DMF dimethyl formamide-   DMSO dimethyl sulfoxide-   cDNA complimentary DNA-   Dppp (R)-(+)-1,2-bis(diphenylphosphino)propane-   DuPhos (+)-1,2-bis((2S,5 S)-2,5-diethylphospholano)benzene-   EDC N-(3-dimthylaminopropyl)-N′-ethylcarbodiimide-   EDCI N-(3-dimthylaminopropyl)-N′-ethylcarbodiimide hydrochloride-   EDTA ethylenediaminetetraacetic acid-   (S,S)-EtDuPhosRh(I) (+)-1,2-bis((2S,5    S)-2,5-diethylphospholano)benzene(1,5-cyclooctadiene)rhodium(I)    trifluoromethanesulfonate-   Et₃N or TEA triethylamine-   EtOAc ethyl acetate-   Et₂O diethyl ether-   EtOH ethanol-   GMF glass microfiber filter-   Grubbs II    (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro    (phenylmethylene)(triycyclohexylphosphine)ruthenium-   HCl hydrochloric acid-   HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HEPES 4-(2-hydroxyethyl)piperaxine-1-ethanesulfonic acid-   Hex hexanes-   HOBt or HOBT 1-hydroxybenzotriazole-   H₂O₂ hydrogen peroxide-   IBX 2-iodoxybenzoic acid-   H₂SO₄ sulfuric acid-   Jones reagent CrO₃ in aqueous H₂SO₄, 2 M-   K₂CO₃ potassium carbonate-   K₂HPO₄ potassium phosphate dibasic-   KOAc potassium acetate-   K₃PO₄ potassium phosphate-   LAH lithium aluminum hydride-   LG leaving group-   LiOH lithium hydroxide-   MeOH methanol-   MgSO₄ magnesium sulfate-   MsCl methanesulfonyl chloride-   MsOH or MSA methylsulfonic acid-   NaCl sodium chloride-   NaH sodium hydride-   NaHCO₃ sodium bicarbonate-   Na₂CO₃ sodium carbonate-   NaOH sodium hydroxide-   Na₂SO₃ sodium sulfite-   Na₂SO₄ sodium sulfate-   NBS N-bromosuccinimide-   NCS N-chlorosuccinimide-   NH₃ ammonia-   NH₄Cl ammonium chloride-   NH₄OH ammonium hydroxide-   NH₄COOH ammonium formate-   NMM N-methylmorpholine-   OTf triflate or trifluoromethanesulfonate-   Pd₂(dba)₃ tris(dibenzylideneacetone)dipalladium(0)-   Pd(OAc)₂ palladium(II) acetate-   Pd/C palladium on carbon-   Pd(dppf)Cl₂    [1,1′-bis(diphenylphosphino)-ferrocene]dichloropalladium(II)-   Ph₃PCl₂ triphenylphosphine dichloride-   PG protecting group-   POCl₃ phosphorus oxychloride-   PPTS pyridinium p-toluenesulfonate-   i-PrOH or IPA isopropanol-   PS Polystyrene-   PtO₂ platinum oxide-   rt room temperature-   SEM-Cl 2-(trimethylsilyl)ethoxymethyl chloride-   SiO₂ silica oxide-   SnCl₂ tin(II) chloride-   TBAI tetra-n-butylammonium iodide-   TFA trifluoroacetic acid-   THF tetrahydrofuran-   TMSCHN₂ trimethylsilyldiazomethane-   T3P propane phosphonic acid anhydride-   TRIS tris (hydroxymethyl) aminomethane-   pTsOH p-toluenesulfonic acid-   TsCl p-toluenesulfonyl chloride

IV. Methods of Preparation

The compounds of the present invention can be prepared in a number ofways well known to one skilled in the art of organic synthesis using themethods described below, together with synthetic methods known in theart of synthetic organic chemistry, or variations thereon as appreciatedby those skilled in the art. Preferred methods include, but are notlimited to, those described below. All references cited herein arehereby incorporated in their entirety by reference. The reactions areperformed in a solvent or solvent mixture appropriate to the reagentsand materials employed and suitable for the transformations beingaffected. It will be understood by those skilled in the art of organicsynthesis that the functionality present on the molecule should beconsistent with the transformations proposed. This will sometimesrequire a judgment to modify the order of the synthetic steps or toselect one particular process scheme over another in order to obtain adesired compound of the invention. Restrictions to the substituents thatare compatible with the reaction conditions will be readily apparent toone skilled in the art and alternate methods must then be used. It willalso be recognized that another major consideration in the planning ofany synthetic route in this field is the judicious choice of theprotecting group used for protection of the reactive functional groupspresent in the compounds described in this invention. A particularlyuseful compendium of synthetic methods which may be applicable to thepreparation of compounds of the present invention may be found inLarock, R. C., Comprehensive Organic Transformations, 2^(nd) editionVCH, New York (1999).

The compounds of the present invention may be prepared using thereactions and techniques described in this section. The reactions areperformed in solvents appropriate to the reagents and materials employedand are suitable for the transformations being effected. Also, in thedescription of the synthetic methods described below, it is to beunderstood that all proposed reaction conditions, including solvent,reaction atmosphere, reaction temperature, duration of the experimentand workup procedures, are chosen to be the conditions standard for thatreaction, which should be readily recognized by one skilled in the art.One skilled in the art of organic synthesis understands that thefunctionality present on various portions of the edict molecule must becompatible with the reagents and reactions proposed. Not all compoundsof Formula I falling into a given class may be compatible with some ofthe reaction conditions required in some of the methods described. Suchrestrictions to the substituents, which are compatible with the reactionconditions, will be readily apparent to one skilled in the art andalternate methods must be used. A particularly useful compendium ofsynthetic methods which may be applicable to the preparation ofcompounds of the present invention may be found in Larock, R. C.,Comprehensive Organic Transformations, 2^(nd) edition VCH, New York(1999).

Generic Schemes

Compounds of the present invention, represented by Formula (I′), can beprepared according to the general routes shown in Schemes 1 to 7.Compounds where L=N and M=C can be obtained as shown in Scheme 1starting from bromide 1. An aza-Michael addition of 1 to unsaturatedester 2 can yield ester 3. Compound 3 can then be coupled with anappropriate alkene such as 4 using standard Heck coupling conditions(Felpin, F.-X.; Nassar-Hardy, L.; Le Callonnec, F.; Fouquet, E.Tetrahedron 2011, 67, 2815-2831) to provide ester 5. Reduction of thenaphthyridine and the alkene followed by ester deprotection can yieldcompounds of Formula (I′). It will be apparent to those skilled in theart that single stereoisomers can obtained via chiral HPLC or SFCpreparative purifications of suitable intermediates from this sequence(such as 3 or 5) or the final acids of Formula (I′).

Scheme 2 describes synthesis of compounds of Formula (I′) where M=C,L=N, and X═(CH₂)₃. Thus, as shown in Method A, bromide 3 can be coupledwith a suitable alkene, exemplified by 4-hydroxy-1-butene in Scheme 2,via a Heck coupling protocol in the presence of palladium acetate and aphosphine ligand. Subsequent oxidation of the alcohol and reduction ofthe double bond can yield ketone 6. Ketone 6 can be alternativelyobtained via a Sonogashira coupling of bromide 3 with a suitable alkyne,exemplified by 4-hydroxy-1-butyne in Scheme 2, followed by reduction ofthe triple bond and oxidation of the alcohol to the ketone. Condensationof 6 with 2-amino-3-formylpyridine under Friedlainder conditions (JoseMarco-Contelles; Elena Perez-Mayoral; Abdelouahid Samadi; Maria do CarmoCarreiras; Elena Soriano (2009). “Recent Advances in the FriedlanderReaction”. Chemical Reviews. 109 (6): 2652-71) can yield thecorresponding naphthyridine, which upon partial reduction anddeprotection of the ester can provide compounds of Formula (I′). Analternative method of obtaining compounds of Formula (I′) is shown inScheme 2, Method B, where, in contrast to Method A, the Sonogashiracoupling and naphthyridine ring formation precede the aza-Michaelreaction. Thus, N-Boc protected bromide 7 can be transformed into 8using the protocol described for Method A. Subsequently, Friedlindernaphthyridine ring formation as described earlier, followed by partialreduction of the naphthyridine ring and removal of the Boc group canyield 9. Aza-Michael under basic conditions and ester hydrolysis canafford compounds of Formula (I′).

Compounds of Formula (I′) where M=N, L=C, and R⁴≠H can be synthesized asshown in Scheme 3, exemplified with a compound where R⁴=NHCbz.Condensation of aldehyde 10 with a suitable R⁴-substituted Homer-Emmonsreagent (11) followed by alkene reduction and reprotection of the aminecan yield intermediate 12. N-alkylation of 12 with chloride 13 followedby cleavage of the ketal can afford ketone 14. Subsequent naphthyridinering formation via Friedlainder condensation followed by partialreduction can afford 15. A 3-step sequence that removes the Boc group,re-functionalizes the primary amine by reacting with CbzCl, andhydrolyzes the resulting ester can yield compounds of Formula (I′).Compounds of Formula (I′) where X═(CH₂)₂ can be obtained via a Mitsunobucoupling with alcohol 16, followed by deprotection of the Boc groups,acylation of the free amine with CBzCl, and final ester hydrolysis.Using either of the methods shown in Scheme 3, compounds of Formula (I′)where X═(CH₂)₃₋₆ can also be accessed.

Compounds of Formula (I′) where M=N, L=C, and R³H can be obtained bystarting from aldehyde 10. Condensation of 10 with a suitablephosphorous reagent can yield the corresponding unsaturated ester whichcan be protected (for example, with a tosyl group) to obtain 17. AHayashi reaction (Hayashi, T. Synlett 2001, 879-887) with a suitableboronic acid in the presence of a rhodium catalyst adds the R³ group ina conjugate manner to yield 18 after removal of the protecting group.Further functionalization as described before to allow installation of adesired arginine mimic incorporating linkers of various lengths canafford compounds of Formula (I′).

Compounds of Formula (I′) where L=M=C and R³≠H can be synthesized asshown in Scheme 5 using methods described in previous schemes.

Scheme 6 describes synthesis of compounds of Formula (I′) where L=M=Cand R³≠H which can be prepared using methods similar to those describedin Scheme 2.

Scheme 7 represents synthesis of compounds of Formula (I′) where the L=Nand, A, G, E, M are CHR^(6b). Deprotonation and alkylation ofγ-butyrolactone (32) followed by reductive ring opening can yield a diolwhich can be converted to the bis-mesylate 34. Other leaving groups suchas tosylate, chloride, or bromide can also be utilized in place of themesylate to facilitate the subsequent pyrrolidine ring formation with2-aminoester 35. Aminoesters such as 35 can be prepared using methodsknown in the literature (for example, Hutchinson, J. H. et al. J. MedChem. 2003, 46, 4790; Henderson, N. C. et al. Nature Medicine 2013, 19,1617). Wacker oxidation of the resulting alkene (36) followed by furthertransformations similar to the ones described earlier can yieldcompounds of formula (I′).

EXAMPLES

The following Examples are offered as illustrative, as a partial scopeand particular embodiments of the invention and are not meant to belimiting of the scope of the invention. Abbreviations and chemicalsymbols have their usual and customary meanings unless otherwiseindicated. Unless otherwise indicated, the compounds described hereinhave been prepared, isolated and characterized using the schemes andother methods disclosed herein or may be prepared using the same.

As appropriate, reactions were conducted under an atmosphere of drynitrogen (or argon). For anhydrous reactions, DRISOLV® solvents from EMwere employed. For other reactions, reagent grade or HPLC grade solventswere utilized. Unless otherwise stated, all commercially obtainedreagents were used as received.

HPLC/MS and Preparatory/Analytical HPLC Methods Employed inCharacterization or Purification of Examples

NMR (nuclear magnetic resonance) spectra were typically obtained onBruker or JEOL 400 MHz and 500 MHz instruments in the indicatedsolvents. All chemical shifts are reported in ppm from tetramethylsilanewith the solvent resonance as the internal standard. ¹HNMR spectral dataare typically reported as follows: chemical shift, multiplicity(s=singlet, br s=broad singlet, d=doublet, dd=doublet of doublets,t=triplet, q=quartet, sep=septet, m=multiplet, app=apparent), couplingconstants (Hz), and integration.

The term HPLC refers to a Shimadzu high performance liquidchromatography instrument with one of following methods:

HPLC-1: Sunfire C18 column (4.6×150 mm) 3.5 μm, gradient from 10 to 100%B:A for 12 min, then 3 min hold at 100% B.

Mobile phase A: 0.05% TFA in water:CH₃CN (95:5)

Mobile phase B: 0.05% TFA in CH₃CN:water (95:5)

TFA Buffer pH=2.5; Flow rate: 1 mL/min; Wavelength: 254 nm, 220 nm.

HPLC-2: XBridge Phenyl (4.6×150 mm) 3.5 m, gradient from 10 to 100% B:Afor 12 min, then 3 min hold at 100% B.

Mobile phase A: 0.05% TFA in water:CH₃CN (95:5)

Mobile phase B: 0.05% TFA in CH₃CN:water (95:5)

TFA Buffer pH=2.5; Flow rate: 1 mL/min; Wavelength: 254 nm, 220 nm.

HPLC-3: Chiralpak AD-H, 4.6×250 mm, 5 μm.

Mobile Phase: 30% EtOH-heptane (1:1)/70% CO₂

Flow rate=40 mL/min, 100 bar, 35° C.; Wavelength: 220 nm

HPLC-4: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7-μm particles;

Mobile Phase A: 5:95 CH₃CN:water with 10 mM NH₄OAc;

Mobile Phase B: 95:5 CH₃CN:water with 10 mM NH₄OAc;

Temperature: 50° C.; Gradient: 0-100% B over 3 min, then a 0.75-min holdat 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.

HPLC-5: Waters Acquity UPLC BEH C18, 2.1×50 mm, 1.7-μm particles;

Mobile Phase A: 5:95 CH₃CN:water with 0.1% TFA;

Mobile Phase B: 95:5 CH₃CN:water with 0.1% TFA;

Temperature: 50° C.; Gradient: 0-100% B over 3 min, then a 0.75-min holdat 100% B; Flow: 1.11 mL/min; Detection: UV at 220 nm.

Example 1(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-pyrazol-1-yl)propanoicAcid

Example 1A

A solution of 5-bromo-2-methoxypyridine (2.5 g, 13.30 mmol), tert-butylacrylate (6.75 mL, 46.5 mmol), triethylamine (5.00 mL, 35.9 mmol),palladium(II) acetate (0.336 g, 1.498 mmol) and tri-o-tolylphosphine(0.673 g, 2.211 mmol) in MeCN (3.09 mL) was degassed with Ar for 10 min.Then the reaction mixture was heated at 90° C. for 18 h. The solvent wasremoved in vacuo, toluene was added (10 mL) and the mixture wasconcentrated. Ether was added and the mixture was filtered through a padof silica gel eluting with ether. The solvent was removed and theresidue was purified by flash chromatography (0 to 60% ethylacetate/hexanes) to yield Example 1A (1.125 g, 4.78 mmol, 36% yield) asa light yellow solid. LCMS (ES): m/z 236.2 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 7.49 (d, J=15.8 Hz, 1H), 7.31-7.18 (m, 3H), 6.95 (t, J=8.5 Hz,1H), 6.24 (d, J=16.1 Hz, 1H), 3.93 (s, 3H), 1.54 (s, 9H).

Example 1B

To a solution of 3-bromo-1H-pyrazole (94 mg, 0.638 mmol) and cesiumcarbonate (208 mg, 0.638 mmol) in acetonitrile (4 mL) under Ar was addedExample 1A (150 mg, 0.638 mmol) and the mixture was heated in microwavereactor at 80° C. for 60 min. After cooling down to the roomtemperature, the mixture was partitioned between EtOAc (20 mL) and H₂O(20 mL). The combined organic phase was dried (anhydrous MgSO₄) and thesolvent removed in vacuo. The crude product was purified by flashchromatography (0 to 20% ethyl acetate/hexanes) to yield Example 1B(126.5 mg, 0.331 mmol, 52% yield) as a white solid. ¹H NMR (500 MHz,CDCl₃) δ 8.21-8.10 (m, 1H), 7.64 (dd, J=8.7, 2.6 Hz, 1H), 7.32 (d, J=2.2Hz, 1H), 6.75 (d, J=8.5 Hz, 1H), 6.26 (d, J=2.5 Hz, 1H), 5.65 (dd,J=8.8, 6.3 Hz, 1H), 3.95 (s, 3H), 3.54-3.42 (m, 1H), 3.03 (s, 1H), 1.38(s, 9H)

Example 1C

A solution of Example 1B (25 mg, 0.065 mmol),2-(but-3-en-1-yl)-1,8-naphthyridine (12.05 mg, 0.065 mmol),triethylamine (0.025 mL, 0.177 mmol), palladium(II) acetate (1.655 mg,7.37 μmol) and tri-o-tolylphosphine (3.31 mg, 10.88 μmol) in ACN (0.6mL) was degassed with Ar for 10 min. Then the reaction mixture washeated at 90° C. for 12 h. The reaction mixture was concentrated and thecrude product was purified by flash chromatography (0 to 100% ethylacetate/hexanes) to give Example 1C (22.7 mg, 0.047 mmol, 72% yield) asa yellow solid. LCMS (ES): m/z 486.1 [M+H]⁺.

Example 1D

A solution of Example 1C (20 mg, 0.041 mmol) and PtO₂ (1.871 mg, 8.24μmol) in EtOH (0.4 mL) was stirred under H₂ (balloon, 1 atm) for 16 h.After filtration on a pad of CELITE®, it was concentrated to affordExample 1D (20.2 mg, 0.041 mmol, 100% yield) as an off-white solid whichwas used in the next step without further purification. LCMS (ES): m/z492.1 [M+H]⁺.

Example 1

To a solution of Example 1D (20 mg, 0.041 mmol) was added sulfuric acid(3M aq.) (0.098 mL, 0.297 mmol). The mixture was stirred at 40° C. for 3h. The reaction mixture was cooled to room temperature and adjusted topH 6 using 50% aq. NaOH. The reaction mixture was extracted with CHCl₃(3×) and the combined organic layers were washed with brine, dried overanhydrous Na₂SO₄, filtered and concentrated. The mixture was purified bypreparative LC/MS (Column: XBridge C18, 19×200 mm, 5-μm particles;Mobile Phase A: 5:95 acetonitrile:water with 0.1% trifluoroacetic acid;Mobile Phase B: 95:5 acetonitrile:water with 0.1% trifluoroacetic acid;Gradient: 10-50% B over 20 minutes, then a 5-minute hold at 100% B;Flow: 20 mL/min) to give Example 1 (11.4 mg, 0.026 mmol, 64% yield).LC/MS (m/z)=436.0 (M+H)⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.11 (s, 1H),7.76-7.56 (m, 2H), 7.05 (d, J=7.2 Hz, 1H), 6.74 (d, J=8.6 Hz, 1H), 6.24(d, J=7.2 Hz, 1H), 5.99 (s, 1H), 5.76-5.66 (m, 1H), 3.80 (s, 2H),3.60-3.50 (m, 1H), 3.39-3.28 (m, 1H), 3.26-3.20 (m, 2H), 3.11-3.02 (m,1H), 2.63-2.57 (m, 2H), 2.50-2.47 (m, 4H), 2.42 (br. s., 1H), 1.91 (s,1H), 1.80-1.69 (m, 2H), 1.53 (br. s., 4H). Human αVβ6 IC50 (nM)=6.0;Human αVβ3 IC50 (nM)=2.4; Human αVβ5 IC50 (nM)=1.5; and Human αVβ8 IC50(nM)=262.

Example 2(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

Example 2A

A solution of 1B (50 mg, 0.131 mmol), pent-4-en-2-ol (0.047 mL, 0.458mmol), triethylamine (0.049 mL, 0.353 mmol), palladium(II) acetate (3.31mg, 0.015 mmol) and tri-o-tolylphosphine (6.62 mg, 0.022 mmol) in ACN(1.3 mL) was degassed with Ar for 10 min. Then the mixture was heated at90° C. for 16 h. The crude mixture was concentrated and purified byflash chromatography (0 to 50% ethyl acetate/hexanes) to give Example 2A(29.1 mg, 0.075 mmol, 58% yield) as a yellow solid. LCMS (ES): m/z 388.3[M+H]⁺.

Example 2B

To a solution of Example 2A (29 mg, 0.075 mmol) in CH₂Cl₂ (0.7 mL) atroom temperature was added Dess-Martin periodinane (38.1 mg, 0.090mmol). The mixture was diluted with Et₂O and filtered through a pad ofCELITE® and concentrated. The crude product was purified by flashchromatography (0 to 30% ethyl acetate/hexanes) to yield Example 2B (20mg, 0.052 mmol, 69% yield) as a white solid. LCMS (ES): m/z 386.1[M+H]⁺.

Example 2C

A solution of Example 2B (20 mg, 0.052 mmol) and PtO₂ (2.357 mg, 10.38μmol) in EtOH (0.4 mL) was stirred under H₂ (1 atm) for 16 h. Afterfiltration on a pad of CELITE®, the mixture was concentrated which wasused in the next step without further purification. LCMS (ES): m/z 388.1[M+H]⁺.

Example 2D

A solution of Example 2C (20 mg, 0.052 mmol) in CH₂Cl₂ (0.1 mL) and MeOH(0.300 mL) was added pyrrolidine (1.2 eq, 9.4 μL) followed by additionof 2-aminonicotinaldehyde (6.30 mg, 0.052 mmol). The mixture was thenstirred at room temperature for 16 h. The reaction mixture wasconcentrated to give Example 2D (24.4 mg, 0.052 mmol, 100% yield) as adark brown oil. The compound was used for the next step without furtherpurification. LCMS (ES): m/z 444.2 [M+H]⁺.

Example 2E

A solution of Example 2D (24 mg, 0.051 mmol) and PtO₂ (2.302 mg, 10.14μmol) in EtOH (0.4 mL) was stirred under H₂ (1 atm) (0.102 mg, 0.051mmol) for 16 h. After filtration on a pad of CELITE® and concentration,Example 2E was isolated as an off-white solid which was used in the nextstep without further purification. LCMS (ES): m/z 478.1 [M+H]⁺.

Example 2

To a solution of Example 2E (24.2 mg, 0.051 mmol) in ethyl acetate (0.2mL) was added sulfuric acid (3 M aq., 0.122 mL, 0.370 mmol). The aqueouslayer was separated and stirred at 40° C. for 3 h. The reaction mixturewas cooled to room temperature and adjusted to pH 6 using 50% aq. NaOH.The reaction mixture was extracted with CHCl₃ (3×) and the combinedorganic layers were washed with brine, dried over anhydrous Na₂SO₄,filtered, and concentrated. The mixture was purified via preparativeLC/MS with the following conditions: Column: XBridge C18, 19×200 mm,5-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mMammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mMammonium acetate; Gradient: 10-50% B over 30 minutes, then a 5-minutehold at 100% B; Flow: 20 mL/min to yield Example 2 (4.9 mg, 0.012 mmol,23% yield). LCMS (ES): m/z 422.0 [M+H]⁺. ¹H NMR (500 MHz,) δ 8.50 (s,1H), 7.59 (d, J=2.2 Hz, 1H), 7.45 (d, J=8.9 Hz, 1H), 7.29 (d, J=7.7 Hz,1H), 6.92 (d, J=8.9 Hz, 1H), 6.57 (d, J=7.7 Hz, 1H), 6.26 (d, J=2.2 Hz,1H), 5.74 (dd, J=8.7, 5.7 Hz, 1H), 3.91 (s, 3H), 3.42 (dtd, J=11.3, 5.5,3.2 Hz, 1H), 3.40 (dd, J=14.9, 5.7 Hz, 1H), 3.35 (dtd, J=11.3, 5.5, 4.4Hz, 1H), 3.29 (dd, J=14.9, 8.7 Hz, 1H), 2.82 (t, J=7.5 Hz, 2H), 2.66 (t,J=7.5 Hz, 2H), 2.53 (td, J=7.0, −16.4 Hz, 1H), 2.45 (td, J=7.0, −16.4Hz, 1H), 1.96 (quin, J=7.5 Hz, 2H), 1.94 (dtt, J=13.4, 7.0, 5.5 Hz, 1H),1.94-1.89 (m, 1H), 1.87 (dtt, J=13.4, 7.0, 5.5 Hz, 1H). Human αVβ6 IC50(nM)=6.8; Human αVβ3 IC50 (nM)=2.7; Human αVβ5 IC50 (nM)=0.34; and HumanαVβ8 IC50 (nM)=420.

Example 3 and Example 43-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Example 3, Enantiomer 1)3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Example 4, Enantiomer 2)

Example 3A

To the suspension of 6-methoxynicotinaldehyde (24 g, 175 mmol) in THF(420 mL) was added 60 g molecular sevies (4 Å) followed by ethyl2-(diethoxyphosphoryl)acetate (42.0 mL, 210 mmol), and LiOH (5.03 g, 210mmol). The reaction was stirred at room temperature overnight. Thereaction was filtered over CELITE® and concentrated. The residue wasdissolved in EtOAc and washed with sat. NaHCO₃ (2×) followed by brine(2×). The organic layer was dried (anhydrous Na₂SO₄) and concentrated.Purification by flash chromatography gave Example 3A (31 g, 85%). ¹H NMR(400 MHz, CDCl₃) δ 8.30 (d, J=2.4 Hz, 1H), 7.79 (dd, J=8.8, 2.4 Hz, 1H),7.65 (d, J=16.1 Hz, 1H), 6.79 (d, J=8.6 Hz, 1H), 6.36 (d, J=16.1 Hz,1H), 4.29 (q, J=7.1 Hz, 2H), 3.99 (s, 3H), 1.36 (t, J=7.0 Hz, 3H)

Example 3B

A mixture of 3-bromo-1H-pyrazole (22.62 g, 154 mmol), DABCO (15.70 g,140 mmol), Example 3A (29 g, 140 mmol), potassium carbonate (0.193 g,1.399 mmol) and acetonitrile (280 mL) was stirred at 75° C. overnight.The reaction was quenched with brine and extracted with EtOAc. Theorganic layer was dried (Na₂SO₄) and concentrated. Purification by flashchromatography gave Example 3B (25 g, 50%). ¹H NMR (400 MHz, CDCl₃) δ8.15 (d, J=2.4 Hz, 1H), 7.63 (dd, J=8.7, 2.6 Hz, 1H), 7.33 (d, J=2.3 Hz,1H), 6.74 (d, J=8.6 Hz, 1H), 6.25 (d, J=2.3 Hz, 1H), 5.70 (dd, J=8.5,6.4 Hz, 1H), 4.28-4.03 (m, 2H), 3.93 (s, 3H), 3.57 (dd, J=16.4, 8.6 Hz,1H), 3.08 (dd, J=16.5, 6.4 Hz, 1H), 1.20 (t, J=7.2 Hz, 3H)

Example 3C

A mixture of Example 3B (6.0 g, 16.94 mmol), pent-4-yn-2-ol (2.396 mL,25.4 mmol), triethylamine (9.44 mL, 67.8 mmol),bis(triphenylphosphine)palladium(II) chloride (0.713 g, 1.016 mmol) andcopper(I) iodide (0.129 g, 0.678 mmol) in DMF (33.9 mL) was stirred at80° C. for 2 h. The reaction was diluted with EtOAc, washed with brine 3times, dried over anhydrous Na₂SO₄, the solids were filtered, and thefiltrate was concentrated. Purification by flash chromatography gaveExample 3C (4 g, 68%). LCMS (ES): m/z 358.3 [M+H]⁺.

Example 3D

A solution of Example 3C (22 g, 61.6 mmol) and Pd—C(9.17 g, 8.62 mmol)in EtOH (308 mL) was stirred under a H₂ (balloon, 1 atm) overnight.After filtration on a pad of CELITE® and concentration, Example 3D (20g, 55.3 mmol, 90% yield) was isolated as a brown oil which was used inthe next step without further purification. LCMS (ES): m/z 362.2 [M+H]⁺.

Example 3E

To a solution of Example 3D in CH₂Cl₂ (277 mL) at room temperature wasadded Dess-Martin periodinane (32.9 g, 77 mmol). After 1 hour, themixture was diluted with Et₂O, filtered, and the filtrate wasconcentrated. Purification by flash chromatography gave Example 3E (15.7g, 79%). LCMS (ES): m/z 360.1 [M+H]⁺.

Example 3F

A solution of Example 3E (15.7 g, 43.7 mmol) in CH₂Cl₂ (21.84 mL) andEtOH (65.5 mL) was added pyrrolidine (7.95 mL, 96 mmol) followed byaddition of 2-aminonicotinaldehyde (5.87 g, 48.0 mmol). The mixture wasthen stirred at room temperature for 20 h. The mixture was concentratedat 45° C. to give Example 3F.

The crude material was used as such in the next step. LCMS (ES): m/z446.1 [M+H]⁺.

Example 3G

A solution of Example 3F (19.47 g, 43.7 mmol) and PtO₂ (1.489 g, 6.56mmol) in EtOH (146 mL) was stirred under H₂ for 16 h. After filtrationthrough a CELITE® pad and concentration, Example 3G (19.60 g, 43.60mmol, 100% yield) was obtained as a dark oil, which was used in the nextstep without further purification. LCMS (ES): m/z 450.1 [M+H]⁺.

Example 3 and Example 4

A mixture of Example 3G (580 mg, 1.290 mmol) and 1M sodium hydroxidesolution (3871 μL, 3.87 mmol) in MeOH (8601 μL) was stirred at roomtemperature for 1 h. Methanol was removed under reduced pressure. Theresidue was diluted with water and pH was adjusted to 5-6 using 1N HCldropwise. The product was extracted with chloroform three times, driedover Na₂SO₄ and concentrated. The crude material was separated by SFC(Chiralpak AD-H (3×25 cm, 5 μm), 100 bar, 45° C., 160 mL/min,CO₂/MeOH:ACN [1:1 (v/v)] w 0.1% NH₄OH (60/40)) to give Example 3 (210mg, 38%) and Example 4 (190 mg, 34%). Example 3: LCMS (ES): m/z 422.0[M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.18-8.08 (m, 1H), 7.79-7.63 (m,2H), 7.02 (d, J=7.2 Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 6.36-6.19 (m, 2H),6.03 (d, J=2.2 Hz, 1H), 5.72 (dd, J=8.8, 6.4 Hz, 1H), 3.82 (s, 3H),3.53-3.04 (m, 7H), 2.64-2.57 (m, 2H), 2.48-2.39 (m, 3H), 1.96-1.70 (m,2H). Human αVβ6 IC50 (nM)=3.2; Human αVβ1 IC50 (nM)=65; Human αVβ3 IC50(nM)=3.2; Human αVβ5 IC50 (nM)=11; and Human αVβ8 IC50 (nM)=1,120.Example 4: LCMS (ES): m/z 422.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.13(d, J=2.3 Hz, 1H), 8.23-7.96 (m, 1H), 7.78-7.59 (m, 2H), 7.02 (d, J=7.2Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 6.32-6.20 (m, 2H), 6.03 (d, J=2.2 Hz,1H), 5.72 (dd, J=8.7, 6.4 Hz, 1H), 3.81 (s, 3H), 3.51-2.99 (m, 7H),2.63-2.56 (m, 2H), 2.44 (dd, J=14.9, 7.5 Hz, 3H), 1.91-1.64 (m, 2H).Human αVβ6 IC50 (nM)=210.

Example 5(±)-2-(((Benzyloxy)carbonyl)amino)-3-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)-1H-pyrazol-4-yl)propanoicAcid

Example 5A

To a solution of tert-butyl7-(2-methoxy-2-oxoethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(1 g, 3.26 mmol) in THF (20 mL) was added a 2M solution of lithiumborohydride (2.122 mL, 4.24 mmol) in THF. The reaction mixture wasstirred at room temperature overnight. Water was added slowly to thereaction mixture and the resulting mixture stirred for 10 min at roomtemperature. The mixture was diluted with EtOAc then extracted 3 timeswith EtOAc. The combined organic layers were dried over Na₂SO₄, filteredand concentrated. Purification by flash chromatography gave Example 5A(782 mg, 86%). LCMS (ES): m/z 279.1 [M+H]⁺.

Example 5B

To a solution of methyl2-(((benzyloxy)carbonyl)amino)-2-(dimethoxyphosphoryl)acetate (101 mg,0.306 mmol) in DCM (1 mL) was added DBU (0.042 mL, 0.280 mmol). Thereaction mixture was stirred for 10 minutes under Ar at roomtemperature. A solution of tert-butyl 4-formyl-1H-pyrazole-1-carboxylate(50 mg, 0.255 mmol) in DCM (0.5 mL) was added to the reaction mixture.The reaction mixture was stirred at room temperature under Ar for 1 h.The mixture was concentrated and purified by flash chromatography togive Example 5B (76 mg, 74%). LCMS (ES): m/z 402.2 [M+H]⁺.

Example 5C

To a solution of Example 5B (90 mg, 0.299 mmol) in MeOH (7 mL) was addedHOAc (0.1 mL) and 10% Pd/C (40 mg, 0.038 mmol). The mixture was stirredunder H₂ (1 atm) overnight. The mixture was filtered and concentrated.The crude mixture was used for the next step without purification. LCMS(ES): m/z 170.1 [M+H]⁺.

Example 5D

To a solution of Example 5C (50 mg, 0.296 mmol) in THF (3 mL) and H₂O(1.5 mL) was added sodium bicarbonate (74.5 mg, 0.887 mmol) and Boc₂O(0.106 mL, 0.458 mmol). The reaction mixture was stirred at roomtemperature for 1 h. The mixture was extracted with EtOAc (30 mL). Theorganic layers were combined and concentrated. The mixture was purifiedby preparative HPLC (Phenomenex Luna Axia 5μ C18 30×100 mm; 10 mingradient from 85% A: 15% B to 0% A:100% B (A=90% H₂O/10% ACN+0.1% TFA);(B=90% ACN/10% H₂O+0.1% TFA); detection at 220 nm) to give Example 5D(35 mg, 44%). LCMS (ES): m/z 270.1 [M+H]⁺.

Example 5E

To a mixture of Example 5D and Example 5A (20.67 mg, 0.074 mmol) intoluene (619 μL) was added tris(butyl)phosphine (37.1 μL, 0.149 mmol)and 1,1′-azobis(N,N-dimethylformamide) (25.6 mg, 0.149 mmol). Themixture was stirred at room temperature under Ar overnight. The reactionmixture was concentrated and the crude was purified by prep HPLC(Phenomenex Luna Axia 5μ C18 30×100 mm; 10 min gradient from 85% A: 15%B to 0% A: 100% B (A=90% H₂O/10% ACN+0.1% TFA); (B=90% ACN/10% H₂O+0.1%TFA); detection at 220 nm) to give Example 5E (4 mg, 10%). LCMS (ES):m/z 530.4 [M+H]⁺.

Example 5F

To a solution of Example 5E (4 mg, 7.55 μmol) in TFA (0.2 mL) and DCM (1mL) was stirred at room temperature for 4 h. The solvent was removed andthe residue was used in the next reaction without further purification.LCMS (ES): m/z 430.3 [M+H]⁺.

Example 5G

To a solution of Example 5F (2.48 mg, 7.53 μmol), sodium bicarbonate (5mg, 0.060 mmol) in THF (1.5 mL) and H₂O (0.5 mL) was added benzylcarbonochloridate (5 mg, 0.029 mmol). The reaction mixture was stirredat room temperature for 1 h. The solvent was evaporated. The aqueousresidue was extracted with EtOAc (2×5 mL). The organic layers werecombined and concentrated to give crude Example 5F which was used forthe next step without further purification. LCMS (ES): m/z 463.3 [M+H]⁺.

Example 5

A solution of Example 5G (3.5 mg, 7.55 μmol), LiOH (3 mg, 0.125 mmol) inTHF (1 mL) and H₂O (0.5 mL) was stirred at room temperature overnight.The reaction mixture was purified by preparative LC/MS with thefollowing conditions: Column: XBridge C18, 19×200 mm, 5-μm particles;Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate;Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate;Gradient: 15-55% B over 15 minutes, then a 3-minute hold at 100% B;Flow: 20 mL/min. to give Example 5 (3.3 mg, 96%). LCMS (ES): m/z 450.3[M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.45-7.20 (m, 9H), 6.35 (br d, J=7.3Hz, 1H), 5.21-5.00 (m, 2H), 4.66-4.49 (m, 2H), 4.34 (td, J=6.4, 1.4 Hz,2H), 4.20 (t, J=5.4 Hz, 1H), 3.43-3.37 (m, 2H), 3.02 (t, J=6.3 Hz, 2H),2.93 (br dd, J=8.0, 5.9 Hz, 2H), 2.71 (br t, J=6.0 Hz, 2H), 1.87 (quin,J=5.6 Hz, 2H). Human αV 36 IC50 (nM)=5,000.

Example 6(±)-2-(((Benzyloxy)carbonyl)amino)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicAcid

Example 6A

To a solution of Example 5D (26 mg, 0.065 mmol, 59% yield) inacetonitrile (1 mL) was added 2-(3-chloropropyl)-2-methyl-1,3-dioxolane(40 mg, 0.243 mmol) and Cs₂CO₃ (100 mg, 0.307 mmol). The reactionmixture was heated at 110° C. for 1 h. The mixture was filtered, thefiltrate was concentrated, and the crude product was further purified byprep HPLC (Phenomenex Luna Axia 5μ C18 30×100 mm; 10 min gradient from85% A: 15% B to 0% A: 100% B (A=90% H₂O/10% ACN+0.1% TFA); (B=90%ACN/10% H₂O+0.1% TFA); detection at 220 nm) to give Example 6A (26 mg,59%). LCMS (ES): m/z 398.3 [M+H]⁺.

Example 6B

To a solution of Example 6A (10 mg, 0.028 mmol, 94% yield) in THF (0.5mL) was added 1N HCl (0.5 mL, 0.500 mmol). The reaction mixture wasstirred at room temperature for 1 h. The solvent was evaporated andwater (1 mL) was added. The mixture was extracted with EtOAc (3×5 mL).The organic layers were combined and concentrated to give crude Example6B which was used for the next step without further purification. LCMS(ES): m/z 354.2 [M+H]⁺.

Example 6C

To a solution of Example 6B (22 mg, 0.062 mmol) in EtOH (1 mL) was added2-aminonicotinaldehyde (11.40 mg, 0.093 mmol) and pyrrolidine (10.30 μl,0.125 mmol). The mixture was stirred at room temperature for 2 h andheated at reflux for 1 h. The solvent was evaporated and the crudeproduct was purified by prep HPLC (Phenomenex Luna Axia 5μ C18 30×100mm; 10 min gradient from 85% A: 15% B to 0% A: 100% B (A=90% H₂O/10%ACN+0.1% TFA); (B=90% ACN/10% H₂O+0.1% TFA); detection at 220 nm) togive Example 6C (3.5 mg, 13%). LCMS (ES): m/z 440.1 [M+H]⁺.

Example 6D

To a solution of Example 6C (3.5 mg, 7.96 μmol) in ethanol (2 mL) wasadded PtO₂ (0.362 mg, 1.593 μmol). The mixture was stirred under a H₂atmosphere (balloon, 1 atm) overnight. The mixture was filtered througha CELITE® pad and the filtrate concentrated to give Example 6D as aviscous oil. LCMS (ES): m/z 444.3 [M+H]⁺.

Example 6E

To a solution of Example 6D (3.5 mg, 7.89 μmol) in CH₂Cl₂ (1 mL) wasadded TFA (0.4 mL). The mixture was stirred at room temperature for 2 h.The mixture was concentrated and the crude material was used for thenext step without purification. LCMS (ES): m/z 344.1 [M+H]⁺.

Example 6F

To a solution of Example 6E (2.7 mg, 7.86 μmol), sodium bicarbonate (5mg, 0.060 mmol) in THF (1.5 mL) and H₂O (0.5 mL) was added benzylcarbonochloridate (5 mg, 0.029 mmol). The reaction mixture was stirredat room temperature for 1 h. The solvent was evaporated. The aqueousresidue was extracted with EtOAc (2×5 mL). The organic layers werecollected and concentrated to give Example 6F, which was used for thenext step without further purification. LCMS (ES): m/z 478.3 [M+H]⁺.

Example 6

To a solution of Example 6F (3.75 mg, 7.85 μmol) in THF (1 mL) and water(0.5 mL) was added lithium hydroxide (3 mg, 0.125 mmol) and MeOH (0.1mL). The reaction mixture was stirred at room temperature for 40 min.The solvent was removed under reduced pressure and purified viapreparative LC/MS with the following conditions: Column: XBridge C18,19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile:water with10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with10-mM ammonium acetate; Gradient: 3-40% B over 25 minutes, then a5-minute hold at 100% B; Flow: 20 mL/min. to give Example 6 (1.2 mg,30%). LCMS (ES): m/z 464.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.62-7.15(m, 8H), 6.55 (d, J=7.3 Hz, 1H), 5.39-4.97 (m, 3H), 4.19 (br t, J=5.1Hz, 1H), 4.13-3.93 (m, 2H), 3.46 (t, J=5.6 Hz, 2H), 2.96 (br d, J=5.2Hz, 2H), 2.78 (t, J=6.2 Hz, 2H), 2.54-2.39 (m, 1H), 2.31-2.10 (m, 3H),2.01-1.87 (m, 2H). Human αVβ6 IC50 (nM)=80.

Example 7(±)-3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicAcid (Racemate)

Example 7A

To a solution of 1H-pyrazole-4-carbaldehyde (300 mg, 3.12 mmol) wasadded ethyl 2-(triphenylphosphoranylidene)acetate (1360 mg, 3.90 mmol)in toluene (10 mL). The mixture was heated at 90° C. for 2 h. Thesolvent was removed in vacuo. The crude material was purified by flashchromatography to afford Example 7A (450 mg, 2.71 mmol, 87% yield) as awhite solid. LCMS (ES): m/z 167.1 [M+H]⁺.

Example 7B

To a mixture of Example 7A in CH₂Cl₂ (35 mL) was added4-methylbenzene-1-sulfonyl chloride (952 mg, 4.99 mmol) and TEA (2.088mL, 14.98 mmol). The reaction mixture was stirred at room temperaturefor 3 h. The solvent was evaporated and the mixture was diluted with 30mL water and extracted with EtOAc (50×3 mL). The organic layers werecombined, concentrated and purified by flash chromatography to giveExample 7B (1.15 g, 72%). LCMS (ES): m/z 321.2 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.24 (s, 1H), 7.93 (d, J=8.4 Hz, 2H), 7.89 (s, 1H), 7.51 (d,J=16.1 Hz, 1H), 7.38 (d, J=8.1 Hz, 2H), 6.27 (d, J=16.0 Hz, 1H), 4.26(q, J=7.1 Hz, 2H), 2.46 (s, 3H), 1.33 (t, J=7.1 Hz, 3H).

Example 7C

To a degassed solution of (6-methoxypyridin-3-yl)boronic acid (477 mg,3.12 mmol) and Example 7B (500 mg, 1.56 mmol) in dioxane (7804 μL) andTHF (7804 μL) was added 1N potassium hydroxide (3121 μl, 3.12 mmol) andchloro(1,5-cyclooctadiene)rhodium(I) dimer (92 mg, 0.187 mmol). Themixture was heated at 80° C. 2 h. The mixture was diluted with 10 mLwater and extracted with EtOAc (25×3 mL). The organic portions werecombined, concentrated, and purified by flash chromatography to giveExample 7C (206 mg, 30%). LCMS (ES): m/z 430.0 [M+H]⁺.

Example 7D

To a solution of Example 7C (206 mg, 0.480 mmol) was added 4M HCl indioxane (1 mL) and ethanol (0.3 mL). The reaction mixture was stirredfor 0.5 h. The mixture was concentrated and purified by prep HPLC(Phenomenex Luna Axia 5μ C18 30×100 mm; 10 min gradient from 85% A: 15%B to 0% A: 100% B (A=90% H₂O/10% ACN+0.1% TFA); (B=90% ACN/10% H₂O+0.1%TFA); detection at 220 nm) to give Example 7D (578 mg, 87%). LCMS (ES):m/z 276.1 [M+H]⁺.

Example 7 was prepared from Example 7D according to the method describedin Example 6. LCMS (ES): m/z 422.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ8.04 (d, J=1.9 Hz, 1H), 7.63 (dd, J=8.5, 2.1 Hz, 1H), 7.50 (s, 1H),7.41-7.20 (m, 2H), 6.75 (d, J=8.6 Hz, 1H), 6.45 (br d, J=7.2 Hz, 1H),4.38 (br t, J=8.0 Hz, 1H), 4.11 (td, J=13.7, 7.1 Hz, 2H), 3.87 (s, 3H),3.51-3.38 (m, 2H), 2.89-2.68 (m, 3H), 2.53-2.45 (m, 1H), 2.42-2.30 (m,1H), 2.28-2.04 (m, 2H), 1.98-1.79 (m, 3H), 1.40-1.21 (m, 1H). Human αVβ6IC50 (nM)=323.

Example 8(S)-3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicAcid Example 9(R)-3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicAcid

Example 8 and Example 9

Example 7 (110 mg, 0.26 mmol) was separated by SFC [Berger MGII SFCPrep, Column: Chiralpak AD-H, 21×250 mm, 5 micron Mobile Phase: 20% B=10mM ammonium acetate in (50:50) Acetonitrile/MeOH-80% CO₂, 150 bar, flowconditions: 45 mL/min, 120 bar, 40° C. Detector Wavelength: 265 nm;Injection details: 0.5 mL of 22.2 mg/mL in MeOH/ACN] to give Example 8(38 mg, 28%) and Example 9 (41 mg, 30%). Example 8: ¹H NMR (400 MHz,CD₃OD) δ 8.07 (d, J=2.0 Hz, 1H), 7.65 (br d, J=8.4 Hz, 1H), 7.53 (s,1H), 7.43-7.26 (m, 2H), 6.77 (d, J=8.6 Hz, 1H), 6.48 (d, J=7.5 Hz, 1H),4.40 (t, J=7.9 Hz, 1H), 4.22-4.02 (m, 2H), 3.89 (s, 3H), 3.56-3.41 (m,2H), 2.91-2.71 (m, 3H), 2.59-2.33 (m, 2H), 2.28-2.08 (m, 2H), 2.06-1.85(m, 3H). Human αVβ6 IC50 (nM)=64. Example 9: ¹H NMR (400 MHz, CD₃OD) δ8.07 (d, J=2.0 Hz, 1H), 7.65 (br d, J=8.4 Hz, 1H), 7.53 (s, 1H),7.43-7.26 (m, 2H), 6.77 (d, J=8.6 Hz, 1H), 6.48 (d, J=7.5 Hz, 1H), 4.40(t, J=7.9 Hz, 1H), 4.22-4.02 (m, 2H), 3.89 (s, 3H), 3.56-3.41 (m, 2H),2.91-2.71 (m, 3H), 2.59-2.33 (m, 2H), 2.28-2.08 (m, 2H), 2.06-1.85 (m,3H). Human αVβ6 IC50 (nM)=213.

Example 10(±)-3-(3-Fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrrol-2-yl)propanoicAcid

Example 10A

To a stirred suspension of NaH (60% in mineral oil) (0.138 g, 3.45 mmol)in THF (19.16 mL) at 23° C. was added 4-bromo-1H-pyrrole-2-carbaldehyde(0.500 g, 2.87 mmol) and the reaction mixture stirred at 23° C. under N₂for 1 h. TsCl (0.603 g, 3.16 mmol) was added and the reaction mixturestirred at 23° C. under N₂ for 23 h. The reaction mixture was quenchedwith sat. NH₄Cl and extracted with EtOAc. The organic layer was washedwith water, brine, dried over anhydrous Na₂SO₄, filtered andconcentrated. The crude product was purified by chromatography (0 to 25%hexanes/EtOAc) to yield Example 10A (0.774 g, 2.358 mmol, 82% yield) asa white solid. ¹H NMR (500 MHz, CDCl₃) δ 9.96 (s, 1H), 7.84-7.78 (m,2H), 7.58 (d, J 1.7 Hz, 1H), 7.36 (d, J=8.0 Hz, 2H), 7.11 (d, J=1.9 Hz,1H), 2.45 (s, 3H). LCMS (ES): m/z 330.1 [M+H]⁺.

Example 10B

A solution of Example 10A (0.544 g, 1.658 mmol) and ethyl2-(triphenylphosphoranylidene)acetate (0.722 g, 2.072 mmol) in toluene(5.31 mL) were heated at 90° C. for 2 h. The reaction mixture was cooledto room temperature and the solvent was removed in vacuo. The crudeproduct was purified by chromatography (0 to 30% hexanes/EtOAc) to yieldExample 10B (0.347 g, 0.871 mmol, 53% yield). LCMS (ES): m/z 398.3[M+H]⁺. ¹H NMR (500 MHz, DMSO) δ 7.89 (d, J=16.0 Hz, 1H), 7.85 (d, J=1.4Hz, 1H), 7.80 (d, J=8.3 Hz, 2H), 7.50 (d, J=8.3 Hz, 2H), 7.26 (d, J=1.4Hz, 1H), 6.46 (d, J=16.0 Hz, 1H), 4.18 (q, J=7.1 Hz, 2H), 2.39 (s, 3H),1.25 (t, J=7.2 Hz, 3H).

Example 10C

To a degassed solution of (3-fluoro-4-methoxyphenyl)boronic acid (0.296g, 1.743 mmol) and Example 10B (0.347 g, 0.871 mmol) in dioxane (8.71mL) was added KOH (1M aq.) (1.743 mL, 1.743 mmol) andchloro(1,5-cyclooctadiene)rhodium(I) dimer (0.052 g, 0.105 mmol). Themixture was degassed for 10 min and heated at 100° C. for 1 h. Thereaction mixture was cooled to room temperature, diluted with water andextracted with EtOAc (3×). The combined organic layers were dried overanhydrous Na₂SO₄, filtered and concentrated. The crude was purified byflash chromatography (0 to 25% hexanes/EtOAc) to yield Example 10C(0.264 g, 0.503 mmol, 58% yield) as a clear oil. LCMS (ES): m/z 524.3[M+H]⁺.

Example 10D

A mixture of Example 10C (0.264 g, 0.503 mmol), pent-4-yn-2-ol (0.071mL, 0.755 mmol), triethylamine (0.281 mL, 2.014 mmol),bis(triphenylphosphine)palladium(II) chloride (0.021 g, 0.030 mmol) andcopper(I) iodide (3.84 mg, 0.020 mmol) in DMF (2.52 mL) was stirred at80° C. for 18 h. The reaction mixture was cooled to room temperature,diluted with EtOAc and washed with 10% aq. LiCl. The organic layer waswashed with brine, dried over anhydrous Na₂SO₄, filtered andconcentrated. The crude product was purified by flash chromatography (0to 50% hexanes/ethyl acetate) to yield Example 10D (0.122 g, 0.231 mmol,46% yield) as a yellow oil. LCMS (ES): m/z 528.5 [M+H]⁺.

Example 10E

A mixture of Example 10D (0.120 g, 0.227 mmol) and Pd/C (0.073 g, 0.068mmol) in EtOH (1.995 mL) was stirred under a H₂ atmosphere (balloon, 1atm, 0.458 mg, 0.227 mmol) for 2.5 h. After filtration through a pad ofCELITE® and concentration, Example 10E (0.110 g, 0.207 mmol, 91% yield)was isolated as a clear oil which was used in the next step withoutfurther purification. LCMS (ES): m/z 532.2 [M+H]⁺.

Example 10F

To a solution of Example 10E (0.110 g, 0.207 mmol) in CH₂Cl₂ (1.035 mL)at room temperature was added Dess-Martin periodinane (0.105 g, 0.248mmol) and the reaction mixture stirred at room temperature for 2 h. Themixture was diluted with Et₂O, filtered through CELITE® and the filtratewas concentrated. The crude product was purified by flash chromatography(0 to 35% hexanes/ethyl acetate) to yield Example 10F (0.0613 g, 0.116mmol, 56% yield) as a light yellow oil. LCMS (ES): m/z 530.5 [M+H]⁺. ¹HNMR (500 MHz, CD₃OD) δ 7.36 (d, J=8.3 Hz, 2H), 7.15 (d, J=8.3 Hz, 2H),7.12 (s, 1H), 6.89-6.80 (m, 1H), 6.79-6.72 (m, 1H), 6.56 (dd, J=12.5,2.1 Hz, 1H), 6.21 (d, J=1.1 Hz, 1H), 4.98 (t, J=8.1 Hz, 1H), 4.01 (q,J=7.2 Hz, 2H), 3.82 (s, 3H), 2.89-2.69 (m, 2H), 2.45 (dt, J=18.1, 7.3Hz, 4H), 2.35 (s, 3H), 2.11 (s, 3H), 1.85-1.75 (m, 2H), 1.10 (t, J=7.2Hz, 3H).

Example 10G

To a solution of Example 10F (60 mg, 0.113 mmol) in CH₂Cl₂ (0.100 mL)and EtOH (0.300 mL) was added pyrrolidine (0.011 mL, 0.136 mmol)followed by 2-aminonicotinaldehyde (13.84 mg, 0.113 mmol). The mixturewas then stirred at room temperature overnight. The crude product waspurified by flash chromatography (0 to 50% DCM/EtOAc) to give Example10G (58 mg, 83%). LCMS (ES): m/z 616.6 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ9.12 (dd, J=4.1, 1.9 Hz, 1H), 8.19 (dd, J=8.0, 1.9 Hz, 1H), 8.13 (d,J=8.3 Hz, 1H), 7.48 (dd, J=8.1, 4.3 Hz, 1H), 7.39 (d, J=8.3 Hz, 3H),7.16-7.04 (m, 3H), 6.80-6.76 (m, 2H), 6.62 (dd, J=12.4, 1.9 Hz, 1H),6.09 (s, 1H), 4.98 (t, J=8.0 Hz, 1H), 4.08-3.99 (m, 2H), 3.84 (s, 3H),3.10 (t, J=7.7 Hz, 2H), 2.83 (d, J=7.4 Hz, 1H), 2.76-2.67 (m, 1H), 2.56(t, J=7.6 Hz, 2H), 2.36 (s, 3H), 2.25-2.14 (m, 2H), 1.14 (t, J=7.2 Hz,3H).

Example 10H

A solution of Example 10G (57.9 mg, 0.094 mmol) and PtO₂ (4.27 mg, 0.019mmol) in EtOH (1.710 mL) was stirred under an H₂ (balloon, 1 atm) for 20h. The solvent was removed in vacuo. This material was purified by Prep.HPLC (XBridge Prep C18 5μ OBD 19×100 mm, 10 min gradient, 15 min run,15% to 100% Solvent B=90% MeOH-10% H₂O-0.1% TFA, Solvent A=10% MeOH-90%H₂O-0.1% TFA to yield Example 10H (49.6 mg, 0.068 mmol, 72% yield). LCMS(ES): m/z 620.6 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.54 (d, J=7.4 Hz,1H), 7.38-7.30 (m, 2H), 7.19-7.08 (m, 3H), 6.82 (d, J=8.5 Hz, 1H),6.78-6.73 (m, 1H), 6.57 (d, J=7.4 Hz, 1H), 6.52 (dd, J=12.5, 2.1 Hz,1H), 6.22 (d, J=1.4 Hz, 1H), 4.96 (t, J=8.0 Hz, 1H), 4.01 (q, J=7.1 Hz,2H), 3.81 (s, 3H), 3.53-3.46 (m, 2H), 2.84-2.75 (m, 4H), 2.71 (t, J=7.7Hz, 2H), 2.54 (t, J=7.3 Hz, 2H), 2.34 (s, 3H), 2.01-1.92 (m, 4H), 1.10(t, J=7.2 Hz, 3H).

Example 10

To a solution of Example 10H (49.6 mg, 0.068 mmol) in EtOH (0.500 mL)was added NaOH (0.169 mL, 0.338 mmol) and the reaction mixture stirredat room temperature overnight. The solvent was removed in vacuo andpurification by via preparative LC/MS with the following conditions:Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5acetonitrile:water with 10-mM ammonium acetate; Gradient: 3-40% B over25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. to giveExample 10 (14 mg, 44%). LCMS (ES): m/z 438.2 [M+H]⁺. ¹H NMR (500 MHz,CD₃OD) δ 7.43 (d, J=7.4 Hz, 1H), 7.02-6.83 (m, 4H), 6.51 (d, J=7.3 Hz,1H), 5.86 (s, 1H), 4.36 (dd, J=9.3, 6.6 Hz, 1H), 3.81 (s, 3H), 3.45 (t,J=5.5 Hz, 2H), 2.86-2.80 (m, 1H), 2.76 (t, J=6.1 Hz, 2H), 2.73-2.68 (m,1H), 2.58 (t, J=7.7 Hz, 2H), 2.53-2.40 (m, 2H), 1.95-1.86 (m, 4H). HumanαVβ6 IC50 (nM)=136.

Example 11(±)-3-(6-Methoxypyridin-3-yl)-3-(1-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-pyrazol-4-yl)propanoicAcid

Example 11A

To a solution of Example 7D (70 mg, 0.139 mmol) in acetonitrile (3 mL)was added 6-chlorohexan-2-one (70 mg, 0.520 mmol) and Cs₂CO₃ (200 mg,0.614 mmol). The mixture was stirred at room temperature overnight. Thesolid was filtered and the filtrate concentrated. Purification by flashchromatography gave Example 11A (58 mg, 61%). LCMS (ES): m/z 374.4[M+H]⁺.

Example 11 was prepared from Example 11A according to the methoddescribed in Example 10. LCMS (ES): m/z 436.2 [M+H]⁺. ¹H NMR (500 MHz,CD₃OD) δ 8.04 (s, 1H), 7.75 (s, 1H), 7.67-7.59 (m, 1H), 7.40 (br d,J=7.2 Hz, 1H), 7.30 (s, 1H), 6.75 (d, J=8.6 Hz, 1H), 6.43 (br d, J=7.2Hz, 1H), 4.37 (br dd, J=10.4, 6.2 Hz, 1H), 4.26-4.04 (m, 2H), 3.87 (s,3H), 3.44 (br t, J=5.3 Hz, 2H), 2.89-2.68 (m, 4H), 2.57-2.40 (m, 2H),1.95-1.77 (m, 4H), 1.49-1.14 (m, 2H). Human αVβ6 IC50 (nM)=100.

Example 12(S)-3-(6-Hydroxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

Example 12

A mixture of Example 3 (10 mg, 0.024 mmol) and pyridine hydrochloride(34.3 mg, 0.297 mmol) was heated at 125° C. for 7.5 min. The reactionmixture was cooled to room temperature. This material was purified byPrep. HPLC (Phenomenex Luna AXIA 5u C18 21.2×100 mm, 10 min gradient, 12min run, 0% to 100% Solvent B=90% ACN-10% H₂O-0.1% TFA, Solvent A=10%ACN-90% H₂O-0.1% TFA) to give Example 12 (2.8 mg, 29%). ¹H NMR (400 MHz,CD₃OD) δ 7.62-7.53 (m, 2H), 7.42-7.34 (m, 2H), 6.51-6.42 (m, 2H), 6.10(d, J=2.4 Hz, 1H), 5.62 (dd, J=9.0, 6.4 Hz, 1H), 3.48-3.40 (m, 2H), 3.10(dd, J=14.7, 9.0 Hz, 1H), 2.94 (dd, J=14.6, 6.3 Hz, 1H), 2.76 (t, J=6.2Hz, 2H), 2.64-2.55 (m, 4H), 2.04-1.95 (m, 2H), 1.89 (br. s., 2H). LCMS(ES): m/z 408.4 [M+H]⁺. Human αVβ6 IC50 (nM)=31.

Example 13 (Enantiomer 1) and Example 14 (Enantiomer 2)3-(6-Methoxypyridin-3-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicAcid (Chiral)

Example 13A

To a stirred solution of 4-bromothiazole-2-carbaldehyde (2 g, 10.41mmol) in toluene (30 mL) under nitrogen atmosphere was added(carbethoxymethylene)triphenylphosphorane (4.35 g, 12.5 mmol) and theresulting reaction mixture was stirred at 100° C. for 16 h. The reactionmixture was concentrated and the crude product was purified bycombiflash chromatography (24 g Redisep® SiO₂ column, eluting with 23%EtOAc in n-hexanes) to afford 13A (2 g, 73%) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ 7.67 (d, J=16.00 Hz, 1H), 7.29 (s, 1H), 6.75 (d,J=15.6 Hz, 1H), 4.28 (q, J=7.20 Hz, 2H), 1.33 (t, J=7.20 Hz, 3H). LCMS(ES): m/z 264.2 [M+H]⁺.

Example 13B

A stirred solution of Example 13A in 1,4-dioxane (10 mL) and water (1mL) was purged with argon for 5 min.Chloro(1,5-cyclooctadiene)rhodium(I) dimer (47 mg, 0.095 mmol) and TEA(0.53 mL, 3.81 mmol) were added and the resulting reaction mixture wasstirred at 85° C. for 16 h. The reaction mixture was slowly poured intowater (50 mL) and extracted with EtOAc (2×20 mL). The combined organiclayer was washed with brine (50 mL), dried (Na₂SO₄), filtered andconcentrated. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 22% EtOAc inn-hexanes) to afford 13B (230 mg, 33%) as a pale brown oil. ¹H NMR (400MHz, CDCl₃) δ 8.13 (d, J=2.40 Hz, 1H), 7.55 (dd, J=2.80, 8.60 Hz, 1H),7.10 (s, 1H), 6.71 (d, J=8.40 Hz, 1H), 4.75 (t, J=7.60 Hz, 1H), 4.07 (q,J=6.40 Hz, 2H), 3.91 (s, 3H), 3.42 (dd, J=7.20, 16.00 Hz, 1H), 2.96 (dd,J=7.20, 16.80 Hz, 1H), 1.17 (t, J=7.20 Hz, 3H). LCMS (ES): m/z 371.0[M+H]⁺.

Example 13C

To a stirred solution of Example 13B (300 mg, 0.81 mmol) and2-(but-3-en-1-yl)-1,8-naphthyridine (149 mg, 0.81 mmol) in acetonitrile(4 mL) under argon atmosphere was added tri-o-tolylphosphine (36.9 mg,0.121 mmol), palladium(II) acetate (18.14 mg, 0.081 mmol) and TEA (0.282mL, 2.0 mmol) and the resulting reaction mixture was stirred at 80° C.for 16 h. The reaction mixture was cooled to room temperature, filtered,concentrated and the crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 4% MeOH inCHCl₃) to afford 13C (320 mg, 83%) as a brown oil. LCMS (ES): m/z 475.0[M+H]⁺.

Example 13D

To a solution of Example 3C (200 mg, 0.421 mmol) in ethanol (8 mL) wasadded platinum(IV) oxide (2 mg, 8.81 μmol) under nitrogen atmosphere.The reaction mixture was purged with hydrogen and stirred under hydrogenbladder pressure at room temperature for 16 h. The reaction mixture wasfiltered and the filtrate was concentrated to afford 13D (180 mg, 63%)as a pale yellow oil (crude). LCMS (ES): m/z 481.4 [M+H]⁺.

Example 13 and Example 14

To a stirred solution of Example 13D (150 mg, 0.312 mmol), in THF (3 mL)and methanol (3 mL) mixture was added a solution of LiOH.H₂O (15 mg,0.31 mmol) in water (3 mL) and the resulting reaction mixture wasstirred at room temperature for 4 h. Then citric acid (120 mg, 0.624mmol) was added and the mixture was stirred further at room temperaturefor 1 h. The reaction mixture was filtered, concentrated and the cruderacemic product was purified by preparative HPLC (Column: INTERSIL ODSC18 (250×19) mm 5 micron; M.Phase A: 10 mM NH₄OAc in water; M.Phase B:Acetonitrile, flow rate: 17.0 mL/min; time (min)/% B: 0/20, 8/40, 14/60;Detection: UV at 254 nm) followed by chiral preparative HPLC (Column:Lux-cellulose C4 (250×21.2) mm 5 micron column; flow rate: 19.0 mL/min;Mobile Phase B: 0.1% DEA in MeOH; time (min)/% B: 0/100, 20/100,temperature: 35° C.; Detection: UV at 254 nm) to afford Example 13 (35mg, 27%) as a white solid (first-eluting isomer). LCMS (ES): m/z 453.2[M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.14 (d, J=1.20 Hz, 1H), 7.72 (dd,J=8.60 & 2.40 Hz, 1H), 7.42 (d, J=5.20 Hz, 1H), 6.99 (s, 1H), 6.78 (d,J=7.20 Hz, 1H), 6.46 (d, J=7.60 Hz, 1H), 4.81-4.81 (m, 1H), 3.90 (s,3H), 3.48-3.47 (m, 2H), 3.30-3.40 (m, 1H), 2.77-2.86 (m, 5H), 2.56-2.65(m, 2H), 1.91-1.95 (m, 3H), 1.71-1.74 (m, 1H), 1.46-1.49 (m, 2H). HumanαVβ6 IC50 (nM)=77. Example 14 (32 mg, 24%) was isolated as thesecond-eluting isomer as a white solid. LCMS (ES): m/z 453.2 [M+H]⁺ 0.1HNMR (400 MHz, CD₃OD) δ 8.14 (d, J=1.20 Hz, 1H), 7.72 (dd, J=8.60 & 2.40Hz, 1H), 7.42 (d, J=5.20 Hz, 1H), 6.99 (s, 1H), 6.78 (d, J=7.20 Hz, 1H),6.46 (d, J=7.60 Hz, 1H), 4.81-4.81 (m, 1H), 3.90 (s, 3H), 3.48-3.47 (m,2H), 3.30-3.40 (m, 1H), 2.77-2.86 (m, 5H), 2.56-2.65 (m, 2H), 1.91-1.95(m, 3H), 1.71-1.74 (m, 1H), 1.46-1.49 (m, 2H). Human αVβ6 IC50 (nM)=2.1;Human αVβ6 IC50 (nM)=241; Human αVβ3 IC50 (nM)=1.9; Human αVβ5 IC50(nM)=11; and Human αVβ8 IC50 (nM)=510.

Example 15 (Enantiomer 1) and Example 16 (Enantiomer 2)3-(6-Methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

Example 15A

To a stirred solution of Example 13B (400 mg, 1.08 mmol), pent-4-yn-2-ol(109 mg, 1.29 mmol) in TEA (8 mL) under nitrogen atmosphere was addedcopper(I) iodide (10.26 mg, 0.05 mmol) followed bybis(triphenylphosphine)palladium (II) dichloride (38 mg, 0.05 mmol) andthe resulting reaction mixture was degassed with argon gas for 2 min andthen stirred at 80° C. for 16 h. The reaction mixture was filtered,concentrated and the crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 54% EtOAc in petether) to afford 15A (190 mg, 47%) as a pale yellow oil. ¹H NMR (400MHz, CDCl₃) δ 8.14 (d, J=2.40 Hz, 1H), 7.56 (dd, J=8.80 & 2.40 Hz, 1H),7.27 (s, 1H), 6.71 (d, J=8.40 Hz, 1H), 4.73 (t, J=7.20 Hz, 1H), 4.08 (q,J=7.20 Hz, 2H), 3.90-4.00 (m, 1H), 3.92 (s, 3H), 3.44 (dd, J=16.00 &6.80 Hz, 1H), 2.96 (dd, J=12.40 & 8.00 Hz, 1H), 2.50-2.60 (m, 2H), 1.28(d, J=12.00 Hz, 3H), 1.19 (t, J=7.20 Hz, 3H). LCMS (ES): m/z 375.0[M+H]⁺.

Example 15B

To a degassed solution of Example 15A (200 mg, 0.534 mmol) in EtOH (5mL) was added 10% palladium on carbon (2 mg, 0.019 mmol) and theresulting reaction mixture was stirred under hydrogen bladder pressureat room temperature for 16 h. The reaction mixture was filtered throughCELITE® pad and the filtrate concentrated to afford 15B (170 mg, 84%) asa pale yellow oil. LCMS (ES): m/z 379.4 [M+H]⁺.

Example 15C

To a solution of Example 15B (300 mg, 0.79 mmol) in dichloromethane (15mL) was added DMP (672 mg, 1.59 mmol) at 0° C. and the resulting mixturewas stirred at room temperature for 60 min. The reaction mass wasdiluted with dichloromethane (20 mL), washed with 20% sodium bicarbonatesolution (20 mL), brine solution (10 mL), dried (Na₂SO₄), filtered andthe filtrate concentrated. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 62% EtOAc in petether) to afford 15C (150 mg, 50%) as a pale yellow oil. ¹H NMR (400MHz, CDCl₃) δ 8.16 (d, J=2.40 Hz, 1H), 7.58 (dd, J=8.80 & 2.40 Hz, 1H),6.75 (s, 1H), 6.70 (d, J=8.40 Hz, 1H), 4.76 (t, J=7.60 Hz, 1H), 4.11 (q,J=7.20 Hz, 2H), 3.94 (s, 3H), 3.40 (dd, J=16.40 & 6.80 Hz, 1H), 2.95(dd, J=16.0 & 8.40 Hz, 1H), 2.70-2.80 (m, 2H), 2.45-2.55 (m, 2H), 2.15(s, 3H), 1.90-2.00 (m, 2H), 1.12 (t, J=7.20 Hz, 3H). LCMS (ES): m/z377.0 [M+H]⁺.

Example 15D

To a solution of Example 15C (130 mg, 0.35 mmol) and2-aminonicotinaldehyde (51 mg, 0.41 mmol) in ethanol (5 mL) undernitrogen was added pyrrolidine (0.029 mL, 0.35 mmol) and the resultingmixture was stirred at 70° C. for 4 h. The reaction mixture wasconcentrated and the crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 100% EtOAc toafford 15D (150 mg, 82%) as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ9.08 (d, J=2.40 Hz, 1H), 8.15 (d, J=1.60 Hz, 1H), 8.14 (d, J=2.0 Hz,1H), 8.09 (d, J=8.4 Hz, 1H), 7.57 (dd, J=8.80 & 2.40 Hz, 1H), 7.45 (dd,J=8.80 & 2.80 Hz, 1H), 7.38 (d, J=8.40 Hz, 1H), 6.79 (s, 1H), 6.70 (d,J=8.40 Hz, 1H), 4.76 (t, J=7.60 Hz, 1H), 4.06 (q, J=7.20 Hz, 2H), 3.92(s, 3H), 3.40 (dd, J=16.40 & 6.80 Hz, 1H), 3.10 (dd, J=16.0 & 7.60 Hz,2H), 2.99 (dd, J=16.0 & 8.40 Hz, 1H), 2.86 (t, J=7.20 Hz, 2H), 2.33 (m,2H), 1.15 (t, J=7.20 Hz, 3H). LCMS (ES): m/z 463.2 [M+H]⁺.

Example 15E

To a stirred solution of Example 15D (180 mg, 0.39 mmol) in ethanol (8mL) was added platinum(IV) oxide (2 mg, 8.81 μmol) under nitrogenatmosphere and the reaction mixture was purged with hydrogen and stirredunder hydrogen bladder pressure at room temperature for 16 h. Thereaction mixture was filtered and the filtrate concentrated to afford15E (170 mg, 94%) as a pale yellow oil. ¹H NMR (400 MHz, CD₃OD) δ 8.13(d, J=3.20 Hz, 1H), 7.68 (dd, J=11.20 & 3.20 Hz, 1H), 7.35 (d, J=10.0Hz, 1H), 7.05 (s, 1H), 6.77 (d, J=11.0 Hz, 1H), 6.49 (d, J=8.40 Hz, 1H),4.80-4.90 (m, 1H), 4.06 (q, J=7.20 Hz, 2H), 3.90 (s, 3H), 3.40-3.50 (m,3H), 3.10 (dd, J=16.0 & 7.60 Hz, 1H), 2.70-2.80 (m, 4H), 2.65 (t, J=10.0Hz, 2H), 2.06 (t, J=10.0 Hz, 2H), 1.90-2.00 (m, 2H), 1.15 (t, J=7.20 Hz,3H). LCMS (ES): m/z 467.2 [M+H]⁺.

Example 15 and Example 16

To a stirred solution of Example 15E (150 mg, 0.32 mmol) in THF (3 mL)and methanol (3 mL) was added a solution of LiOH.H₂O (15 mg, 0.64 mmol)in water (3 mL) and the resulting reaction mixture was stirred at roomtemperature for 4 h. Then citric acid (124 mg, 0.64 mmol) was added andthe mixture stirred further at room temperature for 1 h. The reactionmixture was filtered, concentrated and the crude racemic product waspurified by preparative HPLC (Column: SYMMETRY C18 (250×19) mm 5 micron;M.Phase A: 10 mM NH₄OAc in water (Ph=4.5); M.Phase B: Acetonitrile, flowrate: 18.0 mL/min; time (min)/% B: 0/20, 5/40, 14/60; Detection: UV at254 nm) and then separated into individual enantiomers by chiral SFC(Chiralpak AD-H (250×21) mm, 5u;% CO₂: 60%; % Co solvent: 40%(0.2% DEAin methanol); Total Flow: 70 g/min; back pressure: 100 bar; temperature:25° C.; detection: UV at 238 nm.) to afford Example 15 (30 mg, 21%) as awhite solid (first-eluting isomer). ¹H NMR (400 MHz, CD₃OD) δ 8.14 (d,J=1.20 Hz, 1H), 7.69 (dd, J=2.80, 8.60 Hz, 1H), 7.47 (d, J=7.20 Hz, 1H),7.04 (s, 1H), 6.80 (d, J=8.80 Hz, 1H), 6.56 (d, J=7.60 Hz, 1H),4.75-4.80 (m, 1H), 3.91 (s, 3H), 3.42-3.50 (m, 2H), 3.15-3.16 (m, 1H),2.76-2.87 (m, 5H), 2.55-2.61 (m, 2H), 1.95-2.14 (m, 2H), 1.92-1.93 (m,2H). LCMS (ES): m/z 439.2 [M+H]⁺. Human αVβ6 IC50 (nM)=0.7; Human αVβ1IC50 (nM)=55; Human αVβ3 IC50 (nM)=1.4; and Human αVβ8 IC50 (nM)=330.Example 16 (31 mg, 22%, white solid) was isolated as a second-elutingisomer. ¹H NMR (400 MHz, CD₃OD) δ 8.14 (d, J=1.20 Hz, 1H), 7.69 (dd,J=2.80, 8.60 Hz, 1H), 7.47 (d, J=7.20 Hz, 1H), 7.04 (s, 1H), 6.80 (d,J=8.80 Hz, 1H), 6.56 (d, J=7.60 Hz, 1H), 4.75-4.80 (m, 1H), 3.91 (s,3H), 3.42-3.50 (m, 2H), 3.15-3.16 (m, 1H), 2.76-2.87 (m, 5H), 2.55-2.61(m, 2H), 1.95-2.14 (m, 2H), 1.92-1.93 (m, 2H). LCMS (ES): m/z 439.2[M+H]⁺. Human αVβ6 IC50 (nM)=36.

Example 17 (Enantiomer 1) and Example 18 (Enantiomer 2)3-(6-Methoxypyridin-3-yl)-3-(5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicAcid

Example 17A

To a solution of triethyl phosphonoacetate (12.88 g, 57.5 mmol) in THF(100 mL) at 0° C. was added NaH (2.12 g, 53 mmol) portion-wise and theresulting reaction mixture was stirred at the same temperature for 1 h.Thiazole-2-carbaldehyde (5 g, 44 mmol) in THF (100 mL) was added and theresulting reaction mixture was stirred at room temperature for 16 h. Thereaction mixture was quenched with ice-cold water (100 mL) and extractedwith EtOAc (2×200 mL). The combined organic layer was washed with water,brine, dried (Na₂SO₄), filtered and the filtrate concentrated to afford17A (6 g, 74%) as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 7.20 (d,J=3.30 Hz, 1H), 7.80 (d, J=15.0 Hz, 1H), 7.42 (d, J=3.30 Hz, 1H), 6.71(d, J=15.0 Hz, 1H), 4.28 (q, J=7.20 Hz, 2H), 1.34 (t, J=7.20 Hz, 3H).

Example 17B

To a stirred solution of Example 17A (2 g, 10.92 mmol) in dioxane (45mL) and water (15 mL) was added (6-methoxypyridin-3-yl)boronic acid(2.50 g, 16.37 mmol) and the resulting reaction mixture was purged withargon for 10 min. TEA (1.37 mL, 9.82 mmol) andchloro(1,5-cyclooctadiene)rhodium(I) dimer (0.27 g, 0.55 mmol) was addedand the resulting reaction mixture was heated to 80° C. and stirred for16 h. The reaction mixture was cooled to room temperature, diluted withwater (50 mL) and extracted with EtOAc (2×50 mL). The combined organiclayer was dried (Na₂SO₄), filtered and the filtrate concentrated. Thecrude product was purified by combiflash chromatography (40 g Redisep®SiO₂ column, eluting with 25% EtOAc in n-hexanes) to afford 17B (1 g,31%) as a pale brown solid. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J=2.8 Hz,1H), 7.70 (d, J=3.2 Hz, 1H), 7.55 (dd, J=8.4 & 2.40 Hz, 1H), 7.21 (s,1H), 6.69 (s, 1H), 4.82 (t, J=7.60 Hz, 1H), 4.08 (q, J=7.20 Hz, 2H),3.92 (s, 3H), 3.42 (dd, J=16.0 & 7.20 Hz, 1H), 2.99 (dd, J=16.0 & 7.20Hz, 1H), 1.17 (t, J=7.20 Hz, 3H). LCMS (ES): m/z 293.2 [M+H]⁺.

Example 17C

To a stirred solution of Example 17B (700 mg, 2.39 mmol) in DMF (10 mL)was added NBS (639 mg, 3.59 mmol) portion-wise at room temperature andthe resulting reaction mixture was stirred at room temperature for 40 h.The reaction mixture was diluted with ice-cold water (10 mL) andextracted with EtOAc (2×25 mL). The combined organic layer was washedwith water, brine, dried (Na₂SO₄), filtered and the filtrateconcentrated. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 10% EtOAc inn-hexanes) to afford 17C (300 mg, 34%) as a brown oil. ¹H NMR (300 MHz,CDCl₃) δ 8.11 (s, 1H), 7.45-7.60 (m, 2H), 6.71 (d, J=8.70 Hz, 1H), 4.71(t, J=7.60 Hz, 1H), 4.09 (q, J=7.20 Hz, 2H), 3.92 (s, 3H), 3.38 (dd,J=16.0 & 7.2 Hz, 1H), 2.92 (dd, J=16.0 & 7.2 Hz, 1H), 1.18 (t, J=7.20Hz, 3H). LCMS (ES): m/z 373.0 [M+H]⁺.

Example 17D

To a stirred solution of Example 17C (100 mg, 0.27 mmol) in acetonitrile(5 mL) was added 2-(but-3-en-1-yl)-1,8-naphthyridine (74.4 mg, 0.4 mmol)and the reaction mixture was purged with nitrogen for 10 min.Triethylamine (82 mg, 0.808 mmol), tri-o-tolylphosphine (8.20 mg, 0.027mmol), palladium acetate (6.1 mg, 0.027 mmol) were added and thereaction mixture was heated to 90° C. and stirred for 16 h. The reactionmixture was cooled to room temperature, filtered through CELITE®, andthe filtrate was diluted with water (5 mL) and extracted with DCM (2×10mL). The combined organic layer was dried (Na₂SO₄), filtered and thefiltrate concentrated. The crude product was purified by combiflashchromatography (4 g Redisep® SiO₂ column, eluting with 3% methanol inchloroform to afford 17D (85 mg, 49%) as a pale brown oil. LCMS (ES):m/z 475.2 [M+H]⁺.

Example 17E

Example 17D (85 mg, 0.13 mmol) in ethanol (5 mL) was purged withnitrogen for 5 min. Platinum(IV) oxide (10 mg, 0.044 mmol) was added andthe resulting reaction mixture was stirred at room temperature underhydrogen balloon atmosphere for 16 h. The reaction mixture was filteredthrough a CELITE® pad and the filtrate concentrated to afford 17E (70mg, 81%) as a pale brown oil. ¹H NMR (400 MHz, CD₃OD) δ 8.11 (s, 1H),7.67 (dd, J=8.80 & 2.40 Hz, 1H), 7.40 (s, 1H), 7.16 (d, J=7.20 Hz, 1H),6.78 (d, J=8.40 Hz, 1H), 6.35 (d, J=7.20 Hz, 1H), 4.75-4.85 (m, 1H),4.08 (q, J=7.20 Hz, 2H), 3.91 (s, 3H), 3.35-3.45 (m, 2H), 3.00-3.10 (m,1H), 2.80-2.90 (m, 2H), 2.65-2.75 (m, 2H), 2.50-2.60 (m, 2H), 1.90-2.00(m, 2H), 1.60-1.70 (m, 3H), 1.25-1.40 (m, 2H), 1.15 (t, J=7.20 Hz, 3H).LCMS (ES): m/z 481.0 [M+H]⁺.

Example 17 and Example 18: To a stirred solution of Example 17E (70 mg,0.146 mmol) in THF (2 mL) and MeOH (2 mL) was added a solution ofLiOH.H₂O (12.22 mg, 0.29 mmol) in water (1 mL) and the resultingreaction mixture was stirred at room temperature for 40 h. Aftercompletion of the reaction, citric acid (22.39 mg, 0.117 mmol) was addedand the reaction mixture was stirred further at room temperature for 10min. The reaction mixture was concentrated and the crude product waspurified by preparative reverse phase HPLC (Sunfire C18 (150×19) mm, 5micron); Mobile Phase A: 10 mM CH₃COONH₄ in water; Mobile Phase B:Acetonitrile; flow rate: 17 mL/min; Time (min)/% B: 0/20, 24/70) andthen separated into individual enantiomers by chiral SFC (Chiralpak AD-H(250×21) mm, 5u; 60% CO₂ and 40% DEA in methanol as co-solvent); TotalFlow: 75 g/min; Back Pressure: 100 bar; Temperature: 25° C.; Detection:UV at 247 nM) to afford Example 17 (9 mg, 13%) as a white solid(first-eluting isomer). LCMS (ES): m/z 453.2 [M+H]⁺. ¹H NMR (400 MHz,CD₃OD) δ 8.01 (d, J=2.40 Hz, 1H), 7.60 (dd, J=2.40, 8.80 Hz, 1H), 7.27(s, 1H), 7.24 (d, J=3.20 Hz, 1H), 6.65 (d, J=8.80 Hz, 1H), 6.34 (d,J=7.20 Hz, 1H), 4.66 (dd, J=6.80, 9.20 Hz, 1H), 3.77 (s, 3H), 3.29-3.36(m, 2H), 3.01-3.15 (m, 1H), 2.71-2.84 (m, 3H), 2.65 (t, J=6.27 Hz, 2H),2.41 (t, J=7.28 Hz, 2H) 1.71-1.88 (m, 2H), 1.43-1.67 (m, 4H). Human αVβ6IC50 (nM)=16. Example 18 (8 mg, 12%, white solid) was isolated as thesecond-eluting isomer. ¹H NMR (400 MHz, CD₃OD) δ 8.01 (d, J=2.40 Hz,1H), 7.60 (dd, J=2.40, 8.80 Hz, 1H), 7.27 (s, 1H), 7.24 (d, J=3.20 Hz,1H), 6.65 (d, J=8.80 Hz, 1H), 6.34 (d, J=7.20 Hz, 1H), 4.66 (dd, J=6.80,9.20 Hz, 1H), 3.77 (s, 3H), 3.29-3.36 (m, 2H), 3.01-3.15 (m, 1H),2.71-2.84 (m, 3H), 2.65 (t, J=6.27 Hz, 2H), 2.41 (t, J=7.28 Hz, 2H)1.71-1.88 (m, 2H), 1.43-1.67 (m, 4H). LCMS (ES): m/z 453.2 [M+H]⁺. HumanαVβ6 IC50 (nM)=6.7.

Example 19 (Enantiomer 1) and Example 20 (Enantiomer 2)3-(6-Methoxypyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

Example 19A

To a stirred solution of Example 17C (300 mg, 0.808 mmol),pent-4-yn-2-ol (204 mg, 2.424 mmol) in TEA (10 mL) under nitrogenatmosphere was added copper(I) iodide (15 mg, 0.081 mmol) followed byPdCl₂(PPh₃)₂ (57 mg, 0.081 mmol) and the reaction mixture was degassedwith argon for 2 min and then heated at 80° C. for 16 h. The reactionmixture was filtered, washed with EtOAc (5 mL), filtrate wasconcentrated. The crude product was purified by combiflashchromatography (24 g Redise® SiO₂ column, eluting with 20% EtOAc in petether) to afford 19A (300 mg, 94%) as a brown oil. LCMS (ES): m/z 375.0[M+H]⁺.

Example 19B

To a degassed solution of Example 19A (280 mg, 0.748 mmol) in EtOH (2mL) was added 10% palladium on carbon (28 mg, 0.026 mmol) and theresulting reaction mixture was stirred under hydrogen pressure at roomtemperature for 40 h. The reaction mixture was filtered through CELITE®pad and the filtrate concentrated to afford 19B (250 mg, 88%) as a paleyellow oil. LCMS (ES): m/z 379.0 [M+H]⁺.

Example 19C

To a solution of Example 19B (250 mg, 0.661 mmol) in dichloromethane (2mL) was added Dess Martin periodinane (560 mg, 1.321 mmol) at 0° C. andthe resulting mixture was stirred at room temperature for 16 h. Thereaction mass was diluted with dichloromethane (20 mL), washed with 20%sodium bicarbonate solution (20 mL), brine solution (10 mL), dried oversodium sulphate, filtered and the filtrate concentrated. The crudeproduct was purified by combiflash chromatography (12 g Redisep® SiO₂column, eluting with 45% EtOAc in pet ether) to afford 19C (170 mg, 68%)as a pale brown oil. ¹H NMR (400 MHz, CD₃OD) δ 8.12 (d, J=2.80 Hz, 1H),7.67 (dd, J=8.80 & 2.80 Hz, 1H), 7.41 (s, 1H), 6.78 (d, J=8.80 Hz, 1H),4.80-4.90 (m, 1H), 4.10 (q, J=7.20 Hz, 2H), 3.91 (s, 3H), 3.35-3.45 (m,1H), 3.00-3.10 (m, 1H), 2.80-2.90 (m, 2H), 2.50-2.60 (m, 2H), 2.12 (s,3H), 1.80-1.90 (m, 2H), 1.18 (t, J=7.20 Hz, 3H). LCMS (ES): m/z 377.0[M+H]⁺.

Example 19D

To a solution of Example 19C (130 mg, 0.345 mmol),2-aminonicotinaldehyde (46 mg, 0.380 mmol) in ethanol (5 mL) undernitrogen was added pyrrolidine (0.029 mL, 0.345 mmol) and the resultingreaction mixture was stirred at 80° C. for 16 h. The reaction mixtureconcentrated and the crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 3% MeOH in CHCl₃to afford 19D (100 mg, 63%) as a brown oil. ¹H NMR (400 MHz, CD₃OD) δ9.05 (s, 1H), 8.42 (s, 1H), 8.33 (d, J=8.40 Hz, 1H), 8.12 (s, 1H),7.60-7.70 (m, 2H), 7.65 (d, J=8.0 Hz, 1H), 7.54 (d, J=8.40 Hz, 1H), 6.78(d, J=8.80 Hz, 1H), 4.75-4.80 (m, 1H), 4.10 (q, J=7.20 Hz, 2H), 3.91 (s,3H), 2.95-3.20 (m, 4H), 2.20-2.30 (m, 2H), 1.30-1.45 (m, 2H), 1.15 (t,J=7.20 Hz, 3H). LCMS (ES): m/z 463.3 [M+H]⁺.

Example 19E

To a stirred solution of Example 19D (100 mg, 0.216 mmol) in ethanol (25mL) was added platinum(IV) oxide (10 mg, 0.044 mmol) under nitrogenatmosphere and the reaction mixture was purged with hydrogen and stirredunder hydrogen bladder pressure at room temperature for 16 h. Thereaction mixture was filtered and filtrate concentrated to afford 19E(80 mg, 79%) as a pale yellow oil. LCMS (ES): m/z 467.2 [M+H]⁺.

Example 19 and Example 20

A solution of Example 19E (80 mg, 0.171 mmol) in THF (2 mL) and methanol(2 mL) was added to a solution of LiOH.H₂O (29 mg, 0.686 mmol) in water(1 mL) and the resulting reaction mixture was stirred at roomtemperature for 16 h. After the completion of the reaction, citric acid(99 mg, 0.514 mmol) was added and the mixture was stirred at roomtemperature for 10 min. The reaction mixture was filtered, concentratedand the crude product was purified by preparative HPLC (Inertsil ODS(250×20) mm, 5 micron); Mobile Phase A: 10 mM CH₃COONH₄ in water; MobilePhase B: acetonitrile; flow rate: 17 mL/min; Time (min)/% B: 0/10,12/55) and then separated into individual enantiomers by chiralpreparative SFC (Chiralpak AD-H (250×21) mm, 5u; 60% CO₂ and 40% DEA inmethanol as co-solvent); Total Flow: 75 g/min; Back Pressure: 100 bar;Temperature: 25° C.; Detection: UV at 247 nM) to afford Example 19 (23mg, 20%, white solid) as the first-eluting isomer. ¹H NMR (400 MHz,CD₃OD) δ 8.11 (d, J=2.51 Hz, 1H), 7.68 (dd, J=8.53, 2.51 Hz, 1H), 7.38(s, 1H), 7.32 (d, J=7.03 Hz, 1H), 6.75 (d, J=8.53 Hz, 1H), 6.45 (d,J=7.53 Hz, 1H), 4.73-4.80 (m, 1H), 3.86 (s, 3H), 3.38-3.44 (m, 2H),3.14-3.26 (m, 1H), 2.90-2.94 (m, 1H), 2.78-2.85 (m, 2H), 2.72 (t, J=6.27Hz, 2H), 2.56-2.64 (m, 2H), 1.82-2.01 (m, 4H). LCMS (ES): m/z 439.2[M+H]⁺. Human αVβ6 IC50 (nM)=44. Example 20 (21 mg, 18%, white solid)was isolated as the second-eluting isomer. ¹H NMR (400 MHz, CD₃OD) δ8.11 (br. s., 1H), 7.68 (dd, J=8.53, 2.51 Hz, 1H), 7.38 (br. s., 1H),7.32 (d, J=7.53 Hz, 1H), 6.75 (d, J=8.53 Hz, 1H), 6.45 (d, J=7.03 Hz,1H), 4.73-4.80 (m, 1H), 3.88 (s, 3H), 3.37-3.43 (m, 2H), 3.20 (dd,J=14.81, 6.27 Hz, 1H), 2.79-2.98 (m, 3H), 2.73 (t, J=6.02 Hz, 2H), 2.61(t, J=7.78 Hz, 2H), 1.78-2.06 (m, 4H). LCMS (ES): m/z 439.2 [M+H]⁺.Human αVβ6 IC50 (nM)=18.

Example 21(3S)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)pyrrolidin-1-yl)propanoicAcid (Diastereomeric)

Example 21A

To a solution of diisopropylamine (0.994 mL, 6.98 mmol) in THF (9.44 mL)at 0° C. was added n-BuLi (1.6 M in hexanes, 4.16 mL, 6.66 mmol)dropwise. The reaction mixture was stirred at this temperature for 15min. HMPA (5.63 mL, 32.3 mmol) was added dropwise and the reactionmixture was stirred at 0° C. for 15 min then cooled to −78° C. Asolution of dihydrofuran-2(3H)-one (0.488 mL, 6.34 mmol) dissolved inTHF (28.3 mL) was then added dropwise over a period of 30 min viasyringe pump. The reaction mixture was stirred at −78° C. for 30 min.TBAI (0.358 g, 0.970 mmol) was then added in one portion followed by thedropwise addition of 5-bromopent-1-ene (0.826 mL, 6.98 mmol). Thereaction mixture was stirred at −78° C. for 1 h then warmed to 0° C. andstirred for 3 h. The reaction mixture was quenched with sat. NH₄Cl andwarmed to rt. The aqueous layer was extracted with EtOAc (3×) and thecombined organic layers were washed with water, brine, dried overanhydrous Na₂SO₄ and concentrated in vacuo. The crude product waspurified by flash chromatography (0 to 25% hexanes/EtOAc) to yieldExample 21A (0.201 g, 1.30 mmol, 21% yield) as a light yellow oil. LCMS(ES): m/z 155 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 5.81 (ddt, J=17.0, 10.3,6.7 Hz, 1H), 5.10-4.90 (m, 2H), 4.35 (td, J=8.7, 3.0 Hz, 1H), 4.20 (td,J=9.4, 6.9 Hz, 1H), 2.62-2.49 (m, 1H), 2.45-2.35 (m, 1H), 2.18-2.06 (m,2H), 2.00-1.83 (m, 2H), 1.56-1.38 (m, 3H).

Example 21B

LAH (1.0 M in THF) (5.84 mL, 5.84 mmol) was added dropwise to a solutionof Example 21A (0.180 g, 1.17 mmol) in THF (3.5 mL) at 0° C. Thereaction mixture was stirred at 0° C. for 30 min then refluxed for 1 h.The reaction mixture was then cooled to 0° C., diluted with diethylether and carefully quenched with water. The precipitate formed wasfiltered and the filtrate was sequentially washed with water and brine.The organic layer was separated, dried over anhydrous Na₂SO₄,concentrated in vacuo and air-dried under vacuum to yield Example 21B(0.183 g, 1.16 mmol, 99% yield) as a clear oil which was used as suchfor the next step. ¹H NMR (500 MHz, CDCl₃) δ 5.81 (br dd, J=17.1, 10.2Hz, 1H), 5.05-4.90 (m, 2H), 3.80 (ddd, J=10.7, 6.2, 4.5 Hz, 1H),3.72-3.62 (m, 2H), 3.52 (dd, J=10.7, 6.9 Hz, 1H), 2.10-2.03 (m, 2H),1.76-1.64 (m, 2H), 1.48-1.24 (m, 5H).

Example 21C

To a solution of Example 21B (180 mg, 1.14 mmol), DMAP (13.9 mg, 0.114mmol) and triethylamine (0.476 mL, 3.41 mmol) in DCM (2.28 mL) was addedMsCl (0.222 mL, 2.84 mmol) and the reaction mixture was stirred at 0° C.for 30 min and then at rt overnight. The reaction mixture was washedwith water then 5% aq. NaHCO₃. The organic layer was dried overanhydrous Na₂SO₄, filtered and concentrated in vacuo. The crude productwas purified by flash chromatography (0 to 60% hexanes/EtOAc) to yieldExample 21C (293 mg, 0.932 mmol, 82% yield) as a light yellow oil. ¹HNMR (500 MHz, CDCl₃) δ 5.79 (ddt, J=17.1, 10.3, 6.7 Hz, 1H), 5.08-4.95(m, 2H), 4.38-4.28 (m, 2H), 4.25 (dd, J=9.9, 4.4 Hz, 1H), 4.19-4.13 (m,1H), 3.04 (d, J=1.7 Hz, 6H), 2.11-2.05 (m, 2H), 1.99-1.94 (m, 1H),1.94-1.81 (m, 2H), 1.51-1.37 (m, 4H).

Example 21D

A solution of Example 21C (268 mg, 0.852 mmol), (S)-Ethyl3-amino-3-(6-methoxypyridin-3-yl)propanoate (287 mg, 1.28 mmol) andtriethylamine (0.356 mL, 2.56 mmol) in 1,4-Dioxane (3.12 mL) was stirredat 75° C. for 16 h. Upon cooling to room temperature, the reactionmixture was diluted with water and extracted with EtOAc (3×). Thecombined organic layer was washed with brine, dried over anhydrousNa₂SO₄ and concentrated in vacuo. The crude product was purified byflash chromatography (0 to 100% hexanes/EtOAc) to yield Example 21D(76.5 mg, 0.221 mmol, 26% yield) as a light yellow oil. LCMS (ES): m/z347 [M+H]⁺.

Example 21E

A slurry of Example 21D (76.5 mg, 0.221 mmol) and PdCl₂ (39.2 mg, 0.221mmol) and CuCl (65.6 mg, 0.662 mmol) in DMF (3.53 mL) and water (0.883mL) was stirred under an O₂ atmosphere (balloon, 1 atm) at roomtemperature for 8 h. After filtration of the reaction mixture through aCELITE® pad and subsequent washing of the cake with EtOAc, the filtratewas washed with 10% LiCl, water and brine. The organic layer was driedover anhydrous Na₂SO₄, filtered and concentrated. The crude product waspurified by flash chromatography (0 to 15% DCM/MeOH) to yield Example21E (38.4 mg, 0.106 mmol, 48% yield) as a brown oil. LCMS (ES): m/z 363[M+H]⁺.

Example 21F

To a solution of Example 21E (38.4 mg, 0.106 mmol) in CH₂Cl₂ (0.167 mL)and EtOH (0.500 mL) was added pyrrolidine (0.011 mL, 0.127 mmol)followed by 2-aminonicotinaldehyde (12.9 mg, 0.106 mmol). The mixturewas then stirred at room temperature overnight. The crude product waspurified via preparative HPLC using the following conditions: Column:Phenomenex Luna AXIA 5μ C18 21.2×100 mm, Mobile Phase A: 10:90methanol:water with 0.1% TFA; Mobile Phase B: 90:10 methanol:water with0.1% TFA; Gradient: 5-100% B over 10 minutes, then a 5-minute hold at100% B; Flow: 20 mL/min. to give Example 21F (30 mg, 0.067 mmol, 63%yield) as a yellow oil. LCMS (ES): m/z 449 [M+H]⁺.

Example 21G

A slurry of Example 21F (30.0 mg, 0.067 mmol) and PtO₂ (3.04 mg, 0.013mmol) in EtOH (1.22 mL) was stirred under a H₂ atmosphere (balloon, 1atm) at room temperature for 5 h. After filtration of the reactionmixture through a CELITE® pad and subsequent washing of the cake withEtOH, the filtrate was concentrated in vacuo and air-dried under vacuumto yield Example 21G (26.6 mg, 0.059 mmol, 88% yield) as a brown oilwhich was used as such for the next step. LCMS (ES): m/z 453 [M+H]⁺.

Example 21

To a solution of Example 21G (26.6 mg, 0.059 mmol) in EtOH (1.73 mL) wasadded 1M aq. NaOH (0.176 mL, 0.176 mmol) and the reaction mixture wasstirred at room temperature overnight. The solvent was removed in vacuoand purified by preparative HPLC using the following conditions: Column:Luna AXIA C18, 30×100 mm, 5-μm particles; Mobile Phase A: 10:90methanol:water with 10-mM ammonium acetate; Mobile Phase B: 90:10methanol:water with 10-mM ammonium acetate; Gradient: 10-100% B over 10minutes, then a 5-minute hold at 100% B; Flow: 40 mL/min. to giveExample 21 (13.2 mg, 52%) as a tan solid. LCMS (ES): m/z 425 [M+H]⁺. ¹HNMR (500 MHz, CD₃OD) δ 8.26 (d, J=2.5 Hz, 1H), 7.91-7.82 (m, 1H), 7.24(dd, J=7.2, 0.8 Hz, 1H), 6.88 (d, J=8.5 Hz, 1H), 6.41 (dd, J=7.3, 1.5Hz, 1H), 4.52 (br t, J=6.2 Hz, 1H), 3.95 (s, 3H), 3.54-3.47 (m, 1H),3.44-3.39 (m, 2H), 3.31-3.21 (m, 2H), 2.91 (s, 1H), 2.82 (br dd, J=14.9,8.3 Hz, 2H), 2.74 (br t, J=6.2 Hz, 2H), 2.56 (t, J=7.2 Hz, 2H), 2.32 (brdd, J=14.9, 7.4 Hz, 1H), 2.22-2.11 (m, 1H), 1.91 (quin, J=5.9 Hz, 2H),1.71-1.56 (m, 3H), 1.49-1.39 (m, 2H). Human αVβ6 IC50 (nM)=1.4; HumanαVβ1 IC50 (nM)=6,500; Human αVβ3 IC50 (nM)=4.4; Human αVβ5 IC50 (nM)=10;and Human αVβ8 IC50 (nM)=180.

Example 22(±)-3-(2-Methylpyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoic Acid

Example 22A

To a solution of 2-methylpyrimidine-5-carbaldehyde (1.0 g, 8.19 mmol) inTHF (15 mL) was added 5 g of molecular sieves (4 Å) followed by ethyl2-(diethoxyphosphoryl)acetate (1.967 mL, 9.83 mmol) and LiOH (0.235 g,9.83 mmol). After stirring overnight at room temperature, the reactionwas filtered over CELITE® and the volatiles were removed. The residuewas dissolved in EtOAc and sequentially washed with 10% NaHCO₃ aqsolution and brine. The organic layer was dried over anhydrous Na₂SO₄,filtered, and concentrated under reduced pressure. The crude product waspurified by flash chromatography (0 to 50% EtOAc/Hexanes) to giveExample 22A (0.841 g, 4.38 mmol, 53% yield) as a white solid. LCMS (ESI)m/z 193.1 (M+H)⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.79 (s, 1H), 7.61 (d,J=16.3 Hz, 1H), 7.28 (s, 1H), 6.56 (d, J=16.3 Hz, 1H), 4.31 (d, J=7.2Hz, 2H), 2.79 (s, 3H), 1.37 (t, J=7.2 Hz, 3H)

Example 22B

To a solution of 3-bromo-1H-pyrazole (5 g, 34.0 mmol) in CH₂Cl₂ (100 mL)was added DIEA (17.82 mL, 102 mmol) and di-tert-butyl dicarbonate (11.14g, 51.0 mmol). A catalytic amount of DMAP (0.042 g, 0.340 mmol) wasadded, and the reaction was stirred at rt for 1 h. The reaction was thenpartitioned between CH₂Cl₂ and water. The organic layer was separatedand washed with sat. NaCl. The organic layer was dried with anhydroussodium sulfate, filtered, and concentrated. The crude product waspurified by flash chromatography (0 to 10% hexanes/ethyl acetate) toyield Example 22B (7.73 g, 31.3 mmol, 92% yield) as a white solid. ¹HNMR (500 MHz, CDCl₃) δ 8.07 (s, 2H), 1.67 (s, 9H)

Example 22C

A mixture of Example 22B (7.0 g, 28.3 mmol), pent-4-yn-2-ol (4.01 mL,42.5 mmol), triethylamine (15.79 mL, 113 mmol),bis(triphenylphosphine)palladium(II) chloride (1.193 g, 1.700 mmol) andcopper(I) iodide (0.216 g, 1.133 mmol) in DMF (100 mL) was stirred at80° C. for 2 h. The reaction was diluted with 300 mL of EtOAc, washedwith 10% LiCl solution and brine, dried over anhydrous Na₂SO₄, andconcentrated. The crude product was purified by flash chromatography (0to 100% ethyl acetate/hexanes) to yield Example 22C (7.0 g, 28.0 mmol,99% yield) as a tan solid. LCMS (ESI) m/z 251 (M+H)⁺.

Example 22D

A mixture of Example 22C (6.60 g, 26.4 mmol) and Pd/C (8.42 g, 7.91mmol) in MeOH (200 mL) was stirred under a H₂ atmosphere (balloon, 1atm) for 16 h. After filtration on a pad of CELITE® and concentration,Example 22D (6.68 g, 26.3 mmol, 100% yield) was isolated as a lightbrown oil which was used in the next step without further purification.LCMS (ESI) m/z: 277.1 (M+Na)⁺.

Example 22E

To a solution of Example 22D (6.60 g, 26.0 mmol) in CH₂Cl₂ (250 mL) atroom temperature was added Dess-Martin periodinane (13.21 g, 31.1 mmol)and the reaction was stirred for 1 hour. The mixture was diluted withEt₂O, filtered through a CELITE® pad, and concentrated to give anoff-white solid. The crude product was purified by flash chromatography(0 to 80% EtOAc/Hexanes) to yield Example 22E (4.61 g, 18.27 mmol, 70%yield) as a white solid. LCMS (ESI) m/z 253.1 (M+H)⁺. ¹H NMR (500 MHz,CDCl₃) δ 7.96 (d, J=2.8 Hz, 1H), 6.22 (d, J=2.8 Hz, 1H), 2.69 (t, J=7.6Hz, 2H), 2.49 (t, J=7.3 Hz, 2H), 2.13 (s, 3H), 1.95 (quin, J=7.5 Hz,2H), 1.63 (s, 9H).

Example 22F

A solution of Example 22E (4.49 g, 17.80 mmol) in CH₂Cl₂ (150 mL) wasadded pyrrolidine (3.24 mL, 39.20 mmol) followed by the addition of2-aminonicotinaldehyde (2.173 g, 17.80 mmol). The mixture was thenstirred at room temperature for 40 h and then concentrated. The crudeproduct was purified by flash chromatography (0 to 10% MeOH/CH₂Cl₂) toyield Example 22F (4.26 g, 12.59 mmol, 71% yield). LCMS (ESI) m/z 339.1(M+H)⁺.

Example 22G

To a solution of Example 22F (2.31 g, 6.83 mmol) in CH₂Cl₂ (40 mL) wasadded TFA (10 mL, 130 mmol) at 0° C. under N₂ (1 atm) and the reactionmixture was allowed to warm up to rt and stirred at rt for 1 h under N₂(1 atm). CH₂Cl₂ and TFA were removed under vacuum to give crude productas a brown oil. The crude product was purified by flash chromatography(0 to 10% MeOH/CH₂Cl₂) to give the TFA salt of Example 22G (2.03 g, 5.76mmol, 84% yield) as a light brown oil. LCMS (ESI) m/z 240.1 (M+H)⁺. ¹HNMR (500 MHz, CDCl₃) δ 11.84 (br. s., 2H), 9.09 (dd, J=4.3, 1.5 Hz, 1H),8.28 (dd, J=8.0, 1.7 Hz, 1H), 8.16 (d, J=8.3 Hz, 1H), 7.66 (d, J=1.9 Hz,1H), 7.52 (dd, J=8.1, 4.5 Hz, 1H), 7.42 (d, J=8.3 Hz, 1H), 6.27-6.18 (m,1H), 3.06 (t, J=7.3 Hz, 2H), 2.85 (s, 2H), 2.25 (d, J=7.4 Hz, 2H). To asolution of the TFA salt of Example 22G (2.0 g, 5.68 mmol) in MeOH (50mL) was added Diaion WA21J Resin (10 g, 5.68 mmol) and the reaction wasallowed to stir at rt under N₂ (1 atm) for 0.5 h. The resin wasfiltered, washed well with MeOH and the filtrate was concentrated togive Example 22G (1.168 g, 4.90 mmol, 86% yield) as a light brown oilwhich was used in the next step without further purification. LCMS (ESI)m/z: 239.1 (M+H)⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.12 (dd, J=4.1, 1.9 Hz,1H), 8.20 (dd, J=8.0, 1.9 Hz, 1H), 8.16-8.11 (m, 1H), 7.53 (d, J=1.4 Hz,1H), 7.58-7.52 (m, 1H), 7.51-7.46 (m, 1H), 7.45-7.40 (m, 1H), 6.16 (s,1H), 3.14 (t, J=7.4 Hz, 2H), 2.83 (t, J=7.3 Hz, 2H), 2.31 (t, J=7.3 Hz,2H).

Example 22H

A slurry of Example 22G (900 mg, 3.78 mmol) and platinum(IV) oxide (172mg, 0.755 mmol) in EtOH (8 mL) was stirred under a H₂ atmosphere(balloon, 1 atm) for 16 h. After filtration on a pad of CELITE® andconcentration, Example 22H (911 mg, 3.76 mmol, 100% yield) was isolatedas a light yellow oil which was used in the next step without furtherpurification. LCMS (ESI) m/z: 243.1 (M+H)⁺,

Example 22I

A mixture Example 22H (100 mg, 0.413 mmol) and cesium carbonate (403 mg,1.238 mmol) in acetonitrile (2.0 mL) was stirred for 5 min. Example 22A(79 mg, 0.413 mmol) was added and the mixture was heated at 80° C. for16 h. After cooling, the reaction was filtered and the filtrate wasconcentrated. The crude product was purified by flash chromatography (0to 15% MeOH/CH₂Cl₂) to give Example 22I (90 mg, 0.207 mmol, 50% yield)as a light brown oil. LCMS (ESI) m/z 435.1 (M+H)⁺.

Example 22

To a solution of Example 22I (63 mg, 0.145 mmol) in MeOH (1.5 mL) wasadded 1 M aq. NaOH (0.725 mL, 0.725 mmol) and the reaction mixturestirred at room temperature under Ar, 1 atm for 1 h. The mixture waspurified by Prep. HPLC (Phenomenex Luna AXIA 5u 21.2×100 mm, 10 mingradient, 17 min run, 0% to 70% Solvent A: 90% H₂O-10% ACN-0.1% TFA,Solvent B: 10% ACN-90% H₂O 0.1% TFA) to give Example 22A (83 mg, 0.111mmol, 3TFA, 76% yield) as a light brown oil. LCMS (ESI) m/z 407.0(M+H)+. ¹H NMR (500 MHz, DMSO-d₆) δ 8.61 (s, 2H), 7.83-7.70 (m, 1H),7.19-7.01 (m, 1H), 6.36-6.22 (m, 1H), 6.13-6.01 (m, 1H), 5.85-5.69 (m,1H), 3.24 (d, J=24.8 Hz, 2H), 2.63-2.57 (m, 4H), 2.49-2.44 (m, 2H),2.43-2.37 (m, 2H), 1.95-1.87 (m, 2H), 1.86-1.76 (m, 2H), 1.73 (br. s.,2H), 1.05-0.93 (m, 1H). Human αVβ6 IC50 (nM)=64.

The following examples (in Table A) were prepared using methodsanalogous to the ones indicated in the table.

TABLE A Example Structure & Name Analytical Data Method 23

¹H NMR (500 MHz, CD₃OD) δ 7.43 (s, 1H), 7.37 (br d, J = 7.2 Hz, 1H),7.28 (s, 1H), 6.40 (br d, J = 7.0 Hz, 1H), 4.34 (t, J = 6.4 Hz, 2H),4.20 (br t, J = 5.6 Hz, 1H), 4.06 (br t, J = 6.6 Hz, 2H), 3.55-3.40 (m,2H), 3.12-2.99 (m, 2H), 2.98- 2.86 (m, 2H), 2.82-2.71 (m, 2H), 1.95-1.83(m, 2H), 1.70-1.56 (m, 2H), 1.51-1.35 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H)LC/MS (m/z) = 416.0 (M + H)⁺. Human αVβ6 IC50 (nM) = 1,020. Example 5 24

¹H NMR (500 MHz, CD₃OD) δ 7.49 (s, 1H), 7.36 (d, J = 7.3 Hz, 1H), 7.27(s, 1H), 7.07-6.94 (m, 3H), 6.47 (d, J = 7.3 Hz, 1H), 4.34 (t, J = 8.0Hz, 1H), 4.20-4.00 (m, 2H), 3.83 (s, 3H), 3.49-3.39 (m, 2H), 2.79-2.71(m, 4H), 2.57- 2.43 (m, 1H), 2.39-2.29 (m, 1H), 2.24-2.07 (m, 2H),1.95-1.84 (m, 2H) LC/MS (m/z) = 439. 3 (M + H)⁺. Human αVβ6 IC50 (nM) =117. Example 7 25

¹H NMR (500 MHz, CD₃OD) δ 7.52-7.39 (m, 1H), 7.31 (s, 1H), 7.26 (s, 1H),7.01 (s, 2H), 6.57 (br s, 1H), 4.16-4.02 (m, 1H), 4.02-3.91 (m, 1H),3.65 (t, J = 4.7 Hz, 1H), 3.43 (t, J = 5.6 Hz, 2H), 2.99-2.72 (m, 4H),2.65-2.58 (m, 6H), 2.49 (br t, J = 6.6 Hz, 1H), 2.28 (s, 3H), 2.25-2.07(m, 3H), 1.99-1.85 (m, 2H) LC/MS (m/z) = 511.9 (M + H)⁺. Human αVβ6 IC50(nM) = 395. Example 6 26

¹H NMR (500 MHz, CD₃OD) δ 7.59-7.52 (m, 1H), 7.38-7.22 (m, 5H),6.54-6.42 (m, 1H), 4.40 (t, J = 8.0 Hz, 1H), 4.13 (dt, J = 11.0, 6.5 Hz,2H), 3.48- 3.37 (m, 2H), 2.81-2.68 (m, 4H), 2.54-2.34 (m, 2H), 2.16 (brd, J = 10.5 Hz, 2H), 1.96-1.84 (m, 2H) LC/MS (m/z) = 459.0 (M + H)⁺.Human αVβ6 IC50 (nM) = 27. Example 7 27

¹H NMR (500 MHz, CD₃OD) δ 8.55 (s, 2H), 8.46-8.42 (m, 1H), 7.76-7.72 (m,1H), 7.61-7.55 (m, 1H), 6.65-6.57 (m, 1H), 6.18- 6.15 (m, 1H), 5.89-5.84(m, 1H), 4.43 (d, J = 6.9 Hz, 2H), 3.56-3.49 (m, 2H), 3.49-3.44 (m, 1H),3.28 (dd, J = 16.6, 6.2 Hz, 1H), 2.86-2.80 (m, 2H), 2.75- 2.67 (m, 3H),2.11-2.01 (m, 2H), 2.00-1.94 (m, 2H), 1.40 (t, J = 7.0 Hz, 3H) LC/MS(m/z) = 437.0 (M + H)⁺. Human αVβ6 IC50 (nM) = 9.4; Human αVβ1 IC50 (nM)= 144; Human αVβ3 IC50 (nM) = 2.3; Human αVβ5 IC50 (nM) = 0.76; andHuman αVβ8 IC50 (nM) = 1,800. Example 22 28

¹H NMR (500 MHz, DMSO- d₆) δ 8.70 (s, 1H), 7.99 (s, 2H), 7.79 (s, 2H),7.72- 7.67 (m, 1H), 7.55-7.48 (m, 1H), 6.48-6.40 (m, 1H), 5.99 (d, J =1.7 Hz, 1H), 5.65 (s, 1H), 3.87- 3.78 (m, 2H), 3.38 (br. S., 1H), 2.72(br. s., 2H), 2.51 (br. S., 5H), 1.80 (d, J = 7.2 Hz, 4H). LC/MS (m/z) =443.1 (M + H)⁺. Human αVβ6 IC50 (nM) = 5,500. Example 22 29

¹H NMR (500 MHz, DMSO- d₆) δ 8.86 (s, 1H), 8.27 (s, 1H), 8.05-7.90 (m,2H), 7.87-7.80 (m, 1H), 7.79- 7.72 (m, 1H), 7.65-7.59 (m, 1H), 7.04-6.97(m, 1H), 6.25-6.18 (m, 1H), 6.09-6.05 (m, 1H), 6.02- 5.93 (m, 1H), 3.57(br. s., 1H), 3.25-3.21 (m, 1H), 3.19-3.14 (m, 1H), 2.62- 2.56 (m, 2H),2.49-2.46 (m, 2H), 2.44-2.36 (m, 2H), 1.96-1.89 (m, 1H), 1.87-1.79 (m,2H), 1.77- 1.69 (m, 2H). LC/MS (m/z) = 442.2 (M + H)⁺. Human αVβ6 IC50(nM) = 11.20; Example 22 Human αVβ1 IC50 (nM) = 286; Human αVβ3 IC50(nM) = 1.7; Human αVβ5 IC50 (nM) = 6.5; and Human αVβ8 IC50 (nM) =2,900. 30

¹H NMR (500 MHz, DMSO- d₆) δ 7.66 (br. s., 1H), 7.19 (br. s., 1H),7.10-7.00 (m, 2H), 6.74-6.62 (m, 1H), 6.30-6.23 (m, 1H), 6.07- 5.99 (m,1H), 5.74-5.51 (m, 1H), 4.47 (t, J = 8.7 Hz, 2H), 3.23 (br. s., 2H),3.15- 3.06 (m, 2H), 2.60 (br. s., 2H), 2.51-2.40 (m, 6H), 1.89-1.79 (m,2H), 1.78- 1.65 (m, 2H). LC/MS (m/z) = 433.2 (M + H)⁺. Human αVβ6 IC50(nM) = 5.7; Human αVβ1 IC50 (nM) = 100; Human αVβ3 IC50 (nM) = 11; HumanαVβ5 IC50 (nM) = 230; and Example 22 Human αVβ8 IC50 (nM) = 2,010. 31

¹H NMR (500 MHz, DMSO- d₆) δ 7.77 (br s, 1H), 7.45- 7.26 (m, 5H), 7.01(d, J = 7.0 Hz, 1H), 6.22 (br d, J = 7.3 Hz, 2H), 6.05 (s, 2H), 5.81 (brs, 1H), 3.27-3.20 (m, 2H), 3.20-3.07 (m, 1H), 2.60 (br t, J = 6.1 Hz,2H), 2.43 (br t, J = 7.5 Hz, 2H), 2.21 (s, 3H), 2.15 (s, 3H), 1.91 (brs, 2H), 1.88- 1.80 (m, 2H), 1.80-1.69 (m, 2H), 1.00 (d, J = 6.1 Hz, 1H).LC/MS (m/z) = 485.0 (M + H)⁺. Human αVβ6 IC50 (nM) = 5.2; Human αVβ1IC50 (nM) = 63; Human αVβ3 IC50 (nM) = 7.5; and Example 22 Human αVβ8IC50 (nM) = 3,300. 32

¹H NMR (500 MHz, DMSO- d₆) δ 7.68 (s, 1H), 7.14 (t, J = 7.9 Hz, 1H),7.10-6.97 (m, 1H), 6.83 (br s, 1H), 6.82-6.77 (m, 1H), 6.68 (br d, J =7.4 Hz, 1H), 6.24 (d, J = 7.2 Hz, 1H), 6.02 (s, 1H), 5.71-5.60 (m, 1H),3.69 (br s, 6H), 3.31-3.20 (m, 3H), 3.07-2.96 (m, 5H), 2.59 (br t, J =5.9 Hz, 2H), 2.49- 2.45 (m, 2H), 2.42 (br t, J = 7.5 Hz, 2H), 1.86-1.78(m, 2H), 1.78-1.69 (m, 2H) LC/MS (m/z) = 476.2 (M + H)⁺. Human αVβ6 IC50(nM) = 4.3; Human αVβ1 Example 22 IC50 (nM) = 43; Human αVβ3 IC50 (nM) =5.5; and Human αVβ8 IC50 (nM) = 2,700. 33

¹H NMR (500 MHz, DMSO- d₆) δ 9.16-9.00 (m, 3H), 8.29-8.17 (m, 1H), 7.58-7.49 (m, 1H), 7.03-6.91 (m, 1H), 6.25-6.10 (m, 3H), 3.64-3.51 (m, 1H),3.38-3.11 (m, 3H), 2.99- 2.90 (m, 1H), 2.77-2.68 (m, 1H), 1.98-1.67 (m,4H), 1.33-1.14 (m, 3H), 1.00 (d, J = 6.1 Hz, 1H) LC/MS (m/z) = 444.4(M + H)⁺. Human αVβ6 IC50 (nM) = 2,800. Example 22 34

¹H NMR (500 MHz, DMSO- d₆) δ 8.55 (s, 2H), 7.74 (s, 1H), 7.02 (br d, J =7.2 Hz, 1H), 6.22 (br d, J = 7.2 Hz, 1H), 6.04 (s, 1H), 5.75 (br t, J =7.4 Hz, 1H), 3.86 (s, 3H), 3.22 (br s, 3H), 3.17- 3.07 (m, 1H),2.65-2.56 (m, 2H), 2.48-2.43 (m, 2H), 2.44-2.34 (m, 2H), 1.85- 1.76 (m,2H), 1.73 (br d, J = 5.2 Hz, 2H). LC/MS (m/z) = 423.3 (M + H)⁺. HumanαVβ6 IC50 (nM) = 10. Example 22 35

¹H NMR (500 MHz, DMSO- d₆) δ 7.70 (br d, J = 12.6 Hz, 2H), 7.23 (br s,1H), 7.05 (br d, J = 7.0 Hz, 1H), 6.25 (br d, J = 7.2 Hz, 1H), 6.03 (s,1H), 5.67 (br s, 1H), 4.34 (br s, 2H), 4.19 (br s, 2H), 3.31- 3.19 (m,1H), 3.16 (s, 1H), 2.59 (br s, 2H), 2.49-2.44 (m, 2H), 2.41 (br s, 2H),1.95-1.85 (m, 2H), 1.85- 1.76 (m, 2H), 1.73 (br s, 2H) LC/MS (m/z) =450.4 (M + H)⁺. Human αVβ6 IC50 (nM) = 17. Example 22 36

¹H NMR (400 MHz, CD₃OD) δ 7.42 (d, J = 7.60 Hz, 1H), 7.05-7.13 (m, 3H),6.95 (s, 1H), 6.46 (d, J = 7.60 Hz, 1H), 4.79-4.80 (m, 1H), 3.86 (s,3H), 3.45 (t, J = 5.60 Hz, 2H), 3.23-3.26 (m, 1H), 2.73-2.85 (m, 5H),2.54-2.64 (m, 2H), 1.91-2.01 (m, 3H), 1.73-1.82 (m, 1H), 1.47-1.49 (m,2H). LC/MS (m/z) = 470.3 (M + H)⁺. Human αVβ6 IC50 (nM) = 157. Example13 37

¹H NMR (400 MHz, CD₃OD) δ 7.42 (d, J = 7.60 Hz, 1H), 7.05-7.13 (m, 3H),6.95 (s, 1H), 6.46 (d, J = 7.60 Hz, 1H), 4.79-4.80 (m, 1H), 3.86 (s,3H), 3.45 (t, J = 5.60 Hz, 2H), 3.23-3.26 (m, 1H), 2.73-2.85 (m, 5H),2.54-2.64 (m, 2H), 1.91-2.01 (m, 3H), 1.73-1.82 (m, 1H), 1.47-1.49 (m,2H). LC/MS (m/z) = 470.3 (M + H)⁺. Human αVβ6 IC50 (nM) = 2.0; HumanαVβ1 IC50 (nM) = 160; Human αVβ3 IC50 (nM) = 1.7; Human Example 13 αVβ5IC50 (nM) = 1.1; and Human αVβ8 IC50 (nM) = 870. 38

¹H NMR (400 MHz, CD₃OD) δ 7.46 (d, J = 3.20 Hz, 1H), 7.03-7.13 (m, 4H),6.56 (d, J = 7.20 Hz, 1H), 4.75-4.80 (m, 1H), 3.87 (s, 3H), 3.48-3.50(m, 2H), 3.15-3.16 (m, 1H), 2.76- 2.87 (m ,5H), 2.55-2.61 (m, 2H),2.00-2.14 (m, 2H), 1.90-1.98 (m, 2H). LC/MS (m/z) = 456.2 (M + H)⁺.Human αVβ6 IC50 (nM) = 2.1; Human αVβ1 IC50 (nM) = 66; Human αVβ3 IC50(nM) = 2.3; and Human αVβ8 IC50 (nM) = 860. Example 15 39

¹H NMR (400 MHz, CD₃OD) δ 7.46 (d, J = 3.20 Hz, 1H), 7.03-7.13 (m, 4H),6.56 (d, J = 7.20 Hz, 1H), 4.75-4.80 (m, 1H), 3.87 (s, 3H), 3.48-3.50(m, 2H), 3.15-3.16 (m, 1H), 2.76- 2.87 (m, 5H), 2.55-2.61 (m, 2H),2.00-2.14 (m, 2H), 1.90-1.98 (m, 2H). LC/MS (m/z) = 456.2 (M + H)⁺.Human αVβ6 IC50 (nM) = 23. Example 15 40

¹H NMR (400 MHz, CD₃OD) δ 7.32-7.41 (m, 2 H), 7.12 (s, 1H), 7.10 (s,1H), 7.00-7.07 (m, 1 H), 6.45 (d, J = 7.03 Hz, 1 H), 4.75 (dd, J = 9.54,6.53 Hz, 1 H), 3.86 (s, 3 H), 3.42- 3.48 (m, 2 H), 3.13-3.22 (m, 1 H),2.82-2.95 (m, 3 H), 2.77 (t, J = 6.02 Hz, 2 H), 2.53 (t, J = 7.28 Hz, 2H), 1.87-1.98 (m, 2 H), 1.56-1.78 (m, 4 H). LCMS (ES): m/z 470.2 [M +H]⁺. Human αVβ6 IC50 (nM) = 17; Human αVβ3 IC50 (nM) = 28; Human αVβ5IC50 (nM) = 10; and Human αVβ8 IC50 (nM) = 2,600. Example 17 41

¹H NMR (400 MHz, CD₃OD) δ 7.32-7.41 (m, 2 H), 7.12 (s, 1H), 7.10 (s,1H), 7.00-7.07 (m, 1 H), 6.45 (d, J = 7.03 Hz, 1 H), 4.75 (dd, J = 9.54,6.53 Hz, 1 H), 3.86 (s, 3 H), 3.42- 3.48 (m, 2 H), 3.13-3.22 (m, 1 H),2.82-2.95 (m, 3 H), 2.77 (t, J = 6.02 Hz, 2 H), 2.53 (t, J = 7.28 Hz, 2H), 1.87-1.98 (m, 2 H), 1.56-1.78 (m, 4 H). LCMS (ES): m/z 470.2 [M +H]⁺. Human αVβ6 IC50 (nM) = 5.9. Example 17 42

¹H NMR (400 MHz, CD₃OD) δ 7.34-7.42 (m, 2H), 6.98-7.11 (m, 3H), 6.50 (d,J = 7.53 Hz, 1H), 4.65-4.78 (m, 1H), 3.86 (s, 3H), 3.41-3.46 (m, 2H),3.17-3.26 (m, 1H), 2.90- 2.98 (m, 1H), 2.86 (t, J = 7.28 Hz, 2H), 2.76(t, J = 6.27 Hz, 2H), 2.60-2.66 (m, 2H), 1.86-2.02 (m, 4H). LCMS (ES):m/z 456.2 [M + H]⁺. Human αVβ6 IC50 (nM) = 28. Example 19 43

¹H NMR (400 MHz, CD₃OD) δ 7.34-7.42 (m, 2H), 6.98-7.11 (m, 3H), 6.50 (d,J = 7.53 Hz, 1H), 4.65-4.78 (m, 1H), 3.86 (s, 3H), 3.41-3.46 (m, 2H),3.17-3.26 (m, 1H), 2.90- 2.98 (m, 1H), 2.86 (t, J = 7.28 Hz, 2H), 1.76(t, J = 6.27 Hz, 2H), 2.60-2.66 (m, 2H), 1.86-2.02 (m ,4H). LCMS (ES):m/z 456.2 [M + H]⁺. Human αVβ6 IC50 (nM) = 18. Example 19 44

¹H NMR (500 MHz, CD₃OD) δ 7.73 (s, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.28(s, 1H), 7.09-6.91 (m, 3H), 6.43 (d, J = 7.3 Hz, 1H), 4.33 (dd, J =10.0, 6.7 Hz, 1H), 4.26-4.17 (m, 1H), 4.15-4.07 (m, 1H), 3.83 (s, 3H),3.43 (t, J = 5.6 Hz, 2H), 2.80-2.70 (m, 4H), 2.57- 2.40 (m, 2H),1.94-1.79 (m, 4H), 1.49-1.34 (m, 1H), 1.28-1.14 (m, 1H). LCMS (ES): m/z453.4 [M + H]⁺. Human αVβ6 IC50 (nM) = 64. Example 11

(S)-3-(1-Methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid Ditrifluoroacetic Acid Salt

Example 45A

SOCl₂ (9.93 μL, 0.136 mmol) was added dropwise to a room temperaturesolution of Example 12 (37.6 mg, 0.059 mmol) in EtOH (0.592 mL). Afterstirring overnight, the solvent was removed in vacuo and the residue wasdissolved in DCM and washed with sat. NaHCO₃ (2×). The organic phase wasdried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. Thecrude product was purified by flash chromatography (0 to 10% MeOH/DCM)to afford 45A (17.2 mg, 0.038 mmol, 64% yield) as a clear oil. LCMS(ES): m/z 436.5 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.66-7.57 (m, 2H),7.39 (d, J=2.2 Hz, 1H), 7.17 (d, J=7.4 Hz, 1H), 6.49 (d, J=9.6 Hz, 1H),6.36 (d, J=7.2 Hz, 1H), 6.11 (d, J=2.2 Hz, 1H), 5.64 (dd, J=9.1, 6.3 Hz,1H), 4.10-4.01 (m, 2H), 3.43-3.35 (m, 3H), 3.16 (dd, J=16.1, 6.2 Hz,1H), 2.71 (t, J=6.2 Hz, 2H), 2.61 (t, J=7.6 Hz, 2H), 2.54 (t, J=7.6 Hz,2H), 1.98-1.84 (m, 4H), 1.15 (t, J=7.0 Hz, 3H).

Example 45B

A mixture of Example 45A (10 mg, 0.023 mmol), methyl4-nitrobenzenesulfonate (5.0 mg, 0.023 mmol) and Cs₂CO₃ (11.2 mg, 0.034mmol) in DMF (0.221 mL) was stirred at room temperature. After 24 h,additional Cs₂CO₃ (2.8 mg) and methyl 4-nitrobenzenesulfonate (1.3 mg)were added and the reaction was stirred at room temperature for 7 h. Thereaction mixture was diluted with DCM and filtered through a Celite®pad. The filtrate was concentrated in vacuo and the residue was purifiedby preparative HPLC (Column: Phenomenex Luna AXIA 5u C18 21.2×100 mm;Mobile Phase A: 10% MeOH-90% H₂O-0.1% TFA; Mobile Phase B: 90% MeOH-10%H₂O-0.1% TFA; Gradient: 0% to 100% B over 10 minutes, then a 5 minutehold at 100% B; Flow: 20 mL/min) to afford Example 45B,ditrifluoroacetic acid salt (10.1 mg, 0.013 mmol, 56% yield) as a clearoil. LCMS (ES): m/z 450.5 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.72 (d,J=2.5 Hz, 1H), 7.65 (d, J=2.2 Hz, 1H), 7.59-7.49 (m, 2H), 6.59 (d, J=7.4Hz, 1H), 6.49 (d, J=9.4 Hz, 1H), 6.13 (d, J=2.5 Hz, 1H), 5.64 (dd,J=9.4, 6.1 Hz, 1H), 4.07 (qd, J=7.1, 3.0 Hz, 2H), 3.54 (s, 3H), 3.49 (d,J=5.8 Hz, 2H), 3.41 (dd, J=16.2, 9.4 Hz, 1H), 3.16 (dd, J=16.2, 6.1 Hz,1H), 2.81 (t, J=6.1 Hz, 2H), 2.68 (dt, J=15.8, 7.8 Hz, 4H), 2.07-1.89(m, 4H), 1.15 (t, J=7.2 Hz, 3H) and Example 3G (3.2 mg, 4.72 μmol, 21%yield) as a clear oil in ˜5:1 ratio by analytical HPLC.

Example 45

To a solution of Example 45B (4.1 mg, 6.1 μmol) in EtOH (0.178 mL) wasadded 1M aq. NaOH (30 μL, 0.030 mmol) and the reaction mixture wasstirred at room temperature. After 1 h, the reaction was concentrated invacuo. The residue was acidified with 1M aq. HCl and then reconcentratedin vacuo. The residue was purified by preparative HPLC (Column:Phenomenex Luna AXIA 5μ C18 21.2×100 mm, 5-μm particles; Mobile Phase A:10:90 MeOH:H₂O with 0.1% TFA; Mobile Phase B: 90:10 MeOH:H₂O with 0.1%TFA; Gradient: 5-100% B over 10 minutes, then a 2-minute hold at 100% B;Flow: 20 mL/min) to afford Example 45, ditrifluoroacetic acid salt (1.4mg, 2.0 μmol, 34% yield) as an off-white solid. LCMS (ES): m/z 422.6[M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.71 (d, J=2.5 Hz, 1H), 7.66 (d, J=2.2Hz, 1H), 7.61-7.44 (m, 2H), 6.59 (d, J=7.2 Hz, 1H), 6.49 (d, J=9.4 Hz,1H), 6.13 (d, J=2.5 Hz, 1H), 5.67-5.58 (m, 1H), 3.54 (s, 3H), 3.52-3.46(m, 2H), 3.43-3.33 (m, 1H), 3.14 (dd, J=16.5, 6.1 Hz, 1H), 2.81 (br t,J=6.2 Hz, 2H), 2.68 (dt, J=11.8, 7.4 Hz, 4H), 2.01-1.88 (m, 4H). HumanαVβ6 IC50 (nM)=1.6; Human αVβ3 IC50 (nM)=1.6; and Human αVβ8 IC50(nM)=3020.

Example 46(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)phenyl)-1H-pyrazol-1-yl)propanoicAcid

Example 46A

To a degassed mixture of Example 3B (100 mg, 0.282 mmol), 2.0 M aq.Na₂CO₃ (0.282 mL, 0.565 mmol) and Pd(Ph₃P)₄ (16.3 mg, 0.014 mmol) in DMF(1.41 mL) was added (3-acetylphenyl)boronic acid (50.9 mg, 0.311 mmol)and the reaction was stirred at 90° C. in a sealed reaction vial. After8 h, the reaction was cooled to room temperature, diluted with water andextracted with EtOAc (3×). The combined organic layers were washed with10% aq. LiCl, dried over anhydrous Na₂SO₄ and concentrated in vacuo. Theresidue was purified by preparative HPLC (Column: Phenomenex Luna AXIA 5m C18 21.2×100 mm, 5-μm particles; Mobile Phase A: 10:90 MeOH:H₂O with0.1% TFA; Mobile Phase B: 90:10 MeOH:H₂O with 0.1% TFA; Gradient:20-100% B over 10 minutes, then a 5-minute hold at 100% B; Flow: 20mL/min) to afford Example 46A, ditrifluoroacetic acid salt (21.4 mg,0.054 mmol, 19% yield) as a clear oil. LCMS (ES): m/z 394.1 [M+H]⁺. 1HNMR (400 MHz, CDCl₃) δ 8.51 (d, J=2.4 Hz, 1H), 8.37 (t, J=1.7 Hz, 1H),8.08 (dd, J=8.8, 2.4 Hz, 1H), 8.01 (dt, J=7.9, 1.3 Hz, 1H), 7.91 (dt,J=7.8, 1.5 Hz, 1H), 7.56 (d, J=2.4 Hz, 1H), 7.51 (t, J=7.7 Hz, 1H), 6.96(d, J=9.0 Hz, 1H), 6.63 (d, J=2.4 Hz, 1H), 5.90 (dd, J=8.1, 6.8 Hz, 1H),4.13 (q, J=7.3 Hz, 2H), 4.05 (s, 3H), 3.62 (dd, J=16.5, 8.4 Hz, 1H),3.23 (dd, J=16.5, 6.6 Hz, 1H), 2.68 (s, 3H), 1.20 (t, J=7.2 Hz, 3H).

Example 46B

The title compound was synthesized according to the method described forthe synthesis of Example 10G, using Example 46A as the startingmaterial: (12.5 mg, 0.026 mmol, 48% yield, orange oil). LCMS (ES): m/z480.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.10-9.06 (m, 1H), 8.76 (t,J=1.7 Hz, 1H), 8.50 (d, J=8.6 Hz, 1H), 8.46 (dd, J=8.1, 2.0 Hz, 1H),8.26-8.21 (m, 2H), 7.84 (dd, J=8.8, 2.6 Hz, 1H), 7.81 (d, J=2.4 Hz, 1H),7.69-7.54 (m, 4H), 6.80 (dd, J=5.6, 3.2 Hz, 2H), 5.95 (dd, J=9.0, 6.4Hz, 1H), 4.10 (q, J=7.1 Hz, 2H), 3.90 (s, 3H), 3.65 (dd, J=16.2, 9.1 Hz,1H), 3.32-3.26 (m, 1H), 1.16 (t, J=7.2 Hz, 3H).

Example 46C

The title compound was synthesized according to the method described forthe synthesis of Example 10H, using Example 46B as the startingmaterial: (12.0 mg, 0.025 mmol, 95% yield, orange oil). LCMS (ES): m/z484.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.25 (t, J=1.5 Hz, 1H), 8.19 (d,J=2.6 Hz, 1H), 7.83-7.70 (m, 4H), 7.43 (t, J=7.9 Hz, 1H), 7.28-7.23 (m,1H), 6.95 (d, J=7.5 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 6.68 (d, J=2.4 Hz,1H), 5.91 (dd, J=9.0, 6.4 Hz, 1H), 4.08 (q, J=7.3 Hz, 2H), 3.88 (s, 3H),3.59 (dd, J=16.2, 9.1 Hz, 1H), 3.42 (dd, J=10.8, 5.3 Hz, 2H), 3.26 (dd,J=16.2, 6.3 Hz, 1H), 2.77 (t, J=6.3 Hz, 2H), 1.98-1.85 (m, 2H), 1.14 (t,J=7.2 Hz, 3H).

Example 46

To a solution of Example 46C (12 mg, 0.025 mmol) in EtOH (0.730 mL) wasadded 1M aq. NaOH (74 μL, 0.074 mmol) and the reaction mixture wasstirred at room temperature. After 5 h, the reaction was concentrated invacuo. The residue was acidified with 1M aq. HCl and then reconcentratedin vacuo. The residue was purified by preparative HPLC (Column: XBridgeC18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile:waterwith 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:waterwith 10 mM ammonium acetate; Gradient: 16-56% B over 20 minutes, then a4-minute hold at 100% B; Flow: 20 mL/min) to afford Example 46 (7.8 mg,0.017 mmol, 67% yield). LCMS (ES): m/z 456.3 [M+H]⁺. ¹H NMR (500 MHz,CD₃OD) δ 8.25 (s, 1H), 8.17 (d, J=2.1 Hz, 1H), 7.84-7.65 (m, 4H), 7.43(t, J=7.7 Hz, 1H), 7.33 (d, J=7.4 Hz, 1H), 6.96 (d, J=7.5 Hz, 1H), 6.76(d, J=8.7 Hz, 1H), 6.67 (d, J=2.2 Hz, 1H), 5.89 (t, J=7.5 Hz, 1H), 3.88(s, 3H), 3.50 (dd, J=16.0, 8.5 Hz, 1H), 3.47-3.39 (m, 2H), 3.19 (dd,J=16.0, 6.5 Hz, 1H), 2.79 (t, J=6.3 Hz, 2H), 1.96-1.86 (m, 2H). HumanαVβ6 IC50 (nM)=28 Human αVβ3 IC50 (nM)=14; Human αVβ5 IC50 (nM)=11; andHuman αVβ8 IC50 (nM)=8200.

Example 47 Ethyl(S)-3-(6-methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate

Example 47

SOCl₂ (0.066 mL, 0.906 mmol) was added dropwise to a room temperaturesolution of Example 2 (0.166 g, 0.394 mmol) in EtOH (3.94 mL). Afterstirring at room temperature overnight, the solvent was removed in vacuoto give Example 47, trichloridric acid salt (251 mg, 0.449 mmol) as acrude yellow-brown solid which was used in the next step withoutpurification. 15 mg of this crude material was further purified bypreparative HPLC (Column: XBridge C18, 19×200 mm, 5-μm particles; MobilePhase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; MobilePhase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Gradient:21-61% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20mL/min) to afford Example 47 (11.9 mg, 0.025 mmol). LCMS (ES): m/z 450.3[M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.07 (d, J=2.4 Hz, 1H), 7.65 (dd,J=8.7, 2.5 Hz, 1H), 7.61 (d, J=2.3 Hz, 1H), 7.49 (d, J=7.3 Hz, 1H), 6.74(d, J=8.7 Hz, 1H), 6.54 (d, J=7.3 Hz, 1H), 6.11 (d, J=2.3 Hz, 1H), 5.79(dd, J=9.0, 6.4 Hz, 1H), 4.06 (qd, J=7.1, 1.9 Hz, 2H), 3.88 (s, 3H),3.51-3.46 (m, 2H), 3.46-3.41 (m, 1H), 3.20 (dd, J=16.0, 6.3 Hz, 1H),2.79 (t, J=6.2 Hz, 2H), 2.72-2.52 (m, 4H), 2.06-1.86 (m, 4H), 1.14 (t,J=7.1 Hz, 3H). Human αVβ6 IC50 (nM)=11; Human αVβ3 IC50 (nM)=1120; andHuman αVβ5 IC50 (nM)=270.

Example 48(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)-1H-pyrazol-1-yl)propanoicAcid

Example 48A

The title compound was synthesized according to the method described inPatent WO 2011026937: (549 mg, 4.35 mmol, 73% yield, white solid). LCMS(ES): m/z 127.3 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 11.12-10.87 (m, 1H),8.15-8.10 (m, 1H), 6.00 (d, J=3.1 Hz, 1H), 2.47 (s, 3H).

Example 48B

A suspension of Example 48A (50 mg, 0.396 mmol), commercially available5-bromopent-1-ene (0.063 mL, 0.528 mmol) and K₂CO₃ (60.3 mg, 0.436 mmol)in DMF (1.32 mL) was stirred at room temperature. After 24 h, thereaction mixture was diluted water and extracted with EtOAc (2×). Thecombined organic layers were dried over anhydrous Na₂SO₄ andconcentrated in vacuo. The crude product was purified by flashchromatography (0 to 25% EtOAc/hexanes) to afford Example 48B (61 mg,0.314 mmol, 79% yield) as a clear oil. LCMS (ES): m/z 195.2 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.06 (d, J=3.1 Hz, 1H), 5.96 (d, J=3.1 Hz, 1H),5.92-5.67 (m, 1H), 5.16-4.95 (m, 2H), 4.25 (t, J=6.5 Hz, 2H), 2.59 (s,3H), 2.31-2.13 (m, 2H), 1.95-1.80 (m, 2H).

Example 48C

To a solution of Example 48B (61 mg, 0.314 mmol) in MeOH (0.785 mL) wasadded 6M aq. NaOH (0.052 mL, 0.314 mmol) and the reaction was stirred atroom temperature. After 1 h, the volatiles were removed in vacuo and theresidue was dissolved in EtOAc and washed with water (2×). The aqueouslayer was back-extracted with EtOAc (2×) and the combined organic layerswere dried over anhydrous Na₂SO₄ and concentrated in vacuo to affordExample 48C (48.7 mg, 0.320 mmol) as a crude yellow oil which was usedin the next step without further purification. LCMS (ES): m/z 153.2[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.78-8.45 (m, 1H), 7.37 (d, J=2.5 Hz,1H), 5.86 (ddt, J=17.0, 10.2, 6.6 Hz, 1H), 5.74 (d, J=2.2 Hz, 1H),5.12-5.04 (m, 1H), 5.00 (dd, J=10.3, 1.5 Hz, 1H), 4.17 (t, J=6.6 Hz,2H), 2.28-2.17 (m, 2H), 1.94-1.83 (m, 2H).

Example 48D

A mixture of Example 48C (48.7 mg, 0.320 mmol) and Cs₂CO₃ (313 mg, 0.960mmol) in CH₃CN (2.13 mL) was stirred at room temperature. After 5 min.,Example 3A (66.3 mg, 0.320 mmol) was added and the reaction was heatedat 80° C. for 5 h. Upon cooling to room temperature, the reaction wasfiltered and the filtrate concentrated in vacuo. The crude product waspurified by flash chromatography (0 to 50% EtOAc/hexanes) to affordExample 48D (35.6 mg, 0.099 mmol, 31% yield) as a light yellow oil. LCMS(ES): m/z 360.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, J=2.5 Hz,1H), 7.64 (dd, J=8.5, 2.5 Hz, 1H), 7.19 (d, J=2.2 Hz, 1H), 6.71 (d,J=8.5 Hz, 1H), 5.93-5.77 (m, 1H), 5.61 (d, J=2.2 Hz, 1H), 5.53 (dd,J=8.4, 6.5 Hz, 1H), 5.06 (dd, J=17.1, 1.7 Hz, 1H), 4.99 (dd, J=10.2, 1.7Hz, 1H), 4.17-4.04 (m, 4H), 3.92 (s, 3H), 3.50 (dd, J=16.2, 8.5 Hz, 1H),3.01 (dd, J=16.2, 6.6 Hz, 1H), 2.29-2.15 (m, 2H), 1.93-1.76 (m, 2H),1.19 (t, J=7.2 Hz, 3H).

Example 48E

A solution of Example 48D (35.6 mg, 0.099 mmol), CuCl (29.4 mg, 0.297mmol) and PdCl₂ (17.6 mg, 0.099 mmol) in DMF (2.03 mL) and water (0.508mL) was stirred under an O₂ atmosphere (1 atm, balloon) at roomtemperature. After 7 h, the reaction was filtered through a Celite® padand the filtrate was concentrated in vacuo. The residue was purified bypreparative HPLC (Column: Phenomenex Luna AXIA 5u C18 21.2×100 mm;Mobile Phase A: 10:90 MeOH:H₂O with 0.1% TFA; Mobile Phase B: 90:10MeOH:H₂O with 0.1% TFA; Gradient: 5-100% B over 10 minutes, then a2-minute hold at 100% B; Flow: 20 mL/min) to afford Example 48E,ditrifluoroacetic acid salt (19.9 mg, 0.033 mmol, 33% yield) as a brownoil. LCMS (ES): m/z 376.1 [M+H]⁺.

Example 48F

The title compound was synthesized according to the method described forthe synthesis of Example 10G, using Example 48E as the startingmaterial: (15.2 mg, 0.033 mmol, 100% yield, orange oil). LCMS (ES): m/z462.2.

Example 48G

The title compound was synthesized according to the method described forthe synthesis of Example 10H, using Example 48F as the startingmaterial: (15.4 mg, 0.033 mmol, 100% yield, brown oil). LCMS (ES): m/z466.2.

Example 48

To a solution of Example 48G (15.4 mg, 0.033 mmol) in EtOH (0.599 mL)was added 1M aq. NaOH (0.099 mL, 0.099 mmol) and the reaction mixturewas stirred at room temperature. After 1 h, the reaction wasconcentrated in vacuo. The residue was acidified with 1M aq. HCl andthen reconcentrated in vacuo. The residue was purified by preparativeHPLC (Column: XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A:5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B:95:5 acetonitrile:water with 10 mM ammonium acetate; Gradient: 10-50% Bover 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min) toafford Example 48 (4.6 mg, 0.010 mmol, 31% yield). LCMS (ES): m/z 438.2[M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.08 (s, 1H), 7.66 (dd, J=8.7, 2.4 Hz,1H), 7.44-7.33 (m, 2H), 6.74 (d, J=8.7 Hz, 1H), 6.51 (br d, J=6.8 Hz,1H), 5.62 (br dd, J=9.4, 4.8 Hz, 1H), 5.54 (s, 1H), 4.38-4.25 (m, 1H),4.17-4.07 (m, 1H), 3.88 (s, 3H), 3.48-3.39 (m, 2H), 3.35 (br s, 1H),3.01-2.88 (m, 1H), 2.80-2.71 (m, 4H), 2.17 (br dd, J=13.5, 6.8 Hz, 1H),2.09 (br dd, J=13.3, 6.9 Hz, 1H), 1.91 (quin, J=6.0 Hz, 2H). Human αVβ6IC50 (nM)=29; Human αVβ3 IC50 (nM)=7.5; and Human αVβ5 IC50 (nM)=2.7.

Example Structure & Name Analytical Data Method 49

¹H NMR (500 MHz, DMSO- d₆) δ 8.48 (d, J = 1.5 Hz, 1H), 7.94 (br d, J =11.9 Hz, 1H), 7.90-7.86 (m, 2H), 7.84 (br d, J = 7.3 Hz, 1H), 7.04 (d, J= 7.3 Hz, 1H), 6.83 (d, J = 1.8 Hz, 1H), 6.50-6.41 (m, 1H), 4.03 (br s,3H), 3.90-3.81 (m, 1H), 3.39 (br t, J = 6.0 Hz, 2H), 3.35 (s, 3H),3.29-3.25 (m, 2H), 3.22 (br t, J = 7.5 Hz, 2H), 2.66-2.58 (m, 2H),2.57-2.49 (m, 2H). LCMS (ES): m/z 439.1 [M + H]⁺. Hman αVβ6 IC50 (nM) =24. Example 22 50

¹H NMR (500 MHz, DMSO- d₆) δ 8.30 (s, 2H), 7.68 (s, 1H), 7.03 (br d, J =7.3 Hz, 1H), 6.24 (d, J = 7.0 Hz, 1H), 6.02 (s, 1H), 5.58 (br t, J = 7.5Hz, 1H), 3.98 (br t, J = 7.5 Hz, 4H), 3.28-3.20 (m, 3H), 3.05 (br dd, J= 15.9, 7.0 Hz, 1H), 2.59 (br t, J = 6.0 Hz, 2H), 2.47 (br t, J = 7.5Hz, 2H), 2.44-2.37 (m, 2H), 2.27 (quin, J = 7.4 Hz, 2H), 1.86-1.76 (m,2H), 1.73 (br d, J = 5.5 Hz, 2H). ). LCMS (ES): m/z 448.4 [M + H]⁺.Human αVβ6 IC (nM) = 6.4. Example 22 51

¹H NMR (500 MHz, DMSO- d₆) δ 7.70 (br d, J = 12.6 Hz, 2H), 7.23 (br s,1H), 7.05 (br d, J = 7.0 Hz, 1H), 6.25 (br d, J = 7.2 Hz, 1H), 6.03 (s,1H), 5.67 (br s, 1H), 4.34 (br s, 2H), 4.19 (br s, 2H), 3.31- 3.19 (m,1H), 3.16 (s, 1H), 2.59 (br s, 2H), 2.49-2.44 (m, 2H), 2.41 (br s, 2H),1.95-1.85 (m, 2H), 1.85- 1.76 (m, 2H), 1.73 (br s, 2H). LCMS (ES): m/z450.1 [M + H]⁺. Human αVβ6 IC50 (nM) = 4.9. Example 22 & 8 52

¹H NMR (500 MHz, DMSO- d₆) δ 7.70 (br d, J = 12.6 Hz, 2H), 7.23 (br s,1H), 7.05 (br d, J = 7.0 Hz, 1H), 6.25 (br d, J = 7.2 Hz, 1H), 6.03 (s,1H), 5.67 (br s, 1H), 4.34 (br s, 2H), 4.19 (br s, 2H), 3.31- 3.19 (m,1H), 3.16 (s, 1H), 2.59 (br s, 2H), 2.49-2.44 (m, 2H), 2.41 (br s, 2H),1.95-1.85 (m, 2H), 1.85- 1.76 (m, 2H), 1.73 (br s, 2H). LCMS (ES): m/z450.1 [M + H]⁺. Human αVβ6 IC50 (nM) = 730. Example 22 & 9 53

¹H NMR (500 MHz, DMSO- d₆) δ 8.23 (s, 2H), 7.55 (br d, J = 7.3 Hz, 1H),7.48-7.37 (m, 1H), 6.56 (br d, J = 7.6 Hz, 1H), 6.13-6.03 (m, 1H),5.75-5.56 (m, 1H), 3.98 (br t, J = 7.5 Hz, 4H), 3.40 (br d, J = 5.5 Hz,2H), 3.30-3.13 (m, 1H), 3.05 (br dd, J = 16.8, 5.2 Hz, 1H), 2.81-2.60(m, 6H), 2.28 (br t, J = 7.3 Hz, 2H), 2.07- 1.86 (m, 2H), 1.82 (br s,2H). LCMS (ES): m/z 448.4 [M + H]⁺. Human αVβ6 IC50 (nM) = 140. Example22 54

¹H NMR (500 MHz, CD₃OD) δ 8.64 (s, 2H), 7.74 (d, J = 2.2 Hz, 1H), 7.57(d, J = 7.4 Hz, 1H), 6.59 (d, J = 7.4 Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H),5.90 (dd, J = 8.9, 6.2 Hz, 1H), 3.58-3.39 (m, 2H), 3.31-3.24 (m, 2H),2.81 (br t, J = 6.1 Hz, 2H), 2.69 (q, J = 7.2 Hz, 4H), 2.66 (s, 3H),2.07-1.98 (m, 2H), 1.98-1.92 (m, 2H). LCMS (ES): m/z 407.0 [M + H]⁺.Human αVβ6 IC50 (nM) = 18; Human αVβ3 IC50 (nM) = 7.3; and Human αVβ5IC50 (nM) = 0.99. Example 22 & 8 55

¹H NMR (500 MHz, CD₃OD) δ 8.64 (s, 2H), 7.74 (d, J = 2.2 Hz, 1H), 7.57(d, J = 7.4 Hz, 1H), 6.59 (d, J = 7.4 Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H),5.90 (dd, J = 8.9, 6.2 Hz, 1H), 3.58-3.39 (m, 2H), 3.31-3.24 (m, 2H),2.81 (br t, J = 6.1 Hz, 2H), 2.69 (q, J = 7.2 Hz, 4H), 2.66 (s, 3H),2.07-1.98 (m, 2H), 1.98-1.92 (m, 2H). ). LCMS (ES): m/z 407.0 [M + H]⁺.Human αVβ6 IC50 (nM) = 900. Example 22 & 9 56

¹H NMR (500 MHz, CD₃OD) δ 8.53 (s, 2H), 7.71 (d, J = 2.2 Hz, 1H), 7.56(d, J = 7.4 Hz, 1H), 6.58 (d, J = 7.4 Hz, 1H), 6.14 (d, J = 2.2 Hz, 1H),4.41 (q, J = 7.1 Hz, 2H), 3.52-3.46 (m, 2H), 3.46-3.42 (m, 1H), 3.25(dd, J = 16.5, 6.3 Hz, 1H), 2.81 (br t, J = 6.2 Hz, 2H), 2.68 (q, J =7.2 Hz, 4H), 2.04 (s, 1H), 2.03-1.98 (m, 2H), 1.98-1.90 (m, 2H), 1.38(t, J = 7.0 Hz, 3H). ). LCMS (ES): m/z 437.1 [M + H]⁺. Human αVβ6 IC50(nM) = 7.1. Example 22 & 8 57

¹H NMR (500 MHz, DMSO- d₆) δ 7.75-7.70 (m, 1H), 7.32 (d, J = 9.2 Hz,1H), 7.14 (d, J = 9.2 Hz, 1H), 7.01 (d, J = 7.2 Hz, 1H), 6.22 (d, J =7.2 Hz, 1H), 6.06 (d, J = 1.9 Hz, 1H), 5.94 (t, J = 7.4 Hz, 1H), 4.01(s, 3H), 3.29-3.20 (m, 2H), 2.59 (br t, J = 6.2 Hz, 2H), 2.49-2.44 (m,2H), 2.44- 2.38 (m, 2H), 1.87-1.78 (m, 2H), 1.74 (quin, J = 5.9 Hz, 2H),1.23 (s, 2H). LCMS (ES): m/z 422.9 [M + H]⁺. Human αVβ6 IC50 (nM) = 51.Example 22 58

¹H NMR (500 MHz, DMSO- d₆) δ 7.38 (s, 1H), 7.21 (d, = 9.2 Hz, 1H), 7.13(d, J = 9.3 Hz, 1H), 7.02 (d, J = 7.2 Hz, 1H), 6.24 (d, J = 7.2 Hz, 1H),6.07 (s, 1H), 6.00 (br dd, J = 8.4, 6.0 Hz, 1H), 4.01 (s, 3H), 3.32-3.20(m, 2H), 2.72 (qt, J = 15.4, 7.9 Hz, 2H), 2.60 (br t, J = 6.2 Hz, 2H),2.48-2.43 (m, 2H), 1.95-1.83 (m, 2H), 1.75 (quin, J = 5.8 Hz, 2H), 1.24(s, 2H). LCMS (ES): m/z 423.0 [M + H]⁺. Human αVβ6 IC50 (nM) = 2100.Example 22 59

¹H NMR (500 MHz, DMSO- d₆) δ 7.98 (s, 1H), 7.68 (s, 1H), 7.02 (d, J =7.2 Hz, 1H), 6.22 (s, 1H), 6.05 (d, J = 2.1 Hz, 1H), 5.82 (t, J = 7.4Hz, 1H), 3.89 (s, 3H), 3.25 (br s, 2H), 2.62-2.56 (m, 2H), 2.49-2.46 (m,2H), 2.46-2.36 (m, 2H), 1.88- 1.70 (m, 5H), 1.24 (s, 2H LCMS (ES): m/z423.1 [M + H]⁺. Human αVβ6 IC50 (nM) = 110. Example 22 60

¹H NMR (500 MHz, DMSO- d₆) δ 8.22 (s, 1H), 7.77 (s, 1H), 7.55-7.42 (m,1H), 7.39 (s, 1H), 6.51 (br d, J = 7.3 Hz, 1H), 6.11 (s, 1H), 5.80 (dd,J = 9.5, 4.9 Hz, 1H), 3.90-3.77 (m, 3H), 3.35 (br d, J = 5.2 Hz, 1H),3.33-3.21 (m, 1H), 3.21- 3.10 (m, 1H), 2.79-2.58 (m, 7H), 1.98-1.85 (m,2H), 1.85-1.72 (m, 2H). LCMS (ES): m/z 423.0 [M + H]⁺. Human αVβ6 IC50(nM) = 500. Example 22 61

¹H NMR (500 MHz, DMSO- d₆) δ 8.11 (d, J = 1.8 Hz, 1H), 7.65 (s, 1H),7.63-7.56 (m, 1H), 7.50 (br d, J = 7.3 Hz, 1H), 7.27 (s, 1H), 6.75 (d, J= 8.5 Hz, 1H), 6.52 (d, J = 7.3 Hz, 1H), 5.71 (br dd, J = 8.4, 6.6 Hz,1H), 3.80 (s, 2H), 3.40-3.31 (m, 1H), 3.10 (dd, J = 16.3, 6.3 Hz, 1H),2.70 (br t, J = 5.8 Hz, 2H), 2.60 (br t, J = 7.3 Hz, 2H), 2.54 (s, 3H),2.37 (br t, J = 7.3 Hz, 2H), 1.86-1.73 (m, 2H), 1.63-1.53 (m, 2H),1.53-1.42 (m, 2H). LCMS (ES): m/z 436.1 [M + H]⁺. Human αVβ6 IC50 (nM) =56. Example 22 62

¹H NMR (500 MHz, DMSO- d₆) δ 8.12 (s, 1H), 7.67 (br d, J = 8.5 Hz, 1H),7.64-7.61 (m, 1H), 7.28 (s, 1H), 7.02 (d, J = 7.3 Hz, 1H), 6.76 (d, J =8.5 Hz, 1H), 6.24 (d, J = 7.3 Hz, 1H), 5.72 (br t, J = 7.6 Hz, 1H), 3.81(s, 3H), 3.36-3.20 (m, 2H), 3.20- 3.03 (m, 2H), 2.60 (br t, J = 6.1 Hz,2H), 2.46-2.33 (m, 4H), 1.81-1.70 (m, 4H). LCMS (ES): m/z 422.1 [M +H]⁺. Human αVβ6 IC50 (nM) = 170. Example 22

Example 633-(5-methoxypyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Racemic, N1 Pyrazole Regioisomer) Example 643-(5-methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Enantiomer A, N2 Pyrazole Regioisomer) Example 653-(5-methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Enantiomer B, N2 Pyrazole Regioisomer)

Example 63A

To a solution of 3-bromo-5-methoxypyridine (2.0 g, 10.64 mmol), ethylacrylate (4.03 ml, 37.2 mmol), triethylamine (4.00 ml, 28.7 mmol) andtri-o-tolylphosphine (0.54 g, 1.769 mmol) in ACN (13.30 ml) that wasdegassed with nitrogen for 10 min was added palladium(II) acetate (0.27g, 1.20 mmol). The vial was then heated at 90° C. for 8 h, then allowedto stir at room temperature overnight. The reaction was diluted withwater and extracted with EtOAc. The organic layers were combined, driedwith MgSO₄, filtered and concentrated under reduced pressure. The crudeproduct was purified by flash chromatography (0-75% EtOAc/Hex) to giveExample 63A (1.83 g, 8.83 mmol, 83% yield) as a light yellow solid. LCMS(ESI) m/z 208.0 (M+H)+. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.39-8.31 (m,1H), 8.26 (d, J=2.8 Hz, 1H), 7.77-7.59 (m, 2H), 6.71 (d, J=16.0 Hz, 1H),4.28 (q, J=7.0 Hz, 2H), 3.93 (s, 3H), 1.35 (t, J=7.2 Hz, 3H).

To a solution of Example 22H (0.35 g, 1.44 mmol) and Example 63A (0.30g, 1.44 mmol) in acetonitrile (2 mL) was added cesium carbonate (1.41 g,4.33 mmol) and the vial was heated to 80° C. for 16 hours. The reactionwas concentrated under a stream of nitrogen. The crude material [LCMS(ESI) m/z 450.4 and 422.3 (M+H)+] was dissolved in MeOH (7.33 mL) andtreated with 1M NaOH (1.466 mL, 1.466 mmol). The reaction mixture wasallowed to stir at room temperature for 2 hours. The reaction wasfiltered through diatomaceous earth and concentrated under reducedpressure. The crude product was purified by reverse phase HPLC (Start %B=10, Final % B=90, Gradient time=10 min, Flow rate=40 mL/min,Wavelength=220, Solvent A=10% MeOH— 90% water—0.1% TFA, Solvent B=90%MeOH— 10% water-0.1% TFA, Phenominex Luna 5u C18 100×30 MM) to give 324mg of a yellow oil. The material was further separated by chiral SFCseparation (Chromegachiral CC4, 21×250 mm, 5 micron, 43% MeOH/ACN (0.1%NH₄OH)/57% CO₂, 45 mL/min, 120 Bar, 40° C., 220 nm) to give Example 63(racemate), Example 64 (enantiomer A), and Example 65 (enantiomer B).Example 63 (racemate, N1 pyrazole regioisomer, 31.6 mg, 9.8% yield):LCMS (ESI) m/z 422.3 (M+H)⁺. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.19-8.04(m, 1H), 8.02-7.84 (m, 1H), 7.42 (d, J=1.2 Hz, 1H), 7.32-7.22 (m, 2H),6.41 (d, J=7.1 Hz, 1H), 6.06 (d, J=1.0 Hz, 1H), 5.97 (br dd, J=8.8, 5.1Hz, 1H), 3.82 (s, 3H), 3.53-3.35 (m, 3H), 3.08-2.97 (m, 1H), 2.82 (br d,J=6.8 Hz, 1H), 2.73 (br t, J=5.9 Hz, 3H), 2.58 (t, J=7.6 Hz, 2H), 2.17(br d, J=6.8 Hz, 1H), 2.06-1.94 (m, 1H), 1.94-1.84 (m, 2H). Human αVβ6IC50 (nM)=13; Human αVβ3 IC50 (nM)=8.0; Human αVβ5 IC50 (nM)=0.87; andHuman αVβ8 IC50 (nM)=770.

Example 64 (enantiomer A, N2 pyrazole regioisomer, 52 mg, 16% yield)):LCMS (ESI) m/z 422.3 (M+H)⁺. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.50-7.87(m, 2H), 7.67 (s, 1H), 7.39 (d, J=7.3 Hz, 1H), 7.34 (s, 1H), 6.47 (br d,J=7.3 Hz, 1H), 6.11 (d, J=1.5 Hz, 1H), 5.91 (br s, 1H), 3.83 (s, 3H),3.45-3.39 (m, 2H), 3.31 (dt, J=3.2, 1.7 Hz, 1H), 3.09-2.99 (m, 1H), 2.74(t, J=6.1 Hz, 2H), 2.66-2.54 (m, 4H), 2.05-1.84 (m, 4H). Human αVβ6 IC50(nM)=19; Human αVβ3 IC50 (nM)=3.8 and Human αVβ8 IC50 (nM)=110.

Example 65 (enantiomer B, N2 pyrazole regioisomer, 55.5 mg, 17% yield):LCMS (ESI) m/z 422.3 (M+H)⁺. 1H NMR (600 MHz, METHANOL-d4) Shift8.24-8.12 (m, 1H), 8.08 (br s, 1H), 7.64 (s, 1H), 7.52 (br d, J=7.2 Hz,1H), 7.38 (br s, 1H), 6.59 (br d, J=7.2 Hz, 1H), 6.14 (d, J=1.8 Hz, 1H),5.91 (br dd, J=10.9, 4.3 Hz, 1H), 3.88 (s, 3H), 3.49 (t, J=5.4 Hz, 2H),3.04 (br dd, J=14.6, 4.3 Hz, 1H), 2.81 (br t, J=5.9 Hz, 2H), 2.72-2.53(m, 4H), 2.16-2.03 (m, 2H), 2.01-1.89 (m, 3H). Human αVβ6 IC50 (nM)=410;Human αVβ3 IC50 (nM)=4.3; Human αVβ5 IC50 (nM)=1.1.

TABLE A Example Structure & Name Analytical Data Method 66

1H NMR (600 MHz, DMSO-d6) δ 7.87-7.66 (m, 3H), 7.06 (br s, 1H), 6.77 (brs, 1H), 6.33-6.19 (m, 1H), 6.04 (d, J = 1.8 Hz, 1H), 5.69 (dd, J = 9.2,5.9 Hz, 1H), 3.31- 2.98 (m, 6H), 2.61 (br t, J = 6.1 Hz, 2H), 2.55 (s,1H), 2.51 (br s, 2H), 2.45 (br t, J = 7.5 Hz, 2H), 1.95-1.87 (m, 7H),1.87-1.80 (m, 2H), 1.79-1.70 (m, 2H) LC/MS [M + H]+ = 461.1. Human αVβ6IC50 (nM) = 21 Example 22 67

1H NMR (500 MHz, METHANOL-d4) δ 8.25-8.06 (m, 1H), 7.93 (br s, 1H), 7.62(d, J = 2.1 Hz, 1H), 7.47 (d, J = 7.3 Hz, 1H), 7.34 (s, 1H), 6.56 (d, J= 7.5 Hz, 1H), 6.13 (d, J = 2.3 Hz, 1H), 5.87 (dd, J = 10.8, 4.7 Hz,1H), 3.89-3.75 (m, 4H), 3.52-3.43 (m, 2H), 3.24-3.15 (m, 5H), 3.01 (dd,J = 14.7, 4.8 Hz, 1H), 2.79 (t, J = 6.1 Hz, 2H), 2.72-2.53 (m, 5H),2.15-1.82 (m, 4H) LC/MS [M + H]+ = 477.3 Human αVβ6 IC50 (nM) = 210.Example 22, 8 68

1H NMR (500 MHz, METHANOL-d4) δ 8.25-8.09 (m, 1H), 7.93 (br s, 1H), 7.62(d, J = 2.3 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.34 (d, J = 2.0 Hz, 1H),6.57 (d, J = 7.3 Hz, 1H), 6.13 (d, J = 2.3 Hz, 1H), 5.87 (dd, J = 10.9,4.7 Hz, 1H), 3.90-3.71 (m, 4H), 3.54- 3.44 (m, 2H), 3.27 (s, 1H), 3.25-3.13 (m, 4H), 3.01 (dd, J = 14.6, 4.6 Hz, 1H), 2.80 (t, J = 6.2 Hz, 2H),2.72-2.54 (m, 4H), 2.15- 1.83 (m, 4H) LC/MS [M + H]+ = 477.3 Human αVβ6IC50 (nM) = 2.8. Example 22,9 69

1H NMR (600 MHz, METHANOL-d4) Shift 8.35- 8.21 (m, 2H), 7.68-7.55 (m,2H), 7.47 (d, J = 7.3 Hz, 1H), 6.55 (d, J = 7.3 Hz, 1H), 6.12 (d, J =1.9 Hz, 1H), 5.87 (dd, J = 10.8, 4.5 Hz, 1H), 3.46 (t, J = 5.6 Hz, 2H),3.29- 3.22 (m, 1H), 3.00 (dd, J = 14.6, 4.6 Hz, 1H), 2.78 (t, J = 6.2Hz, 2H), 2.69-2.48 (m, 4H), 2.34 (s, 3H), 2.13-2.01 (m, 1H), 2.00- 1.85(m, 3H) LC/MS [M + H]+ = 406.3 Human αVβ6 IC50 (nM) = 15 Example 22, 870

1H NMR (600 MHz, METHANOL-d4) Shift 8.28 (br d, J = 19.8 Hz, 2H),7.68-7.54 (m, 2H), 7.46 (d, J = 7.3 Hz, 1H), 6.55 (d, J = 7.3 Hz, 1H),6.11 (d, J = 1.9 Hz, 1H), 5.87 (dd, J = 10.8, 4.6 Hz, 1H), 3.46 (t, J =5.6 Hz, 2H), 3.25 (s, 1H), 3.00 (dd, J = 14.6, 4.6 Hz, 1H), 2.78 (t, J =6.2 Hz, 2H), 2.68- 2.48 (m, 4H), 2.34 (s, 3H), 2.10- 2.00 (m, 1H),1.98-1.85 (m, 3H) LC/MS [M + H]+ = 406.3 Human αVβ6 IC50 (nM) = 4900Example 22, 9 71

1H NMR (500 MHz, DMSO-d6) δ 7.75-7.64 (m, 1H), 7.22-6.93 (m, 4H),6.32-6.18 (m, 2H), 6.02 (s, 1H), 5.67 (br t, J = 7.3 Hz, 1H), 3.80 (s,5H), 3.24 (br d, J = 4.6 Hz, 1H), 3.00 (br dd, J = 16.0, 6.3 Hz, 3H),2.61 (br t, J = 6.3 Hz, 2H), 2.44 (br t, J = 7.6 Hz, 2H), 1.84 (br t, J= 7.9 Hz, 2H), 1.79-1.71 (m, 2H) LC/MS [M + H]+ = 439.2 Human αVβ6 IC50(nM) = 15. Example 22 72

1H NMR (600 MHz, DMSO-d6) δ 7.60-7.49 (m, 1H), 7.27 (br d, J = 5.5 Hz,1H), 7.20-6.98 (m, 4H), 6.28 (br d, J = 7.0 Hz, 1H), 5.94-5.78 (m, 1H),5.54 (br dd, J = 8.8, 6.2 Hz, 1H), 3.01-2.85 (m, 1H), 2.71 (br s, 4H),2.64- 2.53 (m, 4H), 2.47 (br d, J = 5.9 Hz, 2H), 2.38 (br t, J = 7.3 Hz,4H), 2.30 (br d, J = 7.3 Hz, 2H), 1.75-1.46 (m, 4H) LC/MS [M + H]+ =463.2 Human αVβ6 IC50 (nM) = 24 Example 22 73

1H NMR (600 MHz, DMSO-d6) δ 8.15-7.98 (m, 1H), 7.75 (d, J = 1.8 Hz, 1H),7.02 (d, J = 7.3 Hz, 1H), 6.81 (br d, J = 4.8 Hz, 1H), 6.53 (s, 1H),6.24 (d, J = 7.3 Hz, 2H), 6.06 (s, 1H), 5.71 (dd, J = 8.8, 5.9 Hz, 1H),3.80 (s, 3H), 3.09- 2.96 (m, 1H), 2.60 (br t, J = 6.2 Hz, 3H), 2.49-2.48(m, 1H), 2.43 (br t, J = 7.5 Hz, 3H), 1.83 (br t, J = 7.5 Hz, 3H),1.79-1.66 (m, 3H) LC/MS [M + H]+ = 422.2 Human αVβ6 IC50 (nM) = 25Example 22 74

1H NMR (600 MHz, DMSO-d6) δ 7.53 (d, J = 2.2 Hz, 1H), 7.19 (d, J = 1.1Hz, 1H), 7.17-7.10 (m, 2H), 7.08-7.01 (m, 1H), 6.82- 6.75 (m, 1H), 6.01(d, J = 7.3 Hz, 1H), 5.82 (d, J = 1.8 Hz, 1H), 5.54 (br dd, J = 8.8, 6.2Hz, 1H), 3.22- 3.07 (m, 4H), 3.01 (br s, 3H), 2.92-2.80 (m, 2H), 2.72(br s, 3H), 2.64-2.53 (m, 3H), 2.38 (br t, J = 6.1 Hz, 1H), 1.69 (s,2H), 1.61 (br t, J = 7.5 Hz, 2H), 1.55- 1.49 (m, 3H) LC/MS [M + H]+ =463.1 Human αVβ6 IC50 (nM) = 13 Example 22 75

1H NMR (600 MHz, DMSO-d6) Shift 7.77 (br s, 1H), 7.49 (s, 1H), 7.31 (s,2H), 7.02 (br d, J = 7.2 Hz, 1H), 6.24 (br s, 2H), 6.07 (s, 1H), 5.76(br s, 1H), 3.28-3.16 (m, 2H), 3.18-3.05 (m, 2H), 2.60 (br t, J = 6.1Hz, 2H), 2.49-2.47 (m, 2H), 2.41 (br d, J = 6.6 Hz, 2H), 1.87-1.79 (m,2H), 1.78-1.70 (m, 2H) LC/MS [M + H]+ = 458.98 Human αVβ6 IC50 (nM) = 28Example 22 76

1H NMR (600 MHz, DMSO-d6) Shift 7.91-7.77 (m, 1H), 7.70 (s, 1H), 7.05(br d, J = 7.2 Hz, 1H), 6.53 (br s, 1H), 6.41-6.31 (m, 2H), 6.26 (d, J =7.2 Hz, 1H), 6.22 (s, 1H), 6.13-6.03 (m, 1H), 5.53 (br dd, J = 9.1, 5.6Hz, 1H), 3.23 (br s, 2H), 3.15 (br d, J = 5.9 Hz, 2H), 3.04 (br d, J =5.5 Hz, 2H), 2.60 (br t, J = 6.0 Hz, 2H), 2.44 (br t, J = 7.5 Hz, 4H),2.24 (br t, J = 7.4 Hz, 2H), 1.87-1.65 (m, 6H) LC/MS [M + H]+ = 493.2Human αVβ6 IC50 (nM) = 55 Example 22 77

1H NMR (500 MHz, DMSO-d6) δ 7.98-7.88 (m, 1H), 7.73 (s, 1H), 7.64 (br d,J = 11.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 6.34- 6.17 (m, 2H), 6.03 (s,1H), 5.75 (br t, J = 7.3 Hz, 1H), 3.91 (s, 3H), 3.29-3.13 (m, 4H), 3.02(br dd, J = 16.3, 6.6 Hz, 2H), 2.60 (br t, J = 6.1 Hz, 2H), 2.43 (br t,J = 7.5 Hz, 2H), 1.84 (br t, J = 7.5 Hz, 2H), 1.78-1.68 (m, 2H) LC/MS[M + H]+ = 440.2 Human αVβ6 IC50 (nM) = 18 Example 63 78

1H NMR (500 MHz, METHANOL-d4) Shift 8.31- 8.21 (m, 1H), 8.15 (br s, 1H),7.54 (s, 1H), 7.45-7.34 (m, 2H), 6.49 (d, J = 7.3 Hz, 1H), 6.03 (d, J =1.7 Hz, 1H), 5.97 (dd, J = 10.5, 4.2 Hz, 1H), 3.55 (dd, J = 15.8, 10.4Hz, 1H), 3.43 (t, J = 5.6 Hz, 2H), 2.99 (dd, J = 15.8, 4.3 Hz, 1H),2.92-2.84 (m, 1H), 2.81- 2.72 (m, 3H), 2.60 (t, J = 7.7 Hz, 2H), 2.31(s, 4H), 2.04-1.95 (m, 1H), 1.94-1.87 (m, 2H) LC/MS [M + H]+ = 406.3Example 22 79

1H NMR (600 MHz, DMSO-d6) Shift 7.76-7.66 (m, 1H), 7.52 (d, J = 1.8 Hz,1H), 7.09 (br d, J = 6.8 Hz, 1H), 6.31-6.25 (m, 1H), 6.20 (br d, J = 3.5Hz, 1H), 6.14 (s, 1H), 5.95 (s, 1H), 4.95 (br s, 1H), 3.29- 3.03 (m,3H), 2.61 (br t, J = 6.0 Hz, 3H), 2.48-2.39 (m, 5H), 2.22 (br t, J = 7.3Hz, 3H), 1.82 (br t, J = 7.5 Hz, 2H), 1.78-1.72 (m, 3H), 1.66 (br t, J =7.1 Hz, 3H) LC/MS [M + H]+ = 493.2 Human αVβ6 IC50 (nM) = 300 Example 6380

1H NMR (400 MHz, METHANOL-d4) δ 8.24-8.12 (m, 1H), 8.08 (br s, 1H), 7.74(d, J = 2.2 Hz, 1H), 7.35 (s, 1H), 7.12 (d, J = 7.3 Hz, 1H), 6.34 (d, J= 7.3 Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H), 5.90 (t, J = 7.6 Hz, 1H), 4.18(d, J = 4.2 Hz, 2H), 3.73 (t, J = 4.5 Hz, 2H), 3.40 (s, 3H), 3.37 (br s,1H), 3.34 (dt, J = 3.2, 1.7 Hz, 1H), 3.29- 3.15 (m, 1H), 3.14-3.01 (m,1H), 2.70 (t, J = 6.3 Hz, 2H), 2.63 (t, J = 7.6 Hz, 2H), 2.58-2.49 (m,2H), 2.01-1.84 (m, 4H) LC/MS [M + H]+ = 466.4 Human αVβ6 IC50 (nM) = 1.8Example 63 81

The isomers were separated using a preparative chiral SFC equipped withChiralpak AD-H (30 × 250 mm, 5 μm) using an isocratic method of 20%MeOH/0.1% DEA in CO₂, 150 bar at 35° C. with a flow rate of 70 mL/minand monitored @220 nm. ¹H NMR (400 MHz, DMSO-d₆) δ 8.56 (s, 2H), 7.75(d, J = 2.2 Hz, 1H), 7.01 (d, J = 7.1 Hz, 1H), 6.28 (br s, 1H), 6.23 (d,J = 7.3 Hz, 1H), 6.04 (d, J = 2.2 Hz, 1H), 5.77 (dd, J = 8.2, 6.2 Hz,1H), 4.32 (q, J = 6.9 Hz, 2H), 3.26-3.20 (m, 3H), 3.18- 3.10 (m, 1H),2.60 (br t, J = 6.4 Hz, 2H), 2.47 (m, 2H), 2.42 (br t, J = 7.5 Hz, 2H),1.88-1.69 (m, 4H), 1.30 (t, J = 7.0 Hz, 3H). MS (ESI); (m/z): 437.13(M + H)⁺. Human αVβ6 IC50 (nM) = 480 Example 22 82

The isomers were separated using a preparative chiral SFC equipped withChiralpak AD-H (30 × 250 mm, 5 μm). The separations were performed usingan isocratic method of 20% MeOH/0.1% DEA in CO₂, 150 bar at 35° C. witha flow rate of 70 mL/min and monitored @220 nm. ¹H NMR (400 MHz,METHANOL- d₄) δ 8.59-8.51 (m, 2H), 7.66 (d, J = 2.0 Hz, 1H), 7.42 (d, J= 7.1 Hz, 1H), 6.53 (d, J = 7.1 Hz, 1H), 6.13 (d, J = 2.0 Hz, 1H), 5.85(dd, J = 9.7, 5.3 Hz, 1H), 4.01 (s, 3H), 3.49-3.43 (m, 2H), 3.25 (dd, J= 14.7, 9.8 Hz, 1H), 3.04 (dd, J = 14.5, 5.7 Hz, 1H), 2.78 (t, J = 6.1Hz, 2H), 2.68-2.52 (m, 4H), 2.12-1.86 (m, 4H). MS (ESI) (m/z): 423.19(M + H)⁺. Example 22 Human αVβ6 IC50 (nM) = 8.5 83

¹H NMR (400 MHz, ACETONITRILE-d₃) δ 8.52 (s, 2H), 7.57 (d, J = 2.2 Hz,1H), 7.50- 7.43 (m, 1H), 6.50 (d, J = 7.3 Hz, 1H), 6.13-6.08 (m, 1H),5.76 (dd, J = 9.5, 5.4 Hz, 1H), 3.96 (s, 3H), 3.48-3.44 (m, 2H), 3.21-3.11 (m, 2H), 2.77 (br t, J = 6.1 Hz, 2H), 2.71-2.62 (m, 4H), 2.06- 2.00(m, 2H), 1.94-1.87 (m, 2H). MS (ESI) (m/z): 423.10 (M + H)⁺. Human αVβ6IC50 (nM) = 310 Example 22 84

¹H NMR (500 MHz, DMSO-d₆) δ 9.14-9.04 (m, 1H), 8.73 (s, 2H), 7.83-7.77(m, 1H), 7.01 (d, J = 7.3 Hz, 1H), 6.34-6.26 (m, 1H), 6.22 (d, J = 7.0Hz, 1H), 6.06 (d, J = 2.1 Hz, 1H), 5.84 (br t, J = 7.5 Hz, 1H),3.31-3.20 (m, 2H), 3.16 (br dd, J = 16.2, 6.4 Hz, 2H), 2.60 (br t, J =6.0 Hz, 2H), 2.48 (m, 2H), 2.42 (br t, J = 7.3 Hz, 2H), 1.88-1.79 (m,2H), 1.78- 1.70 (m, 2H). MS (ESI) (m/z): 393.2 (M + H)⁺. Human αVβ6 IC50(nM) = 110 Example 22

Example 85 Example 85:(S)-3-(2-hydroxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

To(S)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid (Example 82, 21 mg, 0.050 mmol) in acetonitrile (1 mL) was addedHCl, 1M (0.045 mL, 1.491 mmol). The reaction mixture was stirred at rtfor 5 mins. The sample was concentrated and then lyophilyzed to give(S)-3-(2-hydroxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid, 3 TFA Example 85 (10 mg, 0.013 mmol, 25.5% yield). ¹H NMR (400MHz, DEUTERIUM OXIDE) δ 8.32-8.28 (m, 2H), 7.69-7.65 (m, 1H), 7.41-7.34(m, 1H), 6.44-6.35 (m, 1H), 6.17-6.11 (m, 1H), 5.79-5.69 (m, 1H),3.42-3.36 (m, 2H), 3.33-3.17 (m, 2H), 2.70-2.64 (m, 2H), 2.63-2.54 (m,4H), 2.00-1.91 (m, 2H), 1.87-1.78 (m, 2H). MS (ESI) (m/z): 409.12(M+H)⁺. Human αVβ6 IC50 (nM)=52

Example 86 and Example 87(S)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Example 86)3-(2-methylpyrimidin-5-yl)-3-(5-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Example 87)

Benzyl 2-(prop-2-yn-1-yl)-1,8-naphthyridine-1(2H)-carboxylate (86A)

A solution of 1,8-naphthyridine (1.30 g, 9.99 mmol) and freshly preparedtributyl(propa-1,2-dien-1-yl)stannane (3.90 g, 9.49 mmol) in DCM (35 mL)at 0° C. (ice water bath) was treated with benzyl carbonochloridate(2.045 g, 11.99 mmol) dropwise. After 1 hr at 0° C. the ice bath wasremoved and stirring was continued at RT ON. The r×n was concentratedand purified directly by Biotage (40 g col, 10-35% EtOAc/Hexanes, 16 CV)to give desired product 86A (2.0 g, elutes around 25% ETOAc/hexanes) asa clear wax. ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.44-8.30 (m, 1H),7.46-7.42 (m, 2H), 7.41-7.31 (m, 4H), 7.05 (dd, J=7.5, 4.8 Hz, 1H), 6.54(d, J=9.5 Hz, 1H), 6.23 (dd, J=9.5, 5.8 Hz, 1H), 5.33 (d, J=5.5 Hz, 2H),5.29-5.19 (m, 1H), 2.52-2.37 (m, 2H), 1.90 (t, J=2.5 Hz, 1H).

Tert-butyl 3-bromo-1H-pyrazole-1-carboxylate (86B)

To 3-bromo-1H-pyrazole (5 g, 34.0 mmol) and DIEA (17.83 ml, 102 mmol) inDCM (85 ml) at 0° C. was added BOC-anhydride (11.85 ml, 51.0 mmol)followed by DMAP (0.042 g, 0.340 mmol). The reaction mixture was allowedto warm to rt and then was stirred for 3 h at rt. Water was added andthe layers were separated. The organic solvent layer was washed withbrine and dried over sodium sulfate. The sample was filtered,concentrated, and the residue was dissolved in a small amount ofdichloromethane and charged to a 80 g silica gel cartridge which waseluted with 0-30% ethyl acetate/hexanes over a period of 50 mins. Thedesired fractions were combined and dried in vacuo to give tert-butyl3-bromo-1H-pyrazole-1-carboxylate 86B (8.2 g, 33.2 mmol, 98% yield). ¹HNMR (400 MHz, CHLOROFORM-d) δ 8.05-7.96 (m, 1H), 6.43 (d, J=2.7 Hz, 1H),1.67 (s, 9H). MS (ESI) (m/z): 190.77 (M+H-tBu)⁺.

Benzyl2-(3-(1-(tert-butoxycarbonyl)-1H-pyrazol-3-yl)prop-2-yn-1-yl)-1,8-naphthyridine-1(2H)-carboxylate86C

A soln of tert-butyl 3-bromo-1H-pyrazole-1-carboxylate 86B (1.624 g,6.57 mmol), benzyl2-(prop-2-yn-1-yl)-1,8-naphthyridine-1(2H)-carboxylate 86A (2.0 g, 6.57mmol), and TEA (3.21 mL, 23.00 mmol) in acetonitrile (30 mL) was purgedwith N2 bubble and sonication for 10 min. Solid copper(I) iodide (0.063g, 0.329 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.231g, 0.329 mmol) were then added, the vial capped and then heated to 70°C. for 6 hrs (oil bath with timer). The reaction mixture was dilutedwith EtOAc, washed with H2O, brine, dried (MgSO4) and concentrated togive a dark wax. The wax was purified by Biotage (80 g col, 10-45%EtOAc/Hexanes, 14 CV) to give desired prod (1.50 g, yellow wax). MS(ESI) (m/z): 493.03 (M+Na)

Tert-butyl3-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazole-1-carboxylate(86D)

A suspension of benzyl2-(3-(1-(tert-butoxycarbonyl)-1H-pyrazol-3-yl)prop-2-yn-1-yl)-1,8-naphthyridine-1(2H)-carboxylate86C (1.5 g, 3.19 mmol), and Pd—C(100 mg, 0.094 mmol) in ethanol (25 mL)was hydrogenated (PARR) at 45 psi for 5 hrs. Crude LCMS and NMR showthat the triple bond is reduced but most of the material is still Cbzprotected. The r×n was then re-subjected to the same conditions, for 18h longer (Ethanol, 100 mg 10% Pd/C, 45 psi). The reaction mixture wasfiltered through Celite and then concentrated to give the desiredproduct (1.02 g, clear wax). MS (ESI) (m/z): 243.1 (M-Boc)

2-(3-(1H-pyrazol-3-yl)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine (86E)

To a soln of tert-butyl3-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazole-1-carboxylate86D (1.02 g, 2.98 mmol) at room temperature in DCM (1 mL) was added asoln of HCl (3 ml, 12.00 mmol) (4M in Dioxane) dropwise. The clear solnwas stirred at rt for 2 h. The reaction mixture was concentrated andtaken directly towards purification by Biotage, (40 g col, 0-10%MeOH/DCM, 12CV, then 10% MeOH/DCM, 6CV) to give desired product 86E (835mg, white solid). The isomers were separated using a preparative chiralSFC equipped with Chiralcel OD-H (30×250 mm, 5 μm). The separations wereperformed using an isocratic method of 15% MeOH/0.1% DEA in CO₂, 150 barat 35° C. with a flow rate of 70 mL/min and monitored @ 314 nm.

(S)-2-(3-(1H-pyrazol-3-yl)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine(86F)

¹H NMR (400 MHz, DMSO-d₆) δ 12.66-12.20 (m, 1H), 7.77 (d, J=5.1 Hz, 1H),7.55-7.37 (m, 1H), 7.30 (br d, J=7.1 Hz, 1H), 6.95-6.79 (m, 1H),6.54-6.47 (m, 1H), 6.05 (s, 1H), 3.40 (br d, J=3.4 Hz, 1H), 2.68 (br t,J=6.2 Hz, 2H), 2.61 (br t, J=7.3 Hz, 2H), 1.97-1.82 (m, 1H), 1.75-1.65(m, 2H), 1.64-1.37 (m, 3H)

(R)-2-(3-(1H-Pyrazol-3-yl)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine(86G)

¹H NMR (400 MHz, DMSO-d₆) δ 12.66-12.25 (m, 1H), 7.84-7.69 (m, 1H),7.52-7.39 (m, 1H), 7.33 (br d, J=6.8 Hz, 1H), 7.05-6.90 (m, 1H), 6.52(t, J=6.2 Hz, 1H), 6.08-6.00 (m, 1H), 3.41 (br d, J=3.4 Hz, 1H), 2.69(br t, J=6.2 Hz, 2H), 2.60 (br t, J=7.3 Hz, 2H), 1.93-1.83 (m, 1H),1.77-1.65 (m, 2H), 1.63-1.40 (m, 3H)

Tert-butyl (E)-3-(2-methylpyrimidin-5-yl)acrylate (86H)

To a mixture of 2-methylpyrimidine-5-carbaldehyde (5.0 g, 40.9 mmol),tert-butyl diethylphosphonoacetate (11.58 mL, 49.1 mmol), and molecularsieves (4A) (20 g, 189 mmol) in THF (100 mL) was added lithium hydroxide(1.176 g, 49.1 mmol). The mixture was stirred at rt for 72 h and thenfiltered. The filter cake washed with THF. The combined organic layerswere concentrated in vacuo and the residue was dissolved in EtOAc andwashed with H2O. The combined organic layers were dried over Na2SO4,filtered, concentrated, and the residue subjected to flash columnchromatography (ethyl acetate/hexanes 1:1) to afford tert-butyl(E)-3-(2-methylpyrimidin-5-yl)acrylate 86H (7.04 g, 32.0 mmol, 78%yield) as a white solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.75 (br s,2H), 7.48 (br d, J=16.1 Hz, 1H), 6.47 (br d, J=16.1 Hz, 1H), 2.75 (br s,3H), 1.53 (br s, 9H). MS (ESI) (m/z): 221.08 (M+H)⁺.

Tert-butyl3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(86I) and tert-butyl3-(2-methylpyrimidin-5-yl)-3-(5-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(86J)

The title compounds were prepared using a method analogous to Example22A by reaction of(S)-2-(3-(1H-pyrazol-3-yl)propyl)-1,2,3,4-tetrahydro-1,8-naphthyridine(86F) with acrylate (86H). The crude product was dissolved in a smallamount of dichloromethane and charged to a 24 g gold silica gelcartridge. The column was eluted with 0-8% dichloromethane/methanol overa period of 60 mins. TLC using 2.5-5% MeOH/DCM eluted 3× showed theseparated regioisomers. The desired fractions were combined and dried invacuo to give tert-butyl3-(2-methylpyrimidin-5-yl)-3-(3-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(86I) (124.9 mg, 0.270 mmol, 32.7% yield, 2nd eluting peak ofregioisomers) and tert-butyl3-(2-methylpyrimidin-5-yl)-3-(5-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(86J) (14.9 mg, 0.032 mmol, 3.90% yield, 1st eluting peak of theregioisomers). For 86I: ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.62 (s, 2H),7.87 (d, J=4.9 Hz, 1H), 7.38 (d, J=1.7 Hz, 1H), 7.16 (br d, J=7.1 Hz,1H), 6.54-6.45 (m, 1H), 6.07 (d, J=1.2 Hz, 1H), 5.67 (t, J=7.5 Hz, 1H),4.88 (br s, 1H), 3.43 (br dd, J=15.9, 8.3 Hz, 2H), 3.11 (dd, J=16.1, 6.8Hz, 1H), 2.73 (s, 5H), 2.68 (t, J=7.5 Hz, 2H), 2.01-1.91 (m, 1H),1.82-1.72 (m, 2H), 1.64-1.57 (m, 3H), 1.37 (s, 9H). MS (ESI) (m/z):463.33 (M+H)⁺. NOE-at 7.38 ppm—shows NOE with C-alpha H, pyrimidine H,pyrazole H4 and t-butyl group. For 86J: ¹H NMR (400 MHz, CHLOROFORM-d) δ8.57 (s, 2H), 7.86 (br d, J=4.6 Hz, 1H), 7.50 (s, 1H), 7.17 (br d, J=6.8Hz, 1H), 6.51 (t, J=6.2 Hz, 1H), 6.06 (s, 1H), 5.69 (dd, J=8.6, 6.1 Hz,1H), 4.94-4.81 (m, 1H), 3.57 (dd, J=16.1, 9.0 Hz, 1H), 3.47-3.38 (m,1H), 3.06 (dd, J=16.4, 5.9 Hz, 1H), 2.82-2.69 (m, 6H), 2.60 (dt, J=15.3,7.6 Hz, 1H), 1.99-1.86 (m, 1H), 1.84-1.70 (m, 2H), 1.68-1.44 (m, 3H),1.36 (s, 9H). NOE-at 7.5 ppm—shows NOE with pyrazole H4 (6.06) and tBu.

Tert-butyl(R)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(86K) and tert-butyl(S)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(86L)

The diastereomers of tert-butyl3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate86I were separated using a preparative chiral SFC equipped withChiralpak AD-H (30×250 mm, 5 μm). The separations were performed usingan isocratic method of 25% MeOH/0.1% DEA in CO₂, 150 bar at 35° C. witha flow rate of 70 mL/min. For 86K: ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.62(s, 2H), 7.89-7.82 (m, 1H), 7.38 (d, J=2.3 Hz, 1H), 7.16 (d, J=7.2 Hz,1H), 6.49 (dd, J=7.2, 5.0 Hz, 1H), 6.06 (d, J=2.3 Hz, 1H), 5.66 (t,J=7.6 Hz, 1H), 4.90-4.81 (m, 1H), 3.48-3.36 (m, 2H), 3.17-3.06 (m, 1H),2.73 (s, 3H), 2.67 (t, J=7.6 Hz, 2H), 1.99-1.92 (m, 1H), 1.85-1.71 (m,2H), 1.57-1.52 (m, 3H), 1.37 (s, 9H). MS (ESI) (m/z): 463.3 (M+H)⁺. For86L: ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.62 (s, 2H), 7.86 (d, J=3.7 Hz,1H), 7.38 (d, J=2.3 Hz, 1H), 7.16 (d, J=7.2 Hz, 1H), 6.49 (dd, J=7.2,5.0 Hz, 1H), 6.07 (d, J=2.3 Hz, 1H), 5.71-5.62 (m, 1H), 4.98-4.85 (m,1H), 3.48-3.37 (m, 2H), 3.16-3.05 (m, 1H), 2.73 (s, 3H), 2.67 (t, J=7.6Hz, 2H), 2.00-1.91 (m, 1H), 1.83-1.71 (m, 2H), 1.58-1.53 (m, 3H), 1.37(s, 9H). MS (ESI) (m/z): 463.29 (M+H)⁺.

Example 86(S)-3-(2-Methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

To tert-butyl(S)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate86L (50 mg, 0.108 mmol) in CH₂Cl₂ (1.5 mL) was added TFA (0.4 mL, 5.19mmol). The reaction mixture was stirred at rt overnight. The sample wasconcentrated and dried. The sample was desalted using a Sep-Pak pluscartridge: Solvent A: 95:5 (water/acetonitrile) with 0.1% NH₄OH; SolventB: acetonitrile with 0.1% NH₄OH. Preparation of Sep-Pak plus long (820mg/1.6 ml): added 20 mL of methanol to wet the material and then washedwith solvent A (20 mL). Loading: sample in solvent A was loaded untocolumn then washed with solvent A(15 mL). Elution: acetonitrile with0.1% NH₄OH (10 mL) was added to elute product followed by a final washwith Methanol (6 mL). TLC was utilized to detect product elution on eachfraction. The desired fractions were combined and lyophilized to givedesired product, Example 86. ¹H NMR (400 MHz, METHANOL-d₄) δ 8.62 (s,2H), 7.70 (s, 1H), 7.69-7.66 (m, 1H), 7.52 (d, J=7.1 Hz, 1H), 6.67 (t,J=6.6 Hz, 1H), 6.17 (s, 1H), 5.90 (dd, J=9.5, 5.6 Hz, 1H), 3.54 (br d,J=4.9 Hz, 1H), 3.43-3.35 (m, 1H), 3.16-3.09 (m, 1H), 2.86-2.69 (m, 3H),2.66 (s, 4H), 2.03-1.94 (m, 1H), 1.85-1.76 (m, 2H), 1.70-1.56 (m, 3H).MS (ESI) (m/z): 407.2 (M+H)⁺. Human αVβ6 IC50 (nM)=270

Example 873-(2-Methylpyrimidin-5-yl)-3-(5-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

Sample was prepared using methods analogous to Example 86. ¹H NMR showsa mixture of diastereomers. MS (ESI) (m/z): 407.2 (M+H)⁺. Human αVβ6IC50 (nM)=1382

Example Structure & Name Analytical Data Method 88

¹H NMR (400 MHz, METHANOL-d₄) δ 8.69- 8.59 (m, 2H), 7.68 (s, 1H), 7.67(s, 1H), 7.57-7.50 (m, 1H), 6.72-6.64 (m, 1H), 6.15 (d, J = 2.0 Hz, 1H),5.94- 5.86 (m, 1H), 3.65-3.51 (m, 1H), 3.40-3.35 (m, 1H), 3.18-3.06 (m,1H), 2.90- 2.75 (m, 2H), 2.74-2.68 (m, 2H), 2.67 (s, 3H), 2.07-1.95 (m,1H), 1.86-1.74 (m, 2H), 1.68-1.53 (m, 3H). MS (ESI) (m/z): 407.18 (M +H)⁺. Human αVβ6 IC50 (nM) = 110 Example 86 (using 86G) 89

¹H NMR (400 MHz, METHANOL-d₄) δ 8.52 (s, 2H), 7.68 (m, 2H), 7.49 (d, J =6.8 Hz, 1H), 6.66 (t, J = 6.4 Hz, 1H), 6.15 (d, J = 2.0 Hz, 1H), 5.86(dd, J = 9.4, 6.0 Hz, 1H), 3.99 (s, 3H), 3.58-3.52 (m, 1H), 3.45-3.36(m, 1H), 3.09 (dd, J = 15.7, 5.9 Hz, 1H), 2.85-2.77 (m, 2H), 2.75-2.58(m, 2H), 1.98 (br d, J = 9.0 Hz, 1H), 1.84-1.76 (m, 2H), 1.69-1.56 (m,3H). MS (ESI) (m/z): 423.18 (M + H)⁺. Human αVβ6 IC50 (nM) = 100 Example86 90

¹H NMR (500 MHz, METHANOL-d₄) δ 8.54 (s, 2H), 7.71-7.64 (m, 2H), 7.46(dd, J = 7.2, 1.0 Hz, 1H), 6.63 (dd, J = 7.1, 5.9 Hz, 1H), 6.14 (d, J =2.3 Hz, 1H), 5.85 (dd, J = 9.5, 6.0 Hz, 1H), 4.00 (s, 3H), 3.56-3.53 (m,1H), 3.31-3.26 (m, 1H), 3.12- 3.05 (m, 1H), 2.83-2.77 (m, 2H), 2.70-2.64(m, 2H), 2.02-1.94 (m, 1H), 1.84- 1.75 (m, 2H), 1.66-1.56 (m, 3H). MS(ESI) (m/z): 423.21 (M + H)⁺. Human αVβ6 IC50 (nM) = 220 86 (using 86G)91

¹H NMR shows a mixture of diastereomers. MS (ESI) (m/z): 407.2 (M + H).Human αVβ6 IC50 (nM) = 1400 Example 87 92

¹H NMR shows a mixture of diastereomers. MS (ESI) (m/z): 423.2 (M + H)Human αVβ6 IC50 (nM) = 6700 Example 87 93

¹H NMR shows a mixture of diastereomers. MS (ESI) (m/z): 423.15 (M + H)Human αVβ6 IC50 (nM) = 1030 Example 87 94

¹H NMR (500 MHz, METHANOL-d₄) δ 8.13- 8.02 (m, 1H), 7.82 (s, 1H), 7.43(d, J = 1.7 Hz, 1H), 7.26 (t, J = 2.1 Hz, 1H), 7.07 (d, J = 7.3 Hz, 1H),6.24 (d, J = 7.3 Hz, 1H), 6.11 (d, J = 1.7 Hz, 1H), 5.92 (t, J = 7.2 Hz,1H), 3.86-3.73 (m, 4H), 3.40-3.33 (m, 2H), 3.27 (dd, J = 15.4, 7.3 Hz,1H), 3.17-3.11 (m, 4H), 3.04 (dd, J = 15.4, 7.1 Hz, 1H), 2.81-2.65 (m,4H), 2.58-2.48 (m, 2H), 1.92- 1.82 (m, 4H) LC/MS [M + H]+ = 477.3 HumanαVβ6 IC50 (nM) = 19 Example 22 95

¹H NMR (500 MHz, METHANOL-d₄) δ 8.13- 8.02 (m, 1H), 7.82 (s, 1H), 7.43(d, J = 1.7 Hz, 1H), 7.26 (t, J = 2.1 Hz, 1H), 7.07 (d, J = 7.3 Hz, 1H),6.24 (d, J = 7.3 Hz, 1H), 6.11 (d, J = 1.7 Hz, 1H), 5.92 (t, J = 7.2 Hz,1H), 3.86-3.73 (m, 4H), 3.40-3.33 (m, 2H), 3.27 (dd, J = 15.4, 7.3 Hz,1H), 3.17-3.11 (m, 4H), 3.04 (dd, J = 15.4, 7.1 Hz, 1H), 2.81-2.65 (m,4H), 2.58-2.48 (m, 2H), 1.92- 1.82 (m, 4H) LC/MS [M + H]+ = 477.3 HumanαVβ6 IC50 (nM) = 230 Example 22

Example 96, Example 97, and Example 98(±)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Example 96) Example 97

Enantiomer 1 from Example 96

Example 98

Enantiomer 2 from Example 96

(1s,5s)-9-(4,4-diethoxybutyl)-9-borabicyclo[3.3.1]nonane (96A)

The title compound 96A was prepared as described in Journal of OrganicChemistry (2005) 70, 1771-1779 Keen et al.

Tert-butyl2-chloro-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate (96B)

The title compound 96B was prepared following the procedure described inWO 2011/059839.

Tert-butyl2-(4,4-diethoxybutyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate(96C)

The title compound was prepared as described in Journal of OrganicChemistry (2005) 70, 1771-1779 Keen et al. with the exception thatdegassed water was added to the reaction mixture. Potassium carbonate(1.741 g, 12.60 mmol), palladium(II) acetate (0.094 g, 0.420 mmol), DPPF(0.233 g, 0.420 mmol), and tert-butyl2-chloro-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate 96B(1.188 g, 4.20 mmol) were placed in a Schlenk flask. The flask wassealed and the contents were flushed with nitrogen. To the contents ofthe Schlenk flask was added a mixture of THF (50 mL) and water (5 mL)which had been degassed by passing a stream of nitrogen through it. Thereaction mixture was again degassed by alternating vacuum and nitrogen(3 times). Then, the solution of(1s,5s)-9-(4,4-diethoxybutyl)-9-borabicyclo[3.3.1]nonane 96A (12.61mmol) in THF (35 mL) was added. The contents of the Schlenk flask weredegassed once more and then the mixture was heated at 80° C. for 18 hunder sealed nitrogen atmosphere. The cooled mixture was diluted withwater and extracted with EtOAc. The organic layer was washed with brine,dried over MgSO4, filtered and evaporated. Purification of the resultingresidue by silica gel flash column chromatography (5-95% EtOAc inhexanes) gave tert-butyl2-(4,4-diethoxybutyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96C (1.34 g, 3.42 mmol, 81% yield). LCMS (ESI): m/z 393 [M+H]⁺. ¹H NMR(400 MHz, CHLOROFORM-d) δ 7.45 (d, J=7.6 Hz, 1H), 6.98 (d, J=7.6 Hz,1H), 4.52 (t, J=5.5 Hz, 1H), 3.90-3.72 (m, 1H), 3.70-3.40 (m, 6H,overlapping multiplets), 2.78 (t, J=7.6 Hz, 2H), 2.70 (br t, J=5.5 Hz,2H), 1.94-1.62 (m, 8H), 1.42 (br s, 9H), 1.25-1.04 (m, 6H).

Tert-butyl2-(4-oxobutyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate(96D)

In a round bottom flask, tert-butyl2-(4,4-diethoxybutyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96C (500 mg, 1.274 mmol) was stirred at rt in a mixture of 1:1 AcOH (5mL)/water (5 mL) for 18 h. The solvent was evaporated to remove as muchAcOH as possible. The mixture was diluted with water and adjusted to pH8 by addition of sat'd aq. sodium bicarbonate solution. The aqueouslayer was extracted with EtOAc and the combined organic extracts weredried over MgSO4, filtered and evaporated. Purification by silica gelflash column chromatography (10-100% EtOAc in hexanes) gave tert-butyl2-(4-oxobutyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96D (295 mg, 0.926 mmol, 72.7% yield). LCMS (ESI): m/z 319 [M+H]⁺. ¹HNMR (400 MHz, CHLOROFORM-d) δ 9.79 (s, 1H), 7.48 (d, J=7.6 Hz, 1H), 6.98(d, J=7.6 Hz, 1H), 3.06-2.85 (m, 1H), 2.81 (t, J=7.6 Hz, 1H), 2.76-2.62(m, 2H), 2.51 (t, J=7.3 Hz, 2H), 2.15-1.98 (m, 2H), 1.93-1.82 (m, 2H),1.59 (br s, 2H), 1.80-1.52 (m, 4H), 1.43 (s, 9H).

tert-butyl2-(3-(1H-pyrazol-3-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate(96E)

In a round bottom flask, a solution of diethyl(E)-(2-(2-tosylhydrazono)ethyl)phosphonate (1.15 g, 3.30 mmol, preparedas described in WO 2007/073503) in THF (6 mL) was slowly added to asuspension of 60% NaH as dispersion in mineral oil (264 mg, 6.60 mmol)in THF (6 mL) while cooling at 0° C. This mixture was stirred at 0° C.for 30 min during which the mixture became a yellow suspension. Asolution of tert-butyl2-(4-oxobutyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96D (700 mg, 2.198 mmol) in THF was added to the suspension at 0° C.after which the ice bath was removed. After stirring at rt for 1 h, themixture was heated at reflux 82° C. for 5.5 h followed by stirring at rtfor 14 h. The mixture was diluted with sat'd aq. ammonium chloride andextracted with EtOAc. The combined organic extracts were dried overMgSO₄, filtered and evaporated. Purification of the residue by silicagel flash column chromatography (30-100% EtOAc in hexanes) gave thetitle compound that was still considerably impure. Purification bypreparative HPLC (XBridge C18 19×100 mm Flow rate: 20 mL/min.Wavelength: 220 nM. Solvent A: 0.1% TFA in 95:5 H₂O/CH₃CN. Solvent B:0.1% TFA in 5:95 H₂O/CH₃CN) followed by passing the desired fractionsthrough a Solid Phase Extraction carbonate cartridge (AgilentTechnologies PL-HCO3 MP SPE) to remove TFA and evaporation gave thetitle compound tert-butyl2-(3-(1H-pyrazol-3-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96E (255 mg, 0.715 mmol, 32.5% yield). LCMS (ESI): m/z 357 [M+H]⁺. ¹HNMR (400 MHz, CHLOROFORM-d) δ 7.56-7.38 (m, 2H), 7.00 (d, J=7.6 Hz, 1H),6.08 (s, 1H), 2.83-2.75 (m, 2H), 2.75-2.70 (m, 2H), 2.65 (br t, J=6.7Hz, 2H), 2.61-2.13 (m, 2H), 2.05 (quin, J=7.0 Hz, 2H), 1.94-1.77 (m,2H), 1.77-1.49 (m, 2H), 1.49-1.24 (br s, 9H).

tert-butyl2-(3-(1-(3-(tert-butoxy)-1-(2-methylpyrimidin-5-yl)-3-oxopropyl)-1H-pyrazol-3-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate(96F) and tert-butyl2-(3-(1-(3-(tert-butoxy)-1-(2-methylpyrimidin-5-yl)-3-oxopropyl)-1H-pyrazol-5-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate(96G)

In a small pressure vessel, tert-butyl2-(3-(1H-pyrazol-3-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96E (93 mg, 0.261 mmol), tert-butyl(E)-3-(2-methylpyrimidin-5-yl)acrylate (86 mg, 0.391 mmol), and cesiumcarbonate (255 mg, 0.783 mmol) were stirred and heated at 70° C. inCH₃CN (3 mL) for 5 h, after which stirring was continued at rt for 16 h.The reaction mixture was filtered to remove cesium carbonate, the solidwas rinsed with CH₃CN, and the filtrate was evaporated. Purification bysilica gel flash column chromatography (1% to 10% MeOH in CH₂Cl₂)enabled separation of the products and the acrylate starting material.The fractions containing the two regioisomers were purified bypreparative HPLC (XBridge C18 19×100 mm, flow rate: 20 mL/min,wavelength: 220 nM, 20 min gradient, 25 min run, 0% to 100% Solvent A:0.1% TFA in 95:5 H₂O/CH₃CN. Solvent B: 0.1% TFA in 5:95 H₂O/CH₃CN). Thefractions containing separated isomers were passed through SPE carbonatecartridges (Agilent Technologies PL-HCO3 MP SPE) to remove TFA and wereevaporated to give (tert-butyl2-(3-(1-(3-(tert-butoxy)-1-(2-methylpyrimidin-5-yl)-3-oxopropyl)-1H-pyrazol-3-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96F (55 mg, 0.095 mmol, 36.6% yield) and tert-butyl2-(3-(1-(3-(tert-butoxy)-1-(2-methylpyrimidin-5-yl)-3-oxopropyl)-1H-pyrazol-5-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96G (14 mg, 0.024 mmol, 9.30% yield). For 96F: LCMS (ESI): m/z 577[M+H]⁺. ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.62 (s, 2H), 7.49-7.44 (m,1H), 7.38-7.30 (m, 2H), 6.96 (d, J=7.6 Hz, 1H), 6.08 (d, J=2.3 Hz, 1H),5.66 (t, J=7.6 Hz, 1H), 3.42 (dd, J=16.0, 8.4 Hz, 1H), 3.09 (dd, J=16.1,6.9 Hz, 1H), 2.80 (br d, J=15.4 Hz, 2H), 2.73 (s, 3H), 2.73-2.52 (m,6H), 2.09-2.02 (m, 1H), 2.15-1.96 (m, 2H), 1.94-1.82 (m, 2H), 1.63-1.41(m, 1H), 1.40 (br s, 9H), 1.36 (s, 9H). For 96G: LCMS (ESI): m/z 577[M+H]⁺. 1H NMR (400 MHz, CHLOROFORM-d) δ 8.55 (s, 2H), 7.49 (s, 1H),7.46 (d, J=7.6 Hz, 1H), 6.92 (d, J=7.8 Hz, 1H), 6.07 (s, 1H), 5.68 (dd,J=8.9, 6.2 Hz, 1H), 3.53 (dd, J=16.0, 8.7 Hz, 1H), 3.07 (dd, J=16.4, 5.9Hz, 1H), 2.81 (br t, J=7.1 Hz, 2H), 2.77-2.67 (m, 3H), 2.72 (s, 3H),2.66-2.50 (m, 1H), 2.18-1.96 (m, 3H), 1.88 (br s, 3H), 1.78-1.64 (m,2H), 1.40 (br s, 9H), 1.36 (br s, 9H).

Example 96 (Racemic)(±)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

Tert-butyl2-(3-(1-(3-(tert-butoxy)-1-(2-methylpyrimidin-5-yl)-3-oxopropyl)-1H-pyrazol-3-yl)propyl)-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azepine-9-carboxylate96F (55 mg, 0.095 mmol) and TFA (0.2 mL, 2.60 mmol) were stirred inCH₂Cl₂ (1 mL) for 18 h. The solvent was evaporated and the residue wasdried in vacuo to give(±)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid, 3 TFA (Example 96, 68 mg, 0.089 mmol, 86% yield). LCMS (ESI): m/z421 [M+H]⁺. ¹H NMR (400 MHz, ACETONITRILE-d₃) δ 8.72 (s, 2H), 7.61 (d,J=2.2 Hz, 1H), 7.57 (d, J=7.6 Hz, 1H), 6.60 (d, J=7.3 Hz, 1H), 6.14 (d,J=2.2 Hz, 1H), 5.85 (dd, J=9.3, 5.4 Hz, 1H), 3.56 (br t, J=5.0 Hz, 2H),3.49 (dd, J=16.8, 9.4 Hz, 1H), 3.22 (dd, J=16.6, 5.4 Hz, 1H), 2.91 (brt, J=5.4 Hz, 2H), 2.74-2.62 (m, 4H), 2.69 (s, 3H), 2.07-1.85 (m, 6H).Human αVβ6 IC50 (nM)=17.

Example 97 (Enantiomer 1) and Example 98 (Enantiomer 2) Enantiomer 1 of3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (97) Enantiomer 2 of3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (98)

(±)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid 96 was separated into individual enantiomers by chiral SFC(Chiralpak AD-H, 30×250 mm, 5 μm, 20% MeOH/0.1% NH₄OH in CO₂ (150 bar),35° C., 70 mL/min, 28 min, λ 220 nm) to give Example 97 (first elutingenantiomer, 12 mg, 32% yield) as a white solid. LCMS (ESI): m/z 421[M+H]⁺. ¹H NMR (400 MHz, METHANOL-d₄) δ 8.65 (s, 2H), 7.70 (s, 1H), 7.50(d, J=7.6 Hz, 1H), 6.65 (d, J=7.3 Hz, 1H), 6.14 (s, 1H), 5.89 (br dd,J=9.2, 6.0 Hz, 1H), 3.43-3.24 (m, 3H), 3.18-3.01 (m, 1H), 2.89-2.74 (m,2H), 2.71-2.51 (m, 4H), 2.67 (s, 3H), 2.14-1.62 (m, 6H). Human αVβ6 IC50(nM)=45. Example 98 (second eluting enantiomer, 14 mg, 35% yield) wasalso isolated as a white solid. LCMS (ESI): m/z 421 [M+H]⁺. ¹H NMR (400MHz, METHANOL-d₄) δ 8.64 (s, 2H), 7.71 (s, 1H), 7.46 (d, J=7.3 Hz, 1H),6.63 (d, J=7.3 Hz, 1H), 6.14 (s, 1H), 5.93-5.83 (m, 1H), 3.38-3.34 (m,2H), 3.27 (br d, J=9.0 Hz, 1H), 3.15 (br d, J=6.4 Hz, 1H), 2.85-2.75 (m,2H), 2.71-2.53 (m, 4H), 2.67 (s, 3H), 2.11-1.75 (m, 6H). Human αVβ6 IC₅₀(nM)=595.

Example 99(±)-3-(2-methylpyrimidin-5-yl)-3-(5-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

The title compound was prepared from 96G using the same method asdescribed for Example 96 to give(±)-3-(2-methylpyrimidin-5-yl)-3-(5-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid Example 99, 3 TFA (14 mg, 69% yield). LCMS (ESI): m/z 421 [M+H]⁺.¹H NMR (400 MHz, ACETONITRILE-d₃) δ 8.55 (s, 2H), 7.54 (d, J=7.6 Hz,1H), 7.49 (s, 1H), 6.55 (d, J=7.6 Hz, 1H), 6.16 (s, 1H), 5.81 (dd,J=10.1, 4.3 Hz, 1H), 3.69-3.50 (m, 3H), 3.16 (dd, J=16.9, 4.4 Hz, 1H),2.91 (br s, 2H), 2.86-2.65 (m, 4H), 2.64 (s, 3H), 2.15-1.74 (m, 6H).Human αVβ6 IC₅₀ (nM)=410.

Example Structure & Name Analytical Data Method 100

¹H NMR (500 MHz, CHLOROFORM-d) δ 8.29 (d, J = 2.1 Hz, 1H), 7.80 (dd, J =8.9, 2.4 Hz, 1H), 7.48-7.40 (m, 2H), 6.92 (d, J = 8.9 Hz, 1H), 6.50 (d,J = 7.5 Hz, 1H), 6.18 (d, J = 2.3 Hz, 1H), 5.97-5.85 (m, 1H), 4.03 (s,3H), 3.64-3.42 (m, 3H), 3.25-3.10 (m, 1H), 2.96-2.84 (m, 2H), 2.79 (td,J = 6.8, 2.8 Hz, 2H), 2.71-2.66 (m, 2H), 2.19- 1.85 (m, 6H). LCMS (ESI):m/z 436 [M + H]⁺. Human αVβ6 IC₅₀ (nM) = 6.4. Example 96 101

¹H NMR (400 MHz, METHANOL-d₄) δ 8.10 (d, J = 1.7 Hz, 1H), 7.68 (dd, J =8.7, 2.1 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.52 (d, J = 7.3 Hz, 1H),6.78 (d, J = 8.8 Hz, 1H), 6.65 (d, J = 7.3 Hz, 1H), 6.11 (d, J = 1.5 Hz,1H), 5.82 (dd, J = 10.0, 5.1 Hz, 1H), 3.90 (s, 3H), 3.44-3.35 (m, 2H),3.32-3.23 (m, 1H), 3.04 (dd, J = 15.0, 5.3 Hz, 1H), 2.90-2.74 (m, 2H),2.62 (br t, J = 6.5 Hz, 3H), 2.15-1.77 (m, 6H). LCMS (ESI): m/z 436 [M +H]⁺. Human αVβ6 IC₅₀ (nM): 4.3. Example 97 102

¹H NMR (400 MHz, METHANOL-d₄) δ 8.10 (d, J = 2.0 Hz, 1H), 7.68 (dd, J =8.7, 2.3 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 7.3 Hz, 1H), 6.78 (d, J =8.6 Hz, 1H), 6.65 (d, J = 7.3 Hz, 1H), 6.11 (d, J = 1.5 Hz, 1H), 5.82(dd, J = 10.0, 5.1 Hz, 1H), 3.90 (s, 3H), 3.44-3.35 (m, 2H), 3.31- 3.21(m, 1H), 3.04 (dd, J = 14.9, 5.1 Hz, 1H), 2.91-2.79 (m, 2H), 2.62 (br t,J = 6.4 Hz, 4H), 2.18- 1.76 (m, 6H). LCMS (ES): m/z 436 [M + H]⁺. HumanαVβ6 IC₅₀ (nM) = 150. Example 98 103

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.56 (s, 2H), 7.44 (d, J = 7.6 Hz, 1H),7.40 (d, J = 1.7 Hz, 1H), 7.09- 7.09 (m, 1H), 6.48 (d, J = 7.3 Hz, 1H),6.13 (d, J = 1.7 Hz, 1H), 5.80 (dd, J = 10.3, 4.6 Hz, 1H), 4.05 (s, 3H),3.66-3.41 (m, 3H), 3.13 (dd, J = 15.7, 4.6 Hz, 1H), 2.90 (br d, J = 5.6Hz, 2H), 2.76 (br t, J = 6.5 Hz, 2H), 2.70 (br t, J = 7.8 Hz, 2H), 2.02(br d, J = 5.9 Hz, 4H). LCMS (ES): m/z 437 [M + H]⁺. Human αVβ6 IC₅₀(nM) = 30. Example 96 104

¹H NMR (400 MHz, METHANOL-d₄) δ 8.56 (s, 2H), 7.67 (s, 1H), 7.51 (d, J =7.6 Hz, 1H), 6.66 (br d, J = 7.6 Hz, 1H), 6.13 (s, 1H), 5.93-5.70 (m,1H), 4.01 (s, 3H), 3.37 (m, 3H), 3.19- 3.00 (m, 1H), 2.89-2.74 (m, 2H),2.64 (br t, J = 7.0 Hz, 4H), 2.20-1.64 (m, 6H). LCMS (ESI): m/z 437 [M +H]⁺. Human αVβ6 IC₅₀ (nM) = 10. Example 97 105

¹H NMR (400 MHz, METHANOL-d₄) δ 8.55 (s, 2H), 7.68 (s, 1H), 7.50 (d, J =7.6 Hz, 1H), 6.65 (d, J = 7.3 Hz, 1H), 6.13 (s, 1H), 5.92-5.71 (m, 1H),4.01 (s, 3H), 3.50-3.25 (s, 3H), 3.23-2.97 (m, 1H), 2.92-2.74 (m, 2H),2.64 (br t, J = 7.0 Hz, 4H), 2.20-1.66 (m, 6H). LCMS (ESI): m/z 437 [M +H]⁺. Human αVβ6 IC₅₀ (nM) = 470. Example 98 106

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.52 (br s, 2H), 7.56 (s, 1H), 7.43 (d,J = 7.3 Hz, 1H), 6.44 (d, J = 7.3 Hz, 1H), 6.10 (s, 1H), 5.80 (dd, J =10.3, 2.9 Hz, 1H), 4.03 (s, 3H), 3.76 (dd, J = 16.0, 10.6 Hz, 1H), 3.62(br s, 2H), 3.09 (dd, J = 16.0, 3.3 Hz, 1H), 2.94-2.67 (m, 6H),2.27-1.90 (m, 6H). LCMS (ESI): m/z 437 [M + H]⁺. Human αVβ6 IC₅₀ (nM) =820. Example 99 107

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.55- 8.40 (m, 2H), 7.84 (br s, 1H),7.51 (br s, 1H), 7.47 (d, J = 7.6 Hz, 1H), 6.51 (d, J = 7.3 Hz, 1H),6.17 (br s, 1H), 6.06-5.92 (m, 1H), 4.00 (s, 3H), 3.63-3.52 (m, 3H),3.25 (br d, J = 14.2 Hz, 1H), 2.91 (br d, J = 5.6 Hz, 2H), 2.77 (br s,2H), 2.70 (br t, J = 7.2 Hz, 2H), 2.22-1.92 (m, 6H). LCMS (ESI): m/z 436[M + H]⁺. Human αVβ6 IC₅₀ (nM) = 4.9. Example 96 108

¹H NMR (400 MHz, CHLOROFORM-d) δ 8.43 (br s, 1H), 8.38 (br s, 1H), 7.90(s, 1H), 7.57 (s, 1H), 7.44 (d, J = 7.1 Hz, 1H), 6.46 (d, J = 6.8 Hz,1H), 6.13 (s, 1H), 6.00 (br d, J = 5.1 Hz, 1H), 3.98 (s, 3H), 3.74 (brdd, J = 16.4, 9.0 Hz, 1H), 3.61 (br s, 2H), 3.23-3.11 (m, 1H), 2.97-2.87 (m, 2H), 2.86-2.75 (m, 2H), 2.75-2.64 (m, 2H), 2.21- 1.89 (m, 6H).LCMS (ESI): m/z 436 [M + H]⁺. Human αVβ6 IC₅₀ (nM) = 170. Example 99

Example 109(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

Ethyl(S)-3-(6-(benzyloxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(109A) and ethyl(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(109B)

A cold (0° C.) solution of ethyl(S)-3-(6-hydroxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(Example 12; 817 mg, 1.876 mmol) benzyl alcohol (0.195 mL, 1.876 mmol)and triphenylphosphine (590 mg, 2.251 mmol) in DCM (35 mL) was treatedwith diisopropyl azodicarboxylate (0.438 mL, 2.251 mmol) dropwise. After15 min the ice bath was removed and stirring was continued at roomtemperature overnight. The reaction was diluted with DCM and washed withH2O, brine, dried (MgSO4) and concentrated. The resulting yellow wax waspurified by Biotage (40 g col, 10-80% EtOAc/DCM, 13CV) to removereagents. The column was then run with (0-8% MeOH/DCM, 12CV) to give the1st band, 0-alkylated product, ethyl(S)-3-(6-(benzyloxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(109A), 330 mg (30% yield). LCMS (ES): ret. time=0.88 min, m/z 526.07[M+H]⁺, along with the 2nd band, N-alkylated product, ethyl(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(109B) 690 mg (70% yield). LCMS (ES): ret.time=0.73 min, m/z 526.07[M+H]⁺.

Example 109:(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

A solution of ethyl(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate109A (600 mg, 1.141 mmol) in MeOH (6 mL) was treated in one portion witha solution of 1N aqueous NaOH (3.42 mL, 3.42 mmol). The suspension wasstirred at room temperature for 30 min. The reaction was concentratedand then the solution was diluted with H2O, made slightly acidic with 1NHCl, and extracted with DCM (5×). The organic layers were combined,dried (MgSO4) and conc. to give a 556 mg of a white solid. A portion (15mg) of the crude material was purified via preparative LC/MS with thefollowing conditions: Column: XBridge C18, 19×200 mm, 5-μm particles;Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate;Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate;Gradient: 6-46% B over 20 minutes, then a 4-minute hold at 100% B; Flow:20 mL/min to give(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid (Example 109), 7.9 mg, LCMS (ES): m/z 498.19[M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 7.86 (s, 1H), 7.66 (d, J=1.8 Hz, 1H), 7.44 (dd, J=9.5,2.4 Hz, 1H), 7.31-7.24 (m, 5H), 7.02 (d, J=7.3 Hz, 1H), 6.36 (d, J=9.2Hz, 1H), 6.24 (d, J=7.3 Hz, 1H), 6.00 (d, J=1.8 Hz, 1H), 5.50 (t, J=7.5Hz, 1H), 5.09-4.99 (m, 2H), 3.91 (s, 1H), 3.58-3.35 (m, 2H), 3.20-3.04(m, 2H), 2.94 (br d, J=6.4 Hz, 1H), 2.90 (s, 1H), 2.74 (s, 1H),2.65-2.60 (m, 1H), 2.43 (s, 1H), 1.90 (s, 2H), 1.82 (br t, J=7.5 Hz,2H), 1.78-1.69 (m, 2H). Human αVβ6 IC₅₀ (nM)=4.2

Example 110 Ethyl(S)-3-(6-(benzyloxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate

In a similar manner as for the preparation of Example 109, ethyl(S)-3-(6-(benzyloxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate109B was saponified to give(S)-3-(6-(benzyloxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid (Example 110), 8.2 mg., LCMS (ES): m/z 498.2[M+H]⁺, ¹H NMR (500MHz, DMSO-d₆) δ 8.10 (s, 1H), 7.74-7.65 (m, 2H), 7.43-7.29 (m, 5H), 7.02(br d, J=7.0 Hz, 1H), 6.82 (d, J=8.5 Hz, 1H), 6.30 (br s, 1H), 6.23 (d,J=7.0 Hz, 1H), 6.03-6.00 (m, 1H), 5.72 (br t, J=7.5 Hz, 1H), 5.31 (s,2H), 3.68 (br s, 2H), 3.32-3.25 (m, 2H), 3.20-3.11 (m, 1H), 3.02 (br dd,J=16.0, 6.6 Hz, 2H), 2.90 (s, 1H), 2.74 (s, 1H), 2.60 (br s, 1H),2.50-2.42 (m, 1H), 1.87-1.79 (m, 2H), 1.78-1.71 (m, 2H). Human αVβ6 IC₅₀(nM)=9.3

Example 111(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

Ethyl(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(111A) and ethyl(S)-3-(6-(cyclopropylmethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(111B)

To a room temperature solution of ethyl(S)-3-(6-hydroxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(Example 12) (100 mg, 0.230 mmol) in DMSO (2 mL) was added Cs2CO3 (135mg, 0.413 mmol) followed by (bromomethyl)cyclopropane (31.0 mg, 0.230mmol). The reaction mixture was stirred overnight. The reaction wasdiluted with ice/H2O, then extracted with EtOAc. The organic layers werecombined, dried (MgSO4) and concentrated. The residue was then purifiedby Prep. HPLC (30×100 Luna col, 5-80% MeCN/H2O, 10 mmol NH4OAc, 35ml/min, 16 min grad.) to give N-alkylated material, ethyl(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate111A, 48 mg (42% yield), LCMS (ES): ret.time=0.69 min, m/z 490.08[M+H]⁺, along with the O-alkylated, ethyl(S)-3-(6-(cyclopropylmethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate111B, 17 mg (15% yield), LCMS (ES): ret.time=0.74 min, m/z 490.11[M+H]⁺.

(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid (Example 111)

(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid was prepared and purified in a similar manor using the procedurefrom Example 109 using ethyl(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(111A) to give Example 111, 16.5 mg, LCMS (ES): m/z 462.22[M+H]⁺, ¹H NMR(500 MHz, DMSO-d₆) δ 7.76 (s, 1H), 7.68 (s, 1H), 7.44 (br d, J=9.5 Hz,1H), 7.02 (br d, J=7.0 Hz, 1H), 6.35 (d, J=9.2 Hz, 1H), 6.30-6.22 (m,1H), 6.03 (s, 1H), 5.54-5.48 (m, 1H), 3.69 (br dd, J=10.1, 7.3 Hz, 2H),3.23 (br s, 2H), 3.17 (s, 1H), 2.63-2.54 (m, 2H), 2.49-2.40 (m, 2H),1.91 (s, 2H), 1.83 (br t, J=7.5 Hz, 2H), 1.79-1.70 (m, 2H), 1.24 (s,2H), 1.15 (br dd, J=7.5, 4.1 Hz, 1H), 0.43 (br d, J=7.9 Hz, 2H), 0.34(br d, J=3.7 Hz, 2H). Human αVβ6 IC₅₀ (nM)=19

Example 112(S)-3-(6-(cyclopropylmethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicAcid

(S)-3-(6-(cyclopropylmethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid was prepared and purified in a similar manor using the procedurefrom Example 109 using ethyl(S)-3-(6-(cyclopropylmethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(111B) to give Example 112, 1.5 mg, LCMS (ES): m/z 462.22[M+H]⁺, ¹H NMR(500 MHz, DMSO-d₆) δ 7.76 (s, 1H), 7.68 (s, 1H), 7.44 (br d, J=9.5 Hz,1H), 7.02 (br d, J=7.0 Hz, 1H), 6.35 (d, J=9.2 Hz, 1H), 6.30-6.22 (m,2H), 6.03 (s, 1H), 5.54-5.48 (m, 1H), 3.69 (br dd, J=10.1, 7.3 Hz, 2H),3.23 (br s, 2H), 3.05 (br d, J=6.1 Hz, 1H), 2.63-2.54 (m, 2H), 2.49-2.40(m, 2H), 1.91 (s, 2H), 1.83 (br t, J=7.5 Hz, 2H), 1.79-1.70 (m, 2H),1.24 (s, 2H), 1.15 (br d, J=3.4 Hz, 1H), 0.43 (br d, J=7.9 Hz, 2H), 0.34(br d, J=3.7 Hz, 2H). Human αVβ6 IC₅₀ (nM)=3.5

Example 1133-(6-methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicAcid

Ethyl 1-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)-1H-pyrazole-3-carboxylate(113B)

DMF (40 mL) was added to a flask containing ethyl1H-pyrazole-3-carboxylate (1.5 g, 10.70 mmol), sodium hydride (0.514 g,12.84 mmol, 60% dispersion in mineral oil) at 0° C. After 15 min at 0°C., the reaction mixture was allowed to warm up to RT and stirred at RTfor 30 min. The reaction mixture was cooled to 0° C. and a solution of2-(3-bromopropyl)-2-methyl-1,3-dioxolane (2.69 g, 12.84 mmol), andpotassium iodide (0.355 g, 2.141 mmol) in DMF (20 mL) was added. Thereaction mixture was stirred at 0° C. for 15 min, then allowed to warmup to RT and stirred at RT for 16 h. After cooling to 0° C., thereaction mixture was quenched with aq NH₄Cl (30 mL), and all DMF wasremoved under high vacuum. The residue was diluted with EtOAc (200 mL),washed with brine, dried over Na₂SO₄, filtered, and concentrated. Flashchromatography (EtOAc/hexanes) afforded Example 113A (0.881 g, 3.28mmol, 31% yield) and Example 113B (1.724 g, 6.43 mmol, 60% yield). LCMS(ES): m/z 269.10 [M+H]⁺. Example 113A: ¹H NMR (400 MHz, CDCl₃) δ 7.43(d, J=1.7 Hz, 1H), 6.79 (d, J=2.0 Hz, 1H), 4.55 (t, J=7.3 Hz, 2H), 4.30(q, J=7.1 Hz, 2H), 3.88 (br d, J=2.9 Hz, 4H), 1.97-1.84 (m, 2H),1.71-1.57 (m, 2H), 1.34 (t, J=7.1 Hz, 3H), 1.26 (s, 3H). Example 113B:¹H NMR (400 MHz, CDCl₃) δ 7.38 (d, J=1.7 Hz, 1H), 6.74 (d, J=1.7 Hz,1H), 4.34 (q, J=7.1 Hz, 2H), 4.17 (br t, J=7.2 Hz, 2H), 3.98-3.69 (m,4H), 2.02-1.90 (m, 2H), 1.67-1.52 (m, 2H), 1.34 (t, J=7.1 Hz, 3H), 1.24(s, 3H).

(1-(3-(2-Methyl-1,3-dioxolan-2-yl)propyl)-1H-pyrazol-3-yl)methanol(113C)

LiAlH₄ (3.21 mL, 6.41 mmol, 2 M in THF) was added at 0° C. to a solutionof 113B (1.72 g, 6.41 mmol) in THF (50 mL) After 1 h at 0° C., thefollowing were added sequentially at 0° C.: H₂O (1.1 mL), 1 N NaOH (1.1mL), and H₂O (3.3 mL). The resulting suspension was stirred at 0° C. for15 min and RT for 15 min, and then filtered through a pad of Celite.After the filtrate was concentrated and dried under high vacuum, CH₂Cl₂(100 mL) was added. The resulting light white suspension was stirredover Na₂SO₄ for 30 min. It was filtered through a pad of Celite,concentrated and dried under high vacuum to afford Example 113C (1.42 g,6.26 mmol, 98% yield) as a colorless liquid, which was used directlywithout further purification. LCMS (ES): m/z 227.10 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 7.35 (d, J=2.0 Hz, 1H), 6.23 (d, J=2.2 Hz, 1H), 4.69 (s,2H), 4.12 (t, J=7.2 Hz, 2H), 4.03-3.80 (m, 4H), 2.45-2.23 (m, 1H),2.06-1.92 (m, 2H), 1.72-1.61 (m, 2H), 1.32 (s, 3H).

1-(3-(2-Methyl-1,3-dioxolan-2-yl)propyl)-1H-pyrazole-3-carbaldehyde(113D)

Dess-Martin periodinane (3.17 g, 7.48 mmol) was added at RT to asolution of 113C (1.41 g, 6.23 mmol) in CH₂Cl₂ (50 mL). After stirringat RT for 1 h, the reaction mixture was concentrated and the residuesubjected to flash chromatography (EtOAc/hexanes) to afford Example 113D(1.33 g, 5.93 mmol, 95% yield) as a very light tan liquid. LCMS (ES):m/z 225.09 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.89 (s, 1H), 7.42 (d,J=2.2 Hz, 1H), 6.72 (d, J=2.4 Hz, 1H), 4.19 (t, J=7.2 Hz, 2H), 3.94-3.73(m, 4H), 2.15-1.80 (m, 2H), 1.69-1.46 (m, 2H), 1.24 (s, 3H).

(6-Methoxypyridin-3-yl)(1-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)-1H-pyrazol-3-yl)methanol(113E)

(6-methoxypyridin-3-yl)magnesium chloride (21.4 mL, 3.85 mmol) was addeddropwise to a solution of 113D (0.665 g, 2.97 mmol) in THF (10 mL) at−40° C. The reaction mixture was warmed up to 10° C. over 3 h with theoriginal cooling bath still on. The cooling bath was removed and thereaction mixture was stirred at RT for 1 h. After being cooled to 0° C.,the reaction mixture was quenched with aq NH₄Cl, and all THF was removedunder vacuum. The residue was extracted with EtOAc (3×) and brine in thepresence of solid NaCl. The combined organic layers were dried overNa₂SO₄, filtered, and concentrated. Flash chromatography (MeOH/CH₂Cl₂)gave 113E (0.774 g, 2.32 mmol, 78% yield). LCMS (ES): m/z 334.21 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, J=2.0 Hz, 1H), 7.62 (dd, J=8.6, 2.2Hz, 1H), 7.28 (d, J=2.0 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 6.00 (d, J=2.0Hz, 1H), 5.81 (d, J=2.2 Hz, 1H), 4.06 (t, J=7.2 Hz, 2H), 3.92-3.83 (m,5H), 3.89 (s, 3H), 1.98-1.84 (m, 2H), 1.66-1.54 (m, 2H), 1.26 (s, 3H).

Methyl3-(6-methoxypyridin-3-yl)-3-(1-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)-1H-pyrazol-3-yl)propanoate(113F)

TiCl₄ (1.0 M in CH₂Cl₂, 0.774 mL, 0.774 mmol) was added at 0° C. to asolution of 113E (258 mg, 0.774 mmol) in CH₂Cl₂ (7 mL). After stirringat 0° C. for 30 min, 1-(tert-butyldimethylsilyloxy)-1-methoxyethene(0.338 mL, 1.548 mmol) was added dropwise. The reaction mixture wasstirred at 0° C. for 1 h, and quenched by addition of saturated NaHCO₃solution and extracted with CH₂Cl₂ (3×). The combined organic layerswere dried over Na₂SO₄, filtered, and concentrated. Flash chromatography(MeOH/CH₂Cl₂) afforded a mixture containing the desired product. It wasfurther purified by pre-HPLC with the following conditions: Column:SunFire Prep 19×55 mm, 5-μm particles; Mobile Phase A: 5:95acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5acetonitrile:water with 10-mM ammonium acetate; Gradient: 20-100% B over10 minutes, then a 2-minute hold at 100% B; Flow: 20 mL/min to give 113F(15.5 mg, 5.1% yield). LCMS (ES): m/z 390.11 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.11 (d, J=2.4 Hz, 1H), 7.51 (dd, J=8.7, 2.3 Hz, 1H), 7.27 (d,J=8.6 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 5.95 (d, J=2.2 Hz, 1H), 4.53 (t,J=7.8 Hz, 1H), 4.09 (t, J=7.1 Hz, 2H), 3.97-3.88 (m, 4H), 3.92 (s, 3H),3.62 (s, 3H), 3.22 (dd, J=15.8, 7.2 Hz, 1H), 2.91 (dd, J=15.8, 8.4 Hz,1H), 2.02-1.87 (m, 2H), 1.73-1.53 (m, 2H), 1.31 (s, 3H).

Methyl3-(6-methoxypyridin-3-yl)-3-(1-(4-oxopentyl)-1H-pyrazol-3-yl)propanoate(113G)

A mixture of 113F (24.5 mg, 0.063 mmol) and pyridiniump-toluenesulfonate (22 mg, 0.088 mmol) in acetone (9 mL) and water (1mL) was heated at 73° C. for 3 h. Acetone was removed under vacuum. Theresidue was extracted with EtOAc (3×) and washed with brine in thepresence of solid NaCl. The combined organic layers were dried overNa₂SO₄, filtered, concentrated and dried under high vacuum to afford113G (21.7 mg, 0.063 mmol, 100% yield), which was used directly for thenext step without further purification. LCMS (ES): m/z 346.12 [M+H]⁺. ¹HNMR (400 MHz, CDCl3) δ 8.10 (d, J=2.0 Hz, 1H), 7.51 (dd, J=8.6, 2.4 Hz,1H), 7.24 (d, J=2.0 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 5.96 (d, J=2.2 Hz,1H), 4.52 (t, J=7.8 Hz, 1H), 4.09 (t, J=8.0 Hz, 2H), 3.92 (s, 3H), 3.62(s, 3H), 3.20 (dd, J=15.8, 7.5 Hz, 1H), 2.90 (dd, J=15.9, 8.3 Hz, 1H),2.39 (t, J=7.0 Hz, 2H), 2.11 (s, 3H), 2.10-2.06 (m, 2H).

Methyl3-(1-(3-(1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)-3-(6-methoxypyridin-3-yl)propanoate(113H)

Pyrrolidine (0.056 mL, 0.677 mmol) was added to a solution of 113G and2-aminonicotinaldehyde (46.0 mg, 0.376 mmol) in CH₂Cl₂ (4 mL). After thereaction mixture was stirred at RT overnight, all volatiles were removedand the residue subjected to flash chromatography (MeOH/CH₂Cl₂) toafford a mixture containing 113H (60 mg). LCMS (ES): m/z 432.08 [M+H]⁺.It was used directly for the next step without further purification.

Methyl3-(6-methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoate(113I)

The mixture of 113H (60 mg, used crude) and platinum(IV) oxide (16.74mg, 0.074 mmol) in MeOH (15 mL) was subjected to hydrogenation under aballoon of H₂ overnight at RT. The reaction mixture was filtered througha pad of Celite and the filter cake washed twice with MeOH. The combinedfiltrates were concentrated, the residue subjected to Prep-HPLC with thefollowing conditions: Column: SunFire Prep 19×55 mm, 5-μm particles;Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate;Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate;Gradient: 20-100% B over 10 minutes, then a 2-minute hold at 100% B;Flow: 20 mL/min to give 113I (14.3 mg, 0.033 mmol, 44.6% yield over twosteps). LCMS (ES): m/z 436.12 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d,J=2.0 Hz, 1H), 7.52 (dd, J=8.6, 2.2 Hz, 1H), 7.30 (d, J=2.2 Hz, 1H),7.11 (d, J=7.3 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 6.26 (d, J=7.1 Hz, 1H),5.95 (d, J=2.0 Hz, 1H), 4.53 (t, J=7.8 Hz, 1H), 4.10 (t, J=7.0 Hz, 2H),4.05 (br s, 1H), 3.92 (s, 3H), 3.62 (s, 3H), 3.43 (br t, J=5.5 Hz, 2H),3.22 (dd, J=15.8, 7.2 Hz, 1H), 2.91 (dd, J=15.8, 8.4 Hz, 1H), 2.70 (brt, J=6.1 Hz, 2H), 2.57 (t, J=7.5 Hz, 2H), 2.21 (quin, J=7.2 Hz, 2H),1.91 (quin, J=5.9 Hz, 2H).

Example 113:3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicAcid

A solution of lithium hydroxide monohydrate (6.39 μl, 0.230 mmol) inwater (1 mL) was added at RT to a solution of 113I (14.3 mg, 0.033 mmol)in MeOH (1 mL) and THF (1 mL). After the resulting clear solution wasstirred at RT overnight, all volatiles were removed under high vacuum.Water (2 mL) was added, followed by HCl (1N, 0.23 mL, 0.23 mmol). Themixture was concentrated and dried under high vacuum. The residue wasdissolved in DMF (1.5 mL), filtered and subjected to preparative LC/MSusing the following conditions: Column: XBridge C18, 19×200 mm, 5-μmparticles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammoniumacetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammoniumacetate; Gradient: 2-42% B over 15 minutes, then a 5-minute hold at 100%B; Flow: 20 mL/min. Fractions containing the desired product werecombined and dried via centrifugal evaporation. The material was furtherpurified via preparative LC/MS with the following conditions: Column:XBridge C18, 19×200 mm, 5-μm particles; Mobile Phase A: 5:95acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5acetonitrile:water with 10-mM ammonium acetate; Gradient: 0-32% B over30 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractionscontaining the desired product were combined and dried via centrifugalevaporation to give3-(6-methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicacid (Example 113 (13.4 mg, 97% yield). LCMS (ES): m/z 422.08 [M+H]⁺. ¹HNMR (500 MHz, DMSO-d₆) δ 8.05 (s, 1H), 7.59 (br s, 2H), 7.03 (br d,J=7.0 Hz, 1H), 6.72 (d, J=8.5 Hz, 1H), 6.23 (br d, J=7.0 Hz, 1H), 6.05(s, 1H), 4.35 (br t, J=7.6 Hz, 1H), 4.02 (br t, J=7.0 Hz, 2H), 3.81 (s,3H), 3.25-3.17 (m, 2H), 3.00 (br dd, J=15.7, 7.2 Hz, 1H), 2.86-2.73 (m,1H), 2.61 (br t, J=5.5 Hz, 2H), 2.36 (br t, J=7.3 Hz, 2H), 2.07-1.95 (m,2H), 1.81-1.67 (m, 2H). Human αVβ6 IC50 (nM)=35.

Example 114(R)-3-(4-fluoro-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)-3-(2-methylpyrimidin-5-yl)propanoicAcid (Example 114)

Tert-butyl(R)-3-(4-fluoro-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)-3-(2-methylpyrimidin-5-yl)propanoate(114A)

To a stirred solution of tert-butyl(R)-3-(2-methylpyrimidin-5-yl)-3-(3-(33-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate(366 mg, 0.791 mmol) in ACN (2.5 mL) under nitrogen atmosphere was addedSelectfluor (280 mg, 0.791 mmol). Resulting solution was kept undermicrowave conditions at 70° C. for 30 min. Selectfluor (280 mg, 0.791mmol) was added again to ensure the maximum product formation and thereaction was continued to stir at the same conditions for 1 h. Thereaction mass was evaporated under vacuum to get the crude product. Thecrude product was purified by preparative HPLC (Sunfire OBD (250×30) mm;5 micron column; Mobile Phase A: 0.1% TFA in water; Mobile Phase B: ACN,flow rate: 27.0 mL/min; time (min)/% B: 0/30, 18/70) to afford the titlecompound 114A (20 mg, 5%) as a colourless liquid. LC-MS retentiontime=2.63 min; m/z=481.4 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1 mL/min; Detection: UV at 220 nm.

(R)-3-(4-Fluoro-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)-3-(2-methylpyrimidin-5-yl)propanoicAcid (Example 114)

To a stirred solution of tert-butyl(R)-3-(4-fluoro-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)-3-(2-methylpyrimidin-5-yl)propanoate(114A) (20 mg, 0.042 mmol) in DCM (0.2 mL) was added TFA (0.2 mL, 2.60mmol) and the resulting mixture was stirred at RT for 4 h. The reactionmixture was evaporated under reduced pressure to afford the desiredproduct (22 mg, 88%) as a brown solid (as a TFA salt). LC-MS retentiontime=1.09 min; m/z=425.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1 mL/min; Detection: UV at 220 nm.¹H NMR (400 MHz, CD₃OD) δ ppm 8.62 (s, 2H), 7.75 (d, J=4.40 Hz, 1H),7.55 (d, J=7.20 Hz, 1H), 6.58 (d, J=7.20 Hz, 1H), 5.79 (dd, J=6.00, 9.00Hz, 1H), 3.45-3.52 (m, 3H), 3.24 (dd, J=6.00, 16.40 Hz, 1H), 2.81 (m,2H), 2.68-2.75 (m, 4H), 2.66 (s, 3H), 2.01-2.07 (m, 2H), 1.94-1.98 (m,2H). Human αVβ6 IC50 (nM)=4800.

Example 115 and Example 116 Example 115: First Eluting Enantiomer of3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicAcid Example 116: First Eluting Enantiomer of3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicAcid

Ethyl 3-iodo-1H-pyrazole-5-carboxylate (115A)

To a stirred solution of ethyl 5-amino-1H-pyrazole-3-carboxylate (5 g,32.2 mmol) in DCM (100 mL) under nitrogen atmosphere were addeddiiodomethane (4.54 mL, 56.4 mmol) followed by tert-butyl nitrite (5.80mL, 48.3 mmol) and the reaction mixture was stirred at RT for 14 h. Thereaction mixture was concentrated under reduced pressure to get crudecompound. The crude compound was purified by flash silica gel columnchromatography by using 0-50% ethyl acetate and pet-ether as mobilephase to afford the title compound 115A (3.4 g, 39%) as pale yellowsolid. LC-MS retention time=1.651 min; m/z=265.0 [M−H]⁺ Column-KINETIXXB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile PhaseA: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in2% Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at50% B with flow rate 1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400MHz, DMSO-d₆) δ ppm 14.28-13.94 (br. s., 1H), 7.00-6.89 (br. s., 1H),4.28 (br. s., 2H), 1.28 (t, J=4.00 Hz, 3H).

Ethyl3-iodo-1-((2-(trimethylsiloxy)methyl)ethoxy)methyl)-1H-pyrazole-5-carboxylate(115B)

To a stirred solution of ethyl 5-iodo-1H-pyrazole-3-carboxylate 115A(3.4 g, 12.78 mmol) in THF (40 mL) under nitrogen atmosphere at 0° C.was added NaH (0.511 g, 12.78 mmol) as small portions and the reactionmixture was stirred at 0° C. for 1 h. SEM-Cl (2.267 mL, 12.78 mmol) wasadded to the above reaction mixture and stirred at RT for 14 h. Reactionmixture was quenched with saturated ammonium chloride (100 mL) and itwas extracted with ethyl acetate (2×80 mL). The combined organic layerwas washed with brine (100 mL), dried over anhydrous sodium sulphate,concentrated under reduced pressure to get crude compound. The crudeproduct was purified by combiflash chromatography (40 g Redisep® SiO₂column, eluting with 30% EtOAc in pet ether) to afford the titlecompound 115B (3.8 g, 74%) as off white solid. LC-MS retentiontime=3.667 min; m/z=397.0 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.05 (s,1H), 5.60 (s, 2H), 4.43 (q, J=7.0 Hz, 2H), 3.66-3.60 (m, 2H), 1.41 (t,J=7.1 Hz, 3H), 0.95-0.89 (m, 2H), −0.01 (s, 9H).

Ethyl(E)-3-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrazole-5-carboxylate(115C)

In a sealed tube, ethyl5-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate115B (3.8 g, 9.59 mmol) in ACN (40 mL) was treated with tert-butylacrylate (4.21 mL, 28.8 mmol) and the solution was degasified with argongas for 5 min. TEA (4.01 mL, 28.8 mmol), tri-o-tolylphosphine (0.292 g,0.959 mmol) followed by palladium(II) acetate (0.215 g, 0.959 mmol) wereadded and the reaction mixture was degasified with argon again for 5min. The reaction mixture was then heated to 80° C. and stirred for 14h. Reaction mixture was cooled, filtered through a pad of Celite and itwas washed with DCM (4×20 mL). Filtrate was concentrated under reducedpressure to get crude compound. The crude product was purified bycombiflash chromatography (40 g Redisep® SiO₂ column, eluting with 35%EtOAc in pet ether) to afford the title compound 115C (2.4 g, 62%) aspale yellow liquid. LC-MS retention time=3.836 min; m/z=397.2 [M+H]⁺Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.63 (d, J=21.60 Hz, 1H), 7.14 (s,1H), 6.43 (d, J=21.20 Hz, 1H), 5.65 (s, 2H), 4.46 (q, J=9.60 Hz, 2H),3.62 (t, J=10.80 Hz, 2H), 1.57 (s, 9H), 1.44 (t, J=9.60 Hz, 3H), 0.93(t, J=10.80 Hz, 2H), −0.01 (s, 9H).

Ethyl3-(3-(tert-butoxy)-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-5-carboxylate(115D)

A mixture of ethyl(E)-3-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-5-carboxylate115C (2.4 g, 6.05 mmol) in 1,4-dioxane (40 mL) and water (10 mL) in asealed tube was degassed with argon gas for 5 min.(3-fluoro-4-methoxyphenyl)boronic acid (1.543 g, 9.08 mmol) and TEA(1.687 mL, 12.10 mmol) were added and the reaction mixture was degassedwith argon again for 5 min. Chloro(1,5-cyclooctadiene)rhodium(I) dimer(0.149 g, 0.303 mmol) was added, degassed with argon for 5 min more andthe reaction mixture was stirred at 85° C. for 14 h. Reaction mixturewas filtered through Celite and the collected solid was washed with DCM(4×15 mL). The combined filtrate was concentrated under reduced pressureto get crude compound. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 30% EtOAc in petether) to afford the title compound 115D (1.3 g, 40%) as colourlessliquid. LC-MS retention time=3.94 min; m/z=323.4 [M+H]⁺ Column-KINETIXXB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile PhaseA: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in2% Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at50% B with flow rate 1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400MHz, CDCl₃) δ ppm 7.03-6.95 (m, 3H), 6.89 (s, 1H), 5.53 (d, J=11.0 Hz,1H), 5.37-5.28 (d, J=11.0 Hz, 1H), 4.72 (t, J=7.8 Hz, 1H), 4.47 (qd,J=7.2, 3.5 Hz, 2H), 3.91 (s, 3H), 3.47-3.38 (m, 2H), 2.98 (dd, J=15.6,8.5 Hz, 1H), 2.85 (dd, J=15.6, 7.0 Hz, 1H), 1.46 (t, J=7.3 Hz, 3H), 1.40(s, 9H), 0.91-0.74 (m, 2H), −0.01 (s, 9H).

tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(hydroxymethyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1H-pyrazol-3-yl)propanoate(115E)

To a stirred solution of ethyl3-(3-(tert-butoxy)-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-5-carboxylate115E (1.1 g, 2.105 mmol) in THF (20 mL) under nitrogen atmosphere wasadded lithium borohydride (1.368 mL, 2 M in THF, 2.74 mmol) at 0° C. andthe reaction mixture was stirred at RT for 48 h. Reaction mixture wasquenched with water (50 mL) and it was extracted with ethyl acetate(2×40 mL). The combined organic layer was washed with brine (30 mL),dried over anhydrous sodium sulphate, concentrated under reducedpressure to get crude compound. The crude product was purified bycombiflash chromatography (24 g Redisep® SiO₂ column, eluting with 70%EtOAc in pet ether) to afford the title compound 115E (0.750 g, 73%) asa colourless liquid. LC-MS retention time=3.517 min; m/z=481.2 [M+H]⁺Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.15-7.01 (m, 3H), 6.32 (s, 1H),5.34 (d, J=11.0 Hz, 1H), 5.18 (d, J=11.0 Hz, 1H), 5.04 (t, J=5.8 Hz,1H), 4.48 (t, J=8.0 Hz, 1H), 4.34 (d, J=6.0 Hz, 2H), 3.79 (s, 3H),3.33-3.24 (m, 2H), 2.88 (dd, J=8.0, 4.0 Hz, 2H), 1.27 (s, 9H), 0.77-0.63(m, 2H), −0.09 (s, 9H).

tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-formyl-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrazol-3-yl)propanoate(115F)

To a stirred solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(hydroxymethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate115E (0.750 g, 1.560 mmol) in DCM (20 mL) under nitrogen atmosphere wasadded Dess-Martin Periodinane (0.993 g, 2.341 mmol) and the resultingsolution was stirred at RT for 14 h. Reaction mixture was filteredthrough a pad of Celite and the same was washed with DCM (4×15 mL). Thecombined filtrate was concentrated under reduced pressure to get crudecompound. The crude product was purified by combiflash chromatography(24 g Redisep® SiO₂ column, eluting with 40% EtOAc in pet ether) toafford the title compound 115F (0.750 g, 89%) as colourless liquid.LC-MS retention time=3.877 min; m/z=479.2 [M+H]⁺ Column-KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at 50% Bwith flow rate 1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,CDCl₃) δ ppm 9.94 (s, 1H), 6.94-6.86 (m, 3H), 6.81 (s, 1H), 5.46 (d,J=11.0 Hz, 1H), 5.28 (d, J=11.0 Hz, 1H), 4.66 (t, J=7.9 Hz, 1H), 3.85(s, 3H), 3.45 (ddd, J=10.6, 9.5, 6.1 Hz, 1H), 3.37 (ddd, J=10.8, 9.4,6.0 Hz, 1H), 2.92 (dd, J=15.8, 8.8 Hz, 1H), 2.79 (dd, J=15.8, 7.3 Hz,1H), 1.33 (s, 9H), 0.87-0.71 (m, 2H), −0.04 (s, 9H).

tert-Butyl(E)-3-(3-fluoro-4-methoxyphenyl)-3-(5-(3-(2-methyl-1,3-dioxolan-2-yl)prop-1-en-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate(115G)

To a stirred solution ofbromo(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)triphenyl-15-phosphane (1.242g, 2.72 mmol) in THF (4 mL) was added nBuLi (1.4 mL, 3.40 mmol, 2.5 Msolution in hexane) at 0° C. and the resulting solution was stirred for30 min. tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-formyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate115F (0.650 g, 1.358 mmol) dissolved in THF (4 mL) was added to theabove solution and stirred at RT for 2 h. Reaction mixture was quenchedwith saturated ammonium chloride (20 mL) and extracted with ethylacetate (2×20 mL). The combined organic layer was washed with brine (10mL), dried over anhydrous sodium sulphate, concentrated under reducedpressure to get crude compound. The crude product was purified bycombiflash chromatography (24 g Redisep® SiO₂ column, eluting with 50%EtOAc in pet ether) to afford the title compound 115G (0.470 g, 60%) aspale yellow liquid. LC-MS retention time=4.090 min; m/z=577.4 [M+H]⁺Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm.

tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate(115H)

To a stirred solution of tert-butyl(E)-3-(3-fluoro-4-methoxyphenyl)-3-(5-(3-(2-methyl-1,3-dioxolan-2-yl)prop-1-en-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate115G (0.470 g, 0.815 mmol) in ethanol (10 mL) was added palladiumhydroxide on carbon (47 mg, 0.067 mmol) and the reaction mixture wasstirred at RT under H₂ bladder for 14 h. Reaction mixture was filteredthrough a pad of Celite and the Celite was washed with MeOH (4×20 mL).The combined filtrate was concentrated under reduced pressure to affordthe title compound 115H (0.430 g, 91%). LC-MS retention time=4.016 min;m/z=579.4 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 6.95-6.82 (m,3H), 6.08 (s, 1H), 5.29 (d, J=11.3 Hz, 1H), 5.12 (d, J=11.3 Hz, 1H),4.57 (t, J=7.9 Hz, 1H), 3.98-3.87 (m, 4H), 3.85 (s, 3H), 3.45-3.28 (m,2H), 2.87 (dd, J=15.4, 8.1 Hz, 1H), 2.75 (dd, J=15.4, 7.9 Hz, 1H),2.62-2.56 (m, 2H), 1.91 (td, J=7.6, 3.9 Hz, 1H), 1.83 (br. s., 1H),1.76-1.65 (m, 2H), 1.56 (s, 3H), 1.31 (s, 9H), 0.84-0.68 (m, 2H), −0.07(s, 9H).

tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(4-oxopentyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrazol-3-yl)propanoate(115I)

To a stirred solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate115H (0.430 g, 0.743 mmol) in THF (8 mL) was added HCl (0.991 mL, 1.486mmol) and the reaction mixture was stirred at RT for 14 h. Reactionmixture was quenched with 10% sodium bicarbonate (50 mL) and it wasextracted with ethyl acetate (2×50 mL). The combined organic layer waswashed with brine (40 mL), dried over anhydrous sodium sulphate,concentrated under reduced pressure to get crude compound. The crudeproduct was purified by combiflash chromatography (24 g Redisep® SiO₂column, eluting with 60% EtOAc in pet ether) to afford the titlecompound 115I (0.300 g, 71%) as colourless liquid. LC-MS retentiontime=4.010 min; m/z=535.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 6.98-6.84(m, 3H), 6.10 (s, 1H), 5.29 (d, J=11.0 Hz, 1H), 5.14 (d, J=11.0 Hz, 1H),4.59 (t, J=7.7 Hz, 1H), 3.87 (s, 3H), 3.47-3.31 (m, 2H), 2.89 (dd,J=15.5, 8.2 Hz, 1H), 2.77 (dd, J=15.3, 7.7 Hz, 1H), 2.62 (t, J=7.6 Hz,2H), 2.52-2.43 (m, 2H), 2.14 (s, 3H), 1.93 (m, 2H), 1.36 (s, 9H),0.87-0.70 (m, 2H), −0.04 (s, 9H).

tert-Butyl3-(5-(3-(1,8-naphthyridin-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrazol-3-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate(115J)

To a stirred solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(4-oxopentyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate115I (0.300 g, 0.561 mmol) in ethanol (10 mL) under nitrogen atmospherewas added pyrrolidine (0.046 mL, 0.561 mmol) and the resulting mixturewas stirred for 10 min at RT. To this solution was added2-aminonicotinaldehyde (0.069 g, 0.561 mmol) and the reaction mixturewas heated at 75° C. for 14 h. Reaction mixture was concentrated underreduced pressure to get crude compound. The crude product was purifiedby combiflash chromatography (24 g Redisep® SiO₂ column, eluting with90% EtOAc in pet ether) to afford the title compound 115J (0.190 g, 50%)as a pale yellow liquid. LC-MS retention time=3.970 min; m/z=621.2[M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.03 (dd, J=4.5, 2.0 Hz, 1H), 8.42(dd, J=8.0, 2.0 Hz, 1H), 8.37 (d, J=8.0 Hz, 1H), 7.58 (dd, J=8.0, 4.5Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.15-7.01 (m, 3H), 6.28 (s, 1H), 5.32(d, J=11.0 Hz, 1H), 5.17 (d, J=11.5 Hz, 1H), 4.51-4.42 (m, 1H), 3.78 (s,3H), 3.35-3.45 (m, 2H), 3.03-2.95 (m, 2H), 2.90-2.84 (m, 2H), 2.63-2.56(m, 2H), 2.13-2.06 (m, 2H), 1.25 (s, 9H), 0.71-0.59 (m, 2H), −0.13 (s,9H).

tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate(115K)

To a stirred solution of tert-butyl3-(5-(3-(1,8-naphthyridin-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate115J (0.140 g, 0.226 mmol) in ethanol (5 mL) was added platinum(IV)oxide (14 mg, 0.062 mmol) and the reaction mixture was stirred at RTunder H₂ bladder pressure for 14 h. Reaction mixture was filteredthrough a pad of Celite and the Celite was washed with MeOH (4×10 mL).The combined filtrate was concentrated under reduced pressure to affordthe title compound 115K (0.130 g, 84%). LC-MS retention time=1.635 min;m/z=625.4 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5 mL/min;Detection: UV at 220 nm.

Example 115: First eluting enantiomer of3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicAcid Example 116: First eluting enantiomer of3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicAcid

To a stirred solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)propanoate115K (0.150 g, 0.240 mmol) in DCM (5 mL) was added TFA (1.5 mL, 19.47mmol) under nitrogen atmosphere and stirred at RT for 14 h. The reactionmixture was concentrated under reduced pressure to get crude compound.The crude compound was purified by reverse phase HPLC (Sunfire C18(150×21.2) mm, 5 micron; Mobile phase A: 10 mM Ammonium acetate inwater, Mobile phase B: ACN; Flow: 18 mL/min, Time (min)/% B: 0/20, 2/20,15/35, 16/100) to afford the racemate compound (50 mg). The individualenantiomers were separated by chiral HPLC (Column: Lux Cellulose C4(250×21.2) mm; 5 micron; Mobile Phase: 0.4% DEA in ACN: MeOH (70:30);Flow: 20 mL/min). First eluting enantiomer Example 115 (Retention time5.52 min., 25 mg, 23%) was isolated as a white solid. LC-MS retentiontime=1.29 min; m/z=439.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.38 (d,J=7.0 Hz, 1H), 7.06-6.94 (m, 3H), 6.50 (d, J=7.5 Hz, 1H), 6.06 (s, 1H),4.48 (t, J=8.0 Hz, 1H), 3.84 (s, 3H), 3.45 (J=5.6 Hz, 2H), 2.93 (dd,J=14.6, 9.0 Hz, 1H), 2.83 (dd, J=15.1, 7.0 Hz, 1H), 2.77 (t, J=6.0 Hz,2H), 2.70-2.63 (m, 2H), 2.59 (t, J=7.5 Hz, 2H), 2.04-1.88 (m, 4H). HumanαVβ6 IC50 (nM)=97. Second eluting enantiomer Example 116 (Retention time7.77 min., 18 mg, 17%) was isolated as a white solid. LC-MS retentiontime=1.29 min; m/z=439.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.38 (d,J=7.0 Hz, 1H), 7.06-6.94 (m, 3H), 6.50 (d, J=7.5 Hz, 1H), 6.06 (s, 1H),4.48 (t, J=8.0 Hz, 1H), 3.84 (s, 3H), 3.45 (J=5.6 Hz, 2H), 2.93 (dd,J=14.6, 9.0 Hz, 1H), 2.83 (dd, J=15.1, 7.0 Hz, 1H), 2.77 (t, J=6.0 Hz,2H), 2.70-2.63 (m, 2H), 2.59 (t, J=7.5 Hz, 2H), 2.04-1.88 (m, 4H). HumanαVβ6 IC50 (nM)=47.

Exam- Prep-HPLC/SFC method, ple Structure ¹H NMR & LCMS Method 117

Chiral Prep-HPLC: Retention time: 5.42 min. Column (Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19.0 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.50-7.52 (m, 1H), 7.41- 7.45 (m, 3H), 7.31-7.33(m, 1H), 6.96 (s, 1H), 6.46 (d, J = 7.20 Hz, 1H), 4.93 (dd, J = 11.60,4.40 Hz, 1H), 3.45 (t, J = Example 13/14 5.60 Hz, 2H), 3.30 (m, 1H),3.11 (s, 3H), 2.98 (s, 3H), 2.82-2.89 (m, 2H), 2.75-2.80 (m, 3H),2.56-2.65 (m, 2H), 1.95-2.00 (m, 1H), 1.91-1.95 (m, 2H), 1.77-1.78 (m,1H), 1.42-1.54 (m, 2H). LC-MS retention time = 1.22 min; m/z = 493.2[M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flowrate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2%ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% Bover 4.6 min, then hold 0.4 min. at 50% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 76 118

Chiral Prep-HPLC: Retention time: 6.49 min. Column (Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19.0 mL/min; Temperature: 35° C.; Detection: UV at 250 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.50-7.52 (m, 1H), 7.41- 7.45 (m, 3H), 7.31-7.33(m, 1H), 6.96 (s, 1H), 6.46 (d, J = 7.20 Hz, 1H), 4.93 (dd, J = 11.60,4.40 Hz, 1H), 3.45 (t, J = Example 13/14 5.60 Hz, 2H), 3.30 (m, 1H),3.11 (s, 3H), 2.98 (s, 3H), 2.82-2.89 (m, 2H), 2.75-2.80 (m, 3H),2.56-2.65 (m, 2H), 1.95-2.00 (m, 1H), 1.91-1.95 (m, 2H), 1.77-1.78 (m,1H), 1.42-1.54 (m, 2H). LC-MS retention time = 1.22 min; m/z = 493.2[M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flowrate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2%ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% Bover 4.6 min, then hold 0.4 min. at 50% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 1.9 119

Chiral Prep-HPLC: Retention time: 5.65 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 17 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 8.77 (d, J = 3.60 Hz, 2H), 7.96-7.99 (m, 2H),7.82-7.85 (m, 1H), 7.28 (d, J = 7.20 Hz, 1H), 6.89 (s, 1H), 6.34 (d, J =7.20 Hz, 1H), 5.04 (dd, J = 10.8, 5.2 Hz, 1H), 3.43-3.44 (m, 2H),Example 13/14 3.30 (m, 1H), 3.03 (dd, J = 14.8, 6.0 Hz, 1H), 2.73-2.83(m, 2H), 2.73 (t, J = 6.4 Hz, 2H), 2.57- 2.59 (m, 2H), 1.92-1.94 (m,3H), 1.70-1.75 (m, 1H), 1.55- 1.59 (m, 2H). LC-MS retention time = 1.42min; m/z = 474.2 [M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6micron column; Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN;50% B to 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 99 120

Chiral Prep-HPLC: Retention time: 6.12 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 17 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 8.77 (d, J = 3.60 Hz, 2H), 7.96-7.99 (m, 2H),7.82-7.85 (m, 1H), 7.28 (d, J = 7.20 Hz, 1H), 6.89 (s, 1H), 6.34 (d, J =7.20 Hz, 1H), 5.04 (dd, J = 10.8, 5.2 Hz, 1H), 3.43-3.44 (m, 2H), 3.30(m, 1H), 3.03 (dd, J = 14.8, Example 13/14 6.0 Hz, 1H), 2.73-2.83 (m,2H), 2.73 (t, J = 6.4 Hz, 2H), 2.57- 2.59 (m, 2H), 1.92-1.94 (m, 3H),1.70-1.75 (m, 1H), 1.55- 1.59 (m, 2H). LC-MS retention time = 1.42 min;m/z = 474.2 [M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 microncolumn; Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm Human αVβ6 IC50 (nM) = 14 121

Chiral Prep-HPLC: Retention time: 6.61 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 17 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 8.05 (d, J = 2.40 Hz, 1H), 7.57 (dd, J = 2.80,9.80 Hz, 1H), 7.40 (d, J = 7.20 Hz, 1H), 6.94 (s, 1H), 6.66 (d, J = 8.80Hz, 1H), 6.45 (d, J = 7.20 Hz, 1H), 4.78 (dd, J = 11.2, 5.2 Hz, 1H),3.44 (t, J = 5.6 Hz, 2H), 3.22 (dd, J = 14.8, 11.2 Hz, 1H), 3.07 (s,Example 13/14 6H), 2.75-2.80 (m, 5H), 2.56- 2.64 (m, 2H), 1.90-1.96 (m,3H), 1.71-1.78 (m, 1H), 1.50- 1.55 (m, 2H). LC-MS retention time = 1.45min; m/z = 466.2 [M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6micron column; Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN;20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 170 122

Chiral Prep-HPLC: Retention time: 7.42 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 17 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 8.05 (d, J = 2.40 Hz, 1H), 7.57 (dd, J = 2.80,9.80 Hz, 1H), 7.40 (d, J = 7.20 Hz, 1H), 6.94 (s, 1H), 6.66 (d, J = 8.80Hz, 1H), 6.45 (d, J = 7.20 Hz, 1H), 4.78 (dd, J = 11.2, 5.2 Hz, 1H),3.44 (t, J = 5.6 Hz, 2H), 3.22 (dd, J = 14.8, 11.2 Hz, 1H), 3.07 (s,Example 13/14 6H), 2.75-2.80 (m, 5H), 2.56- 2.64 (m, 2H), 1.90-1.96 (m,3H), 1.71-1.78 (m, 1H), 1.50- 1.55 (m, 2H). LC-MS retention time = 1.45min; m/z = 466.2 [M + H]⁺ Column: KINETIX XB-C18; (3 × 75) mm, 2.6micron column; Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 nM HCO₂NH₄in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN;20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 3.5 123

Chiral Prep-HPLC: Retention time: 5.90 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 17 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.41 (d, J = 7.20 Hz, 1H), 7.00 (s, 1H),6.92-6.93 (m, 3H), 6.45 (d, J = 7.20 Hz, 1H), 4.76- 4.74 (m, 1H), 3.83(s, 3H), 3.82 (s, 3H), 3.45 (t, J = 5.60 Hz, 2H), 3.22 (dd, J = 14.8,11.2 Hz, 1H), 2.75-2.80 (m, 5H), 2.56-2.60 Example 13/14 (m, 2H),1.90-1.95 (m, 3H), 1.77-1.77 (m, 1H), 1.49-1.54 (m, 2H). LC-MS retentiontime = 1.54 min; m/z = 482.2 [M + H]⁺ Column: KINETIX XB-C18, (3 × 75)mm, 2.6 micron column; Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/ min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 180 124

Chiral Prep-HPLC: Retention time: 7.03 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 17 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.41 (d, J = 7.20 Hz, 1H), 7.00 (s, 1H),6.92-6.93 (m, 3H), 6.45 (d, J = 7.20 Hz, 1H), 4.76- 4.74 (m, 1H), 3.83(s, 3H), 3.82 (s, 3H), 3.45 (t, J = 5.60 Hz, 2H), 3.22 (dd, J = 14.8,11.2 Hz, 1H), 2.75-2.80 (m, 5H), 2.56-2.60 Example 13/14 (m, 2H),1.90-1.95 (m, 3H), 1.77-1.77 (m, 1H), 1.49-1.54 (m, 2H). LC-MS retentiontime = 1.54 min; m/z = 482.2 [M + H]⁺ Column: KINETIX XB-C18, (3 × 75)mm, 2.6 micron column; Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 2.5 125

Chiral Prep-HPLC: Retention time: 6.83 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.28 (d, J = 7.60 Hz, 1H), 7.08 (t, J = 8.0 Hz,1H), 6.88 (d, J = 2.00 Hz, 1H), 6.88 (s, 1H), 6.73-6.78 (m, 2H), 6.33(d, J = 7.20 Hz, 1H), 4.71-4.73 (m, Example 13/14 1H), 3.72 (t, J = 4.80Hz, 4H), 3.33 (t, J = 5.60 Hz, 2H), 3.14 (dd, J = 14.6, 11.0 Hz, 1H),3.02 (t, J = 4.80 Hz, 4H), 2.63-2.74 (m, 5H), 2.43-2.49 (m, 2H),1.81-1.85 (m, 3H), 1.62-1.67 (m, 1H), 1.38-1.42 (m, 2H). LC- MSretention time = 1.68 min; m/z = 507.2 [M + H]⁺ Column: KINETIX XB-C18,(3 × 75) mm, 2.6 micron column; Flow rate: 1 to 1.5 mL/min; Mobile PhaseA: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 nM HCO₂NH₄ in2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6IC50 (nM) = 180 126

Chiral Prep-HPLC: Retention time: 8.53 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.29 (d, J = 7.60 Hz, 1H), 7.08 (t, J = 8.0 Hz,1H), 6.88 (d, J = 2.00 Hz, 1H), 6.88 (s, 1H), 6.73-6.78 (m, 2H), 6.33(d, J = 7.20 Hz, 1H), 4.71-4.73 (m, Example 13/14 1H), 3.72 (t, J = 4.80Hz, 4H), 3.33 (t, J = 5.60 Hz, 2H), 3.14 (dd, J = 14.6, 11.0 Hz, 1H),3.02 (t, J = 4.80 Hz, 4H), 2.63-2.74 (m, 5H), 2.43-2.49 (m, 2H),1.81-1.85 (m, 3H), 1.62-1.67 (m, 1H), 1.38-1.42 (m, 2H). LC- MSretention time = 1.68 min; m/z = 507.2 [M + H]⁺ Column: KINETIX XB-C18,(3 × 75) mm, 2.6 micron column; Flow rate: 1 to 1.5 mL/min; Mobile PhaseA: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6IC50 (nM) = 6.0 127

Chiral Prep-HPLC: Retention time: 6.2 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.49 (d, J = 8.40 Hz, 2H), 7.40-7.43 (m, 3H),6.96 (s, 1H), 6.46 (d, J = 7.20 Hz, 1H), 4.92 (dd, J = 11.60, 4.40 Hz,1H), 3.45 (t, J = 5.60 Hz, 2H), 3.21- 3.23 (m, 1H), 3.11 (s, 3H), 3.01(s, 3H), 2.88 (dd, J = 14.6, 4.0 Hz, 1H), 2.75-2.80 (m, 4H), 2.58-2.63(m, 2H), 1.91-1.94 Example 13/14 (m, 3H), 1.75-1.85 (m, 1H), 1.49-1.56(m, 2H). LC-MS retention time = 1.35 min; m/z = 493.2 [M + H]⁺ Column:KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1 to 1.5mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. Human αVβ6 IC50 (nM) = 60 128

Chiral Prep-HPLC: Retention time: 7.14 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 7.49 (d, J =0 8.40 Hz, 2H), 7.40-7.43 (m, 3H),6.96 (s, 1H), 6.46 (d, J = 7.20 Hz, 1H), 4.92 (dd, J = 11.60, 4.40 Hz,1H), 3.45 (t, J = 5.60 Hz, 2H), 3.21- 3.23 (m, 1H), 3.11 (s, 3H), 3.01(s, 3H), 2.88 (dd, J = 14.6, 4.0 Hz, 1H), 2.75-2.80 (m, 4H), 2.58-2.63(m, 2H), 1.91-1.94 Example 13/14 (m, 3H), 1.75-1.85 (m, 1H), 1.49-1.56(m, 2H). LC-MS retention time = 1.35 min; m/z = 493.2 [M + H]⁺ Column:KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1 to 1.5mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 min; Detection: UV at 220nm. Human αVβ6 IC50 (nM) = 4.3 129

Chiral Prep-HPLC: Retention time: 5.42 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 8.59 (s, 2H), 7.38 (d, J = 7.20 Hz, 1H), 6.93 (s,1H), 6.45 (d, J = 7.20 Hz, 1H), 4.79-4.82 (m, 1H), 4.44 (q, J = 6.80 Hz,2H), 3.44 (t, J = 5.60 Hz, 2H), 3.21 (dd, J = 14.6, 11.0 Hz, 1H),Example 13/14 2.88 (dd, J = 14.4, 4.0 Hz, 1H), 2.75-2.80 (m, 4H),2.59-2.60 (m, 2H), 1.90-1.95 (m, 3H), 1.70-1.79 (m, 1H), 1.52-1.59 (m,2H), 1.41 (t, J = 7.20 Hz, 3H). LC-MS retention time = 1.54 min; m/z468.2 [M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column;Flow rate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 nM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 28 130

Chiral Prep-HPLC: Retention time: 6.2 min. Column: Lux- cellulose C4(250 × 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flowrate: 19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR(400 MHz, CD₃OD) δ ppm 8.59 (s, 2H), 7.38 (d, J = 7.20 Hz, 1H), 6.93 (s,1H), 6.45 (d, J = 7.20 Hz, 1H), 4.79-4.82 (m, 1H), 4.44 (q, J = 6.80 Hz,2H), 3.44 (t, J = 5.60 Hz, 2H), 3.21 (dd, J = 14.6, 11.0 Hz, 1H), 2.88(dd, J = 14.4, 4.0 Hz, 1H), Example 13/14 2.75-2.80 (m, 4H), 2.59-2.60(m, 2H), 1.90-1.95 (m, 3H), 1.70-1.79 (m, 1H), 1.52-1.59 (m, 2H), 1.41(t, J = 7.20 Hz, 3H). LC-MS retention time = 1.54 min; m/z = 468.2 [M +H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; MobilePhase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6min, then hold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection:UV at 220 nm. Human αVβ6 IC50 (nM) = 2.9 131

Prep. Chiral SFC: Retention time: 3.5 min. Column Chiralpak AD-H (250 ×21) mm, 5 micron; Mobile phase: 55% of CO₂ and 45% of (0.2% NH₄OH inMeOH and ACN (1:1)); Total Flow: 70 g/min; Back Pressure: 100 bar;Temperature: 30° C.; Detection UV at 240 nm. ¹H NMR (400 MHz, CD₃OD) δppm 7.35 (d, J = 7.20 Hz, 1H), 7.24-7.28 (m, 1H), 7.18-7.20 (m, 1H),7.12 (d, J = 10.40 Hz, 1H), 6.95 (s, 1H), 6.44 (d, J = 7.60 Hz, 1H),4.81- 4.82 (m, 1H), 3.34 (t, J = 5.60 Example 13/14 Hz, 2H), 3.10 (dd, J= 14.6, 11.0 Hz, 1H), 3.07 (s, 3H), 2.84 (s, 3H), 2.66-2.77 (m, 5H),2.41- 2.50 (m, 2H), 2.09-2.10 (m, 1H), 1.80-1.96 (m, 3H), 1.70- 1.79 (m,1H), 1.52-1.59 (m, 2H). LC-MS retention time = 1.40 min; m/z = 497.2[M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flowrate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2%ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% Bover 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 2.3 132

Prep. Chiral SFC: Retention time: 7.0 min. Column: Chiralpak AD-H (250 ×21) mm, 5 micron; Mobile phase: 55% of CO₂ and 45% of (0.2% NH₄OH inMeOH and ACN (1:1)); Total Flow: 70 g/min; Back Pressure: 100 bar;Temperature: 30° C.; Detection: UV at 240 nm. ¹H NMR (400 MHz, CD₃OD) δppm 7.35 (d, J = 7.20 Hz, 1H), 7.24-7.28 (m, 1H), 7.18-7.20 (m, 1H),7.12 (d, J = 10.40 Hz, 1H), 6.95 (s, 1H), 6.44 (d, J = 7.60 Hz, 1H),4.81- 4.82 (m, 1H), 3.34 (t, J = 5.60 Example 13/14 Hz, 2H), 3.10 (dd, J= 14.6, 11.0 Hz, 1H), 3.07 (s, 3H), 2.84 (s, 3H), 2.66-2.77 (m, 5H),2.41- 2.50 (m, 2H), 2.09-2.10 (m, 1H), 1.80-1.96 (m, 3H), 1.70- 1.79 (m,1H), 1.52-1.59 (m, 2H). LC-MS retention time = 1.40 min; m/z = 497.2[M + H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flowrate: 1 to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2%ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% Bover 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 81 133

Chiral Prep-HPLC: Retention time: 6.0 min. Column: Lux-cellulose C4 (250× 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flow rate:19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR (400MHz, CD₃OD) δ ppm 8.05 (d, J = 2.40 Hz 1H), 7.55 (dd, J = 2.40, 9.00 Hz,1H), 7.38 (d, J = 7.20, Hz, 1H), 7.00 (s, 1H), 6.66 (d, J = 8.80 Hz,1H), 6.51 (d, J = 7.60 Hz, 1H), 4.73 (dd, J = 11.60, 4.40 Hz, 1H), 3.45(t, J = 5.60 Hz, 2H), 3.14 (dd, J = 14.6, 11.0 Hz, 1H), 3.07 (s, 6H),2.80-2.83 (m, 5H), 2.57-2.60 (m, 2H), 2.03-2.10 (m, 2H), 1.90- Example15/16 1.96 (m, 2H). LC-MS retention time = 1.29 min; m/z = 452.2 [M +H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/ 2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 86 134

Chiral Prep-HPLC: Retention time: 6.7 min. Column: Lux-cellulose C4 (250× 21.2) mm 5 micron column; Mobile Phase: 0.1% DEA in MeOH; flow rate:19 mL/min; Temperature: 35° C.; Detection: UV at 251 nm. ¹H NMR (400MHz, CD₃OD) δ ppm 8.05 (d, J = 2.40 Hz, 1H), 7.55 (dd, J = 2.40, 9.00Hz, 1H), 7.38 (d, J = 7.20, Hz, 1H), 7.00 (s, 1H), 6.66 (d, J = 8.80 Hz,1H), 6.51 (d, J = 7.60 Hz, 1H), 4.73 (dd, J = 11.60, 4.40 Hz, 1H), 3.45(t, J = 5.60 Hz, 2H), 3.14 (dd, J = 14.6, 11.0 Hz, 1H), 3.07 (s, 6H),2.80-2.83 (m, 5H), 2.57-2.60 (m, 2H), 2.03-2.10 (m, 2H), 1.90- Example15/16 1.96 (m, 2H). LC-MS retention time = 1.29 min; m/z = 452.2 [M +H]⁺ Column: KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1to 1.5 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/ 2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 1.8 135

Prep. Chiral SFC: Retention time: 3.5 min. Column Chiralpak AD-H (250 ×21) mm, 5 micron; Mobile phase: 55% of CO₂ and 45% of (0.2% NH₄OH inMeOH and ACN (1:1); Total Flow: 70 g/min; Back Pressure: 100 bars;Temperature: 30° C.; Detection: UV at 240 nm. ¹H NMR (400 MHz, CD₃OD) δppm 7.35 (d, J = 7.20 Hz, 1H), 7.24-7.28 (m, 1H), 7.18-7.20 (m, 1H),7.12 (d, J = 10.40 Hz, 1H), 6.95 (s, 1H), 6.44 (d, J = 7.60 Hz, 1H),4.81-4.82 (m, 1H), 3.34 (t, J = 5.60 Hz, 2H), 3.10 (dd, J = 14.6, 11.0Hz, 1H), 3.07 (s, 3H), 2.84 (s, 3H), 2.66-2.77 (m, 5H), 2.41-2.50 (m,2H), 2.09-2.10 (m, 1H), 1.90-2.00 (m, 1H), 1.75-1.85 Example 15/16 (m,2H). LC-MS retention time = 1.40 min; m/z = 497.2 [M + H]⁺ Column:KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1 to 1.5mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/ 2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. Human αVβ6 IC50 (nM) = 4.9 136

Prep-Chiral SFC: Retention time: 7.0 min. Column Chiralpak AD-H (250 ×21) mm, 5 micron; Mobile phase: 55% of CO₂ and 45% of (0.2% NH₄OH inMeOH and ACN (1:1)); Total Flow: 70 g/min; Back Pressure: 100 bars;Temperature: 30° C.; Detection: UV at 240 nm. ¹H NMR (400 MHz, CD₃OD) δppm 7.35 (d, J = 7.20 Hz, 1H), 7.24-7.28 (m, 1H), 7.18-7.20 (m, 1H),7.12 (d, J = 10.40 Hz, 1H), 6.95 (s, 1H), 6.44 (d, J = 7.60 Hz, 1H),4.81-4.82 (m, 1H), 3.34 (t, J = 5.60 Hz, 2H), 3.10 (dd, J = 14.6, 11.0Hz, 1H), 3.07 (s, 3H), 2.84 (s, 3H), 2.66-2.77 (m, 5H), 2.41-2.50 (m,2H), 2.09-2.10 (m, Example 15/16 1H), 1.90-2.00 (m, 1H), 1.75-1.85 (m,2H). LC-MS retention time = 1.40 min; m/z = 497.2 [M + H]⁺ Column:KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1 to 1.5mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/ 2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. Human αVβ6 IC50 (nM) = 12

Example 137 and Example 138 Example 137: First Eluting Enantiomer of3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 138: Second Eluting Enantiomer of3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

5-(2-(1,3-dioxolan-2-yl)thiazole (137A)

A toluene (120 mL) solution of 4-bromothiazole-2-carbaldehyde (7 g,36.50 mmol) and ethylene glycol (2.72 g, 43.7 mmol) in a RB flask wasadded catalytic amount of pTsOH (0.347 g, 1.823 mmol). The RB flask wasattached with Dean-Stark apparatus and reaction mixture was heated toreflux for 12 h. The mixture was cooled to RT, and was partitioned withsaturated aqueous NaHCO₃ solution. The organic layer was separated,washed with saturated aqueous NaHCO₃ (2×120 mL) solution and then oncewith brine (100 mL). The organic layer was dried over anhydrous sodiumsulphate, filtered and the filtrate concentrated under reduced pressure.The residue was purified by combiflash chromatography (40 g Redisep®SiO₂ column, eluting with 20% EtOAc in pet ether) to afford the titlecompound 137A (8 g, 97%) as a colourless liquid. LC-MS retentiontime=1.557 min; m/z=236.0 [M+2H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 254 nm. ¹H NMR (400 MHz, DMSO-d6) δ 7.94 (s,1H), 6.08 (s, 1H), 3.99-4.08 (m, 4H).

5-(2-(1,3-Dioxolan-2-yl)thiazol-4-yl)pent-4-yn-2-ol (137B)

To a stirred solution of 5-(2-(1,3-dioxolan-2-yl)thiazole 137A (5 g,21.18 mmol), 4-pentyn-2-ol (2.67 g, 31.80 mmol) in TEA (100 mL) undernitrogen atmosphere was added copper (I) iodide (0.282 g, 1.483 mmol)followed by bis(triphenylphosphine)palladium (II) dichloride (0.988 g,1.483 mmol) and the reaction mixture was degassed with argon for 2 min.Then reaction mixture was then heated to 80° C. and stirred for 16 h.The reaction mixture cooled to RT and filtered through Celite pad. TheCelite pad was washed with EtOAc (2×250 mL) and the combined filtratewas concentrated. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 90% EtOAc in petether) to afford the title compound 137B (4 g, 87%) as a colourlessLiquid. LC-MS retention time=1.557 min; m/z=240.0 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,DMSO-d6) δ ppm 7.91 (s, 1H), 6.03 (s, 1H), 4.84 (d, J=4.8 Hz, 1H),3.99-4.09 (m, 4H), 2.41 (d, J=6.8 Hz, 2H), 1.193 (d, J=7.2 Hz, 3H).

5-(2-(1,3-Dioxolan-2-yl) thiazol-4-yl) pentan-2-ol (137C)

To a degassed solution of5-(2-(1,3-dioxolan-2-yl)thiazol-4-yl)pent-4-yn-2-ol 137B (4.0 g, 16.72mmol) in EtOH (50 mL) was added 10% palladium on carbon (71 mg, 0.669mmol) and the resulting reaction mixture was stirred under hydrogenbladder pressure at RT for 16 h. The reaction mixture was filteredthrough Celite pad and the Celite pad washed with EtOH (100 mL). Thecombined filtrate was concentrated to afford the crude title compound137C (4.0 g, 87%) as a colourless liquid. LC-MS retention time=1.29 min;m/z=244.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 254 nm.

5-(2-(1,3-dioxolan-2-yl) thiazol-4-yl) pentan-2-ol (137D)

To a solution of 5-(2-(1,3-dioxolan-2-yl) thiazol-4-yl) pentan-2-ol 137C(7.5 g, 30.8 mmol) in DCM (150 mL) was added Dess-Martin periodinane(19.61 g, 42.2 mmol) at 0° C. The resulting reaction mixture was thenstirred at RT for 60 min. The reaction mixture was diluted with DCM (200mL), washed with 20% sodium bicarbonate solution (200 mL), brinesolution (200 mL), dried over sodium sulfate, filtered and the filtrateconcentrated. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 90% EtOAc in petether) to afford the title compound 137D (7.3 g, 86%) as a colourlessLiquid. LC-MS retention time=1.33 min; m/z=242.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,DMSO-d6) δ ppm 7.36 (s, 1H), 6.00 (s, 1H), 3.96-4.08 (m, 4H), 2.68 (t,J=7.6 Hz, 2H), 2.44 (t, J=5.2 Hz, 2H), 2.19 (s, 3H), 1.79 (pent, J=7.2Hz, 2H).

4-(3-(1,8-naphthyridin-2-yl)propyl)-2-(1,3-dioxolan-2-yl)thiazole (137E)

To a solution of 5-(2-(1,3-dioxolan-2-yl) thiazol-4-yl) pentan-2-ol 137D(4.0 g, 16.44 mmol) in ethanol (70 mL) was added pyrrolidine (1.268 mL,15.33 mmol) under a nitrogen atm. and the solution was stirred for 10min. 2-Aminonicotinaldehyde (2.06 g, 16.87 mmol) was then added and theresulting reaction mixture was stirred at 75° C. for overnight. Thereaction mixture was concentrated and the crude product was purified bycombiflash chromatography (24 g Redisep® SiO₂ column, eluting with 100%EtOAc to afford the title compound 137E (4.1 g, 89%) as a colourlessliquid. LC-MS retention time=0.805 min; m/z=328.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 254 nm. ¹H NMR (400 MHz,DMSO-d6) δ ppm 9.02-9.03 (dd, J=2.0, 1.6 Hz, 1H), 8.40-8.43 (m, 1H),8.33-8.38 (d, J=8.4 Hz, 1H), 7.52-7.59 (m, 2H), 7.41 (s, 1H), 6.01 (s,1H), 3.96-4.08 (m, 4H), 3.00-3.04 (t, J=7.6 Hz, 2H), 2.79-2.83 (t, J=7.2Hz, 2H), 2.20 (m, 2H).

2-(1,3-dioxolan-2-yl)-4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazole(137F)

To a stirred solution of4-(3-(1,8-naphthyridin-2-yl)propyl)-2-(1,3-dioxolan-2-yl)thiazole 137E(0.3 g, 0.916 mmol) in ethanol (40 mL) was added platinum(IV) oxide (42mg, 0.018 μmol) under nitrogen atmosphere. The reaction mixture then wasdegassed with hydrogen gas and stirred under hydrogen bladder pressureat RT for 16 h. The reaction mixture was filtered through Celite pad,Celite pad washed with EtOH (50 mL) and the combined filtrateconcentrated to afford the title product 137F (270 mg, 53%) as a paleyellow oil. The crude product was taken for the next step withoutfurther purification. LC-MS retention time=1.705 min; m/z=332.2 [M+H]⁺KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min;Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 254 nm.

4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazole-2-carbaldehyde(137G)

To a solution of tert-butyl7-(3-(2-(1,3-dioxolan-2-yl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate2-(1,3-dioxolan-2-yl)-4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazole137F (3.7 g, 11.16 mmol) in ethanol (25 mL) and H₂O (5 mL) was addedconc. HCl (3.39 mL, 112 mmol) and resulting solution was stirred at RTfor 12 h. The reaction mixture was concentrated and the residue quenchedwith sat. aqueous NaHCO₃ (100 mL) solution and extracted in ethylacetate (2×250 mL). The combined organic layer was dried over Na₂SO₄,filtered, concentrated and crude desired product 137G (3.1 g, 69%) wasused next step without purification. LC-MS retention time=1.474 min;m/z=288.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 254 nm.

Ethyl(E)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)acrylate(137H)

To a stirred solution of4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazole-2-carbaldehyde137G (0.14 g, 0.487 mmol) in dry DCM (7.0 mL) was added(carbethoxymethylene)triphenylphosphorane (0.204 g, 0.585 mmol) andresulting reaction mixture was stirred under nitrogen atmosphere at RTfor 12 h. The reaction mixture was concentrated under vacuum and crudeproduct was purified by combiflash chromatography (4.0 g Redisep® SiO₂column, eluting with 0-100% EtOAc in n-hexanes) to afford the titlecompound 137H (0.11 g, 74%) as a semisolid. LC-MS retention time=1.507min; m/z=358.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm.

Ethyl3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-thiazol-2-yl)propanoate(137I)

To a solution ethyl(E)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)acrylate137H (300 mg, 0.839 mmol)) in 1,4-dioxane (15.0 mL) and H₂O (2.5 mL) wasadded (4-(dimethylcarbamoyl)phenyl)boronic acid (16.20 mg, 0.084 mmol).The reaction mixture was degassed with argon for 5 min.Chloro(1,5-cyclooctadiene)rhodium(I) dimer (20.69 mg, 0.042 mmol) andTEA (0.234 mL, 1.678 mmol) were added and the resulting reaction mixturewas heated to 85° C. and stirred for 16 h. The reaction mixture wascooled, poured into water (50 mL) and extracted with EtOAc (2×50 mL).The combined organic layer was washed with brine (50 mL), dried overanhydrous Na₂SO₄, filtered and concentrated under vacuum. The crudeproduct was purified by combiflash chromatography (12 g Redisep® SiO₂column, eluting with 0-20% MeOH in DCM) to afford the title compound137I (290 mg, 68%) as a semisolid. The crude product was taken to thenext step without further purification. LC-MS retention time=2.024 min;m/z=507.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 254 nm.

Example 137: First Eluting Enantiomer of3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 138: Second Eluting Enantiomer of3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

To a stirred solution of ethyl3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoate137I (0.29 g, 0.572 mmol) in THF (6.0 mL) and ethanol (4 mL) was added asolution of LiOH.H₂O (27 mg, 1.145 mmol) in water (2.0 mL) and thesolution was stirred at RT for 12 h. Then, citric acid (50 mg) was addedand stirred at RT for 1 h. The reaction mixture was concentrated and thecrude product was purified by preparative reverse phase preparative HPLC(retention time=14.6 min, Column: INTERSIL ODS C18 (250×19) mm 5 micron;Mobile Phase A: 10 mM NH₄OAc in water; Mobile Phase B: ACN, flow rate:17.0 mL/min; time (min)/% B: 0/20, 8/40, 14/60) to afford title compound(110 mg) as a racemic mixture. The individual enantiomers were thenseparated by preparative HPLC (Column: Lux-cellulose C4 (250×21.2) mm 5micron column; flow rate: 19.0 mL/min; Mobile Phase B: 0.1% DEA in MeOH;time (min)/% B: 0/100, 20/100, temperature: 35° C.; Detection: UV at 220nm). First eluting enantiomer Example 137 (Retention time 7.442 min., 24mg, 9%) was isolated as a white solid. LC-MS retention time=1.192 min;m/z=479.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.47 (m, 3H),7.43 (d, J=8.4 Hz, 2H), 7.04 (s, 1H), 6.56 (d, J=7.6 Hz, 1H), 4.92 (dd,J=11.17, 4.77 Hz, 1H), 3.48 (t, J=6.0 Hz, 2H), 3.23 (dd, J=14.53, 11.14Hz, 1H), 3.11 (s, 3H), 3.01 (s, 3H), 2.88 (dd, J=14.4, 4.8 Hz, 1H),2.74-2.90 (m, 4H), 2.48-2.66 (m, 2H), 1.91-2.01 (m, 1H), 1.31 (s, 1H),1.92-1.97 (m, 2H). Human αVβ6 IC50 (nM)=210. Second eluting enantiomerExample 138 (Retention time 8.044 min., 19.5 mg, 8%) was isolated as awhite solid. LC-MS retention time=1.239; m/z=479.2 [M+H]KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,CD₃OD) δ ppm 7.47 (m, 3H), 7.43 (d, J=8.4 Hz, 2H), 7.04 (s, 1H), 6.56(d, J=7.6 Hz, 1H), 4.92 (dd, J=11.17, 4.77 Hz, 1H), 3.48 (t, J=6.0 Hz,2H), 3.23 (dd, J=14.53, 11.14 Hz, 1H), 3.11 (s, 3H), 3.01 (s, 3H), 2.88(dd, J=14.4, 4.8 Hz, 1H), 2.74-2.90 (m, 4H), 2.48-2.66 (m, 2H),1.91-2.01 (m, 1H), 1.31 (s, 1H), 1.92-1.97 (m, 2H). Human αVβ6 IC50(nM)=4.0.

Ex- Preparative HPLC/SFC method, ample Structure LCMS & ¹H NMR Method139

Preparative SFC method: (retention time = 5.77 min), Chiralpak AD-H (250× 21) mm, 5 u; % CO₂: 60%; % Co solvent: 40% (0.2% DEA in MeOH); TotalFlow: 70 g/min; Back Pressure: 100 bars; Temperature: 25° C.; Detection:UV at 254 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.43- 7.50 (m, 4H), 7.34 (d,J = 7.2 Hz, 1H), 7.04 (s, 1H), 6.57 (d, J = 7.6 Hz, 1H), 3.49 (t, J =6.0, 2H), 3.23 (dd, J = 14.53, 11.14 Hz, 1H),, 3.10 (s, 3H), 2.98 (s,3H), 2.89 (dd, J = 10.0, 4.8 Hz, 1H), 2.58-2.90 (m, 4H), 2.48-2.66Example 137/138 (m, 2H), 1.91-2.01 (m, 1H), 1.31 (s, 1H), 1.92-1.97 (m,2H). LC-MS: retention time = 1.014 min; m/z = 479.2 [M + H]⁺ KINETIXXB-C18, (3 × 75) mm, 2.6 micron column; Flow rate: 1 mL/min; MobilePhase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm.Human αVβ6 IC50 (nM) = 34 140

Preparative SFC method (retention time = 6.83), Chiralpak AD-H (250 ×21) mm, 5 u; % CO₂: 60%; % Co solvent: 40% (0.2% DEA in MeOH); TotalFlow: 70 g/min; Back Pressure: 100 bars; Temperature: 25° C.; Detection:UV at 254 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.43-7.50 (m, 4H), 7.34 (d,J = 7.2 Hz, 1H), 7.04 (s, 1H), 6.57 (d, J = 7.6 Hz, 1H), 3.49 (t, J =6.0, 2H), 3.23 (dd, J = 14.53, 11.14 Hz, 1H),, 3.10 (s, 3H), 2.98 (s,3H), 2.89 (dd, J = 10.0, 4.8 Hz, 1H), 2.58-2.90 (m, 4H), 2.48-2.66 (m,2H), 1.91-2.01 (m, 1H), 1.31 (s, 1H), Example 137/138 1.92-1.97 (m, 2H).LC-MS: retention time = 1.014 min; m/z = 479.2 [M + H]⁺ KINETIX XB-C18,(3 × 75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 3.7 141

Preparative SFC method: (retention time = 3.62 min), Chiralpak AD-H (250× 21) mm, 5 u; % CO₂: 60%; % Co solvent: 40% (0.2% DEA in MeOH); TotalFlow: 70 g/min; Back Pressure: 100 bar; Temperature: 25° C.; Detection:UV at 245 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.36 (d, J = 7.2 Hz, 1H),6.90 (s, 1H), 6.92-6.96 (m, 3H), 6.56 (d, J = 7.2 Hz, 1H), 4.78- 4.89(dd, J = 6.4, 4.8Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.49 (t, J = 5.2Hz, 2H), 3.17 (dd, J = 11.2, 2.8 Hz, 1H), 2.72-2.86 (m, 5H), 2.43-2.48(m, 2H), 1.83-1.87 (m, 2H), 1.80-1.81 (m, 2H). LC-MS: (retention time =Example 137/138 1.204 min), m/z = 468.2 [M + H]⁺ KINETIX XB-C18, (3 ×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% B withflow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) =2.9 142

Preparative SFC method: (retention time = 4.07 min), Chiralpak AD-H (250× 21) mm, 5 u; % CO₂: 60%; % Co solvent: 40% (0.2% DEA in MeOH); TotalFlow: 70 g/min; Back Pressure: 100 bar; Temperature: 25° C.; Detection:UV at 245 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.36 (d, J = 7.2 Hz, 1H),6.90 (s, 1H), 6.92-6.96 (m, 3H), 6.56 (d, J = 7.2 Hz, 1H), 4.78- 4.89(dd, J = 6.4, 4.8 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.49 (t, J = 5.2Hz, 2H), 3.17 (dd, J = 11.2, 2.8 Hz, 1H), 2.72-2.86 (m, 5H), 2.43-2.48(m, 2H), 1.83-1.87 (m, 2H), 1.80-1.81 (m, 2H). LC-MS: (retention time =Example 137/138 1.204 min), m/z = 468.2 [M + H]⁺ KINETIX XB-C18, (3 ×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% B withflow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) =37

Example 143 and Example 144 Example 143: First Eluting Enantiomer of3-(2-Methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicAcid Example 144: Second Eluting Enantiomer of3-(2-Methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicAcid

4-Bromothiazol-2-yl)(2-methoxypyrimidin-5-yl)methanol (143A)

To a stirred solution of 4-bromothiazole (50.0 mg, 0.305 mmol) in THF (2mL) under nitrogen atmosphere was added n-butyllithium (2.5 molarsolution in hexane) (0.183 mL, 0.457 mmol) at −78° C. Resulting paleyellow solution was stirred at −78° C. for 30 min. Then,2-methoxypyrimidine-5-carbaldehyde (37.9 mg, 0.274 mmol) in 0.5 mL THFwas added and the reaction mixture was stirred at −78° C. for 1 h.Reaction was quenched with water (2 mL) and diluted with ethyl acetate(5 mL). The organic layer was separated, washed with brine, dried overanhydrous sodium sulphate and evaporated under vacuum to get the crudeproduct. The crude product was purified by combiflash chromatography (4g Redisep® SiO₂ column, eluting with 72% EtOAc in n-hexanes) to affordthe title compound 143A (30 mg, 32%) as a pale yellow oil. LC-MSretention time=0.84 min; m/z=304.0 [M+H]⁺ AQUITY UPLC BEH C18 (3.0×50mm) 1.7 micron column; Mobile Phase A: 5 mM ammonium acetate in 95%Water/5% ACN; Mobile Phase B: 5 mM ammonium acetate in 5% Water/95% ACN;Gradient time 1.7 min. 20% B to 90% B over 1.7 min. Flow rate 0.7mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.63 (s,2H), 7.55 (s, 1H), 6.05 (s, 1H), 4.03 (s, 3H).

4-Bromothiazol-2-yl)(2-methoxypyrimidin-5-yl)methanone (143B)

To a stirred solution of(4-bromothiazol-2-yl)(2-methoxypyrimidin-5-yl)methanol 143A (200 mg,0.662 mmol) in DCM (6 mL) under nitrogen atmosphere was addedDess-Martin periodinane (562 mg, 1.324 mmol) and the resulting mixturewas stirred at RT for 16 h. The reaction mixture was concentrated undervacuum and the crude product obtained was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 32% EtOAc inn-hexanes) to afford the title compound 143B (120 mg, 60%) as a paleyellow solid. LC-MS retention time=2.32 min; m/z=299.9 [M+H]⁺ KINETIXXB-C18, (3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20%B to 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm9.65 (s, 2H), 7.68 (s, 1H), 4.15 (s, 3H).

Ethyl (E)-3-(4-bromothiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)acrylate(143C)

To a stirred solution of(4-bromothiazol-2-yl)(2-methoxypyrimidin-5-yl)methanone 143B (300 mg,1.000 mmol) in toluene (10 mL) under nitrogen atmosphere was added(carbethoxymethylene)triphenylphosphorane (418 mg, 1.199 mmol) and thereaction mixture was stirred at 100° C. for 16 h. The reaction mixturewas concentrated under reduced pressure to get the crude product. Thecrude product was then purified by combiflash chromatography (24 gRedisep® SiO₂ column, eluting with 33% EtOAc in n-hexanes) to afford thetitle compound 143C (260 mg, 70%, mixture of cis and trans isomers) as awhite solid. LC-MS retention time=2.47 & 2.68 min; m/z=372.0 [M+H]⁺KINETIX XB-C18, (3×75) mm, 2.6 micron column; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm.

Ethyl(E)-3-(4-((E)-4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)acrylate(143D)

To a stirred solution of ethyl(E)-3-(4-bromothiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)acrylate 143C (30mg, 0.081 mmol) in ACN (4 mL) under nitrogen atmosphere was added2-(but-3-en-1-yl)-1,8-naphthyridine (14.9 mg, 0.081 mmol),tri-o-tolylphosphine (3.70 mg, 0.012 mmol), palladium(II) acetate (1.81mg, 0.0081 mmol) and TEA (0.028 mL, 0.20 mmol). The reaction mixture wasdegassed with argon and stirred at 80° C. for 16 h. The reaction mixturewas filtered, washed with EtOAc (5 mL) and the combined filtrateconcentrated. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 3% MeOH inCHCl₃) to afford the title compound 143D (30 mg, 80%) as a brown oil.LC-MS retention time=2.3 & 2.5 min; m/z=474.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm.

Ethyl3-(2-methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoate(143E)

To a stirred solution of ethyl(E)-3-(4-((E)-4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)acrylate143D (50 mg, 0.106 mmol) in ethanol (3 mL) was added platinum(IV) oxide(2 mg, 8.81 μmol) under nitrogen atmosphere. The reaction mixture wasdegassed with hydrogen and stirred under hydrogen bladder pressure at RTfor 16 h. The reaction mixture was filtered through Celite, washedCelite with EtOH (5 mL) and the combined filtrate concentrated underreduced pressure to afford the title crude product 143E (150 mg, 57%) asa pale yellow oil. LC-MS retention time=1.28 min; m/z=482.3 [M+H]⁺AQUITY UPLC BEH C18 (3.0×50 mm) 1.7 micron column; Mobile Phase A: 5 mMammonium acetate in 95% Water/5% ACN; Mobile Phase B: 5 mM ammoniumacetate in 5% Water/95% ACN; Gradient time 1.7 min. 20% B to 90% B over1.7 min. Flow rate 0.7 mL/min; Detection: UV at 220 nm.

Example 143: First Eluting Enantiomer of3-(2-Methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicAcid Example 144: Second Eluting Enantiomer of3-(2-Methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicAcid

To a stirred solution of ethyl3-(2-methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoate143E (80 mg, 0.166 mmol) in THF (3 mL), MeOH (3 mL) and water (3 mL) wasadded LiOH.H₂O (7.96 mg, 0.332 mmol) and the resulting mixture wasstirred at RT for 4 h. Then, citric acid (63.8 mg, 0.332 mmol) was addedand stirred at RT for 10 min. The reaction mixture was filtered,concentrated under reduced pressure to get the crude product. The crudeproduct was purified by preparative HPLC (YMC Trait (150 mm×20 mm ID) 5g column. Mobile Phase A: 10 mM NH4OAc in water; Mobile Phase B:ACN:MeOH (1:1). Flow rate: 18.0 mL/min; time (min)/% B: 0/20, 02/30,15/50, 15.5/100) to afford the pure compound as racemic mixture.Individual enantiomers was separated by chiral preparative SFC(Chiralpak AD-H (250×21) mm, 5 micron column; % CO2: 50%; % Co solvent:50%(0.2% DEA in IPA); Total Flow: 70 g/min; Back Pressure: 100 bars;Temperature: 30° C.; Detection: UV at 240 nm) to get first elutingisomer Example 143 (retention time: 4.2 min, 7 mg, 8.8%) as a whitesolid. LC-MS retention time=1.46 min; m/z=454.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.61 (s,2H), 7.42 (d, J=7.20 Hz, 1H), 7.08 (s, 1H), 6.53 (d, J=7.20 Hz, 1H),4.80-4.83 (m, 1H), 4.01 (s, 3H), 3.45 (t, J=5.60 Hz, 2H), 3.17 (dd,J=14.6, 11.0 Hz, 1H), 2.91-2.96 (m, 1H), 2.76-2.84 (m, 4H), 2.54-2.62(m, 2H), 1.92-1.96 (m, 3H), 1.70-1.78 (m, 1H), 1.51-1.59 (m, 2H). HumanαVβ6 IC50 (nM)=88. Further eluting the same column furnished the secondisomer, Example 144 (retention time: 6.5 min., 7 mg, 8.8%) as a whitesolid. LC-MS retention time=1.46 min; m/z=454.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.61 (s,2H), 7.42 (d, J=7.20 Hz, 1H), 7.08 (s, 1H), 6.53 (d, J=7.20 Hz, 1H),4.80-4.83 (m, 1H), 4.01 (s, 3H), 3.45 (t, J=5.60 Hz, 2H), 3.17 (dd,J=14.6, 11.0 Hz, 1H), 2.91-2.96 (m, 1H), 2.76-2.84 (m, 4H), 2.54-2.62(m, 2H), 1.92-1.96 (m, 3H), 1.70-1.78 (m, 1H), 1.51-1.59 (m, 2H). HumanαVβ6 IC50 (nM)=7.0.

Example 145 and Example 146 Example 145: First Eluting Enantiomer of3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 146: Second Eluting Enantiomer of3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

Ethyl(E)-3-(4-(4-hydroxypent-1-yn-1-yl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)acrylate(145A)

To a stirred solution of ethyl(E)-3-(4-bromothiazol-2-yl)-3-(2-methylpyrimidin-5-yl)acrylate 143C (100mg, 0.282 mmol) and pent-4-yn-2-ol (23.75 mg, 0.282 mmol) in TEA (6 mL)under nitrogen atmosphere was added copper(I) iodide (2.69 mg, 0.014mmol) followed by bis(triphenylphosphine)palladium (II) dichloride (9.9mg, 0.014 mmol). Then, the reaction mixture was degassed with argon for2 min and then heated at 80° C. for 16 h. After cooling to RT, thereaction mixture was filtered through Celite, Celite was washed withEtOAc (5 mL) and the combined filtrate concentrated under reducedpressure to give a brown colour crude oil. The crude product waspurified by combiflash chromatography (12 g Redisep® SiO₂ column,eluting with 69% EtOAc in pet ether) to afford the title compound 145A(90 mg, 47%) as a pale yellow oil. LC-MS retention time=1.82 & 1.96 min;m/z=375.0 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; MobilePhase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm.

Ethyl3-(4-(4-hydroxypentyl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)propanoate(145B)

To a degassed solution of ethyl(E)-3-(4-(4-hydroxypent-1-yn-1-yl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)acrylate145A (120 mg, 0.321 mmol) in EtOH (5 mL) was added 10% palladium oncarbon (20 mg, 0.188 mmol). The resulting reaction mixture was stirredunder hydrogen bladder pressure at RT for 16 h. The reaction mixture wasfiltered through Celite pad and the filtrate concentrated under vacuumto afford the crude title compound 145B (120 mg, 76%) as pale yellowoil. LC-MS retention time=1.90 min; m/z=380.0 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm.

Ethyl3-(2-methoxypyrimidin-5-yl)-3-(4-(4-oxopentyl)thiazol-2-yl)propanoate(145C)

To a solution of ethyl3-(4-(4-hydroxypentyl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)propanoate145B (120 mg, 0.316 mmol) in DCM (15 mL) was added Dess-Martinperiodinane (268 mg, 0.632 mmol) at 0° C. and the resulting mixture wasstirred at RT for 2 h. The reaction mass was diluted with DCM (20 mL),washed with 20% sodium bicarbonate solution (20 mL), brine solution (10mL), dried over sodium sulfate and evaporated under reduced pressure toget white crude solid. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 41% EtOAc in petether) to afford the title compound 145C (100 mg, 76%) as a pale yellowoil. LC-MS retention time=1.44 min; m/z=378.2 [M+H]⁺ LUNA 3.0 C18,(4×20) mm, 2.6 micron column; Mobile Phase A: 0.1% TFA in water. MobilePhase B: 0.1% TFA in ACN; 20% B to 98% B over 2.7 min, then hold 0.3min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm.

Ethyl3-(4-(3-(1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)propanoate(145D)

To a stirred solution of ethyl3-(2-methoxypyrimidin-5-yl)-3-(4-(4-oxopentyl)thiazol-2-yl)propanoate145C (130 mg, 0.344 mmol) and 2-aminonicotinaldehyde (50.6 mg, 0.414mmol) in ethanol (5 mL) under nitrogen was added pyrrolidine (0.029 mL,0.345 mmol) and the resulting reaction mixture was stirred at 70° C. for4 h. The reaction mixture concentrated under the reduced pressure andthe crude product was purified by combiflash chromatography (24 gRedisep® SiO₂ column, eluting with 100% EtOAc to afford the titlecompound 145D (75 mg, 42%) as a pale yellow liquid. LC-MS retentiontime=1.11 min; m/z=464.2 [M+H]⁺ LUNA 3.0 C18, (4×20) mm, 2.6 microncolumn; Mobile Phase A: 0.1% TFA in water. Mobile Phase B: 0.1% TFA inACN; 20% B to 98% B over 2.7 min, then hold 0.3 min. at 20% B with flowrate 1-1.5 mL/min; Detection: UV at 220 nm.

Ethyl3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoate(145E)

To a stirred solution of ethyl3-(4-(3-(1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)-3-(2-methoxypyrimidin-5-yl)propanoate145D (180 mg, 0.388 mmol) in ethanol (8 mL) was added platinum(IV) oxide(2 mg, 8.81 μmol) under nitrogen atmosphere. The reaction mixture wasdegassed with hydrogen and stirred under hydrogen bladder pressure at RTfor 16 h. The reaction mixture was filtered through the Celite, theCelite was washed with EtOH (5 mL) and the combined filtrate evaporatedunder reduced pressure to afford the title crude product 145E (150 mg,94%) as a pale yellow oil. LC-MS retention time=1.11 min; m/z=468.3[M+H]⁺ AQUITY UPLC BEH C18 (3.0×50 mm) 1.7 micron column; Mobile PhaseA: 5 mM ammonium acetate in 95% Water/5% ACN; Mobile Phase B: 5 mMammonium acetate in 5% Water/95% ACN; Gradient time 1.7 min. 20% B to90% B over 1.7 min. Flow rate 0.7 mL/min; Detection: UV at 220 nm.

Example 145: First Eluting Enantiomer of3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 146: Second Eluting Enantiomer of3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

To a stirred solution of ethyl3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoate145E (100 mg, 0.214 mmol) in THF (3 mL), MeOH (3 mL) and water (3 mL)was added LiOH.H₂O (10 mg, 0.428 mmol) and the resulting mixture wasstirred at RT for 4 h. Then, citric acid (82 mg, 0.428 mmol) was addedand stirred at RT for 10 min. The reaction mixture was concentratedunder reduced pressure to get the crude product. The crude product waspurified by preparative HPLC (Sunfire OBD (250 mm×30 mm ID) 5 g. Mobilephase A: 10 mM NH₄OAc in water; Mobile phase B: ACN:MeOH (1:1); Flowrate: 18 mL/min; time (min)/% B: 0/20, 02/20, 15/60, 15.5/100) to affordthe title compound as racemate. Individual enantiomers were separated bychiral SFC (Chiralpak AD-H (250×21) mm, 5 micron column; % CO2: 50%; %Co solvent: 45%(0.2% NH₄OH in MeOH and ACN (1:1); Total Flow: 70 g/min;Back Pressure: 100 bars; Temperature: 30° C.; Detection: UV at 245 nm.)to afford Example 145 (retention time 4.5 min., 24 mg, 23%) as a whitesolid. LC-MS retention time=1.24 min; m/z=440.2 [M+H]⁺ (KINETIX XB-C18,(3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm.). ¹H NMR (400 MHz, CD₃OD) δ ppm 8.61(s, 2H), 7.42 (d, J=7.20 Hz, 1H), 7.08 (s, 1H), 6.53 (d, J=7.20 Hz, 1H),4.80-4.83 (m, 1H), 4.01 (s, 3H), 3.45 (t, J=5.60 Hz, 2H), 3.17 (dd,J=14.6, 11.0 Hz, 1H), 2.91 (dd, J=14.6, 11.8 Hz, 1H), 2.76-2.84 (m, 4H),2.54-2.62 (m, 2H), 2.12-2.14 (m, 1H), 2.02-2.26 (m, 1H), 1.92-1.96 (m,2H). Human αVβ6 IC50 (nM)=4.5. Second eluting enantiomer, Example 146(retention time 8.5 min, 22 mg, 23%) as a white solid. LC-MS retentiontime=1.24 min; m/z=440.2 [M+H]⁺ (KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm.). ¹H NMR (400 MHz, CD₃OD) δ ppm 8.61 (s, 2H), 7.42 (d, J=7.20 Hz,1H), 7.08 (s, 1H), 6.53 (d, J=7.20 Hz, 1H), 4.80-4.83 (m, 1H), 4.01 (s,3H), 3.45 (t, J=5.60 Hz, 2H), 3.17 (dd, J=14.6, 11.0 Hz, 1H), 2.91 (dd,J=14.6, 11.8 Hz, 1H), 2.76-2.84 (m, 4H), 2.54-2.62 (m, 2H), 2.12-2.14(m, 1H), 2.02-2.26 (m, 1H), 1.92-1.96 (m, 2H). Human αVβ6 IC50 (nM)=140.

Ex- Prep-HPLC/SFC conditions, ¹H ample Structure NMR and LC-MS dataMethod 147

Prep-HPLC: Retention time: 9.6 min. Sunfire C18 (250 × 30) mm; 5 micron;Mobile Phase A: 10 mM NH₄OAC in water; Mobile Phase B: ACN: MeOH (1:1).Flow rate: 17.0 mL/min; time (min)/% B: 0/20, 25/100. ¹H NMR (400 MHz,CD₃OD) δ ppm 8.74 (s, 2H), 7.42 (d, J = 3.20 Hz, 1H), 7.08 (s, 1H), 6.53(d, J = 7.20 Hz, 1H), 4.87-4.91 (m, 1H), 3.45 (t, J = 5.60 Hz, 2H), 3.17(dd, J = 14.6, 11.0 Hz, 1H), 2.91 (dd, J = 14.0, 11.0 Hz, 1H), 2.76-2.87(m, 4H), 2.68 (s, 3H), 2.55-2.61 (m, 2H), 2.12-2.18 (m, 1H), 2.00-2.07(m, 1H), 1.90-1.98 (m, 2H). LC-MS retention Example 145/146 time = 0.98min; m/z = 424.2 [M + H]⁺ KINETIX XB-C18, (3 × 75) mm, 2.6 microncolumn; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. Human αVβ6 IC50 (nM) = 1.9 148

Chiral SFC: Retention time: 2.81 min. (Chiralpak AD-H (250 × 21) mm, 5micron column; % CO₂: 50%; % Co solvent: 45% (0.2% NH4OH in MeOH and ACN(1:1)); Total Flow: 70 g/min; Back Pressure: 100 bar; Temperature: 30°C.; Detection: UV at 245 nm). ¹H NMR (400 MHz, CD₃OD) δ ppm 8.74 (s,2H), 7.42 (d, J = 3.20 Hz, 1H), 7.08 (s, 1H), 6.53 (d, J = 7.20 Hz, 1H),4.87- 4.91 (m, 1H), 3.45 (t, J = 5.60 Hz, 2H), 3.17 (dd, J = 14.6, 11.0Hz, 1H), 2.91 (dd, J = 14.0, 11.0 Hz, 1H), 2.76-2.87 (m, 4H), 2.68 (s,3H), 2.55-2.61 (m, 2H), 2.12-2.18 (m, 1H), 2.00-2.07 (m, Example 145/1461H), 1.90-1.98 (m, 2H). LC-MS retention time = 0.98 min; m/z = 424.2[M + H]⁺ KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Mobile Phase A:10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 6.0 149

Chiral SFC: Retention time: 4.59 min. (Chiralpak AD-H (250 × 21) mm; 5micron column; % CO₂: 50%; % Co solvent: 45% (0.2% NH₄OH in MeOH and ACN(1:1); Total Flow: 70 g/min; Back Pressure: 100 bar; Temperature: 30°C.; Detection: UV at 245 nm). ¹H NMR (400 MHz, CD₃OD) δ ppm 8.74 (s,2H), 7.42 (d, J = 3.20 Hz, 1H), 7.08 (s, 1H), 6.53 (d, J = 7.20 Hz, 1H),4.87- 4.91 (m, 1H), 3.45 (t, J = 5.60 Hz, 2H), 3.17 (dd, J = 14.6, 11.0Hz, 1H), 2.91 (dd, J = 14.0, 11.0 Hz, 1H), 2.76-2.87 (m, 4H), 2.68 (s,3H), 2.55-2.61 (m, 2H), 2.12-2.18 (m, 1H), 2.00-2.07 (m, Example 145/1461H), 1.90-1.98 (m, 2H). LC-MS retention time = 0.98 min; m/z = 424.2[M + H]⁺ KINETIX XB-C18, (3 × 75) mm, 2.6 micron column; Mobile Phase A:10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 7.2 150

Chiral SFC: Retention time: 4.54 min, Lux Cellulose C4 (250 × 21.2) mm;5 micron; Mobile Phase: 0.4% DEA in ACN: MeOH (70:30), Flow: 25 mL/min.¹H NMR (400 MHz, CD₃OD) δ ppm 8.37 (s, 1H), 8.31 (s, 1H), 7.70 (s, 1H),7.48 (d, J = 7.53 Hz, 1H), 7.07 (s, 1H), 6.57 (d, J = 7.03 Hz, 1H),4.85- 4.95 (m, 1H), 3.49 (t, J = 5.60 Hz, 2H), 3.24 (dd, J = 14.81,10.79 Hz, 1H), 2.85- 2.95 (m, 2H), 2.83 (t, J = 5.20 Hz, 2H),2.75-2.83(m, 1H), 2.49-2.67 (m, 2H), 2.37 (s, 3H), 2.11-2.24 (m, 1H),2.00- 2.09 (m, 1H), 1.90-1.99 (m, 2H). LC- Example 145/146 MS retentiontime = 1.14 min; m/z = 423.2 [M + H]⁺ Column- KINETIX XB- C18, (3 × 75)mm; 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM)= 87 151

Chiral SFC: Retention time: 5.79 min, Lux Cellulose C4 (250 × 21.2) mm;5 micron; Mobile Phase: 0.4% DEA in ACN: MeOH (70:30), Flow: 25 mL/min.¹H NMR (400 MHz, CD₃OD) δ ppm 8.37 (s, 1H), 8.31 (s, 1H), 7.70 (s, 1H),7.48 (d, J = 7.53 Hz, 1H), 7.07 (s, 1H), 6.57 (d, J = 7.03 Hz, 1H),4.85- 4.95 (m, 1H), 3.49 (t, J = 5.60 Hz, 2H), 3.24 (dd, J = 14.81,10.79 Hz, 1H), 2.85- 2.95 (m, 2H), 2.83 (t, J = 5.20 Hz, 2H),2.75-2.83(m, 1H), 2.49-2.67 (m, 2H), 2.37 (s, 3H), 2.11-2.24 (m, 1H),2.00- 2.09 (m, 1H), 1.90-1.99 (m, 2H). LC- MS retention time = 1.15 min;m/z = Example 145/146 423.2 [M + H]⁺ Column- KINETIX XB- C18, (3 × 75)mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM)= 2.6.

Example 152 and Example 153 Example 152: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoicAcid Example 153: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoicAcid

5-(4-Bromothiazol-2-yl)pent-4-yn-2-ol (152A)

To a solution of 2,4-dibromothiazole (500 mg, 2.058 mmol) andpent-4-yn-2-ol (208 mg, 2.47 mmol) in TEA (5 mL) was added copper(I)iodide (19.6 mg, 103.0 mmol) followed bybis(triphenylphosphine)palladium(II) dichloride (72.2 mg, 103 mmol)under nitrogen atmosphere. The reaction mixture was degassed with argonfor 2 min and then stirred at 80° C. for 16 h. The reaction mixture wasfiltered and the filtrate concentrated under reduced pressure to getcrude product as brown oil. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 52% EtOAc in petether) to afford the title compound 152A (350 mg, 69%) as a pale brownoil. LC-MS retention time=1.23 min; m/z=248.0 [M+H]⁺ LUNA 3.0 C18,(4×20) mm, 2.6 micron column; Mobile Phase A: 0.1% TFA in water. MobilePhase B: 0.1% TFA in ACN; 20% B to 98% B over 2.7 min, then hold 0.3min. at 20% B with flow rate 1.0 mL/min; Detection: UV at 220 nm. ¹H NMR(400 MHz, CDCl₃) δ ppm 7.26 (s, 1H), 4.11 (m, 1H), 2.64-2.67 (m, 2H),1.98 (s, 1H), 1.34 (d, J=6.00 Hz, 3H).

(3-Fluoro-4-methoxyphenyl)(2-(4-hydroxypent-1-yn-1-yl)thiazol-4-yl)methanone(152B)

To a stirred solution of 5-(4-bromothiazol-2-yl)pent-4-yn-2-ol 152A (300mg, 1.219 mmol) in THF (8 mL) under nitrogen atmosphere was added n-BuLi(0.731 mL, 2.5 molar solution in hexane, 1.82 mmol) at −78° C. and theresulting dark brown solution was stirred at the same temperature for 30min. 3-Fluoro-N,4-dimethoxy-N-methylbenzamide (234 mg, 1.097 mmol) in3.0 mL THF was added and the reaction was continued to stir at the sametemperature for 1 h. Reaction was quenched with water (20 mL) anddiluted with ethyl acetate (30 mL). The organic layer was separated,washed with brine, dried over anhydrous sodium sulphate and evaporatedunder vacuum to get the crude product. The crude product was purified bycombiflash chromatography (24 g Redisep® SiO₂ column, eluting with 66%EtOAc in n-hexanes) to afford the title compound 152B (220 mg, 56%) as apale yellow oil. LC-MS retention time=2.42 min; m/z=351.0 [M+H]⁺ KINETIXXB-C18, (3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20%B to 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1.0mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.20 (s,1H), 7.65-7.72 (m, 2H), 7.6 (t, J=8.4 Hz, 1H), 4.14 (q, J=6.00 Hz, 1H),3.99 (s, 3H), 2.70 (m, 2H), 2.04 (s, 1H), 1.35 (dd, J=4.00 Hz, 3H).

Ethyl(E)-3-(3-fluoro-4-methoxyphenyl)-3-(2-(4-hydroxypent-1-yn-1-yl)thiazol-4-yl)acrylate(152C)

To a stirred solution of(3-fluoro-4-methoxyphenyl)(2-(4-hydroxypent-1-yn-1-yl)thiazol-4-yl)methanone(200 mg, 0.626 mmol) 152B in toluene (10 mL) under nitrogen atmospherewas added (carbethoxymethylene)triphenylphosphorane (262 mg, 0.752 mmol)and the reaction mixture was stirred at 100° C. for 16 h. The reactionmixture was concentrated under reduced pressure to get the crudeproduct. The crude product was purified by combiflash chromatography (12g Redisep® SiO₂ column, eluting with 67% EtOAc in n-hexanes) to affordthe title compound 152C (330 mg, 60%) as a white solid. LC-MS retentiontime=1.86 min, (m/z=390.2 [M+H]⁺ AQUITY UPLC BEH C18 (3.0×50) mm, 1.7micron column; Mobile Phase A: 5 mM ammonium acetate in 95% Water/5%ACN; Mobile Phase B: 5 mM ammonium acetate in 5% Water/95% ACN; Gradienttime 1.7 min. 20% B to 90% B over 1.7 min. Flow rate 0.7 mL/min;Detection: UV at 220 nm.

Ethyl3-(3-fluoro-4-methoxyphenyl)-3-(2-(4-hydroxypentyl)thiazol-4-yl)propanoate(152D)

To a degassed solution of ethyl(E)-3-(3-fluoro-4-methoxyphenyl)-3-(2-(4-hydroxypent-1-yn-1-yl)thiazol-4-yl)acrylate152C (200 mg, 0.506 mmol) in EtOH (5 mL) was added 10% palladium oncarbon (20 mg, 0.303 mmol) and the resulting reaction mixture wasstirred under hydrogen bladder pressure at RT for 16 h. The reactionmixture was filtered through Celite and the filtrate was concentratedunder vacuum to afford the crude title compound 152D (180 mg, 96%) aspale yellow oil. LC-MS retention time=2.1 min; m/z=396.2 [M+H]⁺ LUNA 3.0C18, (4×20) mm, 2.6 micron column; Mobile Phase A: 0.1% TFA in water.Mobile Phase B: 0.1% TFA in ACN; 20% B to 98% B over 2.7 min, then hold0.3 min. at 20% B with flow rate 1.0 mL/min; Detection: UV at 220 nm.

Ethyl3-(3-fluoro-4-methoxyphenyl)-3-(2-(4-oxopentyl)thiazol-4-yl)propanoate(152E)

To a solution of ethyl3-(3-fluoro-4-methoxyphenyl)-3-(2-(4-hydroxypentyl)thiazol-4-yl)propanoate152D (180 mg, 0.458 mmol) in DCM (15 mL) was added Dess-Martinperiodinane (324 mg, 0.916 mmol) at 0° C. and the resulting mixture wasstirred at RT for 2 h. The reaction mass was diluted with DCM (20 mL),washed with 20% sodium bicarbonate solution (20 mL), brine solution (10mL), dried over sodium sulfate, filtered and the filtrate evaporatedunder reduced pressure to get white crude product. The crude product waspurified by combiflash chromatography (12 g Redisep® SiO₂ column,eluting with 91% EtOAc in pet ether) to afford the title compound 152E(100 mg, 66%) as a pale yellow solid. LC-MS retention time=1.24 min;m/z=394.3 [M+H]⁺ AQUITY UPLC BEH C18 (3.0×50) mm; 1.7 micron column;Mobile Phase A: 5 mM ammonium acetate in 95% Water/5% ACN; Mobile PhaseB: 5 mM ammonium acetate in 5% Water/95% ACN; Gradient time 1.7 min. 20%B to 90% B over 1.7 min. Flow rate 0.7 mL/min; Detection: UV at 220 nm.

Ethyl3-(2-(3-(1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)-3-(3-fluoro-4-methoxyphenyl)-propanoate(152F)

To a stirred solution of ethyl3-(3-fluoro-4-methoxyphenyl)-3-(2-(4-oxopentyl)thiazol-4-yl)propanoate152E (100 mg, 0.254 mmol) and 2-aminonicotinaldehyde (37.6 mg, 0.303mmol) in ethanol (5 mL) under nitrogen was added pyrrolidine (0.03 mL,0.504 mmol) and the mixture was stirred at 70° C. for 4 h. The reactionmixture concentrated to get the crude brown oil. The crude product waspurified by combiflash chromatography (12 g Redisep® SiO₂ column,eluting with 10% MeOH in chloroform to afford the title compound 152F(75 mg, 42%) as a pale yellow liquid. LC-MS retention time=1.24 min;m/z=480.4 [M+H]⁺ AQUITY UPLC BEH C18 (3.0×50 mm) 1.7 micron column;Mobile Phase A: 5 mM ammonium acetate in 95% Water/5% ACN; Mobile PhaseB: 5 mM ammonium acetate in 5% Water/95% ACN; Gradient time 1.7 min. 20%B to 90% B over 1.7 min. Flow rate 0.7 mL/min; Detection: UV at 220 nm.

Ethyl3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoate(152G)

To a stirred solution of ethyl3-(2-(3-(1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate152F (75 mg, 0.154 mmol) in ethanol (8 mL) was added platinum(IV) oxide(2 mg, 6.61 μmol) under nitrogen atmosphere. The reaction mixture wasdegassed with hydrogen gas and stirred under hydrogen bladder pressureat RT for 16 h. The reaction mixture was filtered, washed with EtOH (5mL), filtrate was evaporated under reduced pressure to afford the titlecrude product 152G (40 mg, 78%) as a pale yellow oil. LC-MS retentiontime=1.31 min; m/z=484.2 [M+H]⁺ LUNA 3.0 C18, (4×20) mm, 2.6 microncolumn; Mobile Phase A: 0.1% TFA in water. Mobile Phase B: 0.1% TFA inACN; 20% B to 98% B over 2.7 min, then hold 0.3 min. at 20% B with flowrate 1.0 mL/min; Detection: UV at 220 nm.

Example 152: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoicAcid Example 153: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoicAcid

To a stirred solution of ethyl3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoate(40.0 mg, 0.083 mmol) 152G in THF (1 mL), MeOH (1 mL) and water (1 mL)was added LiOH.H₂O (3.96 mg, 0.165 mmol) and the resulting mixture wasstirred at RT for 4 h. Then, citric acid (32 mg, 0.165 mmol) was addedand stirred at RT for 10 min. The reaction mixture was filtered,concentrated under reduced pressure to get the crude product. The crudeproduct was purified by preparative HPLC (Sunfire OBD (250×30) mm; 5micron; Mobile Phase A: 10 mM NH₄OAc in water; Mobile Phase B: ACN:MeOH(1:1); Flow rate: 17.0 mL/min; time (min)/% B: 0/20, 02/20, 15/60,15.5/100) to afford the pure racemate. Individual enantiomers wereseparated by chiral SFC (Chiralpak IG (250×4.6) mm, 5 micron column; %CO₂: 50%; % Co solvent: 50% (0.2% NH₄OH in MeOH and ACN (1:1); TotalFlow: 4 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection:UV at 245 nm). First eluting enantiomer, Example 152 (retention time 8.4min., 3 mg, 7%) was isolated as a white solid. LC-MS retention time=1.92min; m/z=456.2 [M+H]⁺ (KINETIX XB-C18, (3×75) mm, 2.6 micron column;Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4min. at 20% B with flow rate 1.0 mL/min; Detection: UV at 220 nm. ¹H NMR(400 MHz, DMSO-d6) δ ppm 7.21 (dd, J=1.60, 12.00 Hz, 1H), 7.09-7.11 (m,3H), 7.02 (dd, J=7.20, Hz, 1H), 6.27 (bs, 1H), 6.26 (dd, J=7.20, Hz,1H), 4.68 (t, J=7.60 Hz, 1H), 3.80 (s, 3H), 3.23 (t, J=7.20 Hz, 2H),3.18 (dd, J=7.60, Hz, 1H), 2.89 (dd, J=8.00, 16.00 Hz, 1H), 2.89 (dd,J=8.00, 16.00 Hz, 1H), 2.59-2.69 (m, 4H), 2.45 (m, 2H), 1.90-1.93 (m,2H), 1.73-1.76 (m, 2H). Human αVβ6 IC50 (nM)=180. Second elutingenantiomer, Example 153 (retention time 11.0 min., 4 mg, 9%) as a whitesolid. LC-MS retention time=1.98 min; m/z=456.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1.0mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, DMSO-d6) δ ppm 7.21(dd, J=1.60, 12.00 Hz, 1H), 7.09-7.11 (m, 3H), 7.02 (dd, J=7.20, Hz,1H), 6.27 (bs, 1H), 6.26 (dd, J=7.20, Hz, 1H), 4.68 (t, J=7.60 Hz, 1H),3.80 (s, 3H), 3.23 (t, J=7.20 Hz, 2H), 3.18 (dd, J=7.60, Hz, 1H), 2.89(dd, J=8.00, 16.00 Hz, 1H), 2.89 (dd, J=8.00, 16.00 Hz, 1H), 2.59-2.69(m, 4H), 2.45 (m, 2H), 1.90-1.93 (m, 2H), 1.73-1.76 (m, 2H). Human αVβ6IC50 (nM)=54.

Example 154, Example 155, Example 156, and Example 157 Example 154:First Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 155: Second Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 156: Second Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 157: Second Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

Phenyl 2-allyl-1,8-naphthyridine-1(2H)-carboxylate (154A)

To a cooled solution of 1,8-naphthyridine (1 g, 7.68 mmol) in THF (35mL) was added phenyl chloroformate (1.060 mL, 8.45 mmol) at 0° C. andthe reaction mixture stirred at the same temperature for 30 min. Allylindium bromide (prepared freshly by adding bromoprop-1-ene (1.992 mL,23.05 mmol) dropwise to a suspension of indium (1.764 g, 15.37 mmol) inDMF (10 mL) at RT and stirring for 20 min) was added at 0° C. andstirred at the same temperature for 10 min. The reaction mixture dilutedwith water (50 mL) and extracted with ethyl acetate (2×50 mL). Thecombined organic layer was washed with water (2×50 mL), brine solution(50 mL), and dried over anhydrous sodium sulphate, filtered and thenconcentrated. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 20% ethylacetate in n-hexane) to afford the title compound 154A (1.25 g, 56%) asan off white solid. LC-MS retention time=2.85 min; m/z=293.2 [M+H]⁺Column: KINETIX XB-C18, (3×75) mm; 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.29 (dd, J=4.77, 1.76 Hz, 1H), 7.67(dd, J=7.53, 2.01 Hz, 1H), 7.38-7.46 (m, 2H), 7.23-7.29 (m, 1H),7.16-7.22 (m, 3H), 6.69 (d, J=9.54 Hz, 1H), 6.28 (dd, J=9.54, 6.02 Hz,1H), 5.67-5.80 (m, 1H), 5.09 (dd, J=6.00, 13.20 Hz, 1H), 5.02 (s, 1H),4.99 (d, J=5.02 Hz, 1H), 2.28-2.37 (m, 1H), 2.10-2.19 (m, 1H).

Phenyl(E)-2-(3-(2-(3-ethoxy-1-(6-methoxypyridin-3-yl)-3-oxopropyl)thiazol-4-yl)allyl)-1,8-naphthyridine-1(2H)-carboxylate(154B)

To a degassed solution of phenyl2-allyl-1,8-naphthyridine-1(2H)-carboxylate 154A (331 mg, 1.131 mmol) inACN (10 mL) was added ethyl3-(4-bromothiazol-2-yl)-3-(6-methoxypyridin-3-yl)propanoate (350 mg,0.943 mmol), TEA (0.263 mL, 1.886 mmol), tri-o-tolylphosphine (28.7 mg,0.094 mmol) and palladium(II) acetate (21.17 mg, 0.094 mmol. Thereaction mixture was then heated to 80° C. and stirred for 16 h. Aftercompletion of the reaction, the reaction mixture was filtered throughCelite and the filtrate was concentrated. The crude product was purifiedby combiflash chromatography (12 g Redisep® SiO₂ column, eluting with40% ethyl acetate in n-hexane) to afford the title compound 154B (250mg, 45%) as a pale brown gummy liquid. LC-MS retention time=3.54 min;m/z=583.2 [M+H]⁺ Column: KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 20% B with flow rate 1.5 mL/min;Detection: UV at 254 nm.

Phenyl2-(3-(2-(3-ethoxy-1-(6-methoxypyridin-3-yl)-3-oxopropyl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate (154C)

To a degassed solution of phenyl(E)-2-(3-(2-(3-ethoxy-1-(6-methoxypyridin-3-yl)-3-oxopropyl)thiazol-4-yl)allyl)-1,8-naphthyridine-1(2H)-carboxylate154B (250 mg, 0.429 mmol) in ethanol (10 mL) was added palladium oncarbon (50 mg, 0.047 mmol) and the reaction mixture was stirred underhydrogen balloon atmosphere at the RT for 16 h. The reaction mixture wasfiltered through Celite pad and the filtrate was concentrated to affordthe title compound (220 mg, 87%) as a pale brown gummy liquid. The crudeproduct 154C was taken to the next step without further purification.LC-MS retention time=1.90 min; m/z=587.2 [M+H]⁺ Column: KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at 50% Bwith flow rate 1.5 mL/min; Detection: UV at 220 nm.

Example 154: First Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 155: Second Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 156: Second Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 157: Second Eluting Diastereomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

To a solution of phenyl2-(3-(2-(3-ethoxy-1-(6-methoxypyridin-3-yl)-3-oxopropyl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate154C (220 mg, 0.375 mmol) in THF (4 mL) and t-BuOH (4 mL) was added asolution of sodium hydroxide (75 mg, 1.875 mmol)) in water (2 mL) andthe resulting reaction mixture was stirred at 70° C. for 40 h. Aftercompletion of the reaction, citric acid (216 mg, 1.125 mmol) was addedand the reaction mixture was stirred at the RT for 10 min. The reactionmixture was concentrated and taken for purification as such. The crudeproduct was purified by preparative reverse phase HPLC (SUNFIRE C18(150×19) mm; 5 micron; Mobile Phase A: 10 mM ammonium acetate (pH=4.5);Mobile Phase B: ACN; flow rate: 15 mL/min; Time (min)/% B: 0/20, 25/60)afford the racemate of title compound (70 mg). Individual diastereomersof3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid was separated by chiral SFC (Luxcellulose-2 (250×30) mm; 5 micron;50% CO₂ and 50% of 0.2% NH₄OH in MeOH+ACN (1:1) as co-solvent; TotalFlow: 80 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection:UV at 245 nM). First eluting diastereomer, Example 154 (Retention time15.2 min., 7 mg, 4%) was isolated as an off white solid. LC-MS retentiontime=1.68 min; m/z=439.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.15 (d,J=2.01 Hz, 1H) 7.71 (dd, J=8.53, 2.51 Hz, 1H), 7.67 (d, J=6.02 Hz, 1H),7.53 (d, J=7.03 Hz, 1H), 7.05 (s, 1H), 6.80 (d, J=8.53 Hz, 1H), 6.64 (t,J=6.53 Hz, 1H), 4.80-4.90 (m, 1H), 3.91 (s, 3H), 3.54-3.63 (m, 1H),3.13-3.25 (m, 1H), 2.88 (dd, J=13.30, 4.77 Hz, 1H), 2.76-2.85 (m, 4H),1.88-2.05 (m, 3H), 1.45-1.70 (m, 3H). Human αVβ6 IC50 (nM)=210. Secondeluting diastereomer, Example 155 (Retention time 17.2 min., 6 mg, 3.6%)was isolated as an off white solid. LC-MS retention time=1.69 min;m/z=439.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.12 (d, J=2.01Hz, 1H), 7.68 (d, J=6.53 Hz, 1H), 7.64 (dd, J=8.53, 2.01 Hz, 1H), 7.52(d, J=7.53 Hz, 1H), 7.03 (s, 1H), 6.78 (d, J=9.04 Hz, 1H), 6.67 (t,J=6.53 Hz, 1H), 4.82 (dd, J=10.29, 5.27 Hz, 1H), 3.91 (s, 3H), 3.58 (m,1H), 3.29-3.33 (m, 1H), 2.70-2.95 (m, 5H), 1.93-2.05 (m, 2H), 1.77-1.88(m, 1H), 1.56-1.74 (m, 2H), 1.43-1.54 (m, 1H). Human αVβ6 IC50 (nM)=8.1.Third eluting diastereomer, Example 156 (Retention time 19.3. min., 6mg, 3.6%) was isolated as an off white solid, LC-MS retention time=1.37min; m/z=439.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.12 (d,J=2.01 Hz, 1H), 7.68 (d, J=6.02 Hz, 1H), 7.65 (dd, J=8.53, 2.51 Hz, 1H),7.50 (d, J=7.03 Hz, 1H), 7.03 (s, 1H), 6.78 (d, J=8.53 Hz, 1H), 6.65 (t,J=6.53 Hz, 1H), 4.83 (dd, J=9.79, 5.27 Hz, 1H), 3.90 (s, 3H), 3.53-3.62(m, 1H), 3.29-3.33 (m, 1H), 2.68-2.95 (m, 5H), 1.91-2.04 (m, 2H),1.76-1.88 (m, 1H), 1.56-1.73 (m, 2H), 1.41-1.55 (m, 1H). Human αVβ6 IC50(nM)=260. Fourth eluting diastereomer, Example 157 (Retention time 23.1min., 6 mg, 3.6%) was isolated as an off white solid. LC-MS retentiontime=1.37 min; m/z=439.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.15 (d,J=2.01 Hz, 1H), 7.71 (dd, J=8.53, 2.51 Hz, 1H), 7.66 (d, J=6.53 Hz, 1H),7.54 (d, J=7.03 Hz, 1H), 7.05 (s, 1H), 6.80 (d, J=9.04 Hz, 1H), 6.67 (t,J=6.53 Hz, 1H), 4.85 (dd, J=13.20, 5.20 Hz, 1H), 3.91 (s, 3H) 3.55-3.63(m, 1H), 3.14-3.25 (m, 1H), 2.88 (dd, J=13.80, 5.27 Hz, 1H), 2.77-2.85(m, 4H), 1.89-2.05 (m, 3H), 1.46-1.70 (m, 3H). Human αVβ6 IC50 (nM)=27.

Example 158, Example 159, Example 160, and Example 161 Example 158:First Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 159: Second Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 160: Third Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 161: Fourth Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

Ethyl 3-(4-bromothiazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate(158A)

Ethyl (E)-3-(4-bromothiazol-2-yl)acrylate 13A (1 g, 3.82 mmol) in1,4-dioxane (35 mL) and water (5 mL) was purged with argon for 5 min.Chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.094 g, 0.191 mmol),(3-fluoro-4-methoxyphenyl)boronic acid (0.973 g, 5.72 mmol) and TEA(1.064 mL, 7.63 mmol) were added and the resulting reaction mixture wasstirred at 85° C. for 16 h. The reaction mixture was diluted with water(50 mL) and extracted with EtOAc (2×50 mL). The combined organic layerwas washed with brine (50 mL), dried (Na₂SO₄), filtered andconcentrated. The crude product was purified by combiflashchromatography (24 g Redisep® SiO₂ column, eluting with 25% EtOAc inn-hexanes) to afford the title compound 158A (500 mg, 34%) as a palebrown oil. LC-MS retention time=3.25 min; m/z=388.0 [M+2H]⁺ (KINETIXXB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile PhaseA: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm). ¹H NMR (400MHz, CDCl₃) Q ppm 7.06-7.10 (m, 2H), 7.05 (s, 1H), 6.85-7.03 (m, 1H),4.74 (t, J=10.00 Hz, 1H), 4.08 (dq, J=9.60, 6.40 Hz, 2H), 3.87 (s, 3H),3.40 (dd, J=9.60, 20.80 Hz, H), 2.97 (dd, J=10.80, 22.00 Hz, H), 1.18(t, J=9.60 Hz, 3H).

Phenyl(E)-2-(3-(2-(3-ethoxy-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)thiazol-4-yl)allyl)-1,8-naphthyridine-1(2H)-carboxylate 158B

To a degassed solution of phenyl2-allyl-1,8-naphthyridine-1(2H)-carboxylate (316 mg, 1.082 mmol 158A inacetonitrile (10 mL) was added ethyl3-(4-bromothiazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate (350 mg,0.901 mmol, TEA (0.251 mL, 1.803 mmol), tri-o-tolylphosphine (27.4 mg,0.090 mmol) and palladium(II) acetate (20.24 mg, 0.090 mmol). Thereaction mixture was then heated to 80° C. and stirred for 16 h. Aftercompletion of the reaction, the reaction mixture was filtered throughCelite and the filtrate concentrated. The crude product was purified bycombiflash chromatography (12 g Redisep® SiO₂ column, eluting with 40%ethyl acetate in n-hexane) to afford the title compound 158B (300 mg,55%) as a pale brown gummy liquid. LC-MS retention time=3.73 min;m/z=600.2 [M+H]⁺ Column: KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 20% B with flow rate 1.5 mL/min;Detection: UV at 254 nm.

Phenyl2-(3-(2-(3-ethoxy-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(158C)

To a degassed solution of phenyl(E)-2-(3-(2-(3-ethoxy-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)thiazol-4-yl)allyl)-1,8-naphthyridine-1(2H)-carboxylate158B (300 mg, 0.500 mmol) in ethanol (10 mL) was added palladium oncarbon (60 mg, 0.056 mmol) and the reaction mixture was stirred at RTunder hydrogen balloon atmosphere for 16 h. The reaction mixture wasfiltered through Celite and the filtrate was concentrated to afford thetitle compound 158C (250 mg, 80%) as a pale brown gummy liquid. LC-MSretention time=3.66 min; m/z=604.2 [M+H]⁺ Column: KINETIX XB-C18, (3×75)mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%Water/98% ACN; 50% B to 100% B over 4.6 min, then hold 0.4 min. at 50% Bwith flow rate 1.5 mL/min; Detection: UV at 220 nm.

Example 158: First Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 159: Second Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 160: Third Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 161: Fourth Eluting Diastereomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

To a stirred solution of phenyl2-(3-(2-(3-ethoxy-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate158C (250 mg, 0.414 mmol) in THF (4 mL) and t-BuOH (4 mL), was added asolution of sodium hydroxide (83 mg, 2.071 mmol)) in water (2 mL) andthe resulting reaction mixture was stirred at 70° C. for 40 h. Aftercompletion of the reaction, citric acid (239 mg, 1.242 mmol) was addedand the reaction mixture was stirred at RT for 10 min. The reactionmixture was concentrated and crude product was purified by preparativereverse phase HPLC (SUNFIRE C18 (150×19) mm, 5 micron; Mobile Phase A:10 mM ammonium acetate (pH=4.5); Mobile Phase B: Acetonitrile; flowrate: 15 mL/min; Time (min)/% B: 0/10, 10/40, 17/40) afford the titlecompound as diastereomeric mixture (70 mg). The individual diastereomersof the title compounds were separated by chiral SFC column:Luxcellulose-2 (250×30) mm; 5 micron; 50% CO₂ and 50% of 0.2% NH₄OH inMethanol+ ACN (1:1) as co-solvent; Total Flow: 80 g/min; Back Pressure:100 bar; Temperature: 30° C.; Detection: UV at 245 nM. First elutingdiastereomer Example 158 (Retention time 15.2 min., 10 mg, 5%) wasisolated as a white solid. LC-MS retention time=2.09 min; m/z=456.2[M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.68 (d, J=5.02 Hz, 1H), 7.47 (d,J=7.03 Hz, 1H), 7.03-7.14 (m, 4H), 6.64 (t, J=6.40 Hz, 1H), 4.78 (dd,J=9.54, 5.52 Hz, 1H), 3.86 (s, 3H), 3.51-3.60 (m, 1H), 3.26 (dd,J=15.81, 10.29 Hz, 1H), 2.69-2.95 (m, 5H), 1.92-2.03 (m, 2H), 1.76-1.88(m, 1H), 1.56-1.71 (m, 2H) 1.43-1.55 (m, 1H). Human αVβ6 IC50 (nM)=7.0.Second eluting diastereomer Example 159 (Retention time 17.2 min., 10mg, 5%) was isolated as a white solid. LC-MS retention time=2.06 min;m/z=456.2 [M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 50% B with flow rate 1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.66 (br. s.,1H), 7.45 (d, J=7.03 Hz, 1H), 7.04-7.15 (m, 3H), 7.03 (s, 1H), 6.63 (br.s., 1H), 4.77-4.86 (m, 1H), 3.86 (s, 3H), 3.51-3.59 (m, 1H), 3.07-3.22(m, 1H), 2.83-2.92 (m, 1H), 2.73-2.83 (m, 4H), 1.85-2.03 (m, 3H),1.50-1.67 (m, 3H). Human αVβ6 IC50 (nM)=370. Third eluting diastereomer,Example 160 (Retention time 18.2. min., 7 mg, 4%) was isolated as awhite solid. LC-MS retention time=2.07 min; m/z=456.2 [M+H]⁺Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.68 (br. s., 1H), 7.52 (d, J=7.03 Hz,1H), 7.03-7.10 (m, 3H), 7.02 (s, 1H), 6.68 (br. s., 1H), 4.78 (dd,J=10.54, 5.02 Hz, 1H), 3.86 (s, 3H), 3.51-3.59 (m, 1H), 3.23-3.31 (m,1H), 2.68-2.96 (m, 5H), 1.93-2.03 (m, 2H), 1.76-1.88 (m, 1H), 1.56-1.73(m, 2H), 1.43-1.54 (m, 1H). Human αVβ6 IC50 (nM)=195. Fourth elutingdiastereomer, Example 161 (Retention time 22.3 min., 7 mg, 4%) wasisolated as a white solid. LC-MS retention time=2.05 min; m/z=456.2[M+H]⁺ Column-KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 50% B with flow rate 1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.66 (d, J=6.02 Hz, 1H), 7.52 (d,J=7.53 Hz, 1H), 7.04-7.15 (m, 3H), 7.04 (s, 1H), 6.67 (t, J=6.40 Hz,1H), 4.81 (dd, J=11.04, 5.02 Hz, 1H), 3.86 (s, 3H), 3.55-3.63 (m, 1H),3.10-3.19 (m, 1H), 2.76-2.90 (m, 5H), 1.89-2.04 (m, 3H), 1.46-1.69 (m,3H). Human αVβ6 IC50 (nM)=12.

Example 162 and Example 163 Example 162: First Eluting Enantiomer of3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 163: Second Eluting Enantiomer of3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

Tert-butyl(E)-7-(3-(2-(3-ethoxy-3-oxoprop-1-en-1-yl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(162A)

To a solution of ethyl(E)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)acrylate137H (300 mg, 0.839 mmol) in THF (5 mL) was added Boc₂O (1.5 mL, 6.46mmol) and the reaction mixture was stirred at 70° C. for 12 h. Aftercompletion of the reaction, the reaction mixture was concentrated andthe crude product was purified by combiflash chromatography (12 gRedisep® SiO₂ column, eluting with 90% ethyl acetate in Pet ether) toafford the title compound 162A (290 mg, 71%) as a pale brown gummyliquid. LC-MS retention time=3.2 and 3.4 min (cis & trans mixture);m/z=458.2 [M+2H]⁺ Column: KINETIX XB-C18, (3×75) mm, 2.6 micron column;Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over4.6 min, then hold 0.4 min. at 20% B with flow rate 1.5 mL/min;Detection: UV at 220 nm.

Tert-butyl7-(3-(2-(1-(3,5-dimethyl-1H-pyrazol-1-yl)-3-ethoxy-3-oxopropyl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate (162B)

To a solution of tert-butyl(E)-7-(3-(2-(3-ethoxy-3-oxoprop-1-en-1-yl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate162A (200 mg, 0.437 mmol) in ACN was added 3,5-dimethyl-1H-pyrazole(42.0 mg, 0.437 mmol) and cesium carbonate (285 mg, 0.874 mmol). Thereaction mixture was then heated at 80° C. and stirred for 16 h. Thereaction mixture was cooled to RT and filtered through Celite. Thefiltrate was concentrated and the crude product was purified bypreparative reverse phase HPLC (SYMMETRY C8 (300×19) mm; 7 micron;Mobile Phase A: 10 mM ammonium acetate; Mobile Phase B:Trifluoroethanol; flow rate: 18 mL/min; Time (min)/% B: 0/50, 27/100) toafford title compound 162B (30 mg, 12%) of required compound as an offwhite gummy liquid. LC-MS retention time=3.72 min; m/z=554.2 [M+H]⁺Column: KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% Water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1.5 mL/min; Detection: UV at 220nm.

Ethyl3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoate(162C)

To a solution of tert-butyl7-(3-(2-(1-(3,5-dimethyl-1H-pyrazol-1-yl)-3-ethoxy-3-oxopropyl)thiazol-4-yl)propyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate162B (30 mg, 0.054 mmol) in DCM (10 mL) was added TFA (0.05 mL, 0.649mmol) and stirred at the RT for 16 h. After the completion of thereaction, the reaction mixture was concentrated to afford the titlecompound 162C (24 mg, 99%) as a pale brown liquid. LC-MS retentiontime=2.87 min; m/z=454.3 [M+H]⁺ Column: KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1.5mL/min; Detection: UV at 220 nm.

Example 162: First Eluting Enantiomer of3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid Example 163: Second Eluting Enantiomer of3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicAcid

To a solution of ethyl3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoate162C (24 mg, 0.055 mmol) in THF (1 mL) and MeOH (1 mL) was added asolution of lithium hydroxide monohydrate (6.94 mg, 0.165 mmol) in water(0.5 mL) and the resulting reaction mixture was stirred at RT for 16 h.After completion of the reaction, citric acid (21.18 mg, 0.110 mmol) wasadded and the reaction mixture was stirred at the RT for 10 min. Thereaction mixture was concentrated and the crude product was purified bypreparative reverse phase HPLC (SUNFIRE C18 (150×19) mm; 5 micron;Mobile Phase A: 10 mM ammonium acetate; Mobile Phase B: ACN; flow rate:15 mL/min; Time (min)/% B: 0/20, 20/60) to afford the title compound (10mg) as racemic mixture. The individual enantiomers of3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid were separated by chiral column (Lux Cellulose C2 (250×21.2) mm, 5micron; Mobile phase: 0.1% DEA in ACN:Trifluoroethanol (70:30); flow: 25mL/min). First eluting enantiomer, Example 162 (Retention time 5.01min., 1.8 mg, 8%) was isolated as an off white solid. LC-MS retentiontime=1.22 min; m/z=426.2 [M+H]⁺ Column: KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.49 (d,J=7.20 Hz, 1H), 7.10 (s, 1H), 6.57 (d, J=7.20 Hz, 1H), 6.06 (dd, J=9.60,5.20 Hz, 1H), 5.91 (s, 1H), 3.49 (m, 2H), 3.42 (dd, J=14.40, 9.60 Hz,1H), 3.04 (dd, J=14.20, 5.60 Hz, 1H), 2.55-2.85 (m, 6H), 2.33 (s, 3H),2.19 (s, 3H), 1.95-2.15 (m, 2H), 1.86-1.95 (m, 2H). Human αVβ6 IC50(nM)=71. Second eluting enantiomer Example 163 (Retention time. 10.61min., 2.2 mg, 9%) was isolated as an off white solid. LC-MS retentiontime=1.22 min; m/z=426.2 [M+H]⁺ Column: KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%Water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% Water/98% ACN; 50% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1.5mL/min; Detection: UV at 220 nm.

¹H NMR (400 MHz, CD₃OD) δ ppm 7.49 (d, J=7.20 Hz, 1H), 7.10 (s, 1H),6.57 (d, J=7.20 Hz, 1H), 6.06 (dd, J=9.60, 5.20 Hz, 1H), 5.91 (s, 1H),3.49 (m, 2H), 3.42 (dd, J=14.40, 9.60 Hz, 1H), 3.04 (dd, J=14.20, 5.60Hz, 1H), 2.55-2.85 (m, 6H), 2.33 (s, 3H), 2.19 (s, 3H), 1.95-2.15 (m,2H), 1.86-1.95 (m, 2H). Human αVβ6 IC50 (nM)=220.

Example 164 and Example 165 Example 164: First Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid Example 165: Second Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid

Ethyl (E)-3-(5-bromo-1-methyl-1H-imidazol-2-yl)acrylate (164A)

To a stirred solution of 5-bromo-1-methyl-1H-imidazole-2-carbaldehyde(2.5 g, 13.23 mmol) in toluene (50 mL) was added(carbethoxymethylene)triphenylphosphorane (6.91 g, 19.84 mmol) undernitrogen atmosphere. The resulting clear solution was heated to 110° C.and stirred for 16 h. After completion of the reaction, the reactionmixture was concentrated and the crude product was purified bycombiflash chromatography (40 g Redisep® SiO₂ column, eluting with 30%ethyl acetate in n-hexanes) to afford the title compound 164A (2 g, 60%)as an off white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.56 (d, J=15.56Hz, 1H), 7.23 (s, 1H), 6.60 (d, J=15.56 Hz, 1H), 4.21 (q, J=7.03 Hz,2H), 3.72 (s, 3H), 1.27 (t, J=7.03 Hz, 3H).

Ethyl3-(5-bromo-1-methyl-1H-imidazol-2-yl)-3-(6-methoxypyridin-3-yl)propanoate(164B)

To a stirred solution of ethyl(E)-3-(5-bromo-1-methyl-1H-imidazol-2-yl)acrylate 164A (1 g, 3.86 mmol)in dioxane (30 mL) and water (10 mL) was added(6-methoxypyridin-3-yl)boronic acid (0.885 g, 5.79 mmol) and thereaction mixture was purged with argon gas for 10 min. TEA (1.076 mL,7.72 mmol) and chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.095 g,0.193 mmol) were added and the reaction mixture was heated to 80° C. andstirred for 16 h. The reaction mixture was cooled to RT, diluted withwater (50 mL) and extracted with ethyl acetate (2×50 mL). The combinedorganic layer was dried (Na₂SO₄), filtered and the filtrateconcentrated. The crude product was purified by combiflashchromatography (40 g Redisep® SiO₂ column, eluting with 25% ethylacetate in n-hexanes) to afford the title compound 164B (350 mg, 25%) asa pale brown gummy liquid. LC-MS retention time=2.23 min; m/z=370.1[M+2H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.05 (d, J=2.51 Hz, 1H), 7.44 (dd,J=8.53, 2.51 Hz, 1H), 6.98 (s, 1H), 6.69 (d, J=8.53 Hz, 1H), 4.50 (dd,J=8.53, 6.53 Hz, 1H), 4.10 (q, J=7.03 Hz, 2H), 3.91 (s, 3H), 3.39 (s,3H), 3.36-3.46 (m, 1H), 2.85 (dd, J=16.56, 6.53 Hz, 1H), 1.20 (t, J=7.03Hz, 3H).

Ethyl(E)-3-(5-(4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)-1-methyl-1H-imidazol-2-yl)-3-(6-methoxy-pyridin-3-yl)propanoate(164C)

To a stirred solution of ethyl3-(5-bromo-1-methyl-1H-imidazol-2-yl)-3-(6-methoxypyridin-3-yl)propanoate164B (300 mg, 0.815 mmol) in acetonitrile (15 mL) was added2-(but-3-en-1-yl)-1,8-naphthyridine (225 mg, 1.22 mmol) and the reactionmixture was purged with nitrogen for 10 min. TEA (247 mg, 2.44 mmol),tri-o-tolylphosphane (24.80 mg, 0.081 mmol) and palladium acetate (18.3mg, 0.081 mmol) were added and the reaction mixture was heated to 90° C.and stirred for 16 h. The reaction mixture was cooled to RT and filteredthrough Celite. The filtrate was diluted with water (5 mL) and extractedwith DCM (2×10 mL). The combined organic layer was dried (Na₂SO₄),filtered and the filtrate concentrated. The crude product was purifiedby combiflash chromatography (4 g Redisep® SiO₂ column, eluting with 3%Methanol in Chloroform to afford the title compound 164C (200 mg, 52%)as a pale brown liquid. LC-MS retention time=2.15 min; m/z=472.4 [M+H]⁺KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min;Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm.

Ethyl3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoate(164D)

To a degassed solution of ethyl(E)-3-(5-(4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)-1-methyl-1H-imidazol-2-yl)-3-(6-methoxypyridin-3-yl)propanoate164C (200 mg, 0.424 mmol) in ethanol (20 mL) was added platinum(IV)oxide (20 mg, 0.088 mmol) and the he reaction mixture was stirred at theRT under Hydrogen balloon atmosphere for 16 h. The reaction mixture wasfiltered through Celite pad, and the filtrate concentrated to afford thetitle compound 164D (200 mg, 99%) as a pale brown liquid. LC-MSretention time=1.17 min; m/z=478.7 [M+H]⁺ AQUITY UPLC BEH C18 (3.0×50)mm; 1.7 micron; Mobile phase A: 10 mM NH₄COOCH₃:ACN (95:5) Mobile phaseB: 10 mM NH₄COOCH₃:ACN (5:95) Method: % B: 0 min-20%:1.1 min−90%:1.7min-90%.

Example 164: First Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid Example 165: Second Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid

To a stirred solution of ethyl ethyl3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoate164D (200 mg, 0.419 mmol) in THF (4 mL) and MeOH (4 mL) was added asolution of LiOH.H₂O (12.22 mg, 0.291 mmol) in water (2 mL) and theresulting reaction mixture was stirred at RT for 16 h. After completionof the reaction, citric acid (241 mg, 1.256 mmol) was added and thereaction mixture was stirred at the RT for 10 min. The reaction mixturewas concentrated and the crude product was purified by preparativereverse phase HPLC (Inersil ODS (250 mm×19 mm ID, 5u); Mobile Phase A:10 mM ammonium acetate-pH-4.5; Mobile Phase B: Acetonitrile; flow rate:17 mL/min; Time (min)/% B: 0/10, 7/22, 12.5/22) afford the titlecompound (50 mg) as racemic mixture. The individual enantiomers werethen separated by chiral SFC (Chiralpak AD-H (250×21) mm, 5u; 50% CO₂and 50% of 0.2% NH₄OH in Methanol as co-solvent); Total Flow: 70 g/min;Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at 220 nM.First eluting enantiomer Example 164 (Retention time 3.40 min., 17 mg,9%) was isolated as a white solid. LC-MS retention time=1.13 min;m/z=450.4 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.04 (d, J=2.01Hz, 1H), 7.62 (dd, J=8.53, 2.51 Hz, 1H), 7.28 (d, J=7.03 Hz, 1H),6.67-6.78 (m, 2H), 6.39 (d, J=7.53 Hz, 1H), 4.63 (dd, J=9.54, 5.52 Hz,1H), 3.87 (s, 3H), 3.52 (s, 3H), 3.39 (t, J=6.0 Hz, 2H), 3.19 (dd,J=16.0, 10.4 Hz, 1H), 2.84 (dd, J=16.0, 5.6 Hz, 1H), 2.56-2.76 (m, 4H),2.42-2.56 (m, 1H), 2.21-2.39 (m, 1H), 1.81-1.96 (m, 2H), 1.42-1.79 (m,4H). Human αVβ6 IC50 (nM)=460. Second eluting enantiomer Example 165(Retention time 6.80 min., 18 mg, 9%) was isolated as a white solid.LC-MS retention time=1.13; m/z=450.4 [M+H]⁺ KINETIX XB-C18, (3×75) mm,2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20%B to 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm8.04 (d, J=2.01 Hz, 1H), 7.62 (dd, J=8.53, 2.51 Hz, 1H), 7.28 (d, J=7.03Hz, 1H), 6.67-6.78 (m, 2H), 6.39 (d, J=7.53 Hz, 1H), 4.63 (dd, J=9.54,5.52 Hz, 1H), 3.87 (s, 3H), 3.52 (s, 3H), 3.39 (t, J=6.0 Hz, 2H), 3.19(dd, J=16.0, 10.4 Hz, 1H), 2.84 (dd, J=16.0, 5.6 Hz, 1H), 2.56-2.76 (m,4H), 2.42-2.56 (m, 1H), 2.21-2.39 (m, 1H), 1.81-1.96 (m, 2H), 1.42-1.79(m, 4H). Human αVβ6 IC50 (nM)=27.

Prep-HPLC/SFC Ex- conditions, LC-MS and 1H ample Structure NMR Method166

Prep-SFC: Retention time 3.40 min. Chiralpak AD-H (250 × 21) mm, 5 u;50% CO₂ and 50% of 0.2% NH₄OH in Methanol as co-solvent); Total Flow: 70g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at 220nM. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.29 (d, J = 7.03 Hz, 1H), 6.96-7.06(m, 3H), 6.76 (s, 1H), 6.39 (d, J = 7.03 Hz, 1H), 4.61 (dd, J = 10.54,5.52 Hz, Example 164/165 1H), 3.84 (s, 3H), 3.51 (s, 3H), 3.41 (t, J =5.2 Hz, 2H), 3.19 (dd, J = 16.0, 10.4 Hz, 1H), 2.84 (dd, J = 16.0, 5.6Hz, 1H), 2.75 (t, J = 6.4 Hz, 2H), 2.64- 2.70 (m, 2H), 2.42-2.55 (m,1H), 2.21-2.38 (m, 1H), 1.83- 1.92 (m, 2H), 1.49-1.82 (m, 4H). LC-MSretention time = 1.46 min; m/z = 467.2 [M + H]⁺ KINETIX XB-C18, (3 × 75)mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 280. 167

Prep-SFC: Retention time 6.80 min. Chiralpak AD-H (250 × 21) mm, 5 u;50% CO₂ and 50% of 0.2% NH₄OH in Methanol as co-solvent); Total Flow: 70g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at 220nM. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.29 (d, J = 7.03 Hz, 1H), 6.96-7.06(m, 3H), 6.76 (s, 1H), 6.39 (d, J = 7.03 Hz, 1H), 4.61 (dd, J = 10.54,5.52 Hz, Example 164/165 1H), 3.84 (s, 3H), 3.51 (s, 3H), 3.41 (t, J =5.2 Hz, 2H), 3.19 (dd, J = 16.0, 10.4 Hz, 1H), 2.84 (dd, J = 16.0, 5.6Hz, 1H), 2.75 (t, J = 6.4 Hz, 2H), 2.64- 2.70 (m, 2H), 2.42-2.55 (m,1H), 2.21-2.38 (m, 1H), 1.83- 1.92 (m, 2H), 1.49-1.82 (m, 4H). LC-MSretention time = 1.47 min; m/z = 467.2 [M + H]⁺ KINETIX XB-C18, (3 × 75)mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 27.

Example 168 and Example 169 Example 168: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid Example 169: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid

Ethyl (E)-3-(4-bromo-1-methyl-1H-imidazol-2-yl)acrylate (168A)

To a stirred solution of 4-bromo-1-methyl-1H-imidazole-2-carbaldehyde(2.4 g, 12.70 mmol) in toluene (25 mL) was addedcarbethoxymethylene)triphenylphosphorane (6.64 g, 19.05 mmol) under anitrogen atmosphere and the resulting clear solution was heated to 110°C. and stirred for 16 h. After completion of the reaction, the reactionmixture was cooled to the RT and concentrated. The crude product waspurified by combiflash chromatography (12 g Redisep® SiO₂ column,eluting with 25% ethyl acetate in n-hexanes) to afford the titlecompound 168A (2.3 g, 58%) as a colourless liquid. LC-MS retentiontime=1.85 min; m/z=261.0 [M+2H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.50 (s,1H), 7.44 (d, J=15.6 Hz, 1H), 6.51 (d, J=15.6 Hz, 1H), 4.18 (q, J=7.20Hz, 2H) 3.76 (s, 3H), 1.25 (t, J=7.20 Hz, 3H).

Ethyl3-(4-bromo-1-methyl-1H-imidazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)-propanoate(168B)

To a stirred solution of ethyl(E)-3-(4-bromo-1-methyl-1H-imidazol-2-yl)acrylate 168A (0.700 g, 2.70mmol) in 1,4-dioxane (10 mL) and water (2.5 mL) was added(3-fluoro-4-methoxyphenyl)boronic acid (0.689 g, 4.05 mmol) and thereaction mixture was purged with argon for 5 min. TEA (0.753 mL, 5.40mmol) and chloro(1,5-cyclooctadiene)rhodium(i) dimer (0.067 g, 0.135mmol) were added and the solution was heated to 85° C. and stirred for14 h. The reaction mixture was cooled, filtered through a pad of Celite,The Celite pad was washed with dichloromethane (4×15 mL) and thecombined filtrate was concentrated. The crude product was then purifiedby combiflash chromatography (40 g Redisep® SiO₂ column, eluting with70% ethyl acetate in n-hexanes) to afford the title compound 168B (0.5g, 23%) as a gummy liquid. LC-MS retention time=2.40 min; m/z=385.0[M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm.

Ethyl(E)-3-(4-(4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)-1-methyl-1H-imidazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate(168C)

To a stirred solution of ethyl3-(4-bromo-1-methyl-1H-imidazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate168B (0.5 g, 0.623 mmol) in acetonitrile (10 mL) was added2-(but-3-en-1-yl)-1,8-naphthyridine (0.344 g, 1.869 mmol) and thereaction mixture was purged with argon for 5 min. TEA (0.261 mL, 1.869mmol), tri-o-tolylphosphine (0.019 g, 0.062 mmol) and palladium(II)acetate (0.014 g, 0.062 mmol) were added and the solution was heated to90° C. and stirred for 14 h. The reaction mixture was cooled, filteredthrough a pad of Celite and the pad was washed with dichloromethane(4×10 mL). The combined filtrate was concentrated and the crude productwas purified by combiflash chromatography (24 g Redisep® SiO₂ column,eluting with 90% ethyl acetate in n-hexanes) to afford the titlecompound 168C (0.14 g, 35%) as a gummy liquid. LC-MS retention time=2.42min; m/z=489.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm.

Ethyl3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoate(168D)

To a degassed solution of ethyl(E)-3-(4-(4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)-1-methyl-1H-imidazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate168C (0.140 g, 0.287 mmol) in ethanol (3 mL) was added platinum(IV)oxide (14 mg, 0.062 mmol) and the reaction mixture was stirred at the RTunder hydrogen balloon atmosphere for 14 h. The reaction mixture wasfiltered through Celite pad and the filtrate concentrated to afford thetitle compound 168D (110 mg, 73%) as a gummy liquid. LC-MS retentiontime=2.69 min; m/z=495.2 [M+H]⁺, KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm.

Example 168: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid Example 169: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicAcid

To a stirred solution of ethyl3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoate168D (0.110 g, 0.222 mmol) in THF (1 mL) and methanol (1 mL) was added asolution of LiOH.H₂O (0.037 g, 0.890 mmol) in water (1 mL) and theresulting reaction mixture was stirred at RT for 14 h. After completionof the reaction, citric acid (128 mg, 0.667 mmol) was added and thereaction mixture was stirred at the RT for 10 min. The reaction mixturewas concentrated and the crude product was purified by preparativereverse phase HPLC to afford the racemate of title compound (90 mg).Individual enantiomers were separated by chiral preparative HPLC.Column: Lux-cellulose C4 (250×21.2) mm, 5 micron, Mobile Phase: ACN:MeOH(1:1), Flow: 19 mL/min, Time (min)/% B: 0/100, 20/100. First elutingenantiomer Example 168 (Retention time 3.86 min., 4 mg, 3%) was isolatedas an off white solid. LC-MS retention time 1.60 min; m/z=467.2 [M+H]⁺KINETIX XB-C18 (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; MobilePhase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹HNMR (400 MHz, CD₃OD) δ ppm 7.38 (d, J=7.03 Hz, 1H), 7.06-6.99 (m, 3H),6.79 (s, 1H), 6.45 (d, J=7.53 Hz, 1H), 4.63 (dd, J=10.79, 4.77 Hz, 1H),3.84 (s, 3H), 3.54 (s, 3H), 3.42 (t, J=6.0 Hz, 2H), 3.18 (dd, J=14.81,11.29 Hz, 1H), 2.83 (dd, J=14.81, 11.29 Hz, 1H), 2.73 (t, J=6.0 Hz, 2H),2.68-2.54 (m, 4H), 1.93-1.87 (m, 3H), 1.61-1.53 (m, 3H). Human αVβ6 IC50(nM)=91. Second eluting enantiomer Example 169 (Retention time 4.73min., 4 mg, 3%) was isolated as a white solid. LC-MS retention time=1.60min; m/z=467.2 [M+H]⁺ KINETIX XB-C18 (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.38 (d, J=7.03Hz, 1H), 7.06-6.99 (m, 3H), 6.79 (s, 1H), 6.45 (d, J=7.53 Hz, 1H), 4.63(dd, J=10.79, 4.77 Hz, 1H), 3.84 (s, 3H), 3.54 (s, 3H), 3.42 (t, J=6.0Hz, 2H), 3.18 (dd, J=14.81, 11.29 Hz, 1H), 2.83 (dd, J=14.81, 11.29 Hz,1H), 2.73 (t, J=6.0 Hz, 2H), 2.68-2.54 (m, 4H), 1.93-1.87 (m, 3H),1.61-1.53 (m, 3H). Human αVβ6 IC50 (nM)=67.

Example 170 and Example 171 Example 170: First Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicAcid Example 171: Second Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicAcid

2-(pent-4-yn-1-yl)-1,8-naphthyridine (170A)

To a solution of hept-6-yn-2-one (1 g, 9.08 mmol) in MeOH (30 mL) wasadded pyrrolidine (0.751 mL, 9.08 mmol) and the solution was stirred atthe RT for 10 min. under nitrogen atmosphere. 2-Aminonicotinaldehyde(1.164 g, 9.53 mmol) was added and the resulting reaction mixture wasstirred at the RT for 16 h. After completion of the reaction, thereaction mixture was concentrated and the crude product was purified bycombiflash chromatography (40 g Redisep® SiO₂ column, eluting with 60%ethyl acetate in n-hexanes) to afford the title compound 170A (1 g, 56%)as pale gummy liquid. LC-MS retention time=1.55 min; m/z=197.2 [M+H]⁺KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min;Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mMHCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹HNMR (400 MHz, CDCl₃) δ ppm 9.10 (dd, J=4.25, 2.00 Hz, 1H), 8.17 (dd,J=8.01, 2.00 Hz, 1H), 8.12 (d, J=8.51 Hz, 1H), 7.45 (dd, J=8.01, 2.00Hz, 1H), 7.42 (d, J=8.2 Hz, 1H), 3.16-3.23 (t, J=7.6 Hz, 2H), 2.30-2.37(m, 2H), 2.13-2.23 (m, 2H), 2.00 (t, J=2.63 Hz, 1H).

2-(3-(1H-1,2,3-triazol-4-yl)propyl)-1,8-naphthyridine (170B)

To a stirred solution of 2-(pent-4-yn-1-yl)-1,8-naphthyridine 170A (600mg, 3.06 mmol) in t-butanol (10 mL) and water (10 mL) was added TMSN₃(0.812 mL, 6.11 mmol), sodium ascorbate (1211 mg, 6.11 mmol) andcopper(II) sulphate pentahydrate (229 mg, 0.917 mmol) at RT. Thereaction mixture was then heated to 80° C. and stirred for 16 h. Thereaction mixture was cooled RT, diluted with methanol (50 mL), filteredthrough Celite pad and the filtrate concentrated. The crude product waspurified by combiflash chromatography (24 g Redisep® SiO₂ column,eluting with 8-10% methanol in chloroform) to afford the title compound170B (0.47 g, 60%) as a brown gummy liquid. LC-MS retention time=0.80min; m/z=240.1 [M+H]⁺ Column-Kinetex XB-C18 (75×3 mm-2.6 μm), Mobilephase A: 0.1% TFA in water; Mobile phase B: ACN, Flow: 1 mL/min,Gradient B: 0 min—20%, 4 min−100%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.04(dd, J=4.52, 2.01 Hz, 1H), 8.34-8.47 (m, 1H), 8.37 (d, J=8.4 Hz, 1H),7.53-7.65 (m, 3H), 3.03 (t, J=7.78 Hz, 2H), 2.65-2.75 (m, 2H), 2.09-2.23(m, 2H).

Ethyl3-(4-(3-(1,8-naphthyridin-2-yl)propyl)-2H-H-1,2,3-triazol-2-yl)-3-(6-methoxy-pyridin-3-yl)propanoate(170C)

In a sealed tube, to a stirred solution of2-(3-(1H-1,2,3-triazol-4-yl)propyl)-1,8-naphthyridine 170B (270 mg,1.128 mmol) in propionitrile (5 mL), ethyl(Z)-3-(6-methoxypyridin-3-yl)acrylate (351 mg, 1.693 mmol) and1,1,3,3-tetramethylguanidine (0.425 mL, 3.39 mmol) were added. Thereaction mixture was heated at 100° C. and stirred for 4 d. The reactionmixture was concentrated and the crude product was purified bycombiflash chromatography (12 g Redisep® SiO₂ column, eluting with 3%methanol in chloroform) to afford the title compound 170C (150 mg, 30%)as a pale brown gummy liquid. LC-MS retention time=2.23 min; m/z=447.2[M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.03 (dd, J=4.40, 1.96 Hz, 1H), 8.42(dd, J=8.07, 1.96 Hz, 1H), 8.37 (d, J=8.31 Hz, 1H), 8.18 (d, J=2.69 Hz,1H), 7.67 (dd, J=8.56, 2.69 Hz, 1H), 7.65 (s, 1H), 7.58 (dd, J=8.07,4.16 Hz, 1H), 7.53 (d, J=8.07 Hz, 1H), 6.80 (d, J=8.80 Hz, 1H), 6.07(dd, J=10.03, 5.38 Hz, 1H), 3.96-4.04 (m, 2H), 3.82 (s, 3H), 3.58 (dd,J=16.63, 10.03 Hz, 1H), 2.96-3.02 (m, 2H), 2.67-2.74 (m, 2H), 2.12(quin, J=7.76 Hz, 2H), 1.06 (t, J=7.09 Hz, 3H).

Ethyl3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoate(170D)

To a degassed solution of ethyl3-(4-(3-(1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)-3-(6-methoxypyridin-3-yl)propanoate170C (150 mg, 0.336 mmol) in ethanol (15 mL) was added platinum(IV)oxide (15 mg, 0.066 mmol). The reaction mixture was stirred at the RTunder hydrogen balloon atmosphere for 16 h. The reaction mixture wasfiltered through Celite pad and the filtrate concentrated to afford thetitle compound 170D (120 mg, 79%) as a pale brown liquid. LC-MSretention time=2.60 min; m/z=451.4 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm.

Example 170: First Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicAcid Example 171: Second Eluting Enantiomer of3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicAcid

To a stirred solution of ethyl3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoate170D (200 mg, 0.444 mmol) in THF (5 mL), water (2 mL) and MeOH (5 mL),LiOH.H₂O (12.22 mg, 0.291 mmol) was added and the resulting reactionmixture was stirred at RT for 4 h. After completion of the reaction,citric acid (171 mg, 0.888 mmol) was added and the reaction mixture wasstirred at the RT for 10 min. The reaction mixture was concentrated andthe crude product was purified by preparative reverse phase preparativeHPLC (Inersil ODS (250×19) mm; 5 micron; Mobile Phase A: 10 mM ammoniumacetate (pH=4.5); Mobile Phase B: Acetonitrile; flow rate: 17 mL/min;Time (min)/% B: 0/10, 7/22, 12.5/22) afford the title compound (80 mg)as racemic mixture. The individual enantiomers were separated by chiralSFC (Luxcellulose-4 (250×21.5) mm; 5 micron; 50% CO₂ and 50% of 0.2%NH₄OH in Methanol and ACN (1:1) as co-solvent); Total Flow: 70 g/min;Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at 225 nM.The first eluting enantiomer, Example 170 (Retention time 7.0 min., 31mg, 15%) was isolated as an off white solid. LC-MS retention time=1.19min; m/z=423.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN;Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.16 (d, J=2.51Hz, 1H), 7.75 (dd, J=8.78, 2.76 Hz, 1H), 7.47 (s, 1H), 7.28 (d, J=8.03Hz, 1H), 6.78 (d, J=8.53 Hz, 1H), 6.45 (d, J=7.03 Hz, 1H), 6.11 (dd,J=9.79, 5.77 Hz, 1H), 3.90 (s, 3H), 3.44 (t, J=5.6 Hz, 2H), 3.35 (dd,J=14.92, 10.2 Hz, 1H), 3.02 (dd, J=14.92, 4.16 Hz, 1H), 2.76 (t, J=6.27Hz, 2H), 2.66-2.72 (m, 2H), 2.55-2.62 (m, 2H), 1.96-2.10 (m, 2H),1.87-1.96 (m, 2H). Human αVβ6 IC50 (nM)=620. The second elutingenantiomer, Example 171 (Retention time. 8.50 min., 27 mg, 13%) wasisolated as an off white solid, LC-MS retention time=1.19 min; m/z=423.2[M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.16 (d, J=2.51 Hz, 1H), 7.75 (dd,J=8.78, 2.76 Hz, 1H), 7.47 (s, 1H), 7.28 (d, J=8.03 Hz, 1H), 6.78 (d,J=8.53 Hz, 1H), 6.45 (d, J=7.03 Hz, 1H), 6.11 (dd, J=9.79, 5.77 Hz, 1H),3.90 (s, 3H), 3.44 (t, J=5.6 Hz, 2H), 3.35 (dd, J=14.92, 10.2 Hz, 1H),3.02 (dd, J=14.92, 4.16 Hz, 1H), 2.76 (t, J=6.27 Hz, 2H), 2.66-2.72 (m,2H), 2.55-2.62 (m, 2H), 1.96-2.10 (m, 2H), 1.87-1.96 (m, 2H). Human αVβ6IC50 (nM)=27.

Ex- Prep-HPLC/SFC conditions, ¹H ample Structure NMR and LC-MS dataMethod 172

Chiral SFC: RT = 8.37 min. Luxcellulose-4 (250 × 21.5) mm, 5 u; 50% CO₂and 50% of 0.2% NH₄OH in Methanol and ACN (1:1) as co- solvent; TotalFlow: 70 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection:UV at 225 nM. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.37 (s, 1H), 7.35 (d, J =7.2 Hz, 1H), 6.90-7.05 (m, 3H), 6.44 (d, J = 7.34 Hz, 1H), 5.94 (dd, J =11.37, 4.28 Hz, 1H), 3.75 (s, 3H), 3.35 (t, J = 6.0 Hz, 2H), 3.25-3.31(m, 1H), 2.83 (dd, J = 14.92, 4.16 Hz, 1H), 2.67 (t, J = 6.2 Hz, 2H),2.61-2.64 (m, 2H), 2.49 (t, Example 170/171 J = 7.70 Hz, 2H), 1.75-2.01(m, 4H). LC-MS: RT = 1.354 min., m/z = 440.2 [M + H]⁺ KINETIX XB-C18, (3× 75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 53 173

Chiral SFC: RT = 9.98 min. Luxcellulose-4 (250 × 21.5) mm, 5 u; 50% CO₂and 50% of 0.2% NH₄OH in Methanol and ACN (1:1) as co- solvent; TotalFlow: 70 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection:UV at 225 nM. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.37 (s, 1H), 7.35 (d, J =7.2 Hz, 1H), 6.90-7.05 (m, 3H), 6.44 (d, J = 7.34 Hz, 1H), 5.94 (dd, J =11.37, 4.28 Hz, 1H), 3.75 (s, 3H), 3.35 (t, J = 6.0 Hz, 2H), 3.25-3.31(m, 1H), 2.83 (dd, J = 14.92, 4.16 Hz, 1H), 2.67 (t, J = 6.2 Hz, 2H),2.61-2.64 (m, 2H), 2.49 (t, Example 170/171 J = 7.70 Hz, 2H), 1.75-2.01(m, 4H). LC-MS: RT = 1.354 min., m/z = 440.2 [M + H]⁺ KINETIX XB-C18, (3× 75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50(nM) = 3.0 174

Chiral SFC: RT = 16 min, Luxcellulose-4 (250 × 21.5) mm, 5 u; 50% CO₂and 50% of 0.2% NH₄OH in Methanol and ACN (1:1) as co- solvent; TotalFlow: 70 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection:UV at 230 nM. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.78 (d, J = 2.01 Hz, 1H),8.27 (d, J = 2.01 Hz, 1H), 7.91 (d, J = 8.03 Hz, 1H), 7.83 (d, J = 8.03Hz, 1H), 7.67 (ddd, J = 8.53, 7.03,1.51 Hz, 1H), 7.54- 7.50 (m, 1H),7.43 (s, 1H), 7.36 (d, J = 7.53 Hz, 1H), 6.45 (d, J = 7.53 Hz, 1H), 6.28(dd, J = 11.04, 4.52 Hz, 1H), 3.42 (dd, J = 14.8, 11.2 Hz, 1H), 3.37Example 170/171 (t, J = 5.6 Hz, 2H), 3.05 (dd, J = 14.8, 4.4 Hz, 1H),2.68-2.60 (m, 4H), 2.54- 2.50 (m, 2H), 1.98-1.92 (m, 2H), 1.78-1.84 (m,2H). LC-MS: RT = 1.359 min, m/z = 440.2 [M + H]⁺ KINETIX XB-C18, (3 ×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% B withflow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) =170. 175

Chiral SFC: RT = 18.34 min. Luxcellulose-4 (250 × 21.5) mm, 5 u; 50% CO₂and 50% of 0.2% NH₄OH in Methanol and ACN (1:1) as co- solvent; TotalFlow: 70 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection:UV at 230 nM. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.78 (d, J = 2.01 Hz, 1H),8.27 (d, J = 2.01 Hz, 1H), 7.91 (d, J = 8.03 Hz, 1H), 7.83 (d, J = 8.03Hz, 1H), 7.67 (ddd, J = 8.53, 7.03, 1.51 Hz, 1H), 7.54-7.50 (m, 1H),7.43 (s, 1H), 7.36 (d, J = 7.53 Hz, 1H), 6.45 (d, J = 7.53 Hz, 1H), 6.28(dd, J = 11.04, 4.52 Hz, 1H), 3.42 (dd, J = 14.8, 11.2 Hz, 1H), 3.37Example 170/171 (t, J = 5.6 Hz, 2H), 3.05 (dd, J = 14.8, 4.4 Hz, 1H),2.68-2.60 (m, 4H), 2.54- 2.50 (m, 2H), 1.98-1.92 (m, 2H), 1.78-1.84 (m,2H). LC-MS: RT = 1.359 min, m/z = 440.2 [M + H]⁺ KINETIX XB-C18, (3 ×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% B withflow rate 1-1.5 mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) =4.3 176

Chiral SFC: RT = 12.5 min (Chiralpak IC (250 × 21 mm, 5 u); 55% CO₂ and45% of 0.2% NH₄OH in Methanol and ACN (1:1) as co-solvent; Total Flow:70 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at220. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.66 (s, 2H), 7.54 (s, 1H), 7.50 (d,J = 7.34 Hz, 1H), 6.58 (d, J = 7.34 Hz, 1H), 6.15 (dd, J = 10.64, 4.77Hz, 1H), 4.02 (s, 3H), 3.44-3.50 (m, 2H), 3.33-3.40 (m, 1H), 3.01 (dd, J= 14.55, 4.77 Hz, 1H), 2.79 (t, J = 6.24 Hz, 2H), 2.52-2.75 (m, 4H),1.99- 2.08 (m, 2H), 1.86-1.98 (m, 2H). Example 170/171 LC-MS: RT = 1.079min, m/z = 424.4 [M + H]⁺ KINETIX XB-C18, (3 × 75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 43. 177

Chiral SFC: RT = 13.7 min (Chiralpak IC (250 × 21 mm, 5 u); 55% CO₂ and45% of 0.2% NH₄OH in Methanol and ACN (1:1) as co-solvent; Total Flow:70 g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at220. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.66 (s, 2H), 7.54 (s, 1H), 7.50 (d,J = 7.34 Hz, 1H), 6.58 (d, J = 7.34 Hz, 1H), 6.15 (dd, J = 10.64, 4.77Hz, 1H), 4.02 (s, 3H), 3.44-3.50 (m, 2H), 3.33-3.40 (m, 1H), 3.01 (dd, J= 14.55, 4.77 Hz, 1H), 2.79 (t, J = 6.24 Hz, 2H), 2.52-2.75 (m, 4H),1.99- 2.08 (m, 2H), 1.86-1.98 (m, 2H). Example 170/171 LC-MS: RT = 1.079min, m/z = 424.4 [M + H]⁺ KINETIX XB-C18, (3 × 75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. Human αVβ6 IC50 (nM) = 315.

Example 178 and Example 179 Example 178: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoicAcid Example 179: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoicAcid

Ethyl (E)-2-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)oxazole-4-carboxylate(178A)

To a stirred solution of ethyl 2-formyloxazole-4-carboxylate (4 g, 23.65mmol) in toluene (100 mL) was added tert-butyl2-(triphenyl-15-phosphanylidene)acetate (13.35 g, 35.5 mmol) and thereaction mixture was heated to 110° C. and stirred for 16 h. Aftercompletion of the reaction, the reaction mixture was cooled andconcentrated under vacuum. The crude product was purified by combiflashchromatography (40 g Redisep® SiO₂ column, eluting 45% ethyl acetate inpet ether) to afford the title compound 178A (5 g, 79%) as an off whitesolid. LC-MS retention time=2.77 min; m/z=268.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.23 (s, 1H), 7.37 (d, J=16.01 Hz, 1H), 6.77 (d, J=16.01Hz, 1H), 4.41 (q, J=7.00 Hz, 2H), 1.52 (s, 9H), 1.40 (t, J=7.13 Hz, 3H).

Ethyl2-(3-(tert-butoxy)-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)oxazole-4-carboxylate(178B)

To a stirred solution of ethyl(E)-2-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)oxazole-4-carboxylate 178A (1g, 3.74 mmol) in dioxane (30 mL) and water (10 mL) was added(3-fluoro-4-methoxyphenyl)boronic acid (0.954 g, 5.61 mmol). Thereaction mixture was purged with argon for 10 min and then TEA (1.043mL, 7.48 mmol) and chloro(1,5-cyclooctadiene)rhodium(i) dimer (0.092 g,0.187 mmol) were added. The reaction mixture was heated to 80° C. andstirred for 16 h. The reaction mixture was cooled to RT, diluted withwater (50 mL) and extracted with ethyl acetate (2×50 mL). The combinedorganic layer was dried (Na₂SO₄), filtered and the filtrateconcentrated. The crude product was purified by combiflashchromatography (40 g Redisep® SiO₂ column, eluting with 35% ethylacetate in n-hexanes) to afford the title compound 178B (700 mg, 47%) asan off white gummy liquid. LC-MS retention time=3.13 min; m/z=338.1[M-56+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm.

Tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(hydroxymethyl)oxazol-2-yl)propanoate(178C)

To a stirred solution of ethyl2-(3-(tert-butoxy)-1-(3-fluoro-4-methoxyphenyl)-3-oxopropyl)oxazole-4-carboxylatecarboxylate 178B (700 mg, 1.779 mmol) in THF (20 mL) and methanol (0.5mL) was added NaBH₄ (202 mg, 5.34 mmol) under nitrogen atmosphere at RT.The reaction mixture was heated to 50° C. and stirred for 16 h. Aftercompletion of the reaction, the reaction mixture was quenched with icecold water (15 mL) and extracted with ethyl acetate (2×30 mL). Thecombined organic layer was dried over anhydrous sodium sulphate,filtered and concentrated. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 45% ethylacetate in n-hexanes) to afford the title compound 178C (300 mg, 48%) asan off white gummy liquid. LC-MS retention time=2.46 min; m/z=352.3[M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.50 (d, J=1.00 Hz, 1H), 6.98-7.09 (m,2H), 6.85-6.94 (m, 1H), 4.58 (d, J=6.02 Hz, 2H), 4.52 (dd J=16.2, 8.03Hz, 1H), 3.86 (s, 3H), 3.19 (dd, J=16.06, 8.53 Hz, 1H), 2.85 (dd,J=16.06, 7.53 Hz, 1H), 2.01 (t, J=6.02 Hz, 1H), 1.36 (s, 9H).

Tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-formyloxazol-2-yl)propanoate (178D)

To a cooled solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(hydroxymethyl)oxazol-2-yl)propanoate178C (250 mg, 0.711 mmol) in DCM (5 mL) was added Dess-Martinperiodinane (604 mg, 1.423 mmol) at 0° C. under nitrogen atmosphere. Thereaction mixture was slowly warmed to RT and stirred at the sametemperature for 16 h. After completion of the reaction, the reactionmixture was diluted with ethyl acetate (10 mL), washed with 10% sodiumbicarbonate solution (2×5 mL), water (5 mL), brine solution (5 mL),dried over anhydrous sodium sulphate, filtered then concentrated. Thecrude product was purified by combiflash chromatography (4 g Redisep®SiO₂ column, eluting with 18% ethyl acetate in n-hexanes) to afford thetitle compound 178D (120 mg, 48%) as an off white gummy liquid. LC-MSretention time=2.76 min; m/z=350.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.83(s, 1H), 8.90 (s, 1H), 7.23 (dd, J=12.55, 2.01 Hz, 1H), 7.03-7.16 (m,2H), 4.60 (dd, J=9.29, 6.78 Hz, 1H), 3.82 (s, 3H), 3.18 (dd, J=16.31,9.29 Hz, 1H), 2.90 (dd, J=16.06, 6.53 Hz, 1H), 1.29 (s, 9H).

Tert-butyl(E)-3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(2-methyl-1,3-dioxolan-2-yl)prop-1-en-1-yl)oxazol-2-yl)propanoate(178E)

To a cooled solution ofbromo(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)triphenyl-15-phosphane (785mg, 1.717 mmol) in THF (25 mL) was added butyllithium (0.859 mL, 2.147mmol, 2.5M solution in hexane) at 0° C. under nitrogen atmosphere bydrop wise and stirred at the same temperature for 30 min. tert-Butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-formyloxazol-2-yl)propanoate 178D (300mg, 0.859 mmol) in THF (25 mL) was added drop wise and the reactionmixture was stirred at the same temperature for 2 h. After completion ofthe reaction, the reaction mixture was quenched with saturated ammoniumchloride solution (5 mL), extracted with ethyl acetate (2×10 mL). Thecombined organic layer was washed with water (10 mL), brine solution (10mL), dried over anhydrous sodium sulphate, filtered and concentrated.The crude product was purified by combiflash chromatography (4 gRedisep® SiO₂ column, eluting with 18% ethyl acetate in n-hexanes) toafford the title compound 178E (320 mg, 83%) as an off white gummyliquid. LC-MS retention time=3.46 min; m/z=448.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm.

Tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)oxazol-2-yl)propanoate(178F)

To a degassed solution of tert-butyl(E)-3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(2-methyl-1,3-dioxolan-2-yl)prop-1-en-1-yl)oxazol-2-yl)propanoate178E (320 mg, 0.715 mmol) in ethanol (10 mL) was added palladiumhydroxide on carbon (30 mg, 0.043 mmol) and the reaction mixture wasstirred at RT under hydrogen balloon atmosphere for 16 h. The reactionmixture was filtered through Celite pad and the filtrate concentrated toafford the title compound 178F (300 mg, 93%) as a pale brown liquid.LC-MS retention time=1.48 min; m/z=450.6 [M+H]⁺ AQUITY UPLC BEH C18(3.0×50 mm, 1.7 μm, Mobile phase A: 10 mM NH₄COOCH₃:ACN (95:5) Mobilephase B: 10 mM NH₄COOCH₃:ACN (5:95), Method: % B: 0 min-20%:1.1min−90%:1.7 min-90%. ¹H NMR (400 MHz, CD3OD) δ ppm 7.55 (s, 1H),7.01-7.09 (m, 3H), 4.51 (dd, J=9.54, 7.03 Hz, 1H), 3.86-3.96 (m, 4H),3.86 (s, 3H), 3.15 (dd, J=16.06, 9.04 Hz, 1H), 2.88 (dd, J=16.06, 7.03Hz, 1H), 2.44-2.57 (m, 2H), 1.59-1.78 (m, 4H), 1.36 (s, 9H), 1.29 (s,3H).

Tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(4-oxopentyl)oxazol-2-yl)propanoate(178G)

To a cooled solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)oxazol-2-yl)propanoate178F (300 mg, 0.667 mmol) in THF (2 mL) was added HCl (0.890 mL, 1.335mmol, 1.5 M) at 0° C. and the solution was stirred at the sametemperature for 6 h. After completion of the reaction, the reactionmixture was diluted with water (25 mL) and extracted with ethyl acetate(2×50 mL). The combined organic layer was washed with 10% sodiumbicarbonate solution (300 mL), water (30 mL), brine solution (30 mL),and dried over anhydrous sodium sulphate, filtered and concentrated toafford the title compound 178G (250 mg, 92%) as an off white gummyliquid. LC-MS retention time=3.00 min; m/z=406.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,CDCl₃) δ ppm 7.26 (s, 1H), 6.98-7.05 (m, 2H), 6.86-6.93 (m, 1H), 4.49(t, J=8.0 Hz, 1H), 3.86 (s, 3H), 3.16 (dd, J=16.01, 8.51 Hz, 1H), 2.83(dd, J=16.01, 7.50 Hz, 1H), 2.41-2.53 (m, 4H), 2.13 (s, 3H), 1.87-1.93(m, 2H), 1.36 (s, 9H).

Tert-butyl3-(4-(3-(1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate(178H)

To a solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(4-oxopentyl)oxazol-2-yl)propanoate178G (250 mg, 0.617 mmol) in ethanol (15 mL) was added pyrrolidine(0.102 mL, 1.233 mmol) and stirred at the RT under nitrogen atmospherefor 10 min. 2-Aminonicotinaldehyde (90 mg, 0.740 mmol) was added and theresulting reaction mixture was heated to 80° C. and stirred for 16 h.After completion of the reaction, the reaction mixture was concentrateand the crude product was purified by combiflash chromatography (12 gRedisep® SiO₂ column, eluting with 65% ethyl acetate in n-hexanes) toafford the title compound 178H (180 mg, 59%) as a pale brown gummyliquid. LC-MS retention time=2.79 min; m/z=492.2 [M+H]⁺ KINETIX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMHCO₂NH₄ in 98% water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.5 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 9.04 (dd, J=4.52, 2.01 Hz, 1H), 8.42 (dd, J=7.6, 2.0 Hz,1H), 8.37 (d, J=8.4 Hz, 1H), 7.74 (s, 1H), 7.57 (dd, J=8.0. 4.0 Hz, 1H),7.55 (d, J=8.0 Hz, 1H), 7.16 (dd, J=12.2, 2.0 Hz, 1H), 7.10 (m, 1H),7.05 (m, 1H), 4.46 (dd, J=9.54, 6.53 Hz, 1H), 3.80 (s, 3H), 3.10 (dd,J=14.8, 11.6 Hz, 1H), 3.03 (t, J=7.6 Hz, 2H), 2.88 (dd, J=16.06, 7.03Hz, 1H), 2.02-2.15 (m, 2H), 1.28 (s, 9H).

Tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-oxazol-2-yl)propanoate(178I)

To a degassed solution of tert-butyl3-(4-(3-(1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate178H (80 mg, 0.163 mmol) in THF (10 mL), was purged with nitrogen for 5min. Platinum(IV) oxide (8 mg, 0.035 mmol) was added and the reactionmixture was stirred under hydrogen balloon atmosphere at RT for 2 h.After completion of the reaction, the reaction mixture was filteredthrough Celite pad and the filtrate was concentrated to afford the titlecompound 178I (70 mg, 87%) as a pale brown liquid. LC-MS retentiontime=1.72 min; m/z=496.2 [M+H]⁺ Column-Luna 3.0 C18(2) 100A° LC column(20×4.0 mm) Mercury MS TM, Mobile phase A: 0.1% TFA in water, Mobilephase B: 0.1% TFA in ACN, Flow: 1 mL/min, Gradient B: 0 min—20%, 2.7min−90%.

Example 178: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoicAcid Example 179: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoicAcid

To a cooled solution of tert-butyl3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoate(130 mg, 0.262 mmol) in DCM (5 mL) was added TFA (0.061 mL, 0.787 mmol)at 0° C. The reaction mixture was slowly warmed to RT and stirred for 18h. After completion of the reaction, the reaction mixture wasconcentrated and the crude product was purified by preparative reversephase HPLC (SUNFIRE C18 (150×19) mm; 5 micron; Mobile Phase A: 10 mMammonium acetate in water; Mobile Phase B: Acetonitrile; flow rate: 17mL/min; Time (min)/% B: 0/20, 12/40) to afford the title compound (60mg) as racemic mixture. The individual enantiomers were separated bychiral SFC (Luxcellulose-4 (250×21.5) mm, 5 micron; 50% CO₂ and 50% of0.2% NH₄OH in Methanol and ACN (1:1) as co-solvent; Total Flow: 70g/min; Back Pressure: 100 bar; Temperature: 30° C.; Detection: UV at 230nM). The first eluting enantiomer Example 178 (Retention time 4.7 min.,20 mg, 16%) was isolated as an off white solid. LC-MS retentiontime=1.42 min; m/z=440.2 [M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98%water/2% ACN; Mobile Phase B: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.5 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.58 (s,1H), 7.46 (d, J=7.03 Hz, 1H), 7.01-7.12 (m, 3H), 6.54 (d, J=7.53 Hz,1H), 4.54 (dd, J=11.55, 5.02 Hz, 1H), 3.87 (s, 3H), 3.47 (t, J=5.6 Hz,2H), 3.10 (dd, J=14.8, 11.6 Hz, 1H), 2.71-2.82 (m, 3H), 2.51-2.63 (m,4H), 1.89-2.09 (m, 4H). Human αVβ6 IC50 (nM)=1.4. Second elutingenantiomer Example 179 (Retention time. 6.8 min., 18 mg, 15%) wasisolated as an off white solid. LC-MS retention time=1.42 min; m/z=440.2[M+H]⁺ KINETIX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM HCO₂NH₄ in 98% water/2% ACN; Mobile PhaseB: 10 mM HCO₂NH₄ in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.5 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm. ¹H NMR (400 MHz, CD₃OD) δ ppm 7.58 (s, 1H), 7.46 (d, J=7.03 Hz, 1H),7.01-7.12 (m, 3H), 6.54 (d, J=7.53 Hz, 1H), 4.54 (dd, J=11.55, 5.02 Hz,1H), 3.87 (s, 3H), 3.47 (t, J=5.6 Hz, 2H), 3.10 (dd, J=14.8, 11.6 Hz,1H), 2.71-2.82 (m, 3H), 2.51-2.63 (m, 4H), 1.89-2.09 (m, 4H). Human αVβ6IC50 (nM)=66.

Example 180 and Example 181 Example 180: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoicAcid Example 181: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoicAcid

(5-methyloxazol-2-yl)methanol (180A)

To a stirred solution of ethyl 5-methyloxazole-2-carboxylate (2.1 g,13.54 mmol) in MeOH (30 mL) was added NaBH₄ (1.280 g, 33.8 mmol) portionwise at 0° C. The resulting mixture slowly warmed to RT and stirred for16 h. The reaction mixture was them concentrated and residue was dilutedwith water (20 mL) and extracted with DCM (2×50 mL). The combinedorganic layer was washed with water, brine, dried (Na₂SO₄), filtered andthe filtrate concentrated to afford the title compound 180A (1.3 g, 85%)as a light yellow oil. LC-MS retention time=0.395 min; m/z=114.2 [M+H]⁺KINETEX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min;Mobile Phase A: 10 mM NH₄COOH in 98% water/2% ACN; Mobile Phase B: 10 mMNH₄COOH in 2% water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 6.75-6.63 (s, 1H), 5.53 (br. s., 1H), 4.40(s, 2H), 2.24 (s, 3H).

5-methyloxazole-2-carbaldehyde (180B)

To a stirred solution of (5-methyloxazol-2-yl)methanol 180A (1.3 g,11.49 mmol) in DCM (30 mL) was added Dess-Martin periodinane (7.31 g,17.24 mmol) at 0° C. portion wise. The resulting reaction mixture wasallowed to warm to RT and stirred for 16 h. The reaction mass wasdiluted with dichloromethane (50 mL), washed with 20% sodium bicarbonatesolution (50 mL), brine solution (50 mL), dried over (Na₂SO₄), filteredand the filtrate concentrated. The crude product was purified bycombiflash chromatography (40 g Redisep® SiO₂ column, eluting with 20%EtOAc in n-hexane) to afford the title compound 180B (0.8 g, 62.7%) as ayellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.68 (s, 1H), 7.08 (s, 1H),2.46 (s, 3H).

Ethyl 3-(5-methyloxazol-2-yl)acrylate (180C)

To a solution of 5-methyloxazole-2-carbaldehyde 180B (100 mg, 0.900mmol) in toluene (3 mL) was added ethyl2-(triphenyl-15-phosphanylidene)acetate (470 mg, 1.350 mmol) at RT. Theresulting mixture was heated to 110° C. and stirred for 18 h. Thereaction mixture was cooled to RT and concentrated under reducepressure. The crude product was purified by combiflash chromatography (4g Redisep® SiO₂ column, eluting with 15% EtOAc in n-hexane) to affordthe title compound 180C (0.1 g, 61%) as a yellow oil. LC-MS retentiontime=1.805 min; m/z=182.2 [M+H]⁺ KINETEX XB-C18, (3×75) mm, 2.6 microncolumn; Flow rate: 1 mL/min; Mobile Phase A: 10 mM NH₄COOH in 98%water/2% ACN; Mobile Phase B: 10 mM NH₄COOH in 2% water/98% ACN; 20% Bto 100% B over 4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5mL/min; Detection: UV at 254 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.40 (d,J=15.89 Hz, 1H), 6.89 (s, 1H), 6.66 (d, J=16.14 Hz, 1H), 4.26 (q, J=7.09Hz, 2H). 2.36 (s, 3H), 1.34 (t, J=7.09 Hz, 3H).

Ethyl 3-(3-fluoro-4-methoxyphenyl)-3-(5-methyloxazol-2-yl)propanoate(180D)

To a stirred solution of ethyl 3-(5-methyloxazol-2-yl)acrylate 180C (0.7g, 3.86 mmol) in dioxane (16 mL) and water (4 mL) was added(3-fluoro-4-methoxyphenyl)boronic acid (0.985 g, 5.79 mmol) at RT. Thereaction mixture was purged with argon for 15 min., and addedtriethylamine (1.077 mL, 7.73 mmol),chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.095 g, 0.193 mmol). Thereaction mixture was warmed to 80° C. and stirred for 16 h. The reactionmixture was cooled RT, filtered through Celite and the filtrate wasconcentrated. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 20% EtOAc inn-hexanes) to afford the title compound 180D (250 mg, 21%) as a yellowoil. LC-MS retention time=2.556 min; m/z=308.2 [M+H]⁺ KINETEX XB-C18,(3×75) mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMNH₄COOH in 98% Water/2% ACN; Mobile Phase B: 10 mM NH₄COOH in 2%Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,CDCl₃) δ ppm 6.93-7.04 (m, 2H), 6.89-6.91 (m, 1H), 6.65 (m, 1H), 4.52(t, J=7.78 Hz, 1H), 4.12 (q, J=7.36 Hz, 2H), 3.87 (s, 3H), 3.26 (dd,J=16.31, 8.28 Hz, 1H), 2.92 (dd, J=16.31, 8.28 Hz, 1H), 2.25 (s, 3H),1.20 (t, J=7.2 Hz, 3H).

Ethyl3-(4-bromo-5-methyloxazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate(180E)

To a stirred solution of ethyl3-(3-fluoro-4-methoxyphenyl)-3-(5-methyloxazol-2-yl)propanoate 180D (900mg, 2.93 mmol) in DMF (5 mL) was added NBS (1042 mg, 5.86 mmol) portionwise at RT and the resulting reaction mixture was stirred for 24 h. Thereaction mixture was diluted with ice cold water (10 mL) and extractedwith EtOAc (2×25 mL). The combined organic layer was washed with water,brine, dried (Na₂SO₄), filtered and the filtrate was concentrated. Thecrude product was purified by combiflash chromatography (12 g Redisep®SiO₂ column, eluting with 10% EtOAc in n-hexanes) to afford the titlecompound 180E (275 mg, 23%) as a yellow oil. LC-MS retention time=2.978min; m/z=386.0 [M+H]⁺ KINETEX XB-C18, (3×75) mm, 2.6 micron column; Flowrate: 1 mL/min; Mobile Phase A: 10 mM NH₄C00H in 98% water/2% ACN;Mobile Phase B: 10 mM NH₄COOH in 2% water/98% ACN; 20% B to 100% B over4.6 min, then hold 0.4 min. at 20% B with flow rate 1-1.5 mL/min;Detection: UV at 254 nm. ¹H NMR (400 MHz, CDCl₃) δ ppm 6.98-7.03 (m,2H), 6.89 (t, J=8.4 Hz, 1H), 4.48 (t, J=7.75 Hz, 1H), 4.08 (qd, J=7.13,2.13 Hz, 2H), 3.86 (s, 3H), 3.26 (dd, J=16.51, 8.51 Hz, 1H), 2.87 (dd,J=16.51, 7.25 Hz, 1H), 2.22 (s, 3H), 1.19 (t, J=7.13 Hz, 3H).

(E)-Ethyl3-(4-(4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)-5-methyloxazol-2-yl)-3-(3-fluoro-4-methoxy-phenyl)propanoate(180F)

To a stirred solution of ethyl3-(4-bromo-5-methyloxazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate180E (250 mg, 0.647 mmol) in acetonitrile (5 mL) was added2-(but-3-en-1-yl)-1,8-naphthyridine (179 mg, 0.971 mmol) and resultingreaction mixture was purged with nitrogen for 15 min. Then addedtriethylamine (0.271 mL, 1.942 mmol), tri-o-tolylphosphine (19.70 mg,0.065 mmol) and palladium acetate (2.91 mg, 0.013 mmol) and reactionmixture was heated to 85° C. and stirred for 16 h. The reaction mixturewas cooled RT, filtered through Celite bed and the filtrate wasconcentrated. The crude product was purified by combiflashchromatography (12 g Redisep® SiO₂ column, eluting with 80% EtOAc in petether) to afford the title compound 180F (170 mg, 54%) as a yellow oil(mixture of isomers). LC-MS retention time=3.22 and 3.313 min; m/z=490.2[M+H]⁺ KINETEX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1mL/min; Mobile Phase A: 10 mM NH₄C00H in 98% water/2% ACN; Mobile PhaseB: 10 mM NH₄C00H in 2% water/98% ACN; 20% B to 100% B over 4.6 min, thenhold 0.4 min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220nm.

Ethyl3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-oxazol-2-yl)propanoate(180G)

To a solution of ethyl(E)-3-(4-(4-(1,8-naphthyridin-2-yl)but-1-en-1-yl)-5-methyloxazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)propanoate180F (170 mg, 0.347 mmol) in ethanol (10 mL) was purged with nitrogenfor 5 min and was added platinum(IV) oxide (20 mg, 0.088 mmol) at RT.The reaction mixture was stirred at RT under hydrogen balloon atmospherefor 16 h. The reaction mixture was filtered through Celite and thefiltrate was concentrated to afford the title compound 180G (150 mg,87%) as yellow oil. LC-MS retention time=3.385 min; m/z=496.2 [M+H]⁺KINETEX XB-C18, (3×75) mm, 2.6 micron column; Flow rate: 1 mL/min;Mobile Phase A: 10 mM NH₄COOH in 98% Water/2% ACN; Mobile Phase B: 10 mMNH₄COOH in 2% Water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4min. at 20% B with flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹HNMR (400 MHz, CDCl₃) δ ppm 6.95-7.10 (m, 3H), 6.83 (t, J=7.6 Hz, 1H),6.31 (d, J=7.6 Hz, 1H), 4.47 (t, J=7.63 Hz, 1H), 4.00-4.14 (m, 2H), 3.85(s, 3H), 3.38-3.40 (m, 2H), 3.22 (dd, J=16.26, 7.75 Hz, 1H), 2.87 (dd,J=16.39, 7.88 Hz, 1H), 2.68 (t, J=6.25 Hz, 2H), 2.55 (t, J=7.38 Hz, 2H),2.39 (t, J=6.88 Hz, 2H), 2.14 (s, 3H), 1.83-1.94 (m, 2H), 1.58-1.71 (m,4H), 1.16 (t, J=7.13 Hz, 3H).

Example 180: First Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoicAcid Example 181: Second Eluting Enantiomer of3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoicAcid

To a stirred solution of ethyl3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoate180G (150 mg, 0.303 mmol) in THF (2 mL) and MeOH (2 mL) was added asolution of LiOH.H₂O (50.8 mg, 1.211 mmol) in water (1 mL) and theresulting reaction mixture was stirred at RT for 18 h. After completionof the reaction, reaction mixture was added citric acid (174 mg, 0.908mmol) and stirred at the RT for 10 min. Then reaction mixture wasconcentrated and the crude product was purified by preparative reversephase HPLC (Inertsil DS(250×19) mm; 5 micron, Mobile phase A:10 mMCH₃COONH₄ (pH=4.5); Mobile phase B: Acetonitrile, Flow: 17 mL/min,Gradient: Time (Min)/% B 0/20, 20/60 to afford the title compound (85mg) as racemic. The individual enantiomers were separated by chiral SFC(Chiralpak IC (250×21) mm; 5 micron; 60% CO₂ and 40% (0.2% NH₄OH) inMeOH+ACN (1:1) as co-solvent; Total Flow: 70 g/min; Back Pressure: 100bar; Temperature: 30° C.; Detection: UV at 230 nM. Example 180(Retention time 4.7 min., 25 mg, 17%) was isolated as off white solid.LC-MS retention time=1.98 min; m/z=468.2 [M+H]⁺ KINETEX XB-C18, (3×75)mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMNH₄COOH in 98% water/2% ACN; Mobile Phase B: 10 mM NH₄COOH in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 220 nm. ¹H NMR (400 MHz,CD₃OD) δ ppm 7.41 (d, J=7.03 Hz, 1H), 7.02-7.10 (m, 3H), 6.45 (d, J=7.03Hz, 1H), 4.48 (dd, J=11.80, 4.77 Hz, 1H), 3.86 (s, 3H), 3.43 (t, J=5.6Hz, 2H), 3.07-3.14 (dd, J=15.2 11.6 Hz, 1H), 2.73-2.78 (m, 3H), 2.57 (m,2H), 2.48 (t, J=7.2 Hz, 2H), 2.19 (s, 3H), 1.90-1.93 (m, 2H), 1.69-1.81(m, 2H), 1.50-1.54 (m, 2H). Human αVβ6 IC50 (nM)=250. Example 181(Retention time 5.6 min., 29 mg, 19%) was isolated as off white solid.LC-MS retention time=1.983 min; m/z=468.2 [M+H]⁺ KINETEX XB-C18, (3×75)mm, 2.6 micron column; Flow rate: 1 mL/min; Mobile Phase A: 10 mMNH₄COOH in 98% water/2% ACN; Mobile Phase B: 10 mM NH₄COOH in 2%water/98% ACN; 20% B to 100% B over 4.6 min, then hold 0.4 min. at 20% Bwith flow rate 1-1.5 mL/min; Detection: UV at 300 nm. ¹H NMR (400 MHz,CD₃OD) δ ppm 7.41 (d, J=7.03 Hz, 1H), 7.02-7.10 (m, 3H), 6.45 (d, J=7.03Hz, 1H), 4.48 (dd, J=11.80, 4.77 Hz, 1H), 3.86 (s, 3H), 3.43 (t, J=5.6Hz, 2H), 3.07-3.14 (dd, J=15.2 11.6 Hz, 1H), 2.73-2.78 (m, 3H), 2.57 (m,2H), 2.48 (t, J=7.2 Hz, 2H), 2.19 (s, 3H), 1.90-1.93 (m, 2H), 1.69-1.81(m, 2H), 1.50-1.54 (m, 2H). Human αVβ6 IC50 (nM)=1060.

Biological Evaluation

All binding assays used the HTRF (homogeneous time resolvedfluorescence) technology from Cisbio International, therefore all assaysare described as HTRF binding assays. The assay results for the Examplesare listed above together with the characterization data. The HTRFbinding assays are established for the following integrins: human αVβ6,human αVβ1, human αVβ3, human αVβ5, and human αVβ8. All assays used thefollowing assay buffer: 20 mM Tris, pH 7.4, 1 mM MgCl₂, 1 mM MnCl₂,0.01% Tween 20, and 0.01% BSA. Alternatively, a SPA-based assay was usedfor evaluation of receptor binding.

The following describes the components and a representative procedurefor the human αVβ6 HTRF binding assay: Recombinant human αVβ6 Integrin(R & D systems, 3817-AV) was biotinylated. Biotinylated human αVβ6Integrin was added to assay vessel at a final concentration of 1.25 nM.FITC-conjugated fibronectin (Cytoskeleton, FNR02) was then added at thefinal concentration of 5 nM. The mixture was centrifuged at 600 rpm forthree minutes using Thermo Fisher Heraeus Multifuge×3 centrifuge andthen incubated at RT for an hour. Streptavidin Terbium (Cisbiointernational 610STLB) was then added at the final concentration of0.625 nM. The resulting mixture was centrifuged at 600 rpm for threeminutes using Thermo Fisher Heraeus Multifuge×3 centrifuge and thenincubated at room temperature overnight in dark before reading HTRFsignals.

The SPA-based assay was carried out according to the protocol andprocedures similar to the ones described in the following reference withappropriate modifications to agents and ligands which are readilyunderstood by one skilled in the art: Pachter J A, Zhang R, Mayer-EzellR., “Scintillation proximity assay to measure binding of solublefibronectin to antibody-captured αVβ1 integrin” Anal Biochem. 1995 Sep.1; 230(1):101-7.

Other features of the invention should become apparent in the course ofthe above descriptions of exemplary embodiments that are given forillustration of the invention and are not intended to be limitingthereof. The present invention may be embodied in other specific formswithout departing from the spirit or essential attributes thereof. Thisinvention encompasses all combinations of preferred aspects of theinvention noted herein. It is understood that any and all embodiments ofthe present invention may be taken in conjunction with any otherembodiment or embodiments to describe additional embodiments. It is alsounderstood that each individual element of the embodiments is its ownindependent embodiment. Furthermore, any element of an embodiment ismeant to be combined with any and all other elements from any embodimentto describe an additional embodiment.

What is claimed is:
 1. A compound of Formula (I)

wherein: A, E, and G are independently N, O, S, NR^(6a), CHR^(6b) orCR^(6b); L¹ and L² are each independently C₁₋₄ alkylene; M and L areindependently N or C with the proviso that M and L are not both N;wherein A, L, E, G, and L form a ring moiety selected from pyrazole,pyrrole, thiazole, imidazole, oxazole, and pyrrolidine; X is a C₁₋₆alkylene substituted with 0, 1, or 2 R^(7b); Z is a covalent bond, O, S,NH, —O—(C₁₋₃ alkylene)-, —S—(C₁₋₃ alkylene)-, or —NH—(C₁₋₃ alkylene)-,wherein the C₁₋₃ alkylene is each independently substituted with 0, 1,or 2 R^(7a); n is an integer of 1 or 2; r is an integer of 0, 1, 2, or3; R¹ is an Arginine mimetic moiety selected from the group consistingof

one of the asterisks in each of the arginine mimetics moiety is anattachment point to X, and the other two asterisks are hydrogen; R² ishydrogen or C₁₋₆ alkyl; R³ is hydrogen, C₁₋₆ alkyl, 3- to 10-memberedcarbocyclyl, carbocyclylalkyl, 6- to 10-membered aryl, arylalkyl, 3- to14-membered heterocyclyl, heterocyclylalkyl, 5- to 14-memberedheteroaryl, or heteroarylalkyl, wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁸; or R²and R³ taken together with the atom to which they are attached form acarbocyclyl or a heterocyclyl, wherein the carbocyclyl and heterocyclylare each independently substituted with 0, 1, 2, or 3 R¹²; R⁴ ishydrogen, C₁₋₁₀ alkyl, 3- to 10-membered carbocyclyl, carbocyclylalkyl,3- to 10-membered heterocyclyl, heterocyclylalkyl, 6- to 10-memberedaryl, arylalkyl, 5- to 14-membered heteroaryl, heteroarylalkyl,NR^(a)R^(b), OR^(a), S(O)_(n)R¹⁰, C(O)NR^(a)R^(b), NHC(O)OR^(a),NHC(O)NR^(a)R^(b), NHC(O)R¹⁰, OC(O)NR^(a)R^(b), OC(O)R¹⁰,NHS(O)_(n)NR^(a)R^(b), or NHS(O)_(n)R¹⁰; wherein the alkyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with 0, 1, 2, or 3 R⁹; R⁵ ishydrogen, R^(5a), or a structural moiety selected from

R^(5a) and R^(5b) are each independently C₁₋₆ alkyl, phenyl, or 5- to7-membered heterocyclyl, wherein the alkyl, phenyl, and heterocyclyl areeach independently substituted with 0 to 3 R^(5d); R^(5c) is C₁₋₆ alkylor 5- to 7-membered carbocyclyl, wherein the alkyl and carbocyclyl areeach independently substituted with 0 to 3 R^(5d); R^(5d), at eachoccurrence, is independently halo, OH, alkoxy, oxo, or alkyl; oralternatively, two adjacent R^(5d), together with the atoms to whichthey are attached, form a carbocyclyl moiety; R^(6a) is eachindependently hydrogen, C₁₋₆ alkyl, haloalkyl, alkoxy, amino,haloalkoxy, hydroxyalkyl, aminoalkyl, or C₃₋₅ cycloalkyl, wherein thecycloalkyl is substituted with 0, 1, 2, or 3 halo, cyano, nitro, amino,or OH; R^(6b) is each independently hydrogen, halo, cyano, nitro, amino,OH, C₁₋₆ alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, aminoalkyl,or C₃₋₅ cycloalkyl, wherein the cycloalkyl is substituted with 0, 1, 2,or 3 halo, cyano, nitro, amino, or OH; R^(7a) and R^(7b) are eachindependently halo, cyano, hydroxyl, amino, C₁₋₆ alkyl, haloalkyl,hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, orsulfonamide; R⁸ is each independently halo, cyano, oxo, nitro, OH,NR^(a)R^(b), C₁₋₆ alkyl, alkoxy, alkylamino, haloalkyl, haloalkoxy,haloaminoalkyl, hydroxyalkyl, aminoalkyl, alkylsulfonyl, sulfonamide, 3to 6 membered carbocyclyl, 3 to 6 membered heterocyclyl, 6- to10-membered aryl, or 5- to 10-membered heteroaryl; or alternatively, twoR⁸ at adjacent positions, together with the atoms to which they areattached, form a carbocyclyl or heterocyclyl; wherein the aryl andheteroaryl, by themselves or as part of another group, are eachindependently substituted with one or more groups independently selectedfrom halo, cyano, hydroxyl, amino, C₁₋₆ alkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, and sulfonamide; andthe carbocyclyl and heterocyclyl, by themselves or as part of anothergroup, are each independently substituted with one or more groupsindependently selected from halo, cyano, hydroxyl, amino, oxo, C₁₋₆alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido,carbamate, and sulfonamide; R⁹ at each occurrence is independently halo,cyano, nitro, OH, NR^(a)R^(b), C₁₋₆ alkyl, alkoxy, alkylamino,haloalkyl, haloalkoxy, haloaminoalkyl, hydroxyalkyl, aminoalkyl,alkylsulfonyl, sulfonamide, 3 to 6 membered carbocyclyl, 3 to 6 memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl;or alternatively, two R⁹ at adjacent positions, together with the atomsto which they are attached, form a carbocyclyl or heterocyclyl; whereinthe aryl and heteroaryl, by themselves or as part of another group, areeach independently substituted with one or more groups independentlyselected from halo, cyano, hydroxyl, amino, C₁₋₆ alkyl, haloalkyl,hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, andsulfonamide; and the carbocyclyl and heterocyclyl, by themselves or aspart of another group, are each independently substituted with one ormore groups independently selected from halo, cyano, hydroxyl, amino,oxo, C₁₋₆ alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy,haloalkoxy, amido, carbamate, and sulfonamide; R¹⁰ is C₁₋₆ alkyl, 3- to10-membered carbocyclyl, 3- to 10-membered heterocyclyl, 6- to10-membered aryl, or 5- to 10-membered heteroaryl; wherein the alkyl,carbocyclyl, heterocyclyl are each independently substituted with 0, 1,2, or 3 R¹¹; R¹¹ is halo, cyano, nitro, OH, amino, C₁₋₆ alkyl, alkoxy,3- to 10-membered carbocyclyl, 3- to 10-membered heterocyclyl, 6- to10-membered aryl, or 5- to 10-membered heteroaryl; wherein the aryl,alkyl, and heteroaryl are each independently substituted with 0, 1, 2,or 3 R¹³; R¹², R¹³ and R¹⁴, at each occurrence, are independently halo,cyano, nitro, OH, amino, C₁₋₆ alkyl, alkoxy, aminoalkyl, haloalkyl,haloalkoxy, haloaminoalkyl, 3 to 6 membered carbocyclyl, 3 to 6 memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl;wherein the aryl and heteroaryl, by themselves or as part of anothergroup, are each independently substituted with one or more groupsindependently selected from halo, cyano, hydroxyl, amino, C₁₋₆ alkyl,haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, haloalkoxy, amido,carbamate, and sulfonamide; and the carbocyclyl and heterocyclyl, bythemselves or as part of another group, are each independentlysubstituted with one or more groups independently selected from halo,cyano, hydroxyl, amino, oxo, C₁₋₆ alkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkoxy, haloalkoxy, amido, carbamate, and sulfonamide; R^(a)and R^(b), at each occurrence, are independently hydrogen, C₁₋₁₀ alkyl,3- to 10-membered carbocyclyl, or 3- to 10-membered heterocyclyl;wherein the alkyl, carbocyclyl, heterocyclyl are each independentlysubstituted with 0, 1, 2, or 3 R¹⁴; R^(e) is OH, C₁₋₄ alkyl, halo,haloalkyl, C₁₋₄ cycloalkyl, amino, amido, carbamate, or sulfonamide;R^(f) is hydrogen, CH₃, CH₂CH₃, or COOCH₂CH₃; and R^(g) is selected fromCH₃, CH₂CH₃, CH₂CCl₃, phenyl, 4-fluorophenyl, 4-methoxyphenyl, benzyl,

or a pharmaceutically acceptable salt thereof.
 2. The compound of claim1 or a pharmaceutically acceptable salt thereof, wherein the compound ofFormula (I) is selected from Formula (IIa), Formula (IIb), Formula(IIc), and Formula (IId):


3. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein the compound of Formula (I) is represented bystructural Formula (IVa) or Formula (IVb):


4. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein the compound of Formula (I) is represented bystructural Formula (IIIa) or Formula (IIIb):


5. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein R¹ is selected from the group consisting of


6. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein R³ is selected hydrogen,


7. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein R⁴ is selected from hydrogen and the followingstructural moieties:


8. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein R⁵ is hydrogen or R^(5a); and R^(5a) is methyl, ethyl,isopropyl, n-butyl, isopentyl, or a structural moiety selected from:


9. The compound of claim 1 or a pharmaceutically acceptable saltthereof, selected from:(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-2-(((Benzyloxy)carbonyl)amino)-3-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)-1H-pyrazol-4-yl)propanoicacid;(±)-2-(((Benzyloxy)carbonyl)amino)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicacid;(±)-3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicacid;(S)-3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicacid;(R)-3-(6-Methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicacid;(±)-3-(3-Fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrrol-2-yl)propanoicacid;(±)-3-(6-Methoxypyridin-3-yl)-3-(1-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-pyrazol-4-yl)propanoicacid;(S)-3-(6-Hydroxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(6-Methoxypyridin-3-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(6-Methoxypyridin-3-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(6-Methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(6-Methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(6-Methoxypyridin-3-yl)-3-(5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(6-Methoxypyridin-3-yl)-3-(5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(6-Methoxypyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(6-Methoxypyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(3S)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)pyrrolidin-1-yl)propanoicacid;(±)-3-(2-Methylpyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-2-((Butoxycarbonyl)amino)-3-(1-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)-1H-pyrazol-4-yl)propanoicacid;(±)-3-(3-Fluoro-4-methoxyphenyl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicacid;(±)-3-(1-(3-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)-2-((2,4,6-trimethylphenyl)sulfonamido)propanoicacid;(±)-3-(3,5-Dichlorophenyl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-4-yl)propanoicacid;(±)-3-(2-Ethoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(Quinoxalin-2-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(Quinolin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2,3-Dihydrobenzofuran-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(+)-3-(3-Morpholinophenyl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(Pyrido[2,3-b]pyrazin-7-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-Methoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(3-Fluoro-4-methoxyphenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(3-Fluoro-4-methoxyphenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(3-Fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(3-Fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-(3-Fluoro-4-methoxyphenyl)-3-(5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-(3-Fluoro-4-methoxyphenyl)-3-(5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;3-(3-fluoro-4-methoxyphenyl)-3-(1-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-pyrazol-4-yl)propanoicacid;(S)-3-(1-Methyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)phenyl)-1H-pyrazol-1-yl)propanoicacid; Ethyl(S)-3-(6-methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate;(±)-3-(6-Methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(3-Fluoro-4-methoxyphenyl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-(Azetidin-1-yl)pyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-(Azetidin-1-yl)pyrimidin-5-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-Methylpyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(2-Methylpyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-Ethoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(6-Methoxypyridazin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(+)-3-(6-Methoxypyridazin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(5-Methoxypyrazin-2-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(5-Methoxypyrazin-2-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(6-Methoxypyridin-3-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(6-Methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±3)-(5-methoxypyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(5-methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(5-methoxypyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-[5-(pyrrolidin-1-yl)pyridin-3-yl]-3-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(S)-3-[5-(morpholin-4-yl)pyridin-3-yl]-3-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(R)-3-[5-(morpholin-4-yl)pyridin-3-yl]-3-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(S)-3-(5-methylpyridin-3-yl)-3-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(R)-3-(5-methylpyridin-3-yl)-3-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(+)-3-(3-fluoro-4-methoxyphenyl)-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(±)-3-[5-(dimethylcarbamoyl)pyridin-3-yl]-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(±)-3-(2-methoxypyridin-4-yl)-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(±)-3-[5-(dimethylcarbamoyl)pyridin-3-yl]-3-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(±)-3-(3,5-dichlorophenyl)-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(+)-4-{[4-(2-carboxy-1-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}ethyl)pyridin-2-yl]amino}butanoicacid;(±)-3-(5-fluoro-6-methoxypyridin-3-yl)-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(±)-3-(5-methylpyridin-3-yl)-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}propanoicacid;(±)-4-{[4-(2-carboxy-1-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1H-pyrazol-1-yl}ethyl)pyridin-2-yl]amino}butanoicacid;3-(5-(2-methoxyethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(2-ethoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(pyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-hydroxypyrimidin-5-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(2-methylpyrimidin-5-yl)-3-(5-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(2-methylpyrimidin-5-yl)-3-(5-(3-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(2-methoxypyrimidin-5-yl)-3-(5-(3-((S)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(2-methoxypyrimidin-5-yl)-3-(5-(3-((R)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(5-morpholinopyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(5-morpholinopyridin-3-yl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(2-methylpyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-methylpyrimidin-5-yl)-3-(5-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(+)-3-(6-methoxypyridin-3-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(6-methoxypyridin-3-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(6-methoxypyridin-3-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(R)-3-(2-methoxypyrimidin-5-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(±)-3-(2-methoxypyrimidin-5-yl)-3-(5-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(+)-3-(5-methoxypyridin-3-yl)-3-(3-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(+)-3-(5-methoxypyridin-3-yl)-3-(5-(3-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(6-(Benzyloxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoate;(S)-3-(1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;(S)-3-(6-(cyclopropylmethoxy)pyridin-3-yl)-3-(3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)propanoicacid;3-(6-methoxypyridin-3-yl)-3-(1-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicacid;(R)-3-(4-fluoro-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-1-yl)-3-(2-methylpyrimidin-5-yl)propanoicacid;(S)-3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicacid;(R)-3-(3-Fluoro-4-methoxyphenyl)-3-(5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-1H-pyrazol-3-yl)propanoicacid;(S)-3-(3-(dimethylcarbamoyl)phenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(3-(dimethylcarbamoyl)phenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(quinoxalin-6-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(quinoxalin-6-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(6-(dimethylamino)pyridin-3-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(6-(dimethylamino)pyridin-3-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(3,4-dimethoxyphenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(3,4-dimethoxyphenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(3-morpholinophenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(3-morpholinophenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(2-ethoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(2-ethoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(4-(dimethylcarbamoyl)-3-fluorophenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(4-(dimethylcarbamoyl)-3-fluorophenyl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(6-(dimethylamino)pyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(6-(dimethylamino)pyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(4-(dimethylcarbamoyl)-3-fluorophenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(4-(dimethylcarbamoyl)-3-fluorophenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(4-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(3-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(3-(dimethylcarbamoyl)phenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(3,4-dimethoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(3,4-dimethoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(2-Methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(R)-3-(2-Methoxypyrimidin-5-yl)-3-(4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)thiazol-2-yl)propanoicacid;(S)-3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(±)-3-(2-methylpyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(2-methylpyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(2-methylpyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(5-methylpyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(5-methylpyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoicacid;(R)-3-(3-fluoro-4-methoxyphenyl)-3-(2-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-4-yl)propanoicacid;(S,S)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S,R)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R,S)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R,R)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S,S)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S,R)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R,S)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R,R)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(R)-3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)thiazol-2-yl)propanoicacid;(S)-3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicacid;(R)-3-(6-methoxypyridin-3-yl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicacid;(S)-3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicacid;(R)-3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-5-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicacid;(S)-3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicacid;(R)-3-(3-fluoro-4-methoxyphenyl)-3-(1-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)-1H-imidazol-2-yl)propanoicacid;(S)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(R)-3-(6-methoxypyridin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(S)-3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(R)-3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(S)-3-(quinolin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(R)-3-(quinolin-3-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(S)-3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(R)-3-(2-methoxypyrimidin-5-yl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)-2H-1,2,3-triazol-2-yl)propanoicacid;(S)-3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoicacid;(R)-3-(3-fluoro-4-methoxyphenyl)-3-(4-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)oxazol-2-yl)propanoicacid;(S)-3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoicacid; and(R)-3-(3-fluoro-4-methoxyphenyl)-3-(5-methyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)oxazol-2-yl)propanoicacid; or a pharmaceutically acceptable salt thereof.
 10. Apharmaceutical composition comprising a compound of claim 1, or apharmaceutically acceptable salt thereof, and a carrier.
 11. Thecompound of claim 1 or a pharmaceutically acceptable salt thereof,wherein R⁴ is hydrogen.
 12. The compound of claim 2 or apharmaceutically acceptable salt thereof, wherein; Z is a covalent bond;X is a C₂₋₄ alkylene; R² is hydrogen; R⁴ is hydrogen; and R⁵ ishydrogen.
 13. The compound of claim 12 or a pharmaceutically acceptablesalt thereof, wherein R³ is 3- to 14-membered heterocyclyl,heterocyclylalkyl, 5- to 14-membered heteroaryl, or heteroarylalkyl,wherein the alkyl, heterocyclyl, and heteroaryl, by themselves or aspart of another group, are each independently substituted with 0, 1, 2,or 3 R⁸.
 14. The compound of claim 12 or a pharmaceutically acceptablesalt thereof, wherein: R¹ is

 and R³ is:


15. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein: Z is a covalent bond; X is a C₂₋₄ alkylene; R² ishydrogen; R³ is hydrogen; and R⁵ is hydrogen.
 16. The compound of claim1 or a pharmaceutically acceptable salt thereof, wherein the compound ofFormula (I) is selected from: